[
  {
    "text": "We also publish more information Independent Limited Assurance Reports 55 on gsk.com, including: Materiality assessment Sustainable Development Goals Engagement with patient organisations Engagement with healthcare professionals Trade association memberships Charitable partnerships External benchmarking Detailed below is how we perform in key ESG ratings that we are   FTSE4Good: Member of FTSE4Good Index since 2004 frequently asked about by investors:   CDP: A- in Climate change, A- in Water security, B in Forests   Access to Medicines: Ranked first in the Access to Medicines (palm oil) and B in Forests (timber) Index in 2022 and an industry leader in the 2021 Antimicrobial   Sustainalytics: Low risk rating Resistance Benchmark   MSCI: AA rating   S&P Global Corporate Sustainability Assessment: Ranked   Moody s Analytics: ESG Overall Score of 62 (out of 100, first in the pharmaceuticals industry with a score of 84 (as at sector average 38) 24 November 2023) and included in the DJSI World and   ISS Corporate Rating: B+ rating Europe indices Cautionary statement This document may contain forward-looking statements.",
    "id": 10,
    "label": [
      {
        "start": 469,
        "end": 483,
        "text": "Climate change",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 463,
        "end": 465,
        "text": "A-",
        "labels": [
          "value"
        ]
      },
      {
        "start": 485,
        "end": 487,
        "text": "A-",
        "labels": [
          "value"
        ]
      },
      {
        "start": 491,
        "end": 505,
        "text": "Water security",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 507,
        "end": 508,
        "text": "B",
        "labels": [
          "value"
        ]
      },
      {
        "start": 512,
        "end": 541,
        "text": "Forests Access to Medicines",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 550,
        "end": 555,
        "text": "first",
        "labels": [
          "value"
        ]
      },
      {
        "start": 563,
        "end": 593,
        "text": "Access to Medicines (palm oil)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 603,
        "end": 619,
        "text": "Forests (timber)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 598,
        "end": 599,
        "text": "B",
        "labels": [
          "value"
        ]
      },
      {
        "start": 925,
        "end": 927,
        "text": "84",
        "labels": [
          "value"
        ]
      },
      {
        "start": 855,
        "end": 857,
        "text": "62",
        "labels": [
          "value"
        ]
      },
      {
        "start": 834,
        "end": 851,
        "text": "ESG Overall Score",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 877,
        "end": 908,
        "text": "in the pharmaceuticals industry",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 11,
    "created_at": "2024-11-05T07:18:39.136888Z",
    "updated_at": "2024-11-05T07:18:39.136888Z",
    "lead_time": 255.433
  },
  {
    "text": "future events or otherwise.",
    "id": 12,
    "annotator": 1,
    "annotation_id": 13,
    "created_at": "2024-11-05T07:18:49.547092Z",
    "updated_at": "2024-11-05T07:18:49.547092Z",
    "lead_time": 5.564
  },
  {
    "text": "Investors should, however, consult any additional An investor can identify these statements by the fact that they do not relate disclosures that the Group may make in any documents which it publishes strictly to historical or current facts.",
    "id": 13,
    "annotator": 1,
    "annotation_id": 14,
    "created_at": "2024-11-05T07:19:00.695311Z",
    "updated_at": "2024-11-05T07:19:00.695311Z",
    "lead_time": 10.996
  },
  {
    "text": "They use words such as 'anticipate', and\/or files with the US Securities and Exchange Commission.",
    "id": 14,
    "annotator": 1,
    "annotation_id": 15,
    "created_at": "2024-11-05T07:19:09.068178Z",
    "updated_at": "2024-11-05T07:19:09.068178Z",
    "lead_time": 8.221
  },
  {
    "text": "All investors, 'believe', 'estimate', 'expect', intend', 'plan', 'project', 'target', 'will' and other wherever located, should take note of these disclosures.",
    "id": 15,
    "annotator": 1,
    "annotation_id": 16,
    "created_at": "2024-11-05T07:19:16.525391Z",
    "updated_at": "2024-11-05T07:19:16.525391Z",
    "lead_time": 7.306
  },
  {
    "text": "Accordingly, no words and terms of similar meaning in connection with any discussion of future assurance can be given that any particular expectation will be met and operating or financial performance.",
    "id": 16,
    "annotator": 1,
    "annotation_id": 17,
    "created_at": "2024-11-05T07:19:33.494889Z",
    "updated_at": "2024-11-05T07:19:33.494889Z",
    "lead_time": 16.829
  },
  {
    "text": "In particular, these include statements investors are cautioned not to place undue reliance on the forward-looking relating to future actions, prospective products or product approvals, future statements.",
    "id": 17,
    "annotator": 1,
    "annotation_id": 18,
    "created_at": "2024-11-05T07:19:46.078000Z",
    "updated_at": "2024-11-05T07:19:46.078000Z",
    "lead_time": 12.428
  },
  {
    "text": "Forward-looking statements are subject to assumptions, inherent performance or results of current and anticipated products, sales efforts, risks and uncertainties, many of which relate to factors that are beyond the expenses, the outcome of contingencies such as legal proceedings, dividend Group s control or precise estimate.",
    "id": 18,
    "annotator": 1,
    "annotation_id": 19,
    "created_at": "2024-11-05T07:19:53.399332Z",
    "updated_at": "2024-11-05T07:19:53.399332Z",
    "lead_time": 7.165
  },
  {
    "text": "The Group cautions investors that a payments and financial results.",
    "id": 19,
    "annotator": 1,
    "annotation_id": 20,
    "created_at": "2024-11-05T07:20:00.390110Z",
    "updated_at": "2024-11-05T07:20:00.390110Z",
    "lead_time": 6.85
  },
  {
    "text": "Other than in accordance with its legal or number of important factors, including those in this report, could cause actual regulatory obligations (including under the Market Abuse Regulations, UK results to differ materially from those expressed or implied in any forward- Listing Rules and the Disclosure Guidance and Transparency Rules of the looking statement.",
    "id": 20,
    "annotator": 1,
    "annotation_id": 21,
    "created_at": "2024-11-05T07:20:09.921209Z",
    "updated_at": "2024-11-05T07:20:09.921209Z",
    "lead_time": 9.386
  },
  {
    "text": "Financial Conduct Authority), the Group undertakes no obligation to update 2 GSK ESG Performance Report 2023 March 2024 CEO s statement We are pleased to report sector-leading ESG performance in 2023.",
    "id": 21,
    "annotator": 1,
    "annotation_id": 22,
    "created_at": "2024-11-05T07:20:23.782435Z",
    "updated_at": "2024-11-05T07:20:23.782435Z",
    "lead_time": 13.713
  },
  {
    "text": "GSK is a global biopharma company focused on prevention and   Significant commitment to strengthening health security with 12 changing the course of disease.",
    "id": 22,
    "annotator": 1,
    "annotation_id": 23,
    "created_at": "2024-11-05T07:20:33.793752Z",
    "updated_at": "2024-11-05T07:20:33.793752Z",
    "lead_time": 9.866
  },
  {
    "text": "Our purpose is to unite science, R&D projects targeting pathogens deemed  critical  or  urgent  technology and talent to get ahead of disease together and by the WHO and the US CDC positively impact the health of 2.5 billion people.",
    "id": 23,
    "annotator": 1,
    "annotation_id": 24,
    "created_at": "2024-11-05T07:20:41.809542Z",
    "updated_at": "2024-11-05T07:20:41.809542Z",
    "lead_time": 7.869
  },
  {
    "text": "We are   Ready for phase III trials of a low-carbon version of our rescue delivering against our purpose through our R&D based on science metered dose inhaler (MDI) medication, Ventolin, to begin in of the immune system and new technologies and leveraging our 2024 with the potential to reduce greenhouse gas emissions leadership in developing new vaccines and specialty medicines from the use of this inhaler by 90%   important as our Scope 3 for infectious diseases, HIV, respiratory\/immunology and emissions increased in 2023 due to increased sales of this oncology.",
    "id": 24,
    "annotator": 1,
    "annotation_id": 25,
    "created_at": "2024-11-05T07:20:55.032503Z",
    "updated_at": "2024-11-05T07:20:55.032503Z",
    "lead_time": 13.079
  },
  {
    "text": "product We understand that being a responsible business means getting   Decreased overall water use by 24% and by 11% for sites in high ahead of disease together in the right way.",
    "id": 25,
    "label": [
      {
        "start": 82,
        "end": 99,
        "text": "overall water use",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 100,
        "end": 106,
        "text": "by 24%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 111,
        "end": 117,
        "text": "by 11%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 131,
        "end": 152,
        "text": "high ahead of disease",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 26,
    "created_at": "2024-11-05T07:21:39.065088Z",
    "updated_at": "2024-11-05T07:23:21.633241Z",
    "lead_time": 70.27999999999999
  },
  {
    "text": "Environmental, social water-stress regions, against our 2020 baseline and governance (ESG) impacts are embedded in our strategy to   At the end of the year, women held 45% of VP-and-above roles support our long-term growth, build trust with our stakeholders, globally, and we had 35.7% ethnically diverse leaders at reduce risk and deliver positive social impact.",
    "id": 26,
    "label": [
      {
        "start": 279,
        "end": 285,
        "text": " 35.7%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 168,
        "end": 171,
        "text": "45%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 157,
        "end": 162,
        "text": "women",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 286,
        "end": 312,
        "text": "ethnically diverse leaders",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 27,
    "created_at": "2024-11-05T07:22:28.781099Z",
    "updated_at": "2024-11-05T07:22:28.781099Z",
    "lead_time": 49.549
  },
  {
    "text": "VP-and-above in the US and 18.4% ethnically diverse leaders at VP-and-above in the UK Our approach is centred around six core areas: Access to healthcare; global health and health security; environment;   Set out new AI principles to shape how we use AI and machine diversity, equity and inclusion; ethical standards; and product learning to transform R&D in a way that is safe, ethical and governance.",
    "id": 27,
    "label": [
      {
        "start": 27,
        "end": 32,
        "text": "18.4%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 33,
        "end": 75,
        "text": "ethnically diverse leaders at VP-and-above",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 28,
    "created_at": "2024-11-05T07:24:13.471643Z",
    "updated_at": "2024-11-05T07:24:13.471643Z",
    "lead_time": 46.727
  },
  {
    "text": "responsible We continue to be recognised for our sector-leading ESG This report sets out the progress we are making in each area and performance.",
    "id": 28,
    "annotator": 1,
    "annotation_id": 29,
    "created_at": "2024-11-05T07:24:27.728693Z",
    "updated_at": "2024-11-05T07:24:27.728693Z",
    "lead_time": 14.097
  },
  {
    "text": "In 2023, we ranked 1st in the S&P Global Corporate supplements our Annual Report and the disclosures we publish on Sustainability Assessment for the pharmaceutical industry, and our website.",
    "id": 29,
    "label": [
      {
        "start": 19,
        "end": 22,
        "text": "1st",
        "labels": [
          "value"
        ]
      },
      {
        "start": 30,
        "end": 62,
        "text": "S&P Global Corporate supplements",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 30,
    "created_at": "2024-11-05T07:25:43.123602Z",
    "updated_at": "2024-11-05T07:25:43.123602Z",
    "lead_time": 75.238
  },
  {
    "text": "maintained leading scores in the MSCI, ISS Corporate Rating and We measure our ESG progress through our ESG Performance Sustainalytics ESG ratings.",
    "id": 30,
    "label": [
      {
        "start": 10,
        "end": 25,
        "text": " leading scores",
        "labels": [
          "value"
        ]
      },
      {
        "start": 33,
        "end": 37,
        "text": "MSCI",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 39,
        "end": 59,
        "text": "ISS Corporate Rating",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 31,
    "created_at": "2024-11-05T07:26:36.024873Z",
    "updated_at": "2024-11-05T07:26:36.024873Z",
    "lead_time": 52.732
  },
  {
    "text": "Rating, introduced in 2022 as one of our corporate key We keep our approach to ESG under constant review, responding performance indictors to drive performance and provide greater to our operating environment as it evolves.",
    "id": 31,
    "annotator": 1,
    "annotation_id": 32,
    "created_at": "2024-11-05T07:26:54.976001Z",
    "updated_at": "2024-11-05T07:26:54.976001Z",
    "lead_time": 15.169
  },
  {
    "text": "This includes the transparency in our ESG reporting.",
    "id": 32,
    "annotator": 1,
    "annotation_id": 33,
    "created_at": "2024-11-05T07:27:00.713543Z",
    "updated_at": "2024-11-05T07:27:00.713543Z",
    "lead_time": 5.588
  },
  {
    "text": "The executive leadership team rapidly changing ESG regulatory landscape and expectations of and the Board, via the Corporate Responsibility Committee, companies  ESG disclosures.",
    "id": 33,
    "annotator": 1,
    "annotation_id": 34,
    "created_at": "2024-11-05T07:27:11.084829Z",
    "updated_at": "2024-11-05T07:27:11.084829Z",
    "lead_time": 10.218
  },
  {
    "text": "In 2023, we began necessary review the metrics that make up this Rating each year to ensure preparations for new sustainability reporting requirements, they are sufficiently challenging and ambitious.",
    "id": 34,
    "annotator": 1,
    "annotation_id": 35,
    "created_at": "2024-11-05T07:27:44.607777Z",
    "updated_at": "2024-11-05T07:27:44.607777Z",
    "lead_time": 33.375
  },
  {
    "text": "including the EU s Corporate Sustainability Reporting Directive I am proud of the continued progress we have made this year, (CSRD), and committed to adopt TNFD-aligned disclosures leveraging science, technology and talent to deliver a positive based on 2025 data.",
    "id": 35,
    "annotator": 1,
    "annotation_id": 36,
    "created_at": "2024-11-05T07:27:55.592582Z",
    "updated_at": "2024-11-05T07:27:55.592582Z",
    "lead_time": 10.831
  },
  {
    "text": "impact on some of society s most urgent challenges.",
    "id": 36,
    "annotator": 1,
    "annotation_id": 37,
    "created_at": "2024-11-05T07:27:59.102926Z",
    "updated_at": "2024-11-05T07:27:59.102926Z",
    "lead_time": 3.355
  },
  {
    "text": "Our 2023 We look forward to delivering further strong ESG performance ESG Performance Rating was  on track  for the second alongside our improving outlook for sustained growth through consecutive year.",
    "id": 37,
    "annotator": 1,
    "annotation_id": 38,
    "created_at": "2024-11-05T07:28:23.076392Z",
    "updated_at": "2024-11-05T07:28:23.076392Z",
    "lead_time": 23.816
  },
  {
    "text": "More details can be found on pages 5-8.",
    "id": 38,
    "annotator": 1,
    "annotation_id": 39,
    "created_at": "2024-11-05T07:28:25.166911Z",
    "updated_at": "2024-11-05T07:28:25.166911Z",
    "lead_time": 1.93
  },
  {
    "text": "The the decade.",
    "id": 39,
    "annotator": 1,
    "annotation_id": 40,
    "created_at": "2024-11-05T07:28:27.257358Z",
    "updated_at": "2024-11-05T07:28:27.257358Z",
    "lead_time": 1.932
  },
  {
    "text": "performance against the metrics that contribute to this rating and the overall ESG Performance Rating score have been independently assured for 2023, along with other priority ESG data in this report.",
    "id": 40,
    "annotator": 1,
    "annotation_id": 41,
    "created_at": "2024-11-05T07:28:49.479086Z",
    "updated_at": "2024-11-05T07:28:49.479086Z",
    "lead_time": 22.063
  },
  {
    "text": "Our 2023 performance included:   Reaching 89 million people in lower income countries through Emma Walmsley access partnerships Chief Executive Officer   Gavi confirming the rollout of our malaria vaccine, Mosquirix, in up to 12 countries in Africa   Progressed 11 global health pipeline assets for priority WHO diseases and worked with partners to get ready to start phase III trial for our promising candidate vaccine, M72\/AS01E, against tuberculosis 3 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach Environmental, social and governance (ESG) is embedded in our strategy.",
    "id": 41,
    "annotator": 1,
    "annotation_id": 42,
    "created_at": "2024-11-05T07:29:23.887864Z",
    "updated_at": "2024-11-05T07:29:23.887864Z",
    "lead_time": 34.266
  },
  {
    "text": "It helps us deliver our purpose and supports our sustainable performance and long-term growth.",
    "id": 42,
    "annotator": 1,
    "annotation_id": 43,
    "created_at": "2024-11-05T07:30:45.825379Z",
    "updated_at": "2024-11-05T07:30:45.825379Z",
    "lead_time": 4.134
  },
  {
    "text": "We are a global biopharma company with a purpose to unite Stakeholder engagement science, technology and talent to get ahead of disease together.",
    "id": 43,
    "annotator": 1,
    "annotation_id": 44,
    "created_at": "2024-11-05T07:30:54.333714Z",
    "updated_at": "2024-11-05T07:30:54.333714Z",
    "lead_time": 8.363
  },
  {
    "text": "Our approach to ESG is guided by continuous engagement To deliver on our purpose, we need to consider ESG impacts with our stakeholders.",
    "id": 44,
    "annotator": 1,
    "annotation_id": 45,
    "created_at": "2024-11-05T07:31:03.511242Z",
    "updated_at": "2024-11-05T07:31:03.511242Z",
    "lead_time": 9.028
  },
  {
    "text": "Our key stakeholders include our patients, across everything we do, from the lab to the patient.",
    "id": 45,
    "annotator": 1,
    "annotation_id": 46,
    "created_at": "2024-11-05T07:31:09.813828Z",
    "updated_at": "2024-11-05T07:31:09.813828Z",
    "lead_time": 6.147
  },
  {
    "text": "That s why shareholders, customers and employees.",
    "id": 46,
    "annotator": 1,
    "annotation_id": 47,
    "created_at": "2024-11-05T07:31:29.884354Z",
    "updated_at": "2024-11-05T07:31:29.884354Z",
    "lead_time": 19.916
  },
  {
    "text": "We undertake formal ESG is embedded in our strategy and supports our sustainable materiality assessments every two-to-three years and engage performance and long-term growth.",
    "id": 47,
    "annotator": 1,
    "annotation_id": 48,
    "created_at": "2024-11-05T07:31:39.756233Z",
    "updated_at": "2024-11-05T07:31:39.756233Z",
    "lead_time": 9.727
  },
  {
    "text": "It helps us to build trust with our stakeholders to ensure that our ESG focus areas continue with and generate value for our stakeholders, reduce risk to our to address the most material issues for our business.",
    "id": 48,
    "annotator": 1,
    "annotation_id": 49,
    "created_at": "2024-11-05T07:32:03.347763Z",
    "updated_at": "2024-11-05T07:32:03.347763Z",
    "lead_time": 23.443
  },
  {
    "text": "operations and create positive social impact.",
    "id": 49,
    "annotator": 1,
    "annotation_id": 50,
    "created_at": "2024-11-05T07:32:08.134516Z",
    "updated_at": "2024-11-05T07:32:08.134516Z",
    "lead_time": 4.637
  },
  {
    "text": "How we engage with our stakeholders is covered throughout We have identified six ESG focus areas that address what is most this report.",
    "id": 50,
    "annotator": 1,
    "annotation_id": 51,
    "created_at": "2024-11-05T07:32:25.496497Z",
    "updated_at": "2024-11-05T07:32:25.496497Z",
    "lead_time": 17.191
  },
  {
    "text": "This includes engagement with our people (see page material to our business and the issues that matter the most to our 8), our partnerships with NGOs and our membership of cross- stakeholders.",
    "id": 51,
    "annotator": 1,
    "annotation_id": 52,
    "created_at": "2024-11-05T07:32:40.616861Z",
    "updated_at": "2024-11-05T07:32:40.616861Z",
    "lead_time": 14.964
  },
  {
    "text": "These focus areas are core to our strategy and are industry collaborations.",
    "id": 52,
    "annotator": 1,
    "annotation_id": 53,
    "created_at": "2024-11-05T07:32:44.994842Z",
    "updated_at": "2024-11-05T07:32:44.994842Z",
    "lead_time": 4.226
  },
  {
    "text": "where we can have the greatest positive impact on some of society s most urgent challenges, including those set out in the We also discuss our engagement with stakeholders in our Annual UN Sustainable Development Goals (UN SDGs).",
    "id": 53,
    "annotator": 1,
    "annotation_id": 54,
    "created_at": "2024-11-05T07:33:11.146653Z",
    "updated_at": "2024-11-05T07:33:11.146653Z",
    "lead_time": 26.002
  },
  {
    "text": "Report, which includes how our Board considers stakeholders in decision-making.",
    "id": 54,
    "annotator": 1,
    "annotation_id": 55,
    "created_at": "2024-11-05T07:33:17.638285Z",
    "updated_at": "2024-11-05T07:33:17.638285Z",
    "lead_time": 6.34
  },
  {
    "text": "(See our section 172 statement on page 123).",
    "id": 55,
    "annotator": 1,
    "annotation_id": 56,
    "created_at": "2024-11-05T07:33:20.326008Z",
    "updated_at": "2024-11-05T07:33:20.326008Z",
    "lead_time": 2.542
  },
  {
    "text": "They are: For more information on our approach to stakeholder   Access to healthcare engagement, see our policies and publications on gsk.com.",
    "id": 56,
    "annotator": 1,
    "annotation_id": 57,
    "created_at": "2024-11-05T07:33:34.296699Z",
    "updated_at": "2024-11-05T07:33:34.296699Z",
    "lead_time": 13.831
  },
  {
    "text": "Global health and health security gsk.com: Materiality   Engaging with patient organisations   Engaging   Environment with healthcare professionals   Investors hub   ESG   Diversity, equity and inclusion (DEI)   Ethical standards ESG governance   Product governance Our ESG performance is monitored regularly by both our Board- level Corporate Responsibility Committee (CRC) and the GSK These focus areas were informed by our most recent materiality Leadership Team (GLT).",
    "id": 57,
    "annotator": 1,
    "annotation_id": 58,
    "created_at": "2024-11-05T07:34:10.324138Z",
    "updated_at": "2024-11-05T07:34:10.324138Z",
    "lead_time": 35.893
  },
  {
    "text": "The CRC oversees our progress against assessment in 2022, which reaffirmed that the most material our commitments, including performance and how we are issues for our business were well aligned with our six ESG focus meeting the expectations of our stakeholders.",
    "id": 58,
    "annotator": 1,
    "annotation_id": 59,
    "created_at": "2024-11-05T07:34:23.364860Z",
    "updated_at": "2024-11-05T07:34:23.364860Z",
    "lead_time": 12.896
  },
  {
    "text": "It collaborates with areas.",
    "id": 59,
    "annotator": 1,
    "annotation_id": 60,
    "created_at": "2024-11-05T07:34:26.312066Z",
    "updated_at": "2024-11-05T07:34:26.312066Z",
    "lead_time": 2.79
  },
  {
    "text": "We recognise that being a responsible business is not a other Board committees, such as the Remuneration Committee static requirement.",
    "id": 60,
    "annotator": 1,
    "annotation_id": 61,
    "created_at": "2024-11-05T07:34:36.382958Z",
    "updated_at": "2024-11-05T07:34:36.382958Z",
    "lead_time": 9.928
  },
  {
    "text": "We began work on our double materiality and the Audit & Risk Committee, to ensure that ESG performance assessment, which will be completed in 2024.",
    "id": 61,
    "annotator": 1,
    "annotation_id": 62,
    "created_at": "2024-11-05T07:34:50.900857Z",
    "updated_at": "2024-11-05T07:34:50.900857Z",
    "lead_time": 14.359
  },
  {
    "text": "This means that we is integrated across the business.",
    "id": 62,
    "annotator": 1,
    "annotation_id": 63,
    "created_at": "2024-11-05T07:34:55.086370Z",
    "updated_at": "2024-11-05T07:34:55.086370Z",
    "lead_time": 4.036
  },
  {
    "text": "will continue to evolve our approach in response to the rapidly changing operating environment and strive for continuous The GLT and senior management are responsible for delivery improvement to ensure we maintain strong ESG performance.",
    "id": 63,
    "annotator": 1,
    "annotation_id": 64,
    "created_at": "2024-11-05T07:35:04.706743Z",
    "updated_at": "2024-11-05T07:35:04.706743Z",
    "lead_time": 9.47
  },
  {
    "text": "against our six focus areas, and report regularly to the CRC on progress (see pages pages 128-129 of our Annual Report).",
    "id": 64,
    "annotator": 1,
    "annotation_id": 65,
    "created_at": "2024-11-05T07:35:09.722706Z",
    "updated_at": "2024-11-05T07:35:09.722706Z",
    "lead_time": 4.874
  },
  {
    "text": "gsk.com: Our materiality assessment ESG-aligned remuneration Our contribution to the UN SDGs In 2022, the Remuneration Committee, with the support of the The United Nations' 17 Sustainable Development Goals (SDGs) CRC, introduced ESG performance measures into both our set out a vision for ending poverty, hunger and inequality, and short- and long-term incentive plans, to reward delivery of key protecting the planet s natural resources, by 2030.",
    "id": 65,
    "annotator": 1,
    "annotation_id": 66,
    "created_at": "2024-11-05T07:37:14.015778Z",
    "updated_at": "2024-11-05T07:37:14.015778Z",
    "lead_time": 124.146
  },
  {
    "text": "The six ESG ESG measures.",
    "id": 66,
    "annotator": 1,
    "annotation_id": 67,
    "created_at": "2024-11-05T07:37:15.860171Z",
    "updated_at": "2024-11-05T07:37:15.860171Z",
    "lead_time": 1.689
  },
  {
    "text": "The ESG element consists of: human capital areas that we have identified, and which are core to our strategy, management in the form of diversity, equity and inclusion are where we can have the greatest positive impact on some of aspirations, which forms 10% of the annual bonus opportunity for society s most urgent challenges, including those set out in the the GLT; and our climate and nature ambitions, which form 10% of SDGs.",
    "id": 67,
    "annotator": 1,
    "annotation_id": 68,
    "created_at": "2024-11-05T07:38:00.692933Z",
    "updated_at": "2024-11-05T07:38:00.692933Z",
    "lead_time": 44.683
  },
  {
    "text": "As a global biopharma company, we can make the most our long-term incentive plan opportunity for senior leaders.",
    "id": 68,
    "annotator": 1,
    "annotation_id": 69,
    "created_at": "2024-11-05T07:38:07.074074Z",
    "updated_at": "2024-11-05T07:38:07.075074Z",
    "lead_time": 6.223
  },
  {
    "text": "These significant contribution to SDG3: Good Health and Wellbeing.",
    "id": 69,
    "annotator": 1,
    "annotation_id": 70,
    "created_at": "2024-11-05T07:38:10.098526Z",
    "updated_at": "2024-11-05T07:38:10.098526Z",
    "lead_time": 2.88
  },
  {
    "text": "metrics align to our ESG Performance Rating.",
    "id": 70,
    "annotator": 1,
    "annotation_id": 71,
    "created_at": "2024-11-05T07:38:16.378234Z",
    "updated_at": "2024-11-05T07:38:16.378234Z",
    "lead_time": 6.135
  },
  {
    "text": "See page 139 of our We publish our contribution to the SDGs on our website.",
    "id": 71,
    "annotator": 1,
    "annotation_id": 72,
    "created_at": "2024-11-05T07:38:25.259348Z",
    "updated_at": "2024-11-05T07:38:25.259348Z",
    "lead_time": 8.732
  },
  {
    "text": "Annual Report for further information.",
    "id": 72,
    "annotator": 1,
    "annotation_id": 73,
    "created_at": "2024-11-05T07:38:27.829372Z",
    "updated_at": "2024-11-05T07:38:27.829372Z",
    "lead_time": 2.424
  },
  {
    "text": "gsk.com: Our contribution to the SDGs 4 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach continued Our ESG Performance Rating Our ESG Performance Rating helps us integrate ESG into the How we assess performance delivery of our strategy and allows us to measure and verify the The GLT is accountable for delivering progress against our ESG progress we are making.",
    "id": 73,
    "annotator": 1,
    "annotation_id": 74,
    "created_at": "2024-11-05T07:39:08.120646Z",
    "updated_at": "2024-11-05T07:39:08.120646Z",
    "lead_time": 40.136
  },
  {
    "text": "The rating is one of our corporate KPIs metrics and regularly reviews performance along with the Board s and measures progress against key metrics aligned to each of CRC.",
    "id": 74,
    "annotator": 1,
    "annotation_id": 75,
    "created_at": "2024-11-05T07:39:31.331199Z",
    "updated_at": "2024-11-05T07:39:31.331199Z",
    "lead_time": 23.052
  },
  {
    "text": "This helps to ensure that accountability for ESG performance our six focus areas.",
    "id": 75,
    "annotator": 1,
    "annotation_id": 76,
    "created_at": "2024-11-05T07:39:35.373380Z",
    "updated_at": "2024-11-05T07:39:35.373380Z",
    "lead_time": 3.887
  },
  {
    "text": "In 2023, this included 22 metrics, which are is embedded within the business.",
    "id": 76,
    "annotator": 1,
    "annotation_id": 77,
    "created_at": "2024-11-05T07:39:39.041167Z",
    "updated_at": "2024-11-05T07:39:39.041167Z",
    "lead_time": 3.498
  },
  {
    "text": "Each individual metric is summarised on pages 6-8.",
    "id": 77,
    "annotator": 1,
    "annotation_id": 78,
    "created_at": "2024-11-05T07:39:42.301958Z",
    "updated_at": "2024-11-05T07:39:42.301958Z",
    "lead_time": 3.102
  },
  {
    "text": "assessed as either: on track (the metric has been met or We continue to evolve our ESG Performance Rating to ensure it exceeded); on track with work to do (at least 80% of the metric meets the expectations of our stakeholders.",
    "id": 78,
    "annotator": 1,
    "annotation_id": 79,
    "created_at": "2024-11-05T07:39:52.172812Z",
    "updated_at": "2024-11-05T07:39:52.172812Z",
    "lead_time": 9.715
  },
  {
    "text": "The executive has been achieved); or off track (metric has been missed by leadership team and the Board, via the Corporate Responsibility more than 20%).",
    "id": 79,
    "annotator": 1,
    "annotation_id": 80,
    "created_at": "2024-11-05T07:40:04.921719Z",
    "updated_at": "2024-11-05T07:40:04.921719Z",
    "lead_time": 12.588
  },
  {
    "text": "Committee, review the metrics that make up this Rating each year We calculate the overall ESG Performance Rating by aggregating to ensure they are sufficiently challenging and ambitious.",
    "id": 80,
    "annotator": 1,
    "annotation_id": 81,
    "created_at": "2024-11-05T07:40:14.562022Z",
    "updated_at": "2024-11-05T07:40:14.562022Z",
    "lead_time": 9.487
  },
  {
    "text": "This performance across all metrics into a single score to illustrate year, we have removed two metrics, relating to Access and Ethical whether we are on track, on track with work to do, or off track.",
    "id": 81,
    "annotator": 1,
    "annotation_id": 82,
    "created_at": "2024-11-05T07:40:24.532754Z",
    "updated_at": "2024-11-05T07:40:24.532754Z",
    "lead_time": 9.82
  },
  {
    "text": "standards, and added one relating to antimicrobial (AMR) This rating is defined below: resistance.",
    "id": 82,
    "annotator": 1,
    "annotation_id": 83,
    "created_at": "2024-11-05T07:40:29.415805Z",
    "updated_at": "2024-11-05T07:40:29.415805Z",
    "lead_time": 4.728
  },
  {
    "text": "We met one of our 2022 metrics relating to Access by developing and publishing pricing and access principles so it is no On track: 70% or more of all metrics are on track longer required.",
    "id": 83,
    "annotator": 1,
    "annotation_id": 84,
    "created_at": "2024-11-05T07:40:40.303188Z",
    "updated_at": "2024-11-05T07:40:40.303188Z",
    "lead_time": 10.739
  },
  {
    "text": "We have also removed one of our Ethical On track with work to do: more than 50% of all metrics are either standards metrics that tracks the number of employees leaving on track, or on track with work to do GSK for misconduct.",
    "id": 84,
    "annotator": 1,
    "annotation_id": 85,
    "created_at": "2024-11-05T07:41:15.237848Z",
    "updated_at": "2024-11-05T07:41:15.237848Z",
    "lead_time": 34.783
  },
  {
    "text": "Increases or decreases in this number could Off track: more than 50% of all metrics are off track indicate either a higher\/lower number of breaches or stronger\/ weaker enforcement of our processes, so setting a threshold is not an effective measure for success in upholding our standards.",
    "id": 85,
    "annotator": 1,
    "annotation_id": 86,
    "created_at": "2024-11-05T07:41:36.237672Z",
    "updated_at": "2024-11-05T07:41:36.237672Z",
    "lead_time": 20.853
  },
  {
    "text": "We continue to monitor this data internally and publish it externally (see page 32).",
    "id": 86,
    "annotator": 1,
    "annotation_id": 87,
    "created_at": "2024-11-05T07:41:43.268743Z",
    "updated_at": "2024-11-05T07:41:43.268743Z",
    "lead_time": 6.88
  },
  {
    "text": "We have three additional metrics which provide a strong measure of our commitment to ethical standards.",
    "id": 87,
    "annotator": 1,
    "annotation_id": 88,
    "created_at": "2024-11-05T07:41:57.387318Z",
    "updated_at": "2024-11-05T07:41:57.387318Z",
    "lead_time": 13.964
  },
  {
    "text": "We have added a metric within Global health and health security, focused on AMR.",
    "id": 88,
    "annotator": 1,
    "annotation_id": 89,
    "created_at": "2024-11-05T07:42:02.904832Z",
    "updated_at": "2024-11-05T07:42:02.904832Z",
    "lead_time": 5.357
  },
  {
    "text": "AMR is an urgent public health threat, and we have seen increased stakeholder interest in our approach.",
    "id": 89,
    "annotator": 1,
    "annotation_id": 90,
    "created_at": "2024-11-05T07:42:13.118989Z",
    "updated_at": "2024-11-05T07:42:13.118989Z",
    "lead_time": 10.059
  },
  {
    "text": "We updated our biodiversity target which measured the number of high risk materials implementing sustainable sourcing roadmaps as we achieved it in 2022.",
    "id": 90,
    "annotator": 1,
    "annotation_id": 91,
    "created_at": "2024-11-05T07:42:25.211653Z",
    "updated_at": "2024-11-05T07:42:25.211653Z",
    "lead_time": 11.94
  },
  {
    "text": "Our new target focuses on deforestation free sourcing of paper and palm oil.",
    "id": 91,
    "annotator": 1,
    "annotation_id": 92,
    "created_at": "2024-11-05T07:42:45.944399Z",
    "updated_at": "2024-11-05T07:42:45.944399Z",
    "lead_time": 20.591
  },
  {
    "text": "5 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach continued 2023 ESG Performance Rating Our 2023 ESG Performance Rating is on track, based on 95% of all performance metrics being met or exceeded.",
    "id": 92,
    "annotator": 1,
    "annotation_id": 93,
    "created_at": "2024-11-05T07:43:01.975007Z",
    "updated_at": "2024-11-05T07:43:01.975007Z",
    "lead_time": 15.878
  },
  {
    "text": "Assessment of performance against our annual targets has been reviewed, and the overall ESG Performance Rating score has been subject to independent limited assurance for 2023 (see page 55).",
    "id": 93,
    "annotator": 1,
    "annotation_id": 94,
    "created_at": "2024-11-05T07:43:09.945424Z",
    "updated_at": "2024-11-05T07:43:09.945424Z",
    "lead_time": 7.821
  },
  {
    "text": "Our ESG focus areas Our six commitments Our metrics for 2023 Our progress in 2023 Access Make our products   Progress towards our 2030 goal of reaching In 2023, we reached 89 million people available at value- 1.3 billion people in lower income countries with our vaccines and antiretrovirals and based prices that are with our products made 989 million doses of our products sustainable for our available in lower income countries business and implement access strategies that increase the use of our medicines and vaccines to treat and protect underserved people Global health Develop novel   Progress six Global Health pipeline assets to Progressed 11 Global Health pipeline and health products and address priority WHO diseases assets to address priority WHO diseases security technologies to treat including malaria and tuberculosis (TB) and prevent priority   Progress 8 R&D projects that address Progressed 12 active R&D projects that diseases, including pathogens prioritised by the WHO address pathogens considered critical pandemic threats and CDC as posing the highest level and\/or urgent threats due to drug of concern due to drug resistance (critical and\/ resistance or urgent threats) Environment Commit to a net zero, Climate nature positive,   Operational emissions reduction Reduced our operational emissions by healthier planet with (Scope 1 and 2 market-based emissions)1 10% from 2022 ambitious goals set for 2030 and 2045   Industrialisation of low-carbon Ventolin Progressed our low-carbon Ventolin initiated, and clinical and non-clinical data programme with the potential to reduce available to support regulatory submissions greenhouse gas emissions from the inhaler by 90%.",
    "id": 94,
    "annotator": 1,
    "annotation_id": 95,
    "created_at": "2024-11-05T07:44:08.928953Z",
    "updated_at": "2024-11-05T07:44:08.928953Z",
    "lead_time": 58.836
  },
  {
    "text": "Phase III trials of our next generation, lower-carbon propellant will begin in 2024 and, if successful, regulatory submissions will start in 2025   Percentage of carbon offset volume in 35% of carbon offset volume in project project pipeline2 pipeline Water   Average of the percentage of GSK sites and Average of 87% of all sites and key suppliers compliant with wastewater active suppliers compliant with AMR Alliance pharmaceutical ingredient limits and the and API Wastewater discharge limits.",
    "id": 95,
    "annotator": 1,
    "annotation_id": 96,
    "created_at": "2024-11-05T07:44:32.200418Z",
    "updated_at": "2024-11-05T07:44:32.200418Z",
    "lead_time": 23.114
  },
  {
    "text": "percentage of sites and suppliers that are This is down from 94% in 2022, primarily compliant with the AMR Industry Alliance due a scope expansion to include more Common Antibiotic Manufacturing Framework API suppliers and discharge limits Waste and materials   Operational waste and material reduction at 1% reduction of operational waste and GSK sites materials at our sites 1 S cope 1 emissions cover emissions from the direct combustion of fuels on our sites to generate heat and electricity, emissions from our sales fleet vehicles, fugitive losses of propellant during the manufacturing of inhalers and losses from refrigerants used in GSK-owned ancillary equipment and emissions from on-site waste treatment.",
    "id": 96,
    "annotator": 1,
    "annotation_id": 97,
    "created_at": "2024-11-05T07:45:30.213957Z",
    "updated_at": "2024-11-05T07:45:30.213957Z",
    "lead_time": 57.858
  },
  {
    "text": "Scope 2 emissions include any purchased electricity, steam, compressed air and chilled water.",
    "id": 97,
    "annotator": 1,
    "annotation_id": 98,
    "created_at": "2024-11-05T07:45:34.987288Z",
    "updated_at": "2024-11-05T07:45:34.987288Z",
    "lead_time": 4.625
  },
  {
    "text": "2 Percentage of 2.1 MtCO2 offsetting volume in 2030 project pipeline.",
    "id": 98,
    "annotator": 1,
    "annotation_id": 99,
    "created_at": "2024-11-05T07:45:46.694884Z",
    "updated_at": "2024-11-05T07:45:46.694884Z",
    "lead_time": 11.554
  },
  {
    "text": "6 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach continued Our ESG focus areas Our six commitments Our metrics for 2023 Our progress in 2023 Environment Biodiversity   Percentage of paper and palm oil 86% of our paper packaging was derived deforestation free from certified sources or from recycled raw materials and 98% of our core palm oil materials were certified by third- parties as being from sustainable sources.",
    "id": 99,
    "label": [
      {
        "start": 306,
        "end": 309,
        "text": "86%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 273,
        "end": 305,
        "text": "Percentage of paper and palm oil",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 395,
        "end": 417,
        "text": "recycled raw materials",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 422,
        "end": 425,
        "text": "98%",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 100,
    "created_at": "2024-11-05T07:47:18.498315Z",
    "updated_at": "2024-11-05T07:47:18.498315Z",
    "lead_time": 91.646
  },
  {
    "text": "Diversity, equity Enhance recruitment   100% of phase III trials initiated in 2023 that 100% of phase III trials initiated in 2023 and inclusion of diverse patient have proactive plans in place designed to had proactive demographic plans in populations in our enrol appropriately diverse trial participants, place clinical trials; create consistent with the disease epidemiology an inclusive, equitable and Update towards 2025 aspirations through fair and equitable opportunities: diverse workplace; and support diverse   aspire to have women hold at least 45% Women held 45% of VP-and-above roles communities of VP-and-above roles globally by the end globally, compared with 42% in 2022 of 2025   aspire to have at least 30% ethnically 35.7% ethnically diverse leaders at diverse leaders in our roles at VP-and- VP-and-above in the US compared with above in the US by the end of 2025, and 31.3% in 2022.",
    "id": 100,
    "label": [
      {
        "start": 557,
        "end": 560,
        "text": "45%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 537,
        "end": 542,
        "text": "women",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 737,
        "end": 742,
        "text": "35.7%",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 743,
        "end": 769,
        "text": "ethnically diverse leaders",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 101,
    "created_at": "2024-11-05T07:47:55.475198Z",
    "updated_at": "2024-11-05T07:50:22.231329Z",
    "lead_time": 103.785
  },
  {
    "text": "We had 8.1% Black or increase the percentage of Black or African African American leaders at VP-and- American, and Hispanic or Latinx VP-and- above compared with 8.6% in 2022.",
    "id": 101,
    "label": [
      {
        "start": 7,
        "end": 11,
        "text": "8.1%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 48,
        "end": 89,
        "text": "Black or African African American leaders",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 102,
    "created_at": "2024-11-05T07:48:06.369722Z",
    "updated_at": "2024-11-05T07:50:54.562878Z",
    "lead_time": 40.71
  },
  {
    "text": "above leaders year on year We had 6.4 % Hispanic or Latinx leaders at VP-and-above compared with 6.4% in 2022   aspire to have at least 18% ethnically 18.4% ethnically diverse leaders at diverse leaders in our roles at VP-and- VP-and-above in the UK compared with above in the UK by the end of 2025, and 14.3% in 2022.",
    "id": 102,
    "label": [
      {
        "start": 34,
        "end": 39,
        "text": "6.4 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 40,
        "end": 66,
        "text": "Hispanic or Latinx leaders",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 103,
    "created_at": "2024-11-05T07:48:15.049715Z",
    "updated_at": "2024-11-05T07:51:19.682513Z",
    "lead_time": 31.975
  },
  {
    "text": "We had 1.9% Black leaders increase the percentage of Black VP-and- at VP-and-above compared with 1.6% above leaders year on year in 2022   Improve year-on-year spend with US-based Increased year-on-year spend with certified diverse-owned suppliers US-based certified diverse-owned suppliers Ethical Promote ethical   100% of employees and complementary 100% of employees and 99% of standards behaviour across our workers that complete GSK s 2023 mandatory complementary workers completed business by training GSK's 2023 mandatory training supporting our   Percentage of employees who believe they 83% of employees believe they  can and employees to do the  can and do Speak Up if things don t feel do Speak Up if things don t feel right' right thing and right  is above the general industry working with benchmark1 suppliers that share our standards and   80% of direct high-risk suppliers that 89% of direct high-risk suppliers operate in a achieve GSK s minimum EcoVadis score or achieved our minimum EcoVadis score or responsible way have an improvement plan in place have an improvement plan in place 1 The general industry benchmark is 66% according to 2023 research by KornFerry.",
    "id": 103,
    "label": [
      {
        "start": 7,
        "end": 11,
        "text": "1.9%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 12,
        "end": 25,
        "text": "Black leaders",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 104,
    "created_at": "2024-11-05T07:48:31.571375Z",
    "updated_at": "2024-11-05T07:52:04.764899Z",
    "lead_time": 58.925
  },
  {
    "text": "7 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach continued Our ESG focus areas Our six commitments Our metrics for 2023 Our progress in 2023 Product Commit to   Average number of critical and major Received no critical findings from the governance maintaining robust findings per inspection by FDA\/MHRA\/ MHRA and EMA regulators in 2023 quality and safety EMA regulators processes, and using   Percentage of inspections from all 100% of inspections had no critical data and new regulators with no critical findings or official findings or official action indicated technologies action indicated responsibly   Number of FDA warning letters Zero FDA warning letters   Total number of Class I\/II external product 5 product recalls.",
    "id": 104,
    "annotator": 1,
    "annotation_id": 105,
    "created_at": "2024-11-05T07:52:35.435144Z",
    "updated_at": "2024-11-05T07:52:35.435144Z",
    "lead_time": 29.566
  },
  {
    "text": "In these instances, we recalls across all markets engaged with regulators and acted quickly to prioritise patient safety.",
    "id": 105,
    "annotator": 1,
    "annotation_id": 106,
    "created_at": "2024-11-05T07:52:42.840681Z",
    "updated_at": "2024-11-05T07:52:42.840681Z",
    "lead_time": 7.192
  },
  {
    "text": "Register and disclose all human subject Registered and disclosed all human research of GSK products.",
    "id": 106,
    "annotator": 1,
    "annotation_id": 107,
    "created_at": "2024-11-05T07:52:55.203188Z",
    "updated_at": "2024-11-05T07:52:55.203188Z",
    "lead_time": 12.176
  },
  {
    "text": "Specifically, register subject research of GSK products protocol summaries for studies initiated in 2023; and disclose results summaries for studies with results due in 2023 Our culture and people Our purpose   to unite science, technology and talent to get Helping people thrive Ahead of disease Together   puts our people at the heart of Making GSK a place where people thrive is core to our Ahead our success.",
    "id": 107,
    "annotator": 1,
    "annotation_id": 108,
    "created_at": "2024-11-05T07:53:07.085263Z",
    "updated_at": "2024-11-05T07:53:07.085263Z",
    "lead_time": 11.682
  },
  {
    "text": "Together ambition.",
    "id": 108,
    "annotator": 1,
    "annotation_id": 109,
    "created_at": "2024-11-05T07:53:08.679933Z",
    "updated_at": "2024-11-05T07:53:08.679933Z",
    "lead_time": 1.401
  },
  {
    "text": "While thriving is different for each individual, there are common themes that matter to everyone.",
    "id": 109,
    "annotator": 1,
    "annotation_id": 110,
    "created_at": "2024-11-05T07:53:11.672534Z",
    "updated_at": "2024-11-05T07:53:11.672534Z",
    "lead_time": 2.816
  },
  {
    "text": "Firstly, a belief Our culture in our purpose and a desire to live our culture and contribute to We are committed to making GSK a place where people can delivering our ambition.",
    "id": 110,
    "annotator": 1,
    "annotation_id": 111,
    "created_at": "2024-11-05T08:14:23.895540Z",
    "updated_at": "2024-11-05T08:14:23.895540Z",
    "lead_time": 1271.703
  },
  {
    "text": "Secondly, feeling included and able to be thrive, with a culture where we are all ambitious for patients, yourself with opportunities to keep growing, with the support, accountable for impact, and do the right thing.",
    "id": 111,
    "annotator": 1,
    "annotation_id": 112,
    "created_at": "2024-11-05T09:59:04.280204Z",
    "updated_at": "2024-11-05T09:59:04.280204Z",
    "lead_time": 0.997
  },
  {
    "text": "This means we feedback and space needed to succeed.",
    "id": 112,
    "annotator": 1,
    "annotation_id": 113,
    "created_at": "2024-11-05T09:59:09.666610Z",
    "updated_at": "2024-11-05T09:59:09.666610Z",
    "lead_time": 5.236
  },
  {
    "text": "And finally, feeling support our people to do things better and faster, focusing on good, with positive mental, physical, financial and social what matters most.",
    "id": 113,
    "annotator": 1,
    "annotation_id": 114,
    "created_at": "2024-11-05T09:59:13.859149Z",
    "updated_at": "2024-11-05T09:59:13.859149Z",
    "lead_time": 4.031
  },
  {
    "text": "It means setting clear objectives, creating wellbeing.",
    "id": 114,
    "annotator": 1,
    "annotation_id": 115,
    "created_at": "2024-11-05T09:59:15.684703Z",
    "updated_at": "2024-11-05T09:59:15.684703Z",
    "lead_time": 1.664
  },
  {
    "text": "This means GSK should be a place where people feel accountability for results and giving everyone the support and welcome and valued, in an environment (including our policies, space they need to succeed.",
    "id": 115,
    "annotator": 1,
    "annotation_id": 116,
    "created_at": "2024-11-05T09:59:19.119560Z",
    "updated_at": "2024-11-05T09:59:19.119560Z",
    "lead_time": 3.274
  },
  {
    "text": "workplaces and ways of working) that enables and supports them to deliver at their best.",
    "id": 116,
    "annotator": 1,
    "annotation_id": 117,
    "created_at": "2024-11-05T09:59:20.713106Z",
    "updated_at": "2024-11-05T09:59:20.713106Z",
    "lead_time": 1.429
  },
  {
    "text": "It means doing everything responsibly with integrity and care, because people and patients around the world count on us.",
    "id": 117,
    "annotator": 1,
    "annotation_id": 118,
    "created_at": "2024-11-05T09:59:29.423194Z",
    "updated_at": "2024-11-05T09:59:29.423194Z",
    "lead_time": 8.549
  },
  {
    "text": "Our Welcoming and developing outstanding people culture is embedded in everything we do from We are committed to developing outstanding people and giving our recruitment and onboarding, training and development, to our them opportunities to grow.",
    "id": 118,
    "annotator": 1,
    "annotation_id": 119,
    "created_at": "2024-11-05T09:59:39.148523Z",
    "updated_at": "2024-11-05T09:59:39.148523Z",
    "lead_time": 9.558
  },
  {
    "text": "We expect all our people to have an assessments of performance and promotion.",
    "id": 119,
    "annotator": 1,
    "annotation_id": 120,
    "created_at": "2024-11-05T09:59:42.334038Z",
    "updated_at": "2024-11-05T09:59:42.334038Z",
    "lead_time": 3.017
  },
  {
    "text": "agreed development plan, regardless of grade or role, based on a Our Code sets out our culture as well as the commitments GSK conversation to understand what space and support they need to and our people make so we can deliver on our ambition in the succeed.",
    "id": 120,
    "annotator": 1,
    "annotation_id": 121,
    "created_at": "2024-11-05T09:59:49.733611Z",
    "updated_at": "2024-11-05T09:59:49.733611Z",
    "lead_time": 7.25
  },
  {
    "text": "We continue to invest in learning and development right way.",
    "id": 121,
    "annotator": 1,
    "annotation_id": 122,
    "created_at": "2024-11-05T09:59:54.354354Z",
    "updated_at": "2024-11-05T09:59:54.354354Z",
    "lead_time": 4.463
  },
  {
    "text": "Our people sign up to initiatives which everyone can access through our Keep Growing The Code annually and personally commit  I m in .",
    "id": 122,
    "annotator": 1,
    "annotation_id": 123,
    "created_at": "2024-11-05T10:01:04.826272Z",
    "updated_at": "2024-11-05T10:01:04.826272Z",
    "lead_time": 70.295
  },
  {
    "text": "Campus, our training and knowledge sharing platform.",
    "id": 123,
    "annotator": 1,
    "annotation_id": 124,
    "created_at": "2024-11-05T10:01:18.235687Z",
    "updated_at": "2024-11-05T10:01:18.235687Z",
    "lead_time": 13.259
  },
  {
    "text": "gsk.com: See The Code on gsk.com Digital and technology remain core to our purpose and delivery of our ambitions.",
    "id": 124,
    "annotator": 1,
    "annotation_id": 125,
    "created_at": "2024-11-05T10:01:21.362478Z",
    "updated_at": "2024-11-05T10:01:21.362478Z",
    "lead_time": 2.966
  },
  {
    "text": "We have built our people's skills in this area with global events such as DataCon, where all employees can experience immersive sessions to see first-hand how to apply digital, data and tech tools including generative AI to become more digitally fluent.",
    "id": 125,
    "annotator": 1,
    "annotation_id": 126,
    "created_at": "2024-11-05T10:01:30.130672Z",
    "updated_at": "2024-11-05T10:01:30.130672Z",
    "lead_time": 8.627
  },
  {
    "text": "This year, more than 7,000 employees took part from every business unit and 28 countries.",
    "id": 126,
    "annotator": 1,
    "annotation_id": 127,
    "created_at": "2024-11-05T10:01:37.712738Z",
    "updated_at": "2024-11-05T10:01:37.712738Z",
    "lead_time": 7.425
  },
  {
    "text": "In our Data Academy, employees can access resources and online training.",
    "id": 127,
    "annotator": 1,
    "annotation_id": 128,
    "created_at": "2024-11-05T10:01:51.197548Z",
    "updated_at": "2024-11-05T10:01:51.198548Z",
    "lead_time": 13.336
  },
  {
    "text": "We've run programmes to develop our senior leaders' leadership skills in the digital age.",
    "id": 128,
    "annotator": 1,
    "annotation_id": 129,
    "created_at": "2024-11-05T10:01:53.869107Z",
    "updated_at": "2024-11-05T10:01:53.869107Z",
    "lead_time": 2.525
  },
  {
    "text": "We've also piloted a career hub using AI to match employees with mentors, projects and potential job opportunities.",
    "id": 129,
    "label": [
      {
        "start": 21,
        "end": 31,
        "text": "career hub",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 21,
        "end": 31,
        "text": "career hub",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 130,
    "created_at": "2024-11-05T10:02:13.342953Z",
    "updated_at": "2024-11-05T10:02:13.342953Z",
    "lead_time": 19.336
  },
  {
    "text": "We will scale this up in 2024.",
    "id": 130,
    "annotator": 1,
    "annotation_id": 131,
    "created_at": "2024-11-05T10:02:19.111992Z",
    "updated_at": "2024-11-05T10:02:19.111992Z",
    "lead_time": 5.599
  },
  {
    "text": "8 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Our approach continued In 2023, we enhanced our onboarding experience for new joiners Performance with Choice by introducing monthly live virtual sessions with our CEO and Performance with Choice, our approach to hybrid working for other senior leaders.",
    "id": 131,
    "annotator": 1,
    "annotation_id": 132,
    "created_at": "2024-11-05T10:02:27.752364Z",
    "updated_at": "2024-11-05T10:02:27.752364Z",
    "lead_time": 8.495
  },
  {
    "text": "By having access to senior global leaders those in office-based roles (about a quarter of our people), allows from the beginning of their career with us, we aim to provide a the right balance of on-site and remote working.",
    "id": 132,
    "annotator": 1,
    "annotation_id": 133,
    "created_at": "2024-11-05T10:02:38.436181Z",
    "updated_at": "2024-11-05T10:02:38.436181Z",
    "lead_time": 10.528
  },
  {
    "text": "We are clear in more intimate connection to GSK and the patients we serve, our expectations that people take accountability to spend creating emotional connection with our purpose, strategy and enough time together in person, while maintaining flexibility, to culture, to complement ongoing local onboarding activities.",
    "id": 133,
    "annotator": 1,
    "annotation_id": 134,
    "created_at": "2024-11-05T10:02:50.533493Z",
    "updated_at": "2024-11-05T10:02:50.533493Z",
    "lead_time": 11.947
  },
  {
    "text": "help us continue to build our sense of community and connectedness, enable development and achieve our Ahead Supporting our people managers Together ambitions.",
    "id": 134,
    "annotator": 1,
    "annotation_id": 135,
    "created_at": "2024-11-05T10:02:54.883330Z",
    "updated_at": "2024-11-05T10:02:54.883330Z",
    "lead_time": 4.194
  },
  {
    "text": "Data from our annual employee survey shows Our people managers play a crucial role in helping their teams to broad support for our approach and expectations.",
    "id": 135,
    "annotator": 1,
    "annotation_id": 136,
    "created_at": "2024-11-05T10:03:02.793614Z",
    "updated_at": "2024-11-05T10:03:02.793614Z",
    "lead_time": 7.772
  },
  {
    "text": "thrive and connecting the contributions the team makes to the patient and GSK's broader impact.",
    "id": 136,
    "annotator": 1,
    "annotation_id": 137,
    "created_at": "2024-11-05T10:03:05.990780Z",
    "updated_at": "2024-11-05T10:03:05.990780Z",
    "lead_time": 3.057
  },
  {
    "text": "We expect people managers Recognising and rewarding our people to motivate, focus, care for and develop their teams and we Sharing our success and recognising and rewarding our people deliver training anchored in these four areas.",
    "id": 137,
    "annotator": 1,
    "annotation_id": 138,
    "created_at": "2024-11-05T10:03:14.385309Z",
    "updated_at": "2024-11-05T10:03:14.385309Z",
    "lead_time": 8.137
  },
  {
    "text": "In 2023 all of our VPs equitably, not just on the progress we have made but how we were invited to attend a four day in-person event called Leading have made it, continues to be an important part of our culture.",
    "id": 138,
    "annotator": 1,
    "annotation_id": 139,
    "created_at": "2024-11-05T10:03:26.804158Z",
    "updated_at": "2024-11-05T10:03:26.804158Z",
    "lead_time": 12.269
  },
  {
    "text": "In Leaders, a programme to help leaders bring out the best in their addition to our bonus scheme that rewards performance across teams and foster the culture we need to succeed together.",
    "id": 139,
    "annotator": 1,
    "annotation_id": 140,
    "created_at": "2024-11-05T10:03:31.835507Z",
    "updated_at": "2024-11-05T10:03:31.835507Z",
    "lead_time": 4.854
  },
  {
    "text": "We the company, each year we award 10% of our people with extra also continue to invest in growing the next generation of senior  Ahead Together  awards for delivering exceptional performance leaders to support our talent and succession needs through in line with being accountable for their impact, ambitious for bespoke development interventions, equipping them with patients and doing the right thing.",
    "id": 140,
    "annotator": 1,
    "annotation_id": 141,
    "created_at": "2024-11-05T10:04:11.315983Z",
    "updated_at": "2024-11-05T10:04:11.315983Z",
    "lead_time": 39.314
  },
  {
    "text": "And we identify 5% of people leadership skills for the future.",
    "id": 141,
    "label": [
      {
        "start": 22,
        "end": 61,
        "text": "people leadership skills for the future",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 16,
        "end": 18,
        "text": "5%",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 142,
    "created_at": "2024-11-05T10:04:28.517541Z",
    "updated_at": "2024-11-05T10:04:28.517541Z",
    "lead_time": 17.058
  },
  {
    "text": "as having missed performance for those not delivering on their objectives or living the culture.",
    "id": 142,
    "annotator": 1,
    "annotation_id": 143,
    "created_at": "2024-11-05T10:04:31.482877Z",
    "updated_at": "2024-11-05T10:04:31.482877Z",
    "lead_time": 2.805
  },
  {
    "text": "Maintaining momentum on diversity, equity and inclusion How our people experience GSK We are continuing our focus on building a more diverse To ensure we continue to listen to our people, we regularly organisation and an equitable and inclusive culture so that measure their experience of GSK as a place to work.",
    "id": 143,
    "annotator": 1,
    "annotation_id": 144,
    "created_at": "2024-11-05T10:04:40.084138Z",
    "updated_at": "2024-11-05T10:04:40.084138Z",
    "lead_time": 8.457
  },
  {
    "text": "This includes everyone feels welcome, valued and included.",
    "id": 144,
    "annotator": 1,
    "annotation_id": 145,
    "created_at": "2024-11-05T10:04:42.381301Z",
    "updated_at": "2024-11-05T10:04:42.381301Z",
    "lead_time": 2.145
  },
  {
    "text": "By taking steps to an annual survey for all employees featuring questions on ensure equal opportunity and non-discrimination, we are engagement, confidence, inclusivity, our culture focus areas and delivering on our ambition to make our leadership and teams trust priorities.",
    "id": 145,
    "annotator": 1,
    "annotation_id": 146,
    "created_at": "2024-11-05T10:04:55.940201Z",
    "updated_at": "2024-11-05T10:04:55.940201Z",
    "lead_time": 13.409
  },
  {
    "text": "We are proud that our engagement levels more diverse and inclusive.",
    "id": 146,
    "annotator": 1,
    "annotation_id": 147,
    "created_at": "2024-11-05T10:04:58.869736Z",
    "updated_at": "2024-11-05T10:04:58.869736Z",
    "lead_time": 2.78
  },
  {
    "text": "We support development for all with remained high at 81% in 2023.",
    "id": 147,
    "annotator": 1,
    "annotation_id": 148,
    "created_at": "2024-11-05T10:05:09.956254Z",
    "updated_at": "2024-11-05T10:05:09.956254Z",
    "lead_time": 10.934
  },
  {
    "text": "We also continue to see high numerous offerings for our employees, including an award- scores with positive upward trends in confidence in delivery of our winning leadership development programme, Accelerating strategy and our culture focus areas   ambitious for patients, Difference.",
    "id": 148,
    "annotator": 1,
    "annotation_id": 149,
    "created_at": "2024-11-05T10:05:28.294042Z",
    "updated_at": "2024-11-05T10:05:28.294042Z",
    "lead_time": 18.173
  },
  {
    "text": "Also, all our people complete a mandatory DEI accountability for impact and doing the right thing   as well as module as part of our annual training, this year focused on how to measures of inclusion.",
    "id": 149,
    "label": [
      {
        "start": 32,
        "end": 60,
        "text": "mandatory DEI accountability",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 32,
        "end": 60,
        "text": "mandatory DEI accountability",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 150,
    "created_at": "2024-11-05T10:05:35.678622Z",
    "updated_at": "2024-11-05T10:06:16.432123Z",
    "lead_time": 38.437
  },
  {
    "text": "In 2023 we expanded analysis of the survey create an inclusive workplace so all our people can thrive.",
    "id": 150,
    "annotator": 1,
    "annotation_id": 151,
    "created_at": "2024-11-05T10:06:25.145596Z",
    "updated_at": "2024-11-05T10:06:25.145596Z",
    "lead_time": 6.466
  },
  {
    "text": "to understand differences in employee experience across diverse For more details on our DEI aspirations, see the Responsible characteristics.",
    "id": 151,
    "annotator": 1,
    "annotation_id": 152,
    "created_at": "2024-11-05T10:06:31.987463Z",
    "updated_at": "2024-11-05T10:06:31.987463Z",
    "lead_time": 6.692
  },
  {
    "text": "We continue to make good progress in creating a Business section on page Error!",
    "id": 152,
    "annotator": 1,
    "annotation_id": 153,
    "created_at": "2024-11-05T10:06:37.097518Z",
    "updated_at": "2024-11-05T10:06:37.097518Z",
    "lead_time": 4.973
  },
  {
    "text": "Bookmark not defined..",
    "id": 153,
    "annotator": 1,
    "annotation_id": 154,
    "created_at": "2024-11-05T10:06:38.717620Z",
    "updated_at": "2024-11-05T10:06:38.717620Z",
    "lead_time": 1.481
  },
  {
    "text": "culture and workplace where people feel a sense of belonging and can thrive.",
    "id": 154,
    "annotator": 1,
    "annotation_id": 155,
    "created_at": "2024-11-05T10:06:45.366200Z",
    "updated_at": "2024-11-05T10:06:45.366200Z",
    "lead_time": 6.504
  },
  {
    "text": "Health, wellbeing and volunteering To measure the effectiveness of our global managers, their teams Our health and wellbeing benefits support people through provide feedback through an annual One80 survey and different life stages and are fair and inclusive.",
    "id": 155,
    "annotator": 1,
    "annotation_id": 156,
    "created_at": "2024-11-05T10:07:09.551563Z",
    "updated_at": "2024-11-05T10:07:09.551563Z",
    "lead_time": 24.036
  },
  {
    "text": "These include: a managers receive anonymised aggregate feedback.",
    "id": 156,
    "annotator": 1,
    "annotation_id": 157,
    "created_at": "2024-11-05T10:07:14.708841Z",
    "updated_at": "2024-11-05T10:07:14.708841Z",
    "lead_time": 5.016
  },
  {
    "text": "In 2023, 78% global minimum standard of 18 weeks  parental leave for primary of our managers were rated as highly effective by their teams.",
    "id": 157,
    "annotator": 1,
    "annotation_id": 158,
    "created_at": "2024-11-05T10:07:59.801243Z",
    "updated_at": "2024-11-05T10:07:59.801243Z",
    "lead_time": 44.937
  },
  {
    "text": "and secondary carers for all forms of family, a global minimum standard for care of a family member for end of life or serious health emergencies, insured benefits to include same-sex partners wherever possible, and mental health training   available to everyone.",
    "id": 158,
    "label": [
      {
        "start": 216,
        "end": 262,
        "text": "mental health training available to everyone",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 215,
        "end": 263,
        "text": " mental health training available to everyone.",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 159,
    "created_at": "2024-11-05T10:08:58.605076Z",
    "updated_at": "2024-11-05T10:08:58.605076Z",
    "lead_time": 58.648
  },
  {
    "text": "We have also enhanced our financial wellbeing support for employees by introducing the  nudge  financial education platform in over 50 countries, helping people manage their finances and achieve their financial goals.",
    "id": 159,
    "label": [
      {
        "start": 88,
        "end": 123,
        "text": "nudge financial education platform",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 127,
        "end": 144,
        "text": "over 50 countries",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 160,
    "created_at": "2024-11-05T10:09:21.744282Z",
    "updated_at": "2024-11-05T10:09:21.744282Z",
    "lead_time": 22.955
  },
  {
    "text": "In 2023 we reignited volunteering across the company, focused on our ambition and charitable investment themes (Health for people, Health for the planet, Innovators for the future).",
    "id": 160,
    "label": [
      {
        "start": 21,
        "end": 33,
        "text": "volunteering",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 21,
        "end": 33,
        "text": "volunteering",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 161,
    "created_at": "2024-11-05T10:09:49.960140Z",
    "updated_at": "2024-11-05T10:09:49.960140Z",
    "lead_time": 28.059
  },
  {
    "text": "All employees can volunteer for one or two days each year by taking part in team-based hands-on  Together Days  or through skills- based volunteering.",
    "id": 161,
    "annotator": 1,
    "annotation_id": 162,
    "created_at": "2024-11-05T10:10:00.164903Z",
    "updated_at": "2024-11-05T10:10:00.164903Z",
    "lead_time": 10.037
  },
  {
    "text": "A smaller number of people can volunteer up to four days each year for selected skills-based volunteering projects.",
    "id": 162,
    "annotator": 1,
    "annotation_id": 163,
    "created_at": "2024-11-05T10:10:07.468083Z",
    "updated_at": "2024-11-05T10:10:41.835490Z",
    "lead_time": 10.689
  },
  {
    "text": "9 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Access We aim to positively impact the health of 2.5 billion people by the end of 2030.",
    "id": 163,
    "annotator": 1,
    "annotation_id": 164,
    "created_at": "2024-11-05T10:10:52.409508Z",
    "updated_at": "2024-11-05T10:10:52.409508Z",
    "lead_time": 9.275
  },
  {
    "text": "We will do this by making our vaccines and medicines available as widely as possible, through responsible pricing, strategic access programmes and partnerships.",
    "id": 164,
    "annotator": 1,
    "annotation_id": 165,
    "created_at": "2024-11-05T10:11:01.309279Z",
    "updated_at": "2024-11-05T10:11:01.309279Z",
    "lead_time": 8.745
  },
  {
    "text": "89m 24m >1bn people reached in lower income people living with HIV had vaccine doses supplied to countries with our vaccines and access to a generic product Gavi, the vaccine alliance, antiretrovirals in 20231 containing dolutegravir in 2023 since 2010 Our commitment Our ESG Performance Rating metric 2023 Make our products available at value-based prices that are   Progress towards our 2030 goal of reaching 1.3 billion people sustainable for our business and implement access strategies in lower income countries with our products that increase the use of our medicines and vaccines to treat and protect underserved people We have an ambition to positively impact the health of 2.5 billion It takes significant time, risk and investment to successfully people by the end of 2030.",
    "id": 165,
    "annotator": 1,
    "annotation_id": 166,
    "created_at": "2024-11-05T10:11:11.749626Z",
    "updated_at": "2024-11-05T10:11:11.749626Z",
    "lead_time": 10.281
  },
  {
    "text": "To help achieve this, we have a goal to discover and develop new medicines and vaccines.",
    "id": 166,
    "annotator": 1,
    "annotation_id": 167,
    "created_at": "2024-11-05T10:11:22.461640Z",
    "updated_at": "2024-11-05T10:11:22.461640Z",
    "lead_time": 10.564
  },
  {
    "text": "That reach 1.3 billion people in lower income countries with our investment then creates products that make a huge difference to medicines and vaccines.",
    "id": 167,
    "annotator": 1,
    "annotation_id": 168,
    "created_at": "2024-11-05T10:11:51.370420Z",
    "updated_at": "2024-11-05T10:11:51.370420Z",
    "lead_time": 28.762
  },
  {
    "text": "We will do this by making our products patients and society, and generates the financial returns required available at prices that are affordable for patients and to fund the next generation of medicines and vaccines.",
    "id": 168,
    "label": [
      {
        "start": 119,
        "end": 145,
        "text": "prices that are affordable",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 119,
        "end": 145,
        "text": "prices that are affordable",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 169,
    "created_at": "2024-11-05T10:12:03.301935Z",
    "updated_at": "2024-11-05T10:12:53.432294Z",
    "lead_time": 35.82
  },
  {
    "text": "Getting sustainable for our business.",
    "id": 169,
    "annotator": 1,
    "annotation_id": 170,
    "created_at": "2024-11-05T10:12:06.371908Z",
    "updated_at": "2024-11-05T10:12:06.371908Z",
    "lead_time": 2.913
  },
  {
    "text": "the balance right between responsible pricing and sustainable business is a fundamental part of our commitment to ESG.",
    "id": 170,
    "annotator": 1,
    "annotation_id": 171,
    "created_at": "2024-11-05T10:12:14.220987Z",
    "updated_at": "2024-11-05T10:13:15.449171Z",
    "lead_time": 24.828
  },
  {
    "text": "To help us find that balance, we follow our pricing and access principles, which we first published in 2022 and updated in October 2023.",
    "id": 171,
    "annotator": 1,
    "annotation_id": 172,
    "created_at": "2024-11-05T10:13:21.502276Z",
    "updated_at": "2024-11-05T10:13:21.502276Z",
    "lead_time": 4.879
  },
  {
    "text": "gsk.com: Pricing and access principles Putting the right value on innovation We aim to develop differentiated, best- and first-in-class We recognise health inequities, including in higher income medicines and vaccines, pursuing areas of unmet need, and countries, and fund dedicated activities to reach underserved deploying cutting-edge science and advanced technology, populations.",
    "id": 172,
    "annotator": 1,
    "annotation_id": 173,
    "created_at": "2024-11-05T10:13:29.873192Z",
    "updated_at": "2024-11-05T10:13:29.873192Z",
    "lead_time": 8.228
  },
  {
    "text": "These include disease education and helping including genetics, artificial intelligence and data analytics, to uninsured and underinsured patients to navigate health benefits, develop more effective medicines and vaccines with speed, scale as well as access programmes to provide financial and disease and precision.",
    "id": 173,
    "label": [
      {
        "start": 14,
        "end": 62,
        "text": "disease education and helping including genetics",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 14,
        "end": 62,
        "text": "disease education and helping including genetics",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 174,
    "created_at": "2024-11-05T10:13:59.700802Z",
    "updated_at": "2024-11-05T10:13:59.700802Z",
    "lead_time": 29.681
  },
  {
    "text": "We involve the patient in the development of our management support.",
    "id": 174,
    "annotator": 1,
    "annotation_id": 175,
    "created_at": "2024-11-05T10:14:14.705164Z",
    "updated_at": "2024-11-05T10:14:14.705164Z",
    "lead_time": 14.841
  },
  {
    "text": "In the US, for example, we provided medicines and vaccines to identify real-world disease challenges.",
    "id": 175,
    "annotator": 1,
    "annotation_id": 176,
    "created_at": "2024-11-05T10:14:24.332980Z",
    "updated_at": "2024-11-05T10:14:24.332980Z",
    "lead_time": 9.47
  },
  {
    "text": "prescribed medicines and vaccines to more than 71,000 low- income uninsured, underinsured and Medicare Part D patients We set responsible prices in line with the benefits we bring to in 2023, through GSK and ViiV Healthcare s Patient Assistance patients and health systems, measured by clinical, economic and Programs Foundation.",
    "id": 176,
    "annotator": 1,
    "annotation_id": 177,
    "created_at": "2024-11-05T10:14:32.194575Z",
    "updated_at": "2024-11-05T10:14:32.194575Z",
    "lead_time": 7.711
  },
  {
    "text": "social outcomes.",
    "id": 177,
    "annotator": 1,
    "annotation_id": 178,
    "created_at": "2024-11-05T10:14:33.683271Z",
    "updated_at": "2024-11-05T10:14:33.683271Z",
    "lead_time": 1.349
  },
  {
    "text": "We compare our offer to what is already available for patients and we generate evidence from clinical trials to We operate under robust pricing approvals, developing access establish the added value provided by our medicines and vaccines.",
    "id": 178,
    "annotator": 1,
    "annotation_id": 179,
    "created_at": "2024-11-05T10:14:45.327133Z",
    "updated_at": "2024-11-05T10:14:45.327133Z",
    "lead_time": 11.503
  },
  {
    "text": "plans informed by payers.",
    "id": 179,
    "annotator": 1,
    "annotation_id": 180,
    "created_at": "2024-11-05T10:14:47.706681Z",
    "updated_at": "2024-11-05T10:14:47.706681Z",
    "lead_time": 2.223
  },
  {
    "text": "We also work to create stability and We adjust our pricing in line with the socio-economic status of a predictability for payers and our business, engaging proactively country to ensure affordability and availability.",
    "id": 180,
    "annotator": 1,
    "annotation_id": 181,
    "created_at": "2024-11-05T10:14:57.135741Z",
    "updated_at": "2024-11-05T10:14:57.135741Z",
    "lead_time": 9.272
  },
  {
    "text": "This includes using on upcoming product launches for budget planning, and tiered pricing for vaccines that address public health priorities in adjusting prices to account for inflation.",
    "id": 181,
    "label": [
      {
        "start": 23,
        "end": 68,
        "text": "upcoming product launches for budget planning",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 23,
        "end": 68,
        "text": "upcoming product launches for budget planning",
        "labels": [
          "value"
        ]
      },
      {
        "start": 74,
        "end": 101,
        "text": "tiered pricing for vaccines",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 74,
        "end": 101,
        "text": "tiered pricing for vaccines",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 182,
    "created_at": "2024-11-05T10:15:36.686569Z",
    "updated_at": "2024-11-05T10:15:36.686569Z",
    "lead_time": 39.393
  },
  {
    "text": "In the US in 2023, our low and middle income countries based on the World Bank gross combined average net price (after discounts, rebates or other national income classification.",
    "id": 182,
    "annotator": 1,
    "annotation_id": 183,
    "created_at": "2024-11-05T10:15:47.469002Z",
    "updated_at": "2024-11-05T10:15:47.469002Z",
    "lead_time": 10.606
  },
  {
    "text": "ViiV Healthcare provides non-profit allowances) for our pharmaceutical and vaccines portfolio pricing for antiretroviral medicines for HIV for use in public health increased by 0.4%, while the average list price increased by 3.2%, programmes in all low-income, least developed and Sub-Saharan compared with 5.4% (list) for the industry.",
    "id": 183,
    "annotator": 1,
    "annotation_id": 184,
    "created_at": "2024-11-05T10:16:09.429379Z",
    "updated_at": "2024-11-05T10:16:09.429379Z",
    "lead_time": 21.799
  },
  {
    "text": "Over the past five years, African countries.",
    "id": 184,
    "annotator": 1,
    "annotation_id": 185,
    "created_at": "2024-11-05T10:16:11.130058Z",
    "updated_at": "2024-11-05T10:16:11.130058Z",
    "lead_time": 1.542
  },
  {
    "text": "We work within existing payer systems and the average net price for our products increased 0.3% annually, recognise the need to balance health budgets for the societies while the average list price rose by 3.3%, compared we serve.",
    "id": 185,
    "label": [
      {
        "start": 81,
        "end": 95,
        "text": "increased 0.3%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 46,
        "end": 80,
        "text": "average net price for our products",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 186,
    "created_at": "2024-11-05T10:16:52.391830Z",
    "updated_at": "2024-11-05T10:16:52.391830Z",
    "lead_time": 41.113
  },
  {
    "text": "with 4.7% (list) for the industry.",
    "id": 186,
    "annotator": 1,
    "annotation_id": 187,
    "created_at": "2024-11-05T10:16:54.417427Z",
    "updated_at": "2024-11-05T10:16:54.417427Z",
    "lead_time": 1.841
  },
  {
    "text": "1 T he 89 million figure includes people reached with Synflorix, Rotarix, Cervarix, OPV and Mosquirix vaccines and people with access to a generic dolutegravir product through our voluntary licensing agreements; however it does not include people reached through albendazole, for which an assessment will be made in 2025 by the WHO and GSK.",
    "id": 187,
    "annotator": 1,
    "annotation_id": 188,
    "created_at": "2024-11-05T10:17:04.372331Z",
    "updated_at": "2024-11-05T10:17:04.372331Z",
    "lead_time": 9.788
  },
  {
    "text": "10 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Access continued Providing access for patients in lower income countries People living in lower income countries continue to be So far, LF has been eliminated in 19 countries including disproportionately affected by infectious diseases.",
    "id": 188,
    "annotator": 1,
    "annotation_id": 189,
    "created_at": "2024-11-05T10:17:13.703127Z",
    "updated_at": "2024-11-05T10:17:13.703127Z",
    "lead_time": 9.17
  },
  {
    "text": "We want to Bangladesh and Lao PDR, who announced elimination of develop access strategies that make a real difference.",
    "id": 189,
    "annotator": 1,
    "annotation_id": 190,
    "created_at": "2024-11-05T10:17:31.073379Z",
    "updated_at": "2024-11-05T10:17:31.073379Z",
    "lead_time": 17.215
  },
  {
    "text": "In 2023, we the disease in 2023.",
    "id": 190,
    "annotator": 1,
    "annotation_id": 191,
    "created_at": "2024-11-05T10:17:33.949218Z",
    "updated_at": "2024-11-05T10:17:33.949218Z",
    "lead_time": 2.731
  },
  {
    "text": "These are significant milestones in our reached 89 million people with our vaccines and antiretrovirals in collaborative effort to get ahead of disease together.",
    "id": 191,
    "annotator": 1,
    "annotation_id": 192,
    "created_at": "2024-11-05T10:17:42.622416Z",
    "updated_at": "2024-11-05T10:17:42.622416Z",
    "lead_time": 8.517
  },
  {
    "text": "The number lower income countries.",
    "id": 192,
    "annotator": 1,
    "annotation_id": 193,
    "created_at": "2024-11-05T10:17:45.011291Z",
    "updated_at": "2024-11-05T10:17:45.011291Z",
    "lead_time": 2.242
  },
  {
    "text": "of tablets we are donating is declining each year, given the gradual eradication of the NTDs that the medicine is targeting.",
    "id": 193,
    "annotator": 1,
    "annotation_id": 194,
    "created_at": "2024-11-05T10:19:50.310183Z",
    "updated_at": "2024-11-05T10:19:50.310183Z",
    "lead_time": 125.136
  },
  {
    "text": "We systematically evaluate our pipeline, in consultation with The programme has benefited over 935 million people since it global health partners, to identify which products will benefit began, according to WHO data.",
    "id": 194,
    "annotator": 1,
    "annotation_id": 195,
    "created_at": "2024-11-05T10:20:18.943206Z",
    "updated_at": "2024-11-05T10:20:18.943206Z",
    "lead_time": 28.48
  },
  {
    "text": "We remain committed to low- and lower middle-income countries so we can develop supplying albendazole to endemic countries until LF is eliminated effective and focused access plans.",
    "id": 195,
    "label": [
      {
        "start": 129,
        "end": 155,
        "text": "LF is eliminated effective",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 129,
        "end": 155,
        "text": "LF is eliminated effective",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 196,
    "created_at": "2024-11-05T10:21:56.227146Z",
    "updated_at": "2024-11-05T10:21:56.227146Z",
    "lead_time": 97.1
  },
  {
    "text": "In least-developed countries everywhere.",
    "id": 196,
    "annotator": 1,
    "annotation_id": 197,
    "created_at": "2024-11-05T10:21:59.422255Z",
    "updated_at": "2024-11-05T10:21:59.423255Z",
    "lead_time": 3.035
  },
  {
    "text": "and low-income countries, we do not file patents for our medicines or enforce historic patents.",
    "id": 197,
    "annotator": 1,
    "annotation_id": 198,
    "created_at": "2024-11-05T10:22:10.704874Z",
    "updated_at": "2024-11-05T10:22:10.704874Z",
    "lead_time": 11.133
  },
  {
    "text": "This lets other companies HIV manufacture and supply generic versions of our medicines in those countries.",
    "id": 198,
    "annotator": 1,
    "annotation_id": 199,
    "created_at": "2024-11-05T10:22:20.896464Z",
    "updated_at": "2024-11-05T10:22:20.896464Z",
    "lead_time": 10.03
  },
  {
    "text": "We also support equitable access to impactful We support the development of generic versions of our products GSK products by implementing responsible pricing strategies through voluntary licences to help improve access by increasing based on a country s ability to pay (measured by Gross National manufacturing capacity and enabling lower prices in eligible Income).",
    "id": 199,
    "annotator": 1,
    "annotation_id": 200,
    "created_at": "2024-11-05T10:22:54.490979Z",
    "updated_at": "2024-11-05T10:22:54.490979Z",
    "lead_time": 33.436
  },
  {
    "text": "countries.",
    "id": 200,
    "annotator": 1,
    "annotation_id": 201,
    "created_at": "2024-11-05T10:22:55.876118Z",
    "updated_at": "2024-11-05T10:22:55.876118Z",
    "lead_time": 1.225
  },
  {
    "text": "In 2023, Aurobindo, Cipla and Viatris, three generic manufacturers, signed sub-licences of ViiV Healthcare s licence Vaccines with the Medicines Patent Pool to develop, manufacture and supply generic versions of cabotegravir long-acting for HIV We reserve our lowest vaccine prices for Gavi and similar pre-exposure prophylaxis (cabotegravir LA for PrEP) in 90 organisations.",
    "id": 201,
    "label": [
      {
        "start": 286,
        "end": 327,
        "text": "Gavi and similar pre-exposure prophylaxis",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 248,
        "end": 281,
        "text": "reserve our lowest vaccine prices",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 202,
    "created_at": "2024-11-05T10:23:36.083812Z",
    "updated_at": "2024-11-05T10:23:36.083812Z",
    "lead_time": 40.058
  },
  {
    "text": "We have partnered with Gavi since its foundation countries, subject to obtaining regulatory approvals.",
    "id": 202,
    "annotator": 1,
    "annotation_id": 203,
    "created_at": "2024-11-05T10:23:53.082972Z",
    "updated_at": "2024-11-05T10:23:53.082972Z",
    "lead_time": 16.827
  },
  {
    "text": "Compared in 2000 and have supplied more than one billion vaccine doses to with oral HIV prevention options, cabotegravir LA for PrEP is more date, at our lowest prices to the lowest income countries.",
    "id": 203,
    "annotator": 1,
    "annotation_id": 204,
    "created_at": "2024-11-05T10:24:04.041978Z",
    "updated_at": "2024-11-05T10:24:04.041978Z",
    "lead_time": 10.798
  },
  {
    "text": "complex to manufacture and ViiV is supporting the companies In 2023, through our partnership we significantly increased our with technical know-how to enable generic development and supply to deliver around 5 million doses of Cervarix, a critical access as soon as possible.",
    "id": 204,
    "annotator": 1,
    "annotation_id": 205,
    "created_at": "2024-11-05T10:24:14.354194Z",
    "updated_at": "2024-11-05T10:24:14.354194Z",
    "lead_time": 10.156
  },
  {
    "text": "vaccine in lower income countries for addressing cervical cancer.",
    "id": 205,
    "annotator": 1,
    "annotation_id": 206,
    "created_at": "2024-11-05T10:24:24.475194Z",
    "updated_at": "2024-11-05T10:24:24.475194Z",
    "lead_time": 9.973
  },
  {
    "text": "ViiV also works with global health agencies, non-governmental In 2023, we supplied around 41 million doses of our pneumococcal organisations, governments and community partners to plan for vaccine, Synflorix, to seven Gavi-eligible countries at our lowest and support the introduction of ViiV-manufactured cabotegravir price.",
    "id": 206,
    "annotator": 1,
    "annotation_id": 207,
    "created_at": "2024-11-05T10:25:01.020216Z",
    "updated_at": "2024-11-05T10:25:01.020216Z",
    "lead_time": 36.387
  },
  {
    "text": "Our vaccine against rotavirus, Rotarix, reaches children LA for PrEP into national programmes.",
    "id": 207,
    "annotator": 1,
    "annotation_id": 208,
    "created_at": "2024-11-05T10:25:04.043483Z",
    "updated_at": "2024-11-05T10:25:04.043483Z",
    "lead_time": 2.868
  },
  {
    "text": "In late 2023, first orders of across 25 Gavi-eligible countries and four former Gavi countries.",
    "id": 208,
    "annotator": 1,
    "annotation_id": 209,
    "created_at": "2024-11-05T10:25:10.827042Z",
    "updated_at": "2024-11-05T10:25:10.827042Z",
    "lead_time": 6.628
  },
  {
    "text": "cabotegravir LA for PrEP were delivered to a global partner for We have offered vaccines to civil society organisations serving programmatic use in low- and middle-income countries.",
    "id": 209,
    "annotator": 1,
    "annotation_id": 210,
    "created_at": "2024-11-05T10:25:19.969584Z",
    "updated_at": "2024-11-05T10:25:19.969584Z",
    "lead_time": 8.994
  },
  {
    "text": "refugees and working in other emergency situations through the Humanitarian Mechanism since 2017.",
    "id": 210,
    "annotator": 1,
    "annotation_id": 211,
    "created_at": "2024-11-05T10:25:22.405843Z",
    "updated_at": "2024-11-05T10:25:22.405843Z",
    "lead_time": 2.294
  },
  {
    "text": "We are also a long-standing ViiV Healthcare also has voluntary licensing agreements with supplier of oral polio vaccines through UNICEF and, in 2023, 15 generic manufacturers to produce and sell low-cost single or supplied around 130 million doses to help eradicate polio.",
    "id": 211,
    "label": [
      {
        "start": 230,
        "end": 241,
        "text": "130 million",
        "labels": [
          "value"
        ]
      },
      {
        "start": 256,
        "end": 271,
        "text": "eradicate polio",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 212,
    "created_at": "2024-11-05T10:26:03.080665Z",
    "updated_at": "2024-11-05T10:26:03.080665Z",
    "lead_time": 26.666
  },
  {
    "text": "fixed-dose combination products containing our HIV medicine dolutegravir for adults.",
    "id": 212,
    "annotator": 1,
    "annotation_id": 213,
    "created_at": "2024-11-05T10:26:11.447433Z",
    "updated_at": "2024-11-05T10:26:11.447433Z",
    "lead_time": 8.195
  },
  {
    "text": "These agreements cover 95 low- and Neglected tropical diseases middle-income countries, with one direct licence and the others We have been working with our partners since 1999 to tackle via the Medicines Patent Pool.",
    "id": 213,
    "annotator": 1,
    "annotation_id": 214,
    "created_at": "2024-11-05T10:26:17.528443Z",
    "updated_at": "2024-11-05T10:26:17.528443Z",
    "lead_time": 5.937
  },
  {
    "text": "There are similar agreements with neglected tropical diseases (NTDs), including lymphatic filariasis 14 generic manufacturers for children, covering 123 countries, (LF), a debilitating disease caused by a parasite transmitted to as well as separate agreements to enable greater access to humans by mosquitoes, and to reduce morbidity from intestinal dolutegravir in certain upper middle-income countries.",
    "id": 214,
    "annotator": 1,
    "annotation_id": 215,
    "created_at": "2024-11-05T10:26:31.571914Z",
    "updated_at": "2024-11-05T10:26:31.571914Z",
    "lead_time": 13.896
  },
  {
    "text": "This worms and echinococcosis.",
    "id": 215,
    "annotator": 1,
    "annotation_id": 216,
    "created_at": "2024-11-05T10:26:32.467266Z",
    "updated_at": "2024-11-05T10:26:32.467266Z",
    "lead_time": 0.729
  },
  {
    "text": "In 2023, we donated 615 million includes generic dolutegravir dispersible tablet 10mg formulations albendazole tablets to help end these NTDs, taking the total we for children living with HIV, which first received FDA tentative have donated to over 11 billion.",
    "id": 216,
    "annotator": 1,
    "annotation_id": 217,
    "created_at": "2024-11-05T10:26:59.514568Z",
    "updated_at": "2024-11-05T10:26:59.514568Z",
    "lead_time": 26.889
  },
  {
    "text": "approval under the US PEPFAR scheme three years ago and are now available in more than 90 countries.",
    "id": 217,
    "annotator": 1,
    "annotation_id": 218,
    "created_at": "2024-11-05T10:27:05.342105Z",
    "updated_at": "2024-11-05T10:27:05.342105Z",
    "lead_time": 5.675
  },
  {
    "text": "This access has been facilitated by ViiV s public-private partnership with the Clinton Health Access Initiative, Unitaid and two generic manufacturers with sub-licences from the Medicines Patent Pool.",
    "id": 218,
    "annotator": 1,
    "annotation_id": 219,
    "created_at": "2024-11-05T10:27:11.840907Z",
    "updated_at": "2024-11-05T10:27:11.840907Z",
    "lead_time": 6.33
  },
  {
    "text": "In total, around 24 million people living with HIV across 128 countries had access to a generic product containing dolutegravir by the end of 2023.",
    "id": 219,
    "annotator": 1,
    "annotation_id": 220,
    "created_at": "2024-11-05T10:27:20.109507Z",
    "updated_at": "2024-11-05T10:27:20.110507Z",
    "lead_time": 8.111
  },
  {
    "text": "This is more than 90% of people living with HIV on antiretrovirals in generic-accessible low- and middle- income countries.",
    "id": 220,
    "annotator": 1,
    "annotation_id": 221,
    "created_at": "2024-11-05T10:27:36.478640Z",
    "updated_at": "2024-11-05T10:27:36.478640Z",
    "lead_time": 16.216
  },
  {
    "text": "11 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Access continued Malaria To significantly increase supply of the vaccine in the medium term, we are transferring technology know-how to Bharat Biotech of To date, over two million children in Ghana, Kenya and Malawi India, which will be the sole supplier of the vaccine from 2029.",
    "id": 221,
    "annotator": 1,
    "annotation_id": 222,
    "created_at": "2024-11-05T10:27:45.084929Z",
    "updated_at": "2024-11-05T10:27:45.084929Z",
    "lead_time": 8.451
  },
  {
    "text": "We have been reached with at least one dose of Mosquirix (RTS,S\/ continue to make good progress on this product transfer.",
    "id": 222,
    "annotator": 1,
    "annotation_id": 223,
    "created_at": "2024-11-05T10:27:52.192451Z",
    "updated_at": "2024-11-05T10:27:52.192451Z",
    "lead_time": 6.943
  },
  {
    "text": "AS01E) through the WHO-coordinated Malaria Vaccine Implementation Programme.",
    "id": 223,
    "annotator": 1,
    "annotation_id": 224,
    "created_at": "2024-11-05T10:27:53.879442Z",
    "updated_at": "2024-11-05T10:27:53.879442Z",
    "lead_time": 1.533
  },
  {
    "text": "Developed by GSK and our partners, In 2023, results from a landmark study by the London School of Mosquirix is a significant scientific breakthrough   it is the world s Hygiene & Tropical Medicine showed that combining Mosquirix first malaria vaccine and the first vaccine against any human with antimalarial drugs in areas of Africa with seasonal malaria parasite.",
    "id": 224,
    "annotator": 1,
    "annotation_id": 225,
    "created_at": "2024-11-05T10:28:01.613540Z",
    "updated_at": "2024-11-05T10:28:01.613540Z",
    "lead_time": 7.582
  },
  {
    "text": "reduced malaria cases and deaths in young children over a period of five years.",
    "id": 225,
    "annotator": 1,
    "annotation_id": 226,
    "created_at": "2024-11-05T10:28:07.925237Z",
    "updated_at": "2024-11-05T10:28:07.925237Z",
    "lead_time": 6.158
  },
  {
    "text": "These findings confirm the potential of In July 2023, Gavi announced that up to nine African countries seasonal vaccination to provide a high level of protection over are to be allocated doses of Mosquirix from early 2024.",
    "id": 226,
    "annotator": 1,
    "annotation_id": 227,
    "created_at": "2024-11-05T10:28:19.616483Z",
    "updated_at": "2024-11-05T10:28:19.616483Z",
    "lead_time": 11.531
  },
  {
    "text": "In early the first five years of life, when this protection is much needed.",
    "id": 227,
    "annotator": 1,
    "annotation_id": 228,
    "created_at": "2024-11-05T10:28:26.334105Z",
    "updated_at": "2024-11-05T10:28:26.334105Z",
    "lead_time": 6.553
  },
  {
    "text": "2024, Cameroon and Burkina Faso became the first countries to introduce the vaccine into routine immunisation programmes.",
    "id": 228,
    "annotator": 1,
    "annotation_id": 229,
    "created_at": "2024-11-05T10:28:32.726714Z",
    "updated_at": "2024-11-05T10:28:32.726714Z",
    "lead_time": 6.225
  },
  {
    "text": "We have committed to supply 18 million doses to Gavi-eligible countries between 2023 and 2025, with a plan to produce 15 million doses annually from 2026 to 2028.",
    "id": 229,
    "annotator": 1,
    "annotation_id": 230,
    "created_at": "2024-11-05T10:28:38.655441Z",
    "updated_at": "2024-11-05T10:28:38.655441Z",
    "lead_time": 5.772
  },
  {
    "text": "Strengthening healthcare systems We collaborate with partners to strengthen healthcare systems, In September, we announced that we have renewed our which is key to addressing systemic issues which reduce access partnership with Save the Children for another five years.",
    "id": 230,
    "label": [
      {
        "start": 257,
        "end": 269,
        "text": " five years.",
        "labels": [
          "value"
        ]
      },
      {
        "start": 228,
        "end": 245,
        "text": "Save the Children",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 231,
    "created_at": "2024-11-05T10:29:15.341654Z",
    "updated_at": "2024-11-05T10:29:15.341654Z",
    "lead_time": 36.532
  },
  {
    "text": "To date, to healthcare, vaccines and treatments and which perpetuate the partnership has provided more than 3.5 million children with health inequalities in lower income countries.",
    "id": 231,
    "label": [
      {
        "start": 108,
        "end": 128,
        "text": "3.5 million children",
        "labels": [
          "value"
        ]
      },
      {
        "start": 134,
        "end": 153,
        "text": "health inequalities",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 232,
    "created_at": "2024-11-05T10:29:50.827759Z",
    "updated_at": "2024-11-05T10:29:50.827759Z",
    "lead_time": 35.31
  },
  {
    "text": "We work with people essential healthcare, trained and equipped more than 39,000 and underserved communities to make sure that they take the health workers in the most remote and marginalised communities, lead in the decisions that affect them and their health, and we and advocated for the incorporation of stronger policies to help support emergency preparedness and response.",
    "id": 232,
    "label": [
      {
        "start": 73,
        "end": 79,
        "text": "39,000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3,
        "end": 40,
        "text": "work with people essential healthcare",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 233,
    "created_at": "2024-11-05T10:30:53.190199Z",
    "updated_at": "2024-11-05T10:30:53.190199Z",
    "lead_time": 62.189
  },
  {
    "text": "protect children s health at country and global level.",
    "id": 233,
    "annotator": 1,
    "annotation_id": 234,
    "created_at": "2024-11-05T10:30:56.318484Z",
    "updated_at": "2024-11-05T10:30:56.318484Z",
    "lead_time": 2.963
  },
  {
    "text": "We work in partnership with organisations that are active within Building on learnings over the last decade, we are focusing our local communities and look to catalyse additional resources to partnership on reducing the number of  zero dose  children   increase impact.",
    "id": 234,
    "annotator": 1,
    "annotation_id": 235,
    "created_at": "2024-11-05T10:31:11.305648Z",
    "updated_at": "2024-11-05T10:31:11.305648Z",
    "lead_time": 14.83
  },
  {
    "text": "In 2023, GSK and ViiV Healthcare joined forces those who have never received a vaccine   in Ethiopia and with The Global Fund to pledge $7.5 million over three years to Nigeria, which represent more than a third of the zero-dosed create the Gender Equality Fund, which will support community- children in Africa.",
    "id": 235,
    "label": [
      {
        "start": 136,
        "end": 148,
        "text": "$7.5 million",
        "labels": [
          "value"
        ]
      },
      {
        "start": 154,
        "end": 176,
        "text": "three years to Nigeria",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 236,
    "created_at": "2024-11-05T10:31:35.220972Z",
    "updated_at": "2024-11-05T10:31:35.220972Z",
    "lead_time": 23.75
  },
  {
    "text": "based and -led organisations that are working to deliver lasting Last year, we launched two new programmes as part of our changes in health policies and programmes, transform gender long-standing partnership with Amref Health Africa.",
    "id": 236,
    "annotator": 1,
    "annotation_id": 237,
    "created_at": "2024-11-05T10:31:46.414258Z",
    "updated_at": "2024-11-05T10:31:46.414258Z",
    "lead_time": 11.018
  },
  {
    "text": "One focuses norms and eliminate discrimination to improve health outcomes, on malaria in Kenya and Zambia, and the second will address with a focus on TB, HIV and malaria.",
    "id": 237,
    "annotator": 1,
    "annotation_id": 238,
    "created_at": "2024-11-05T10:31:52.921907Z",
    "updated_at": "2024-11-05T10:31:52.921907Z",
    "lead_time": 6.351
  },
  {
    "text": "The Gates Foundation has anti-microbial resistance (AMR) across the region.",
    "id": 238,
    "annotator": 1,
    "annotation_id": 239,
    "created_at": "2024-11-05T10:31:56.760576Z",
    "updated_at": "2024-11-05T10:31:56.760576Z",
    "lead_time": 3.677
  },
  {
    "text": "It will work with committed to match this donation, in support of The Global WHO Regional Office for Africa and the African CDC to identify Fund's work.",
    "id": 239,
    "annotator": 1,
    "annotation_id": 240,
    "created_at": "2024-11-05T10:32:58.501464Z",
    "updated_at": "2024-11-05T10:32:58.501464Z",
    "lead_time": 61.568
  },
  {
    "text": "and assess national AMR plans and support their implementation.",
    "id": 240,
    "annotator": 1,
    "annotation_id": 241,
    "created_at": "2024-11-05T10:33:01.093432Z",
    "updated_at": "2024-11-05T10:33:01.093432Z",
    "lead_time": 2.429
  },
  {
    "text": "Mobilised and connected community-based organisations are a GSK and ViiV Healthcare are committed to responding to vital part of health systems, enabling access to and delivery of humanitarian crises where possible.",
    "id": 241,
    "annotator": 1,
    "annotation_id": 242,
    "created_at": "2024-11-05T10:33:09.926723Z",
    "updated_at": "2024-11-05T10:33:09.926723Z",
    "lead_time": 8.69
  },
  {
    "text": "To date, GSK has donated services, especially for hard-to-reach populations.",
    "id": 242,
    "annotator": 1,
    "annotation_id": 243,
    "created_at": "2024-11-05T10:33:16.637957Z",
    "updated_at": "2024-11-05T10:33:16.637957Z",
    "lead_time": 6.545
  },
  {
    "text": "Positive Action, more than  6 million to a number of partners, including the Red ViiV Healthcare's community grant-giving programme, works Cross, Save the Children and The Global Fund, directly responding directly with the communities most affected by HIV to further the to the humanitarian crisis in Ukraine and neighbouring countries.",
    "id": 243,
    "label": [
      {
        "start": 28,
        "end": 37,
        "text": "6 million",
        "labels": [
          "value"
        ]
      },
      {
        "start": 41,
        "end": 61,
        "text": "a number of partners",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 244,
    "created_at": "2024-11-05T10:34:10.006844Z",
    "updated_at": "2024-11-05T10:34:10.006844Z",
    "lead_time": 53.205
  },
  {
    "text": "ViiV Healthcare mission of ensuring no person living with HIV is In 2023, ViiV Healthcare continued to donate antiretroviral left behind.",
    "id": 244,
    "annotator": 1,
    "annotation_id": 245,
    "created_at": "2024-11-05T10:34:16.188870Z",
    "updated_at": "2024-11-05T10:34:16.188870Z",
    "lead_time": 5.999
  },
  {
    "text": "In 2023, Positive Action invested more than  12 million, medicines to national HIV and AIDS programmes in Poland to reaching approximately 514,000 people and providing 99 grants support people living with HIV who have been affected by the across 31 countries.",
    "id": 245,
    "annotator": 1,
    "annotation_id": 246,
    "created_at": "2024-11-05T10:34:33.707107Z",
    "updated_at": "2024-11-05T10:34:33.707107Z",
    "lead_time": 17.362
  },
  {
    "text": "conflict in Ukraine.",
    "id": 246,
    "annotator": 1,
    "annotation_id": 247,
    "created_at": "2024-11-05T10:34:35.678479Z",
    "updated_at": "2024-11-05T10:34:35.678479Z",
    "lead_time": 1.804
  },
  {
    "text": "To date, the company has donated more than 10,000 packs.",
    "id": 247,
    "annotator": 1,
    "annotation_id": 248,
    "created_at": "2024-11-05T10:36:16.231520Z",
    "updated_at": "2024-11-05T10:36:16.231520Z",
    "lead_time": 100.378
  },
  {
    "text": "Positive Action also launched its Ukraine Emergency Response Fund.",
    "id": 248,
    "annotator": 1,
    "annotation_id": 249,
    "created_at": "2024-11-05T10:36:33.282596Z",
    "updated_at": "2024-11-05T10:36:33.282596Z",
    "lead_time": 16.826
  },
  {
    "text": "Positive Action made  830,000 available to partners based in Ukraine and neighbouring countries to protect the health of people living with and affected by HIV in the region.",
    "id": 249,
    "annotator": 1,
    "annotation_id": 250,
    "created_at": "2024-11-05T10:37:23.639192Z",
    "updated_at": "2024-11-05T10:37:23.639192Z",
    "lead_time": 50.119
  },
  {
    "text": "12 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Access continued 2020 2021 2022 2023 Community investment Cash ( m) 91 83 79 80 A Product and in-kind ( m)1 136 159 209 198 A Time ( m) 0.1 0.2 0.6 3 A Management costs ( m) 18 17 19 23 A Total community investment ( m) 245 259 308 304 A Value of GSK medicine and vaccines provided through our US Patient Assistance Programs 151 186 228 224 A Foundation ($m)1,2 US pricing 1 year change in list and net price3 Change in combined average net price for our pharmaceutical and vaccines portfolio in the US -0.7% +5.5% +1.4% 0.4% since the previous year Change in average list price in the US since the previous year +3.2% +3.8% +3.8% 3.2% 5 year list and net price (compound annual growth rate)3 Change in net price (after discounts, rebates or other allowances) for our products in the US -3.2% -2.0% -1.1% 0.3% over the past 5 years Change in average list price in the US over the past 5 years +5.7% +4.6% +3.9% 3.3% Product reach (doses supplied to lower income countries) Doses of Synflorix vaccines supplied to Gavi (m) 56 39 40 41 PR A Doses of Rotarix vaccines supplied to Gavi (m) 53 49 43 43 PR A Doses of Cervarix vaccines supplied to Gavi (m) 0.4 0.4 0.2 5 PR A Doses of OPV vaccines supplied to UNICEF (m) 110 80 95 130 PR A Doses of Mosquirix (RTS,S\/AS01 E) vaccines supplied (m) 2 1 1 6 PR A Albendazole tablets donated to help eliminate lymphatic filariasis (m) 304 451 440 462 PR A Albendazole tablets donated to help treat intestinal worms (m) 113 75 93 153 PR A Total doses supplied (m) 638 695 712 8405 PR Product reach (people reached in lower income countries) People with access to a generic dolutegravir product through voluntary licensing     20,927 24,058 A agreements ('000)4 Estimated children reached with Synflorix through Gavi ('000) 17,100 12,000 12,116 12,573 A Estimated children reached with Rotarix through Gavi ('000) 25,400 23,540 20,561 20,570 A Estimated girls reached with Cervarix through Gavi ('000) 180 170 106 4,307 A Estimated people reached with OPV through UNICEF ('000) 21,900 16,010 18,975 26,032 A Estimated people reached with Mosquirix (RTS,S\/AS01 E) ('000)   310 326 1,383 A Total people reached ('000) 64,580 52,030 73,011 88,923 A PR Metric contributes to our ESG Performance Rating.",
    "id": 250,
    "annotator": 1,
    "annotation_id": 251,
    "created_at": "2024-11-05T10:39:01.083288Z",
    "updated_at": "2024-11-05T10:39:01.083288Z",
    "lead_time": 97.213
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 251,
    "annotator": 1,
    "annotation_id": 252,
    "created_at": "2024-11-05T10:39:09.143066Z",
    "updated_at": "2024-11-05T10:39:09.143066Z",
    "lead_time": 7.838
  },
  {
    "text": "1 Product donations are valued at the global average cost of goods as reported in year-end results.",
    "id": 252,
    "annotator": 1,
    "annotation_id": 253,
    "created_at": "2024-11-05T10:39:24.705509Z",
    "updated_at": "2024-11-05T10:39:24.705509Z",
    "lead_time": 15.34
  },
  {
    "text": "2 This product donation is included within the total community investment figures reported.",
    "id": 253,
    "annotator": 1,
    "annotation_id": 254,
    "created_at": "2024-11-05T10:39:30.077357Z",
    "updated_at": "2024-11-05T10:39:30.077357Z",
    "lead_time": 5.175
  },
  {
    "text": "3 Calculated across GSK and ViiV Healthcare products.",
    "id": 254,
    "annotator": 1,
    "annotation_id": 255,
    "created_at": "2024-11-05T10:39:56.975141Z",
    "updated_at": "2024-11-05T10:39:56.975141Z",
    "lead_time": 26.693
  },
  {
    "text": "4 A s a chronic and ongoing treatment, the cumulative number of people with access to dolutegravir rather than annual data is reported.",
    "id": 255,
    "annotator": 1,
    "annotation_id": 256,
    "created_at": "2024-11-05T10:40:21.871388Z",
    "updated_at": "2024-11-05T10:40:21.871388Z",
    "lead_time": 24.683
  },
  {
    "text": "The figure is estimated based on sales of generic dolutegravir-based products through our voluntary licensing agreements.",
    "id": 256,
    "annotator": 1,
    "annotation_id": 257,
    "created_at": "2024-11-05T10:40:27.399212Z",
    "updated_at": "2024-11-05T10:40:27.399212Z",
    "lead_time": 5.317
  },
  {
    "text": "In 2022, we updated the methodology to include sales of all generic dolutegravir-based products.",
    "id": 257,
    "annotator": 1,
    "annotation_id": 258,
    "created_at": "2024-11-05T10:41:33.101973Z",
    "updated_at": "2024-11-05T10:41:33.101973Z",
    "lead_time": 65.481
  },
  {
    "text": "5 I n 2023, we also held 149 million doses of OPV vaccine in ready-to-ship stockpile in case of epidemic, making a total of 989 million doses of our products available in lower income countries.",
    "id": 258,
    "label": [
      {
        "start": 25,
        "end": 36,
        "text": "149 million",
        "labels": [
          "value"
        ]
      },
      {
        "start": 46,
        "end": 57,
        "text": "OPV vaccine",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 259,
    "created_at": "2024-11-05T10:41:51.517300Z",
    "updated_at": "2024-11-05T10:41:51.517300Z",
    "lead_time": 18.21
  },
  {
    "text": "This contributed to our 2023 Access Performance Rating metric, which has been independently assured.",
    "id": 259,
    "annotator": 1,
    "annotation_id": 260,
    "created_at": "2024-11-05T10:42:21.727811Z",
    "updated_at": "2024-11-05T10:42:21.727811Z",
    "lead_time": 29.985
  },
  {
    "text": "13 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Access continued 2020 2021 2022 2023 People reached through our healthcare access programmes People accessing a healthcare service, worker or educational session through our work with 400 438 91 103 Save the Children ('000) People accessing a healthcare worker, service or facility as a result of the Bill & Melinda Gates   162 1061  2 CEO Roundtable programme ('000) People reached through ViiV Healthcare s Positive Action for Children Fund grants ('000) 484 188 13   People reached through ViiV Healthcare s Positive Action 2020-2030 Strategy grants ('000)   274 4213 513 People reached through our US Patient Assistance Programs ('000) 96 87 79 71 A PR Metric contributes to our ESG Performance Rating.",
    "id": 260,
    "annotator": 1,
    "annotation_id": 261,
    "created_at": "2024-11-05T10:43:00.721665Z",
    "updated_at": "2024-11-05T10:43:00.721665Z",
    "lead_time": 38.78
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 261,
    "annotator": 1,
    "annotation_id": 262,
    "created_at": "2024-11-05T10:43:35.613087Z",
    "updated_at": "2024-11-05T10:43:35.613087Z",
    "lead_time": 34.662
  },
  {
    "text": "1 2 022 data has been restated due to more data subsequently becoming available.",
    "id": 262,
    "annotator": 1,
    "annotation_id": 263,
    "created_at": "2024-11-05T10:43:41.345325Z",
    "updated_at": "2024-11-05T10:43:41.345325Z",
    "lead_time": 5.522
  },
  {
    "text": "2 T he Bill & Melinda Gates CEO Roundtable programme concluded in 2022 therefore, no amount was reported for 2023.",
    "id": 263,
    "annotator": 1,
    "annotation_id": 264,
    "created_at": "2024-11-05T10:43:48.850337Z",
    "updated_at": "2024-11-05T10:43:48.850337Z",
    "lead_time": 7.289
  },
  {
    "text": "3 Reach data is collected from grantees every six months for the previous six months activity over an 18 month cycle.",
    "id": 264,
    "annotator": 1,
    "annotation_id": 265,
    "created_at": "2024-11-05T10:44:31.538205Z",
    "updated_at": "2024-11-05T10:44:31.538205Z",
    "lead_time": 42.443
  },
  {
    "text": "2022 data has been restated.",
    "id": 265,
    "annotator": 1,
    "annotation_id": 266,
    "created_at": "2024-11-05T10:44:33.773906Z",
    "updated_at": "2024-11-05T10:44:33.773906Z",
    "lead_time": 2.013
  },
  {
    "text": "14 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Global health and health security We want to help address the biggest health challenges faced by people around the world.",
    "id": 266,
    "annotator": 1,
    "annotation_id": 267,
    "created_at": "2024-11-05T10:44:45.671254Z",
    "updated_at": "2024-11-05T10:44:45.671254Z",
    "lead_time": 11.673
  },
  {
    "text": "11 >30 12 Global Health pipeline assets R&D projects relevant to R&D projects targeting pathogens to address priority WHO antimicrobial resistance in deemed  critical  or  urgent  by the diseases progressed in 2023 our pipeline WHO and the US CDC Our commitment Our ESG Performance Rating metrics To develop novel products and technologies to treat and   Progress six Global Health pipeline assets to address priority prevent priority diseases, including pandemic threats WHO diseases   Progress eight active R&D projects that address pathogens prioritised by WHO and CDC as posing the highest level of concern due to drug resistance (critical and\/or urgent threats) Where people live continues to influence their chances of enjoying In 2022, with ViiV Healthcare, we announced an investment a healthy life.",
    "id": 267,
    "annotator": 1,
    "annotation_id": 268,
    "created_at": "2024-11-05T10:46:14.270688Z",
    "updated_at": "2024-11-05T10:46:14.270688Z",
    "lead_time": 88.371
  },
  {
    "text": "People living in lower income countries are of  1 billion over 10 years to accelerate global health R&D.",
    "id": 268,
    "annotator": 1,
    "annotation_id": 269,
    "created_at": "2024-11-05T10:46:21.878115Z",
    "updated_at": "2024-11-05T10:46:21.878115Z",
    "lead_time": 7.4
  },
  {
    "text": "By disproportionately affected by infectious diseases.",
    "id": 269,
    "annotator": 1,
    "annotation_id": 270,
    "created_at": "2024-11-05T10:46:23.955899Z",
    "updated_at": "2024-11-05T10:46:23.955899Z",
    "lead_time": 1.874
  },
  {
    "text": "Among the the end of 2023, we had invested 21%1 of this and progressed 11 biggest drivers of morbidity and mortality are tuberculosis (TB), Global Health pipeline assets to address priority WHO diseases malaria, antimicrobial resistance (AMR), HIV and neglected including climate-aggravated diseases that are tropical diseases.",
    "id": 270,
    "annotator": 1,
    "annotation_id": 271,
    "created_at": "2024-11-05T10:47:09.675241Z",
    "updated_at": "2024-11-05T10:47:09.675241Z",
    "lead_time": 45.48
  },
  {
    "text": "disproportionately affecting lower income countries.",
    "id": 271,
    "annotator": 1,
    "annotation_id": 272,
    "created_at": "2024-11-05T10:47:11.531474Z",
    "updated_at": "2024-11-05T10:47:11.531474Z",
    "lead_time": 1.628
  },
  {
    "text": "GSK has a proud heritage as a leader in global health.",
    "id": 272,
    "annotator": 1,
    "annotation_id": 273,
    "created_at": "2024-11-05T10:47:19.896626Z",
    "updated_at": "2024-11-05T10:47:19.896626Z",
    "lead_time": 8.134
  },
  {
    "text": "We have a Strong and resilient healthcare systems are critical to enabling unique and important role to play in improving health for patients access to the right treatments and vaccines.",
    "id": 273,
    "annotator": 1,
    "annotation_id": 274,
    "created_at": "2024-11-05T10:48:12.361944Z",
    "updated_at": "2024-11-05T10:48:12.361944Z",
    "lead_time": 52.238
  },
  {
    "text": "We are working with around the world by using our science, technology, talent and long-term partners to help strengthen healthcare systems in lower partnerships to deliver health impact at scale and prevent, income countries, driven by local needs.",
    "id": 274,
    "annotator": 1,
    "annotation_id": 275,
    "created_at": "2024-11-05T10:48:19.926524Z",
    "updated_at": "2024-11-05T10:48:19.926524Z",
    "lead_time": 7.336
  },
  {
    "text": "Our work to increase prepare for and respond to future health security challenges.",
    "id": 275,
    "annotator": 1,
    "annotation_id": 276,
    "created_at": "2024-11-05T10:48:21.807991Z",
    "updated_at": "2024-11-05T10:48:21.807991Z",
    "lead_time": 1.607
  },
  {
    "text": "underserved people s access to medicines and vaccines is described in Access, on page 10.",
    "id": 276,
    "annotator": 1,
    "annotation_id": 277,
    "created_at": "2024-11-05T10:48:23.691402Z",
    "updated_at": "2024-11-05T10:48:23.691402Z",
    "lead_time": 1.66
  },
  {
    "text": "Including ViiV Healthcare, we re working on more than 30 potential vaccines and medicines targeting high burden infectious diseases   putting our unique R&D and scientific expertise to work to address some of the world s biggest health challenges.",
    "id": 277,
    "annotator": 1,
    "annotation_id": 278,
    "created_at": "2024-11-05T10:48:31.760597Z",
    "updated_at": "2024-11-05T10:48:31.760597Z",
    "lead_time": 7.853
  },
  {
    "text": "Global health R&D Promising avenues for TB prevention and treatment We are also developing a portfolio of shorter, safer, simpler TB treatments that, in combination with other medicines, could GSK is committed to tackling TB, one of the world s deadliest transform the TB landscape as part of new regimens for both infectious diseases.",
    "id": 278,
    "annotator": 1,
    "annotation_id": 279,
    "created_at": "2024-11-05T10:48:36.870804Z",
    "updated_at": "2024-11-05T10:48:36.870804Z",
    "lead_time": 4.875
  },
  {
    "text": "We have developed a promising candidate drug-sensitive and drug-resistant TB patients.",
    "id": 279,
    "annotator": 1,
    "annotation_id": 280,
    "created_at": "2024-11-05T10:48:41.995144Z",
    "updated_at": "2024-11-05T10:48:41.995144Z",
    "lead_time": 4.838
  },
  {
    "text": "We are advancing vaccine, M72\/AS01E, up to proof of concept (phase IIb).",
    "id": 280,
    "annotator": 1,
    "annotation_id": 281,
    "created_at": "2024-11-05T10:48:44.394603Z",
    "updated_at": "2024-11-05T10:48:44.394603Z",
    "lead_time": 2.195
  },
  {
    "text": "Building on four novel medicines in clinical development through nine R&D our long-standing, successful history of working with external consortia and partnerships that combine expertise, share risk partners, we have partnered with the Bill and Melinda Gates and leverage resources to accelerate innovation.",
    "id": 281,
    "annotator": 1,
    "annotation_id": 282,
    "created_at": "2024-11-05T10:48:56.615585Z",
    "updated_at": "2024-11-05T10:48:56.615585Z",
    "lead_time": 12.012
  },
  {
    "text": "Medical Research Institute (MRI) for its further development.",
    "id": 282,
    "annotator": 1,
    "annotation_id": 283,
    "created_at": "2024-11-05T10:49:00.731104Z",
    "updated_at": "2024-11-05T10:49:00.731104Z",
    "lead_time": 3.899
  },
  {
    "text": "Gates MRI is well positioned to lead the large and complex phase III study GSK is the lead industry partner in two large EU-funded Innovative required.",
    "id": 283,
    "annotator": 1,
    "annotation_id": 284,
    "created_at": "2024-11-05T10:49:06.300955Z",
    "updated_at": "2024-11-05T10:49:06.300955Z",
    "lead_time": 5.358
  },
  {
    "text": "In June 2023, Wellcome and the Bill and Melinda Gates Medicine Initiative projects, ERA4TB and Unite4TB, that together Foundation announced funding of up to $550 million for phase III aim to progress numerous assets from pre-clinical through to phase trials.",
    "id": 284,
    "annotator": 1,
    "annotation_id": 285,
    "created_at": "2024-11-05T10:49:16.314211Z",
    "updated_at": "2024-11-05T10:49:16.314211Z",
    "lead_time": 9.778
  },
  {
    "text": "If these trials are successful, M72\/AS01E could be the first new III-ready compounds.",
    "id": 285,
    "annotator": 1,
    "annotation_id": 286,
    "created_at": "2024-11-05T10:49:19.843301Z",
    "updated_at": "2024-11-05T10:49:19.843301Z",
    "lead_time": 3.305
  },
  {
    "text": "vaccine to help prevent pulmonary TB in over a century.",
    "id": 286,
    "annotator": 1,
    "annotation_id": 287,
    "created_at": "2024-11-05T10:49:30.219311Z",
    "updated_at": "2024-11-05T10:49:30.219311Z",
    "lead_time": 10.148
  },
  {
    "text": "1 B udget phasing is not linear across the 10-year period.",
    "id": 287,
    "annotator": 1,
    "annotation_id": 288,
    "created_at": "2024-11-05T10:49:32.891822Z",
    "updated_at": "2024-11-05T10:49:32.891822Z",
    "lead_time": 2.441
  },
  {
    "text": "15 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Global health and health security continued Breakthroughs in malaria research and treatment It also used data from semi-field studies conducted with the Institut de Recherche en Sciences de la Sant  (IRSS) in a contained The latest data shows that there were an estimated 249 million  MosquitoSphere  facility in Burkina Faso.",
    "id": 288,
    "annotator": 1,
    "annotation_id": 289,
    "created_at": "2024-11-05T10:50:46.379380Z",
    "updated_at": "2024-11-05T10:50:46.379380Z",
    "lead_time": 73.247
  },
  {
    "text": "This suggests that the malaria cases and over 600,000 deaths caused by malaria in 2022, laboratory findings could be successfully translated to according to the WHO, with over 90% of those in Africa.",
    "id": 289,
    "annotator": 1,
    "annotation_id": 290,
    "created_at": "2024-11-05T10:52:12.181117Z",
    "updated_at": "2024-11-05T10:52:12.181117Z",
    "lead_time": 85.579
  },
  {
    "text": "More than the field for malaria control.",
    "id": 290,
    "annotator": 1,
    "annotation_id": 291,
    "created_at": "2024-11-05T10:52:14.159478Z",
    "updated_at": "2024-11-05T10:52:14.159478Z",
    "lead_time": 1.744
  },
  {
    "text": "We continue to pursue this ground- three-quarters were of children under five.",
    "id": 291,
    "annotator": 1,
    "annotation_id": 292,
    "created_at": "2024-11-05T10:52:27.112214Z",
    "updated_at": "2024-11-05T10:52:27.113204Z",
    "lead_time": 12.731
  },
  {
    "text": "To date, together with breaking research while engaging with global health institutions our partners, we ve brought two products for the prevention and and partners to identify the most effective and sustainable treatment of malaria to market   the world s first vaccine against approach for development and mobilisation if successful.",
    "id": 292,
    "annotator": 1,
    "annotation_id": 293,
    "created_at": "2024-11-05T10:52:36.530264Z",
    "updated_at": "2024-11-05T10:52:36.530264Z",
    "lead_time": 9.204
  },
  {
    "text": "malaria (see Access, page 10), and a single-dose, radical cure for P. vivax malaria as reported in 2022.",
    "id": 293,
    "annotator": 1,
    "annotation_id": 294,
    "created_at": "2024-11-05T10:52:51.391781Z",
    "updated_at": "2024-11-05T10:52:51.391781Z",
    "lead_time": 14.652
  },
  {
    "text": "Getting ahead of malaria is Supporting innovation through capacity and particularly challenging due to growing resistance to existing drugs and insecticides and as climate change enables the spread of the capability building disease, so we are investing to develop the next generation of Through our Africa Open Lab initiative, launched in 2014, we transformative tools.",
    "id": 294,
    "annotator": 1,
    "annotation_id": 295,
    "created_at": "2024-11-05T10:54:51.165492Z",
    "updated_at": "2024-11-05T10:54:51.165492Z",
    "lead_time": 119.542
  },
  {
    "text": "support early-career scientists based in sub-Saharan Africa, with a focus on infectious diseases that disproportionately affect In August 2023, we announced that GSK scientists had discovered sub-Saharan populations, such as malaria, TB and AMR.",
    "id": 295,
    "annotator": 1,
    "annotation_id": 296,
    "created_at": "2024-11-05T10:55:15.077721Z",
    "updated_at": "2024-11-05T10:55:15.077721Z",
    "lead_time": 23.68
  },
  {
    "text": "In 2023, a strain of a naturally occurring bacterium that could potentially we agreed grants to ten researchers in six countries in sub-Saharan help eradicate the disease.",
    "id": 296,
    "annotator": 1,
    "annotation_id": 297,
    "created_at": "2024-11-05T10:55:38.427763Z",
    "updated_at": "2024-11-05T10:55:38.427763Z",
    "lead_time": 23.157
  },
  {
    "text": "The Tres Cantos 1 (TC1) strain of the Africa and we announced a further call for proposals in November.",
    "id": 297,
    "annotator": 1,
    "annotation_id": 298,
    "created_at": "2024-11-05T10:55:47.154515Z",
    "updated_at": "2024-11-05T10:55:47.154515Z",
    "lead_time": 8.519
  },
  {
    "text": "Delftia tsuruhatensis bacterium   named after the GSK R&D We are also working with African academic institutions to provide facility where it was discovered   significantly reduces the load of grantees with supplemental training in areas including P. falciparum malaria parasites in mosquitoes.",
    "id": 298,
    "annotator": 1,
    "annotation_id": 299,
    "created_at": "2024-11-05T10:56:59.903796Z",
    "updated_at": "2024-11-05T10:56:59.903796Z",
    "lead_time": 72.547
  },
  {
    "text": "This could epidemiology, statistics and clinical research.",
    "id": 299,
    "annotator": 1,
    "annotation_id": 300,
    "created_at": "2024-11-05T10:57:01.443963Z",
    "updated_at": "2024-11-05T10:57:01.443963Z",
    "lead_time": 1.316
  },
  {
    "text": "potentially inhibit transmission of the parasite to humans.",
    "id": 300,
    "annotator": 1,
    "annotation_id": 301,
    "created_at": "2024-11-05T10:57:16.846538Z",
    "updated_at": "2024-11-05T10:57:16.846538Z",
    "lead_time": 15.173
  },
  {
    "text": "TC1 was shown to be effective in multiple types of Anopheles mosquito and against multiple types of malaria parasite.",
    "id": 301,
    "annotator": 1,
    "annotation_id": 302,
    "created_at": "2024-11-05T10:57:24.685224Z",
    "updated_at": "2024-11-05T10:57:24.685224Z",
    "lead_time": 7.616
  },
  {
    "text": "The ground- breaking research was conducted in collaboration with the Johns Hopkins Malaria Research Institute at Johns Hopkins Bloomberg School of Public Health.",
    "id": 302,
    "annotator": 1,
    "annotation_id": 303,
    "created_at": "2024-11-05T10:58:13.192679Z",
    "updated_at": "2024-11-05T10:58:13.192679Z",
    "lead_time": 48.268
  },
  {
    "text": "Strengthening health security There are many factors that can jeopardise our health security In December 2023, the first patient was dosed in PIVOT-PO, our   from new and emerging infectious diseases to the rise of AMR.",
    "id": 303,
    "annotator": 1,
    "annotation_id": 304,
    "created_at": "2024-11-05T10:58:18.619134Z",
    "updated_at": "2024-11-05T10:58:18.619134Z",
    "lead_time": 5.211
  },
  {
    "text": "pivotal phase III trial for tebipenem.",
    "id": 304,
    "annotator": 1,
    "annotation_id": 305,
    "created_at": "2024-11-05T10:58:20.664227Z",
    "updated_at": "2024-11-05T10:58:20.664227Z",
    "lead_time": 1.842
  },
  {
    "text": "If approved, tebipenem HBr Climate change and nature loss also can change disease will address an unmet medical need for a novel oral antibiotic as patterns.",
    "id": 305,
    "annotator": 1,
    "annotation_id": 306,
    "created_at": "2024-11-05T10:58:54.927968Z",
    "updated_at": "2024-11-05T10:58:54.927968Z",
    "lead_time": 34.062
  },
  {
    "text": "We are using our scientific know-how and collaborating an alternative to intravenous hospital therapy for drug-resistant with others to help the world better prepare for future health cUTIs.",
    "id": 306,
    "annotator": 1,
    "annotation_id": 307,
    "created_at": "2024-11-05T10:59:00.884443Z",
    "updated_at": "2024-11-05T10:59:00.884443Z",
    "lead_time": 5.778
  },
  {
    "text": "In March 2023, we announced an exclusive licence challenges.",
    "id": 307,
    "annotator": 1,
    "annotation_id": 308,
    "created_at": "2024-11-05T10:59:03.417927Z",
    "updated_at": "2024-11-05T10:59:03.417927Z",
    "lead_time": 2.36
  },
  {
    "text": "agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a first-in-class antifungal for the treatment of vulvovaginal Getting ahead of AMR through innovation and candidiasis (VVC) and for reduction in the incidence of recurrent appropriate use VVC.",
    "id": 308,
    "annotator": 1,
    "annotation_id": 309,
    "created_at": "2024-11-05T10:59:12.559435Z",
    "updated_at": "2024-11-05T10:59:12.559435Z",
    "lead_time": 8.937
  },
  {
    "text": "Founded on GSK s science and technology, our primary Vaccines remain an important pathway to getting ahead of contribution to strengthening health security is through our resistant infections.",
    "id": 309,
    "annotator": 1,
    "annotation_id": 310,
    "created_at": "2024-11-05T11:03:20.886020Z",
    "updated_at": "2024-11-05T11:03:20.886020Z",
    "lead_time": 248.095
  },
  {
    "text": "During the year, the US FDA granted a innovation to prevent and mitigate infectious disease.",
    "id": 310,
    "annotator": 1,
    "annotation_id": 311,
    "created_at": "2024-11-05T11:03:26.293411Z",
    "updated_at": "2024-11-05T11:03:26.293411Z",
    "lead_time": 5.178
  },
  {
    "text": "This Fast Track designation for our investigational vaccine against includes investing in innovation to get ahead of infections where gonorrhoea   which is the second most prevalent bacterial new antimicrobials and vaccines are urgently needed.",
    "id": 311,
    "annotator": 1,
    "annotation_id": 312,
    "created_at": "2024-11-05T11:04:03.401890Z",
    "updated_at": "2024-11-05T11:04:03.401890Z",
    "lead_time": 36.881
  },
  {
    "text": "We have sexually transmitted infection worldwide, with an estimated 82 more than 30 R&D projects across medicines and vaccines million new cases globally each year.",
    "id": 312,
    "annotator": 1,
    "annotation_id": 313,
    "created_at": "2024-11-05T11:04:12.333444Z",
    "updated_at": "2024-11-05T11:04:12.333444Z",
    "lead_time": 8.711
  },
  {
    "text": "It is recognised as an urgent that are relevant to AMR, ranging from early- to late-stage unmet medical need due to its growing global incidence and development, with 12 R&D projects targeting pathogens deemed reduced efficacy of available treatments as drug-resistant strains  critical  or  urgent  by the WHO and the US CDC.",
    "id": 313,
    "annotator": 1,
    "annotation_id": 314,
    "created_at": "2024-11-05T11:04:23.318616Z",
    "updated_at": "2024-11-05T11:04:23.318616Z",
    "lead_time": 10.746
  },
  {
    "text": "are increasing.",
    "id": 314,
    "annotator": 1,
    "annotation_id": 315,
    "created_at": "2024-11-05T11:04:45.557195Z",
    "updated_at": "2024-11-05T11:04:45.557195Z",
    "lead_time": 22.008
  },
  {
    "text": "These include gepotidacin, which could be the first novel oral See page 30 of our Annual Report for more about our R&D antibiotic treatment for uncomplicated urinary tract infections pipeline.",
    "id": 315,
    "annotator": 1,
    "annotation_id": 316,
    "created_at": "2024-11-05T11:04:49.105456Z",
    "updated_at": "2024-11-05T11:04:49.105456Z",
    "lead_time": 3.342
  },
  {
    "text": "(uUTIs) in over 20 years.",
    "id": 316,
    "annotator": 1,
    "annotation_id": 317,
    "created_at": "2024-11-05T11:04:49.956323Z",
    "updated_at": "2024-11-05T11:04:49.956323Z",
    "lead_time": 0.64
  },
  {
    "text": "Positive phase III data from the EAGLE-2 and EAGLE-3 phase III trials were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen in April 2023.",
    "id": 317,
    "annotator": 1,
    "annotation_id": 318,
    "created_at": "2024-11-05T11:04:56.393218Z",
    "updated_at": "2024-11-05T11:04:56.393218Z",
    "lead_time": 6.23
  },
  {
    "text": "Through our partnership with Spero Therapeutics, Inc., we have an exclusive licence agreement for tebipenem HBr, a late-stage oral carbapenem antibiotic with the potential to treat complicated urinary tract infections (cUTIs).",
    "id": 318,
    "annotator": 1,
    "annotation_id": 319,
    "created_at": "2024-11-05T11:11:22.715094Z",
    "updated_at": "2024-11-05T11:11:22.715094Z",
    "lead_time": 385.834
  },
  {
    "text": "16 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Global health and health security continued Progressing vaccines against enteric diseases To support the responsible manufacturing of antibiotics, we work with the AMR Industry Alliance to set global limits for wastewater to reduce the burden of AMR antibiotic discharges from factories (see Environment, page 18).",
    "id": 319,
    "annotator": 1,
    "annotation_id": 320,
    "created_at": "2024-11-05T11:11:34.734225Z",
    "updated_at": "2024-11-05T11:11:34.734225Z",
    "lead_time": 11.802
  },
  {
    "text": "AMR is a major threat to health globally, and it is particularly Our work to strengthen responsible manufacturing of antibiotics prevalent in low resource settings, deepening existing health was highlighted as an example of good practice in a 2023 report inequities and risking the efficacy of current medicines to fight on the issue from the Access to Medicine Foundation s AMR diseases.",
    "id": 320,
    "annotator": 1,
    "annotation_id": 321,
    "created_at": "2024-11-05T11:11:40.966629Z",
    "updated_at": "2024-11-05T11:11:40.966629Z",
    "lead_time": 5.884
  },
  {
    "text": "We continue to progress candidate vaccines against Benchmark.",
    "id": 321,
    "annotator": 1,
    "annotation_id": 322,
    "created_at": "2024-11-05T11:11:45.257402Z",
    "updated_at": "2024-11-05T11:11:45.257402Z",
    "lead_time": 4.089
  },
  {
    "text": "several enteric diseases which contribute to the burden of AMR, including invasive non-typhoidal salmonella, klebsiella, shigella, We also continued to support dialogue around how to rebuild typhoid and paratyphoid fever.",
    "id": 322,
    "annotator": 1,
    "annotation_id": 323,
    "created_at": "2024-11-05T11:12:04.843987Z",
    "updated_at": "2024-11-05T11:12:04.843987Z",
    "lead_time": 19.409
  },
  {
    "text": "the ecosystem for antimicrobial innovation, participating in discussions on the topic in Brussels, Washington and London.",
    "id": 323,
    "annotator": 1,
    "annotation_id": 324,
    "created_at": "2024-11-05T11:12:30.091931Z",
    "updated_at": "2024-11-05T11:12:30.091931Z",
    "lead_time": 25.037
  },
  {
    "text": "In 2023, it was announced that we are partnering with LimmaTech Biologics for the further development of one candidate vaccine Partnering for pandemic preparedness against shigellosis, while we continue to develop another As countries continued to manage the repercussions of the candidate vaccine against the disease which uses our vaccine COVID-19 pandemic, health security remained high on the global platform technology, GMMA.",
    "id": 324,
    "annotator": 1,
    "annotation_id": 325,
    "created_at": "2024-11-05T11:12:38.206631Z",
    "updated_at": "2024-11-05T11:12:38.206631Z",
    "lead_time": 7.883
  },
  {
    "text": "Currently, there are no vaccines to agenda during 2023.",
    "id": 325,
    "annotator": 1,
    "annotation_id": 326,
    "created_at": "2024-11-05T11:12:42.466137Z",
    "updated_at": "2024-11-05T11:12:42.466137Z",
    "lead_time": 4.043
  },
  {
    "text": "The United Nations held high-level meetings help prevent shigellosis, a disease which causes 600,000 deaths on pandemic preparedness and response and universal health each year.",
    "id": 326,
    "annotator": 1,
    "annotation_id": 327,
    "created_at": "2024-11-05T11:12:59.725814Z",
    "updated_at": "2024-11-05T11:12:59.725814Z",
    "lead_time": 17.058
  },
  {
    "text": "coverage, while the White House has established a Pandemic Preparedness and Response Office.",
    "id": 327,
    "annotator": 1,
    "annotation_id": 328,
    "created_at": "2024-11-05T11:13:12.618858Z",
    "updated_at": "2024-11-05T11:13:12.618858Z",
    "lead_time": 12.685
  },
  {
    "text": "Ensuring appropriate use of antibiotics Ensuring appropriate access to infectious disease interventions To help pre-empt and respond to the next health security is key to getting ahead of health security threats.",
    "id": 328,
    "annotator": 1,
    "annotation_id": 329,
    "created_at": "2024-11-05T11:13:19.491237Z",
    "updated_at": "2024-11-05T11:13:19.491237Z",
    "lead_time": 6.635
  },
  {
    "text": "We continue emergency, we are working with governments and other to maintain a strong focus on the appropriate use of antibiotics stakeholders to strengthen global preparedness.",
    "id": 329,
    "annotator": 1,
    "annotation_id": 330,
    "created_at": "2024-11-05T11:13:27.117986Z",
    "updated_at": "2024-11-05T11:13:27.118985Z",
    "lead_time": 7.417
  },
  {
    "text": "This means and enabling access to them.",
    "id": 330,
    "annotator": 1,
    "annotation_id": 331,
    "created_at": "2024-11-05T11:13:28.836245Z",
    "updated_at": "2024-11-05T11:13:28.836245Z",
    "lead_time": 1.515
  },
  {
    "text": "We are committed to exploring drawing on what we have learned from COVID-19 and previous lower income focused indications of our antimicrobials and outbreaks, championing innovation and promoting sustainable vaccines in development, to help maximise their health impact.",
    "id": 331,
    "annotator": 1,
    "annotation_id": 332,
    "created_at": "2024-11-05T11:13:40.878429Z",
    "updated_at": "2024-11-05T11:13:40.878429Z",
    "lead_time": 11.837
  },
  {
    "text": "approaches for the biopharmaceutical sector and public health.",
    "id": 332,
    "annotator": 1,
    "annotation_id": 333,
    "created_at": "2024-11-05T11:13:48.928908Z",
    "updated_at": "2024-11-05T11:13:48.928908Z",
    "lead_time": 7.825
  },
  {
    "text": "We continue to train healthcare professionals around the world We continue to monitor the potential threat of pandemic on using and prescribing antibiotics appropriately, and the influenza, and other emerging infectious diseases with pandemic importance of surveillance studies.",
    "id": 333,
    "annotator": 1,
    "annotation_id": 334,
    "created_at": "2024-11-05T11:16:25.833521Z",
    "updated_at": "2024-11-05T11:16:25.833521Z",
    "lead_time": 156.69
  },
  {
    "text": "As well as maintaining our potential, and we engage in pandemic preparedness dialogue.",
    "id": 334,
    "annotator": 1,
    "annotation_id": 335,
    "created_at": "2024-11-05T11:16:41.402645Z",
    "updated_at": "2024-11-05T11:16:41.402645Z",
    "lead_time": 15.353
  },
  {
    "text": "long-running multinational Survey of Antibiotic Resistance g sk.com: Our position on Antimicrobial Resistance programme, we are developing new resistance surveillance programmes to support antimicrobial assets in late-stage development.",
    "id": 335,
    "annotator": 1,
    "annotation_id": 336,
    "created_at": "2024-11-05T11:16:49.680442Z",
    "updated_at": "2024-11-05T11:16:49.680442Z",
    "lead_time": 8.03
  },
  {
    "text": "In January 2023, the Infection Index launched in India.",
    "id": 336,
    "annotator": 1,
    "annotation_id": 337,
    "created_at": "2024-11-05T11:17:01.018490Z",
    "updated_at": "2024-11-05T11:17:01.018490Z",
    "lead_time": 11.15
  },
  {
    "text": "This has been designed to provide convenient access to information and data to support physicians with appropriate antibiotic decision-making.",
    "id": 337,
    "annotator": 1,
    "annotation_id": 338,
    "created_at": "2024-11-05T11:17:06.665931Z",
    "updated_at": "2024-11-05T11:17:06.665931Z",
    "lead_time": 5.41
  },
  {
    "text": "2020 2021 2022 2023 Global health pipeline assets for priority diseases Number of assets progressed through the Global Health pipeline to address priority WHO diseases 10 5 12 11 PR A Number of active R&D projects that address pathogens prioritised by the WHO and CDC as posing       12 PR the highest level of concern due to drug resistance (critical and\/or urgent threats) PR Metric contributes to our ESG Performance Rating.",
    "id": 338,
    "annotator": 1,
    "annotation_id": 339,
    "created_at": "2024-11-05T11:17:14.492702Z",
    "updated_at": "2024-11-05T11:17:14.492702Z",
    "lead_time": 7.603
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 339,
    "annotator": 1,
    "annotation_id": 340,
    "created_at": "2024-11-05T11:17:18.987498Z",
    "updated_at": "2024-11-05T11:17:18.987498Z",
    "lead_time": 4.29
  },
  {
    "text": "17 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment Climate change and nature loss are an urgent threat to human health, as well as a risk to business resilience.",
    "id": 340,
    "annotator": 1,
    "annotation_id": 341,
    "created_at": "2024-11-05T11:17:24.357291Z",
    "updated_at": "2024-11-05T11:17:24.357291Z",
    "lead_time": 5.181
  },
  {
    "text": "To get ahead of disease and to help ensure long-term business success, we need to take action on climate and nature.",
    "id": 341,
    "annotator": 1,
    "annotation_id": 342,
    "created_at": "2024-11-05T11:17:30.616490Z",
    "updated_at": "2024-11-05T11:17:30.616490Z",
    "lead_time": 6.041
  },
  {
    "text": "10% 100% 100% reduction in operational GSK sites with completed of GSK manufacturing sites carbon emissions (Scope 1 baseline biodiversity within AMR Alliance and and 2) in 2023 from 2022 assessments Wastewater API quality limits Our commitment Commit to a net zero, nature positive, healthier planet with Freshwater ambitious goals set for 2030 and 2045   Average of the percentage of GSK sites and suppliers compliant with wastewater active pharmaceutical ingredient Our ESG Performance Rating metrics 20231 (API) limits and the percentage of sites and suppliers that are Climate compliant with the AMR Industry Alliance Common Antibiotic   Operational emissions reduction (Scope 1 and 2 market- Manufacturing Framework and discharge limits based emissions) Land   Industrialisation of low-carbon Ventolin initiated, and clinical   Percentage of paper and palm oil deforestation free and non-clinical data available to support regulatory submissions Waste and materials   Percentage of carbon offset volume in project pipeline   Operational waste and material reduction at our sites Climate change and nature loss are creating new health threats We are also working to address the impacts of climate change on and changing the spread and burden of disease, with the most health.",
    "id": 342,
    "annotator": 1,
    "annotation_id": 343,
    "created_at": "2024-11-05T11:19:41.904391Z",
    "updated_at": "2024-11-05T11:19:41.904391Z",
    "lead_time": 131.067
  },
  {
    "text": "We re investing in R&D for medicines and vaccines for vulnerable communities disproportionately affected.",
    "id": 343,
    "annotator": 1,
    "annotation_id": 344,
    "created_at": "2024-11-05T11:19:48.083860Z",
    "updated_at": "2024-11-05T11:19:48.083860Z",
    "lead_time": 5.961
  },
  {
    "text": "This puts climate aggravated, infectious diseases which disproportionately increasing pressure on healthcare systems, which already account impact the most vulnerable communities and working with our for nearly 5% of global emissions.",
    "id": 344,
    "annotator": 1,
    "annotation_id": 345,
    "created_at": "2024-11-05T11:19:55.423636Z",
    "updated_at": "2024-11-05T11:19:55.423636Z",
    "lead_time": 7.114
  },
  {
    "text": "partners to increase the resilience of healthcare systems to climate change.",
    "id": 345,
    "annotator": 1,
    "annotation_id": 346,
    "created_at": "2024-11-05T11:20:02.506157Z",
    "updated_at": "2024-11-05T11:20:02.506157Z",
    "lead_time": 6.87
  },
  {
    "text": "For more information, see Global health, on page 15.",
    "id": 346,
    "annotator": 1,
    "annotation_id": 347,
    "created_at": "2024-11-05T11:20:04.805901Z",
    "updated_at": "2024-11-05T11:20:04.805901Z",
    "lead_time": 2.098
  },
  {
    "text": "That s why we have set ambitious environmental goals for 2030 and 2045.",
    "id": 347,
    "annotator": 1,
    "annotation_id": 348,
    "created_at": "2024-11-05T11:20:08.556437Z",
    "updated_at": "2024-11-05T11:20:08.556437Z",
    "lead_time": 3.54
  },
  {
    "text": "These aim to address our impacts across our entire Collaboration across our entire value chain   with patients, value chain, from drug discovery to disposal of our products.",
    "id": 348,
    "annotator": 1,
    "annotation_id": 349,
    "created_at": "2024-11-05T11:20:14.115597Z",
    "updated_at": "2024-11-05T11:20:14.115597Z",
    "lead_time": 5.362
  },
  {
    "text": "They suppliers, regulators and peers   is vital to achieving our goals.",
    "id": 349,
    "annotator": 1,
    "annotation_id": 350,
    "created_at": "2024-11-05T11:20:22.029145Z",
    "updated_at": "2024-11-05T11:20:22.029145Z",
    "lead_time": 7.706
  },
  {
    "text": "will help make GSK more resilient, protect our supply chains, help We also collaborate internally to ensure we embed climate and us adapt ahead of anticipated regulation change and provide nature considerations throughout the business.",
    "id": 350,
    "annotator": 1,
    "annotation_id": 351,
    "created_at": "2024-11-05T11:20:27.703129Z",
    "updated_at": "2024-11-05T11:20:27.703129Z",
    "lead_time": 5.458
  },
  {
    "text": "potential growth opportunities as demand increases for medicines and vaccines with a lower environmental impact.",
    "id": 351,
    "annotator": 1,
    "annotation_id": 352,
    "created_at": "2024-11-05T11:20:34.328781Z",
    "updated_at": "2024-11-05T11:20:34.328781Z",
    "lead_time": 6.439
  },
  {
    "text": "Climate We have a clear pathway to a net zero impact on climate with Targets:3 ambitious goals for 2030 and 2045.",
    "id": 352,
    "annotator": 1,
    "annotation_id": 353,
    "created_at": "2024-11-05T11:20:40.801568Z",
    "updated_at": "2024-11-05T11:20:40.801568Z",
    "lead_time": 6.262
  },
  {
    "text": "80% absolute reduction in greenhouse gas emissions from a Our value chain carbon footprint2 is made up of: 2020 baseline, across all scopes, and investment in nature- based solutions for the remaining 20% of our footprint by 2030)   Scope 1 and 2 emissions from our own operations (7%)   100% imported renewable electricity by 2025 and 100%   Scope 3 emissions from our supply chain (31%) renewable electricity (imported and generated) by 2030   Scope 3 emissions from logistics (4%) (Scope 2)   Scope 3 emissions from people using our products (57%),   Net zero greenhouse gas emissions across our full value chain by mostly metered-dose inhalers 2045: 90% absolute reduction in emissions from a 2020 baseline,   Scope 3 emissions from the disposal of our products (1%) across all scopes, and all residual emissions neutralised 1 T hese metrics are related to the ESG Performance Rating 2023 outlined on pages 6-7.",
    "id": 353,
    "label": [
      {
        "start": 0,
        "end": 22,
        "text": "80% absolute reduction",
        "labels": [
          "value"
        ]
      },
      {
        "start": 26,
        "end": 50,
        "text": "greenhouse gas emissions",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 354,
    "created_at": "2024-11-05T11:21:36.961627Z",
    "updated_at": "2024-11-05T11:21:36.961627Z",
    "lead_time": 55.943
  },
  {
    "text": "We also measure and report performance against our environmental sustainability targets, which we publish on +gsk.com.",
    "id": 354,
    "annotator": 1,
    "annotation_id": 355,
    "created_at": "2024-11-05T11:21:43.966332Z",
    "updated_at": "2024-11-05T11:21:43.966332Z",
    "lead_time": 6.776
  },
  {
    "text": "2 Based on 2022 data.",
    "id": 355,
    "annotator": 1,
    "annotation_id": 356,
    "created_at": "2024-11-05T11:21:45.387452Z",
    "updated_at": "2024-11-05T11:21:45.387452Z",
    "lead_time": 1.241
  },
  {
    "text": "3 The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks.",
    "id": 356,
    "annotator": 1,
    "annotation_id": 357,
    "created_at": "2024-11-05T11:21:50.469812Z",
    "updated_at": "2024-11-05T11:21:50.469812Z",
    "lead_time": 4.886
  },
  {
    "text": "18 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued In 2023, The Science Based Targets initiative (SBTi) approved Our Sustainable Procurement Programme requires our suppliers GSK s net zero target for 2045 in line with its Corporate Net-Zero to take action on both climate and nature.",
    "id": 357,
    "annotator": 1,
    "annotation_id": 358,
    "created_at": "2024-11-05T11:21:58.919539Z",
    "updated_at": "2024-11-05T11:21:58.919539Z",
    "lead_time": 8.226
  },
  {
    "text": "At the same time, we Standard, the world s only framework for corporate net zero target actively support our suppliers to adopt new environmental setting in line with climate science.",
    "id": 358,
    "annotator": 1,
    "annotation_id": 359,
    "created_at": "2024-11-05T11:22:03.996790Z",
    "updated_at": "2024-11-05T11:22:03.996790Z",
    "lead_time": 4.859
  },
  {
    "text": "sustainability measures, with a particular focus on the top 30 suppliers by climate and nature impact.",
    "id": 359,
    "annotator": 1,
    "annotation_id": 360,
    "created_at": "2024-11-05T11:22:09.619497Z",
    "updated_at": "2024-11-05T11:22:09.619497Z",
    "lead_time": 5.444
  },
  {
    "text": "g sk.com: Net zero pathway We have started to include contract clauses on carbon reductions Managing our operational footprint for these priority suppliers.",
    "id": 360,
    "annotator": 1,
    "annotation_id": 361,
    "created_at": "2024-11-05T11:22:16.229975Z",
    "updated_at": "2024-11-05T11:22:16.229975Z",
    "lead_time": 6.417
  },
  {
    "text": "In 2023, 23% of our top 30 suppliers by In 2023, we reduced our Scope 1 and 2 carbon emissions by 10% carbon emissions have submitted science based targets for compared with 2022, and by 27% compared with our 2020 validation, and eight of those have had the targets approved.",
    "id": 361,
    "annotator": 1,
    "annotation_id": 362,
    "created_at": "2024-11-05T11:22:26.979360Z",
    "updated_at": "2024-11-05T11:22:26.979360Z",
    "lead_time": 10.535
  },
  {
    "text": "In baseline.",
    "id": 362,
    "annotator": 1,
    "annotation_id": 363,
    "created_at": "2024-11-05T11:22:28.210721Z",
    "updated_at": "2024-11-05T11:22:28.210721Z",
    "lead_time": 1.026
  },
  {
    "text": "This was primarily due to energy efficiency measures 2023, we completed deep-dives for two of our key suppliers to and increasing the amount of renewable electricity we use.",
    "id": 363,
    "annotator": 1,
    "annotation_id": 364,
    "created_at": "2024-11-05T11:22:34.063130Z",
    "updated_at": "2024-11-05T11:22:34.063130Z",
    "lead_time": 5.643
  },
  {
    "text": "For identify opportunities to reduce energy and water usage and example, our Nashik site in India has reduced its emissions by 93% switch to renewable energy sources.",
    "id": 364,
    "annotator": 1,
    "annotation_id": 365,
    "created_at": "2024-11-05T11:22:39.943045Z",
    "updated_at": "2024-11-05T11:22:39.943045Z",
    "lead_time": 5.658
  },
  {
    "text": "since 2020, by moving to renewable biomass for heat and to We are also engaging more broadly across our supply chain.",
    "id": 365,
    "label": [
      {
        "start": 24,
        "end": 51,
        "text": " renewable biomass for heat",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 25,
        "end": 51,
        "text": "renewable biomass for heat",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 366,
    "created_at": "2024-11-05T11:23:12.777729Z",
    "updated_at": "2024-11-05T11:23:12.777729Z",
    "lead_time": 32.612
  },
  {
    "text": "renewable electricity.",
    "id": 366,
    "annotator": 1,
    "annotation_id": 367,
    "created_at": "2024-11-05T11:23:13.630356Z",
    "updated_at": "2024-11-05T11:23:13.630356Z",
    "lead_time": 0.611
  },
  {
    "text": "In May 2023, as part of our Supplier Forum, attended by 56 As a member of the RE100 initiative, we have committed to reach suppliers, we held three sustainability roundtables focused on 100% of our imported electricity from renewable sources by 2025 addressing common challenges and potential solutions.",
    "id": 367,
    "annotator": 1,
    "annotation_id": 368,
    "created_at": "2024-11-05T11:23:23.170612Z",
    "updated_at": "2024-11-05T11:23:23.170612Z",
    "lead_time": 9.32
  },
  {
    "text": "We and 100% of all electricity we generate and import from launched the Sustainability Foundations programme in January renewable sources by 2030.",
    "id": 368,
    "annotator": 1,
    "annotation_id": 369,
    "created_at": "2024-11-05T11:23:54.225319Z",
    "updated_at": "2024-11-05T11:23:54.225319Z",
    "lead_time": 30.828
  },
  {
    "text": "In 2023, we reached 83% imported 2023 with over 50 GSK procurement employees attending three renewable electricity, an increase of 10% from 2022.",
    "id": 369,
    "annotator": 1,
    "annotation_id": 370,
    "created_at": "2024-11-05T11:24:09.484945Z",
    "updated_at": "2024-11-05T11:24:09.484945Z",
    "lead_time": 15.042
  },
  {
    "text": "hours of training, focused on climate and nature.",
    "id": 370,
    "annotator": 1,
    "annotation_id": 371,
    "created_at": "2024-11-05T11:24:11.091826Z",
    "updated_at": "2024-11-05T11:24:11.091826Z",
    "lead_time": 1.364
  },
  {
    "text": "Participants reported a 60% increase in confidence and competence in We signed a power purchase agreement to source renewable explaining our ambition to suppliers and ensuring our electricity to cover 50% of our electricity demand for our sites in environmental goals are aligned.",
    "id": 371,
    "annotator": 1,
    "annotation_id": 372,
    "created_at": "2024-11-05T11:24:23.221680Z",
    "updated_at": "2024-11-05T11:24:23.221680Z",
    "lead_time": 11.899
  },
  {
    "text": "Europe from mid-2026.",
    "id": 372,
    "annotator": 1,
    "annotation_id": 373,
    "created_at": "2024-11-05T11:24:24.187472Z",
    "updated_at": "2024-11-05T11:24:24.187472Z",
    "lead_time": 0.728
  },
  {
    "text": "Two additional wind turbines and the new solar farm at our manufacturing facility in Irvine, Scotland began Supply chain emissions are a shared challenge for our sector, generating renewable energy.",
    "id": 373,
    "annotator": 1,
    "annotation_id": 374,
    "created_at": "2024-11-05T11:24:30.416183Z",
    "updated_at": "2024-11-05T11:24:30.416183Z",
    "lead_time": 5.983
  },
  {
    "text": "so we are working in collaboration across our industry through programmes like Activate, Energize and the Sustainable Markets We seek to follow leading practice in laboratory sustainability.",
    "id": 374,
    "annotator": 1,
    "annotation_id": 375,
    "created_at": "2024-11-05T11:24:47.381152Z",
    "updated_at": "2024-11-05T11:24:47.381152Z",
    "lead_time": 16.765
  },
  {
    "text": "In Initiative (SMI) Health Systems Task Force, to find solutions.",
    "id": 375,
    "annotator": 1,
    "annotation_id": 376,
    "created_at": "2024-11-05T11:24:55.399921Z",
    "updated_at": "2024-11-05T11:24:55.399921Z",
    "lead_time": 7.785
  },
  {
    "text": "2023, seven of our laboratories in the United States, Canada and the UK achieved My Green Lab Certification, which is considered To date, 10 of our top 30 suppliers by carbon emissions have the gold standard for laboratory sustainability best practices registered to join the Activate programme focused on reducing around the world, covering community engagement, energy, water, emissions from the production of active pharmaceutical waste and resource management.",
    "id": 376,
    "label": [
      {
        "start": 6,
        "end": 31,
        "text": "seven of our laboratories",
        "labels": [
          "value"
        ]
      },
      {
        "start": 80,
        "end": 107,
        "text": " My Green Lab Certification",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 377,
    "created_at": "2024-11-05T11:27:17.206985Z",
    "updated_at": "2024-11-05T11:27:17.206985Z",
    "lead_time": 141.602
  },
  {
    "text": "Three of these received the ingredients.",
    "id": 377,
    "annotator": 1,
    "annotation_id": 378,
    "created_at": "2024-11-05T11:27:42.551765Z",
    "updated_at": "2024-11-05T11:27:42.551765Z",
    "lead_time": 25.101
  },
  {
    "text": "highest level of certification.",
    "id": 378,
    "annotator": 1,
    "annotation_id": 379,
    "created_at": "2024-11-05T11:27:44.260774Z",
    "updated_at": "2024-11-05T11:27:44.260774Z",
    "lead_time": 1.476
  },
  {
    "text": "We now have ten laboratories certified In July, our CEO signed an open letter alongside other healthcare across our network with a further ten in the assessment process.",
    "id": 379,
    "annotator": 1,
    "annotation_id": 380,
    "created_at": "2024-11-05T11:27:50.595058Z",
    "updated_at": "2024-11-05T11:27:50.595058Z",
    "lead_time": 6.106
  },
  {
    "text": "leaders in the SMI Health Systems Task Force, calling on our We are a member of EV100 and are committed to transition 100% suppliers to sign-up to the joint minimum climate and of our fleet to electric or hybrid vehicles and to install chargers at 100 sustainability targets set by the Task Force.",
    "id": 380,
    "annotator": 1,
    "annotation_id": 381,
    "created_at": "2024-11-05T11:27:58.874577Z",
    "updated_at": "2024-11-05T11:27:58.874577Z",
    "lead_time": 8.058
  },
  {
    "text": "of our sites by 2030.",
    "id": 381,
    "annotator": 1,
    "annotation_id": 382,
    "created_at": "2024-11-05T11:28:00.508833Z",
    "updated_at": "2024-11-05T11:28:00.508833Z",
    "lead_time": 1.401
  },
  {
    "text": "Plug-in-hybrid or fully electric vehicles made up In December, My Green Lab launched Converge, a collaborative 6% of our sales fleet and 16% of our total fleet in 2023.",
    "id": 382,
    "annotator": 1,
    "annotation_id": 383,
    "created_at": "2024-11-05T11:28:12.354004Z",
    "updated_at": "2024-11-05T11:28:12.354004Z",
    "lead_time": 11.624
  },
  {
    "text": "We have supply chain initiative to encourage suppliers to reduce the chargers at 30 major sites and have increased the number of environmental impact of labs in their value chain.",
    "id": 383,
    "annotator": 1,
    "annotation_id": 384,
    "created_at": "2024-11-05T11:28:21.849323Z",
    "updated_at": "2024-11-05T11:28:21.849323Z",
    "lead_time": 9.226
  },
  {
    "text": "GSK is one of charging points to nearly 500.",
    "id": 384,
    "annotator": 1,
    "annotation_id": 385,
    "created_at": "2024-11-05T11:28:24.368951Z",
    "updated_at": "2024-11-05T11:28:24.370116Z",
    "lead_time": 2.268
  },
  {
    "text": "the founding sponsors of the initiative.",
    "id": 385,
    "annotator": 1,
    "annotation_id": 386,
    "created_at": "2024-11-05T11:28:25.368433Z",
    "updated_at": "2024-11-05T11:28:25.368433Z",
    "lead_time": 0.749
  },
  {
    "text": "Addressing our Scope 3 emissions Emissions from the use of our products Our overall Scope 3 emissions are 10% lower than our baseline The use of our medicines and vaccines makes up 57% of our total year of 2020, although there was a 4% increase in 2022 (our latest footprint.",
    "id": 386,
    "annotator": 1,
    "annotation_id": 387,
    "created_at": "2024-11-05T11:31:33.807289Z",
    "updated_at": "2024-11-05T11:31:33.807289Z",
    "lead_time": 188.166
  },
  {
    "text": "Most of this is from the propellant used in metered-dose available data) compared with 2021.",
    "id": 387,
    "annotator": 1,
    "annotation_id": 388,
    "created_at": "2024-11-05T11:31:41.543340Z",
    "updated_at": "2024-11-05T11:31:41.543340Z",
    "lead_time": 7.502
  },
  {
    "text": "This was primarily driven by inhalers for asthma and chronic obstructive pulmonary disease higher sales of metered dose inhaler products.",
    "id": 388,
    "annotator": 1,
    "annotation_id": 389,
    "created_at": "2024-11-05T11:31:46.833597Z",
    "updated_at": "2024-11-05T11:31:46.833597Z",
    "lead_time": 5.089
  },
  {
    "text": "We set out below (COPD).",
    "id": 389,
    "annotator": 1,
    "annotation_id": 390,
    "created_at": "2024-11-05T11:31:48.592236Z",
    "updated_at": "2024-11-05T11:31:48.592236Z",
    "lead_time": 1.527
  },
  {
    "text": "the steps we are taking to reduce the emissions associated with GSK s rescue metered dose inhaler (MDI) medication, Ventolin metered dose inhalers.",
    "id": 390,
    "annotator": 1,
    "annotation_id": 391,
    "created_at": "2024-11-05T11:31:54.708779Z",
    "updated_at": "2024-11-05T11:31:54.708779Z",
    "lead_time": 5.89
  },
  {
    "text": "Although overall Scope 3 emissions (salbutamol) is an essential medicine prescribed to approximately increased from 2021 to 2022, in the same period, we reduced 35 million people with respiratory conditions worldwide.",
    "id": 391,
    "annotator": 1,
    "annotation_id": 392,
    "created_at": "2024-11-05T11:32:10.459809Z",
    "updated_at": "2024-11-05T11:32:10.459809Z",
    "lead_time": 15.552
  },
  {
    "text": "Patient upstream Scope 3 emissions from our suppliers, see more below.",
    "id": 392,
    "annotator": 1,
    "annotation_id": 393,
    "created_at": "2024-11-05T11:32:16.632609Z",
    "updated_at": "2024-11-05T11:32:16.632609Z",
    "lead_time": 5.925
  },
  {
    "text": "use of this inhaler, due to the current propellant, accounts for just under half (48%) of our carbon footprint.",
    "id": 393,
    "annotator": 1,
    "annotation_id": 394,
    "created_at": "2024-11-05T11:32:23.180045Z",
    "updated_at": "2024-11-05T11:32:23.180045Z",
    "lead_time": 6.294
  },
  {
    "text": "We are investing in a Supply chain emissions low-carbon programme with the potential to reduce greenhouse The goods and services we buy to make our medicines and gas emissions from the inhaler by 90% by transitioning to a next vaccines, and additional upstream emissions, account for generation, lower-carbon propellant.",
    "id": 394,
    "annotator": 1,
    "annotation_id": 395,
    "created_at": "2024-11-05T11:32:32.564260Z",
    "updated_at": "2024-11-05T11:32:32.564260Z",
    "lead_time": 9.149
  },
  {
    "text": "Phase III trials will begin in approximately 31% of our total carbon emissions footprint.",
    "id": 395,
    "annotator": 1,
    "annotation_id": 396,
    "created_at": "2024-11-05T11:32:39.425798Z",
    "updated_at": "2024-11-05T11:32:39.425798Z",
    "lead_time": 6.656
  },
  {
    "text": "In 2023, 2024 and, if successful, regulatory submissions will start in 2025.",
    "id": 396,
    "annotator": 1,
    "annotation_id": 397,
    "created_at": "2024-11-05T11:32:42.306809Z",
    "updated_at": "2024-11-05T11:32:42.306809Z",
    "lead_time": 2.692
  },
  {
    "text": "our supply chain emissions fell by 2%.",
    "id": 397,
    "annotator": 1,
    "annotation_id": 398,
    "created_at": "2024-11-05T11:32:44.210437Z",
    "updated_at": "2024-11-05T11:32:44.210437Z",
    "lead_time": 1.666
  },
  {
    "text": "This is to supplement our existing low carbon dry powder inhalers.",
    "id": 398,
    "annotator": 1,
    "annotation_id": 399,
    "created_at": "2024-11-05T11:32:49.308967Z",
    "updated_at": "2024-11-05T11:32:49.308967Z",
    "lead_time": 4.884
  },
  {
    "text": "Climate-related financial disclosures See pages 62-70 in our Annual Report for our disclosure on climate risk and resilience in line with the Task Force on Climate- related Financial Disclosures (TCFD) framework.",
    "id": 399,
    "annotator": 1,
    "annotation_id": 400,
    "created_at": "2024-11-05T11:32:55.436710Z",
    "updated_at": "2024-11-05T11:32:55.436710Z",
    "lead_time": 5.921
  },
  {
    "text": "19 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued Nature In 2023, we shared more detail on our plan for contributing to a We achieved our overall water reduction target in 2022.",
    "id": 400,
    "annotator": 1,
    "annotation_id": 401,
    "created_at": "2024-11-05T11:33:14.957445Z",
    "updated_at": "2024-11-05T11:33:14.957445Z",
    "lead_time": 19.298
  },
  {
    "text": "In 2023, nature-positive world, in line with the goal of the Global we reduced overall water use in our operations by an additional Biodiversity Framework to halt and reverse biodiversity loss by 1% compared with 2022 and by 6% in sites in high water-stress 2030.",
    "id": 401,
    "label": [
      {
        "start": 188,
        "end": 198,
        "text": "loss by 1%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 79,
        "end": 114,
        "text": "overall water use in our operations",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 402,
    "created_at": "2024-11-05T11:34:03.772457Z",
    "updated_at": "2024-11-05T11:34:03.772457Z",
    "lead_time": 48.581
  },
  {
    "text": "It sets out how we approach action on nature through four regions.",
    "id": 402,
    "annotator": 1,
    "annotation_id": 403,
    "created_at": "2024-11-05T11:34:06.769584Z",
    "updated_at": "2024-11-05T11:34:06.769584Z",
    "lead_time": 2.753
  },
  {
    "text": "This is a decrease of 24% for overall water use and 11% for focus areas   freshwater, land, oceans and atmosphere   sites in high water-stress regions against our 2020 baseline.",
    "id": 403,
    "annotator": 1,
    "annotation_id": 404,
    "created_at": "2024-11-05T11:35:17.085900Z",
    "updated_at": "2024-11-05T11:35:17.085900Z",
    "lead_time": 70.085
  },
  {
    "text": "including the biodiversity of living species across these areas.",
    "id": 404,
    "annotator": 1,
    "annotation_id": 405,
    "created_at": "2024-11-05T11:35:19.393439Z",
    "updated_at": "2024-11-05T11:35:19.393439Z",
    "lead_time": 2.07
  },
  {
    "text": "1 We have implemented water efficiency and reuse systems at a We aim to deliver our contribution in three ways: avoiding or number of our sites, including Pakistan, which is increasing its reducing our impact on nature, protecting and restoring nature, recycled water capacity.",
    "id": 405,
    "annotator": 1,
    "annotation_id": 406,
    "created_at": "2024-11-05T11:35:26.925466Z",
    "updated_at": "2024-11-05T11:35:26.925466Z",
    "lead_time": 7.314
  },
  {
    "text": "At our Wavre site in Belgium, a pilot and helping to accelerate collaborative action.",
    "id": 406,
    "annotator": 1,
    "annotation_id": 407,
    "created_at": "2024-11-05T11:35:29.986575Z",
    "updated_at": "2024-11-05T11:35:29.986575Z",
    "lead_time": 2.843
  },
  {
    "text": "This approach is wastewater treatment station has been installed to enable reuse aligned with the work of the Taskforce on Nature-related of our wastewater to reduce water consumption.",
    "id": 407,
    "annotator": 1,
    "annotation_id": 408,
    "created_at": "2024-11-05T11:35:34.696211Z",
    "updated_at": "2024-11-05T11:35:34.696211Z",
    "lead_time": 4.473
  },
  {
    "text": "Financial Disclosures (TNFD) and the Science Based Target Network (SBTN).",
    "id": 408,
    "annotator": 1,
    "annotation_id": 409,
    "created_at": "2024-11-05T11:36:15.813259Z",
    "updated_at": "2024-11-05T11:36:15.813259Z",
    "lead_time": 40.861
  },
  {
    "text": "For our sites and key suppliers located in water-stressed areas, we are developing catchment-level water replenishment, restoration The overuse of natural resources and the generation of waste and and regeneration projects to deliver our water neutrality target.",
    "id": 409,
    "annotator": 1,
    "annotation_id": 410,
    "created_at": "2024-11-05T11:36:24.964099Z",
    "updated_at": "2024-11-05T11:36:24.964099Z",
    "lead_time": 8.941
  },
  {
    "text": "pollution are key drivers of nature loss, so we have also set underlying targets on waste and materials.",
    "id": 410,
    "annotator": 1,
    "annotation_id": 411,
    "created_at": "2024-11-05T11:36:30.485017Z",
    "updated_at": "2024-11-05T11:36:30.485017Z",
    "lead_time": 5.272
  },
  {
    "text": "We have partnered with a local NGO, Watershed Organisation Trust (WOTR), in Nashik, India on a water replenishment project In May 2023, we were selected to be part of the first group of designed to improve ecosystem conditions, enhance the climate companies to participate in the initial target validation process resilience of local agriculture, and help local villages manage with SBTN to set validated science-based targets for nature, water resources to improve their health and livelihoods.",
    "id": 411,
    "annotator": 1,
    "annotation_id": 412,
    "created_at": "2024-11-05T11:36:42.431717Z",
    "updated_at": "2024-11-05T11:36:42.431717Z",
    "lead_time": 11.728
  },
  {
    "text": "starting with targets for freshwater and land, followed by targets for oceans and biodiversity.",
    "id": 412,
    "annotator": 1,
    "annotation_id": 413,
    "created_at": "2024-11-05T11:36:46.624379Z",
    "updated_at": "2024-11-05T11:36:46.624379Z",
    "lead_time": 3.957
  },
  {
    "text": "These targets will focus on locations We are also a founding partner of the Women + Water across our value chain where nature is particularly under pressure.",
    "id": 413,
    "annotator": 1,
    "annotation_id": 414,
    "created_at": "2024-11-05T11:36:51.621633Z",
    "updated_at": "2024-11-05T11:36:51.621633Z",
    "lead_time": 4.797
  },
  {
    "text": "Collaborative in India, which launched in October 2023, working with the Water Resilience Coalition, an initiative between the UN TNFD published its final framework in September   an outcome Global Compact and the Pacific Institute.",
    "id": 414,
    "annotator": 1,
    "annotation_id": 415,
    "created_at": "2024-11-05T11:36:56.500134Z",
    "updated_at": "2024-11-05T11:36:56.500134Z",
    "lead_time": 4.67
  },
  {
    "text": "This programme brings of the pilot framework that we and others were already testing.",
    "id": 415,
    "annotator": 1,
    "annotation_id": 416,
    "created_at": "2024-11-05T11:37:00.914333Z",
    "updated_at": "2024-11-05T11:37:00.914333Z",
    "lead_time": 4.189
  },
  {
    "text": "together companies from different sectors to leverage women s We announced our commitment to adopting TNFD-aligned leadership to improve access to clean water and sanitation, disclosures in 2026, based on 2025 data.",
    "id": 416,
    "annotator": 1,
    "annotation_id": 417,
    "created_at": "2024-11-05T11:37:12.891039Z",
    "updated_at": "2024-11-05T11:37:12.891039Z",
    "lead_time": 11.759
  },
  {
    "text": "We have already started ultimately supporting the health of local communities.",
    "id": 417,
    "annotator": 1,
    "annotation_id": 418,
    "created_at": "2024-11-05T11:37:14.419835Z",
    "updated_at": "2024-11-05T11:37:14.419835Z",
    "lead_time": 1.303
  },
  {
    "text": "to implement the final recommendations in our 2023 disclosure on page 70 of the Annual Report.",
    "id": 418,
    "annotator": 1,
    "annotation_id": 419,
    "created_at": "2024-11-05T11:37:16.813911Z",
    "updated_at": "2024-11-05T11:37:16.813911Z",
    "lead_time": 2.168
  },
  {
    "text": "We are committed to ensuring that discharges from the manufacturing of APIs, including antibiotics, do not adversely affect gsk.com: Our plan for contributing to a nature positive world people or the environment.",
    "id": 419,
    "annotator": 1,
    "annotation_id": 420,
    "created_at": "2024-11-05T11:37:24.844083Z",
    "updated_at": "2024-11-05T11:37:24.844083Z",
    "lead_time": 7.811
  },
  {
    "text": "In 2023, 87% of all sites and key suppliers were compliant with AMR Alliance and API Wastewater discharge Freshwater limits, down from 94% in 2022.",
    "id": 420,
    "annotator": 1,
    "annotation_id": 421,
    "created_at": "2024-11-05T11:37:42.555316Z",
    "updated_at": "2024-11-05T11:37:42.555316Z",
    "lead_time": 17.468
  },
  {
    "text": "This is driven by us expanding our We continue to work towards our existing water targets (set out scope to include more API suppliers which led to a decrease in the below) and, as part of the SBTN pilot, we are currently working to percentage of key suppliers that were confirmed to be within implement their guidance and validate our freshwater targets.",
    "id": 421,
    "annotator": 1,
    "annotation_id": 422,
    "created_at": "2024-11-05T11:40:01.496364Z",
    "updated_at": "2024-11-05T11:40:01.496364Z",
    "lead_time": 7.936
  },
  {
    "text": "Wastewater API discharge limits.",
    "id": 422,
    "annotator": 1,
    "annotation_id": 423,
    "created_at": "2024-11-05T11:40:03.323754Z",
    "updated_at": "2024-11-05T11:40:03.323754Z",
    "lead_time": 1.599
  },
  {
    "text": "We are now engaging with these Targets additional suppliers to assess their alignment with discharge limits, and support improvements where necessary.",
    "id": 423,
    "annotator": 1,
    "annotation_id": 424,
    "created_at": "2024-11-05T11:40:09.774167Z",
    "updated_at": "2024-11-05T11:40:09.774167Z",
    "lead_time": 6.229
  },
  {
    "text": "100% of GSK sites   Achieve good water stewardship at 100% of our sites by 2025 were within AMR Alliance and Wastewater API quality limits.",
    "id": 424,
    "annotator": 1,
    "annotation_id": 425,
    "created_at": "2024-11-05T11:40:14.540388Z",
    "updated_at": "2024-11-05T11:40:14.540388Z",
    "lead_time": 4.53
  },
  {
    "text": "Reduce overall water use in our operations by 20% by 2030 To support the responsible manufacturing of antibiotics, we work   Be water neutral in our own operations and at key suppliers in with the AMR Industry Alliance to set global limits for wastewater water-stressed regions by 2030 antibiotic discharges from factories.",
    "id": 425,
    "annotator": 1,
    "annotation_id": 426,
    "created_at": "2024-11-05T11:40:24.262936Z",
    "updated_at": "2024-11-05T11:40:24.262936Z",
    "lead_time": 9.492
  },
  {
    "text": "Our work to strengthen   Achieve zero impact active API levels2 for all sites and key responsible manufacturing of antibiotics was highlighted as an suppliers by 2030 example of good practice in a 2023 report on the issue from the We depend on water for the production of our vaccines and Access to Medicine Foundation s AMR Benchmark.",
    "id": 426,
    "annotator": 1,
    "annotation_id": 427,
    "created_at": "2024-11-05T11:40:31.533853Z",
    "updated_at": "2024-11-05T11:40:31.534357Z",
    "lead_time": 7.023
  },
  {
    "text": "medicines.",
    "id": 427,
    "annotator": 1,
    "annotation_id": 428,
    "created_at": "2024-11-05T11:40:32.777599Z",
    "updated_at": "2024-11-05T11:40:32.777599Z",
    "lead_time": 1.023
  },
  {
    "text": "Our primary impact on water availability is through our manufacturing sites located in areas of water-stress.",
    "id": 428,
    "annotator": 1,
    "annotation_id": 429,
    "created_at": "2024-11-05T11:40:37.794488Z",
    "updated_at": "2024-11-05T11:40:37.794488Z",
    "lead_time": 4.824
  },
  {
    "text": "Land 100% of our sites are good water stewards, in line with the Alliance We continue to deliver on our existing land targets (set out below).",
    "id": 429,
    "annotator": 1,
    "annotation_id": 430,
    "created_at": "2024-11-05T11:40:43.513750Z",
    "updated_at": "2024-11-05T11:40:43.513750Z",
    "lead_time": 5.519
  },
  {
    "text": "for Water Stewardship s definition.",
    "id": 430,
    "annotator": 1,
    "annotation_id": 431,
    "created_at": "2024-11-05T11:40:46.633082Z",
    "updated_at": "2024-11-05T11:40:46.633082Z",
    "lead_time": 2.89
  },
  {
    "text": "In 2023, we started the Alliance Additionally, we are piloting the SBTN guidance for setting land for Water Stewardship Standards certification process for our five targets.",
    "id": 431,
    "annotator": 1,
    "annotation_id": 432,
    "created_at": "2024-11-05T11:40:53.555887Z",
    "updated_at": "2024-11-05T11:40:53.555887Z",
    "lead_time": 6.724
  },
  {
    "text": "water-stressed sites in Algeria, India and Pakistan.",
    "id": 432,
    "annotator": 1,
    "annotation_id": 433,
    "created_at": "2024-11-05T11:40:54.823707Z",
    "updated_at": "2024-11-05T11:40:54.823707Z",
    "lead_time": 1.025
  },
  {
    "text": "The site teams Targets have passed their training on the Standard and are working to implement it by 2025.",
    "id": 433,
    "annotator": 1,
    "annotation_id": 434,
    "created_at": "2024-11-05T11:41:02.135619Z",
    "updated_at": "2024-11-05T11:41:02.135619Z",
    "lead_time": 7.092
  },
  {
    "text": "Positive impact on biodiversity at all sites3 by 2030   100% of agricultural and forestry-derived materials sustainably sourced and deforestation free by 2030 1 I n previous ESG Performance Reports, our nature targets are grouped by water, waste and materials, and biodiversity.",
    "id": 434,
    "label": [
      {
        "start": 56,
        "end": 60,
        "text": "100%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 64,
        "end": 127,
        "text": "agricultural and forestry-derived materials sustainably sourced",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 435,
    "created_at": "2024-11-05T11:41:29.470382Z",
    "updated_at": "2024-11-05T11:41:29.470382Z",
    "lead_time": 27.115
  },
  {
    "text": "When we published   Our plan for contributing to a nature positive world  in September 2023, we updated our target categories to align with the four areas of nature as defined by TNFD and SBTN, with underlying targets on waste and materials.",
    "id": 435,
    "annotator": 1,
    "annotation_id": 436,
    "created_at": "2024-11-05T11:41:45.552403Z",
    "updated_at": "2024-11-05T11:41:45.552403Z",
    "lead_time": 15.822
  },
  {
    "text": "The targets remain the same.",
    "id": 436,
    "annotator": 1,
    "annotation_id": 437,
    "created_at": "2024-11-05T11:41:47.316487Z",
    "updated_at": "2024-11-05T11:41:47.316487Z",
    "lead_time": 1.502
  },
  {
    "text": "2 Below the predicted no-effect level.",
    "id": 437,
    "annotator": 1,
    "annotation_id": 438,
    "created_at": "2024-11-05T11:41:51.027630Z",
    "updated_at": "2024-11-05T11:41:51.027630Z",
    "lead_time": 3.461
  },
  {
    "text": "3 GSK-owned sites.",
    "id": 438,
    "annotator": 1,
    "annotation_id": 439,
    "created_at": "2024-11-05T11:41:52.277526Z",
    "updated_at": "2024-11-05T11:41:52.277526Z",
    "lead_time": 1.026
  },
  {
    "text": "20 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued Land degradation, due to poor land management or land For example, we use horseshoe crab blood, which is an important conversion, can have a range of negative health impacts.",
    "id": 439,
    "annotator": 1,
    "annotation_id": 440,
    "created_at": "2024-11-05T11:43:23.193691Z",
    "updated_at": "2024-11-05T11:43:23.193691Z",
    "lead_time": 90.663
  },
  {
    "text": "Our substance that is required by some regulators to be used in primary dependency on land is through the natural materials we pharmaceutical and biomedical quality control processes to source, some of which derive from agricultural commodities.",
    "id": 440,
    "annotator": 1,
    "annotation_id": 441,
    "created_at": "2024-11-05T11:43:35.006516Z",
    "updated_at": "2024-11-05T11:43:35.006516Z",
    "lead_time": 11.536
  },
  {
    "text": "Their ensure the quality and safety of medicines, vaccines and devices.",
    "id": 441,
    "annotator": 1,
    "annotation_id": 442,
    "created_at": "2024-11-05T11:43:39.712845Z",
    "updated_at": "2024-11-05T11:43:39.712845Z",
    "lead_time": 4.467
  },
  {
    "text": "production can drive deforestation and land-use change.",
    "id": 442,
    "annotator": 1,
    "annotation_id": 443,
    "created_at": "2024-11-05T11:43:43.852577Z",
    "updated_at": "2024-11-05T11:43:43.852577Z",
    "lead_time": 3.899
  },
  {
    "text": "We continue to make progress on volume reductions, and we are During 2023, we completed baseline assessments for six sites, advancing a pilot across five of our sites to test the use of non- meaning we have now assessed all our sites, using the Natural animal alternatives.",
    "id": 443,
    "annotator": 1,
    "annotation_id": 444,
    "created_at": "2024-11-05T11:44:20.287845Z",
    "updated_at": "2024-11-05T11:44:20.287845Z",
    "lead_time": 36.208
  },
  {
    "text": "At the same time, we are engaging with England Biodiversity Net Positive methodology.",
    "id": 444,
    "annotator": 1,
    "annotation_id": 445,
    "created_at": "2024-11-05T11:44:28.733333Z",
    "updated_at": "2024-11-05T11:44:28.733333Z",
    "lead_time": 8.215
  },
  {
    "text": "In parallel, we regulators to support wider uptake of these alternatives.",
    "id": 445,
    "annotator": 1,
    "annotation_id": 446,
    "created_at": "2024-11-05T11:44:34.330568Z",
    "updated_at": "2024-11-05T11:44:34.330568Z",
    "lead_time": 5.377
  },
  {
    "text": "have plans in place to improve biodiversity at nine of our sites, an Until horseshoe crab blood can be fully replaced, we are working increase of six from 2022.",
    "id": 446,
    "annotator": 1,
    "annotation_id": 447,
    "created_at": "2024-11-05T11:44:42.008882Z",
    "updated_at": "2024-11-05T11:44:42.008882Z",
    "lead_time": 7.444
  },
  {
    "text": "with our suppliers to improve sustainability.",
    "id": 447,
    "annotator": 1,
    "annotation_id": 448,
    "created_at": "2024-11-05T11:44:53.173195Z",
    "updated_at": "2024-11-05T11:44:53.173195Z",
    "lead_time": 10.939
  },
  {
    "text": "Our new Sustainable In May 2023, we set out ambitious new Sustainable Sourcing Sourcing Standards, discussed above, include a specific Marine Standards for suppliers who provide us with materials that are Sustainable Sourcing Standard which outlines the requirements that highly dependent on nature, like lactose, gelatine and soy.",
    "id": 448,
    "annotator": 1,
    "annotation_id": 449,
    "created_at": "2024-11-05T11:45:28.904771Z",
    "updated_at": "2024-11-05T11:45:28.904771Z",
    "lead_time": 35.455
  },
  {
    "text": "The our suppliers of marine-derived materials must adhere to.",
    "id": 449,
    "annotator": 1,
    "annotation_id": 450,
    "created_at": "2024-11-05T11:45:38.564043Z",
    "updated_at": "2024-11-05T11:45:38.564043Z",
    "lead_time": 9.401
  },
  {
    "text": "We standards, developed in collaboration with third-party experts, conducted physical site audits of key suppliers in 2023 to understand aim to support these suppliers to assess, improve and verify their adoption of this standard.",
    "id": 450,
    "annotator": 1,
    "annotation_id": 451,
    "created_at": "2024-11-05T11:45:44.702590Z",
    "updated_at": "2024-11-05T11:45:44.702590Z",
    "lead_time": 5.925
  },
  {
    "text": "approach to addressing a range of nature impacts   and associated climate and social impacts   including land-use, Atmosphere water stewardship and biodiversity.",
    "id": 451,
    "annotator": 1,
    "annotation_id": 452,
    "created_at": "2024-11-05T11:46:01.864823Z",
    "updated_at": "2024-11-05T11:46:01.864823Z",
    "lead_time": 16.93
  },
  {
    "text": "Air quality is closely linked to climate change, as many of the We have roadmaps in place which aim to achieve 100% drivers of air pollution, such as burning fossil fuels, are also sources sustainably-sourced paper packaging and palm oil by 2025.",
    "id": 452,
    "annotator": 1,
    "annotation_id": 453,
    "created_at": "2024-11-05T11:46:35.843436Z",
    "updated_at": "2024-11-05T11:46:35.843436Z",
    "lead_time": 33.694
  },
  {
    "text": "In of greenhouse gas emissions.",
    "id": 453,
    "annotator": 1,
    "annotation_id": 454,
    "created_at": "2024-11-05T11:46:37.567278Z",
    "updated_at": "2024-11-05T11:46:37.567278Z",
    "lead_time": 1.501
  },
  {
    "text": "Air pollution is a significant risk to 2023, 86% of our paper packaging was derived from certified human health, particularly for patients with respiratory conditions sources or from recycled raw materials and 98% of our core palm like asthma and COPD.",
    "id": 454,
    "label": [
      {
        "start": 45,
        "end": 48,
        "text": "86%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 56,
        "end": 111,
        "text": "paper packaging was derived from certified human health",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 455,
    "created_at": "2024-11-05T11:47:04.170261Z",
    "updated_at": "2024-11-05T11:47:04.170261Z",
    "lead_time": 26.361
  },
  {
    "text": "oil materials were certified by third parties as being from Our approach to air pollution includes reducing pollutants linked sustainable sources.",
    "id": 455,
    "annotator": 1,
    "annotation_id": 456,
    "created_at": "2024-11-05T11:47:14.018023Z",
    "updated_at": "2024-11-05T11:47:14.018023Z",
    "lead_time": 9.591
  },
  {
    "text": "To further improve our Palm Oil sourcing to burning fossil fuels that will be addressed via our SBTi-aligned practices, we have joined Action for Sustainable Derivatives, an climate targets (set out on page 18), as well as looking more industry-led collaboration to tackle environmental and social broadly at our air pollution footprint.",
    "id": 456,
    "annotator": 1,
    "annotation_id": 457,
    "created_at": "2024-11-05T11:47:18.719458Z",
    "updated_at": "2024-11-05T11:47:18.719458Z",
    "lead_time": 4.438
  },
  {
    "text": "supply chain issues around palm oil derivatives.",
    "id": 457,
    "annotator": 1,
    "annotation_id": 458,
    "created_at": "2024-11-05T11:47:20.315916Z",
    "updated_at": "2024-11-05T11:47:20.315916Z",
    "lead_time": 1.364
  },
  {
    "text": "To help accelerate collective action on air pollution, we are While working with suppliers is a key part of our goal to reduce members of the Alliance for Clean Air through the Clean Air Fund our impact on nature, where appropriate we will also look at (CAF) and the World Economic Forum, which aims to drive opportunities to reduce or avoid the use of some natural materials, corporate action on clean air to accelerate climate action and for example through process efficiencies and synthetic create healthy communities around the world.",
    "id": 458,
    "annotator": 1,
    "annotation_id": 459,
    "created_at": "2024-11-05T11:47:26.511665Z",
    "updated_at": "2024-11-05T11:47:26.511665Z",
    "lead_time": 5.969
  },
  {
    "text": "alternatives.",
    "id": 459,
    "annotator": 1,
    "annotation_id": 460,
    "created_at": "2024-11-05T11:47:27.998150Z",
    "updated_at": "2024-11-05T11:47:27.998150Z",
    "lead_time": 1.247
  },
  {
    "text": "For example, an extract from the soapbark tree is an We have done an initial assessment to establish an air pollution essential ingredient in vaccine adjuvants, which are used to footprint in our operations and our supply chain.",
    "id": 460,
    "annotator": 1,
    "annotation_id": 461,
    "created_at": "2024-11-05T11:47:31.256965Z",
    "updated_at": "2024-11-05T11:47:31.256965Z",
    "lead_time": 3.048
  },
  {
    "text": "This highlighted enhance the immune response of vaccines.",
    "id": 461,
    "annotator": 1,
    "annotation_id": 462,
    "created_at": "2024-11-05T11:47:37.236450Z",
    "updated_at": "2024-11-05T11:47:37.236450Z",
    "lead_time": 5.754
  },
  {
    "text": "We are working on a opportunities for reductions in emissions linked to on-site process improvement to deliver a significant yield increase, electricity generation and use of solid fuels, car use and move to reducing our nature impact and improving supply resilience.",
    "id": 462,
    "annotator": 1,
    "annotation_id": 463,
    "created_at": "2024-11-05T11:50:15.820456Z",
    "updated_at": "2024-11-05T11:50:15.820456Z",
    "lead_time": 158.345
  },
  {
    "text": "electric fleet, as well as indicating opportunities in our value chain gsk.com: Our approach to sourcing materials that are highly for the sourcing of plastic and glass products.",
    "id": 463,
    "annotator": 1,
    "annotation_id": 464,
    "created_at": "2024-11-05T11:50:21.214112Z",
    "updated_at": "2024-11-05T11:50:21.214112Z",
    "lead_time": 5.159
  },
  {
    "text": "We are creating dependent on nature reduction plans around these key areas that are aligned to our pathway to zero and which aim to have a positive impact on air Oceans quality.",
    "id": 464,
    "annotator": 1,
    "annotation_id": 465,
    "created_at": "2024-11-05T11:50:33.401559Z",
    "updated_at": "2024-11-05T11:50:33.401559Z",
    "lead_time": 11.971
  },
  {
    "text": "We continue to deliver on our existing ocean target (set out We are conducting an additional air quality assessment, working below), and will apply the relevant science-based methodology with Stockholm Environment Institute (SEI) and the University of on oceans when it becomes available.",
    "id": 465,
    "annotator": 1,
    "annotation_id": 466,
    "created_at": "2024-11-05T11:50:41.016117Z",
    "updated_at": "2024-11-05T11:50:41.016117Z",
    "lead_time": 7.327
  },
  {
    "text": "York, broadening the suite of air pollutants to be taken into Target consideration to understand their impact across our value chain   100% of marine-derived materials to be sustainably sourced and their connection to human health.",
    "id": 466,
    "annotator": 1,
    "annotation_id": 467,
    "created_at": "2024-11-05T11:50:47.765747Z",
    "updated_at": "2024-11-05T11:50:47.765747Z",
    "lead_time": 6.482
  },
  {
    "text": "by 2030 Degradation of the world s oceans, caused by factors such as climate change, marine pollution and over-fishing, poses risks to human health and business resilience.",
    "id": 467,
    "annotator": 1,
    "annotation_id": 468,
    "created_at": "2024-11-05T11:50:53.453546Z",
    "updated_at": "2024-11-05T11:50:53.453546Z",
    "lead_time": 5.447
  },
  {
    "text": "Our impacts and dependencies on oceans come primarily from marine-derived materials that are a critical part of manufacturing vaccines and medicines.",
    "id": 468,
    "annotator": 1,
    "annotation_id": 469,
    "created_at": "2024-11-05T11:50:54.523639Z",
    "updated_at": "2024-11-05T11:50:54.523639Z",
    "lead_time": 0.844
  },
  {
    "text": "1 Including a 20% reduction in routine hazardous and non-hazardous waste.",
    "id": 469,
    "label": [
      {
        "start": 14,
        "end": 27,
        "text": "20% reduction",
        "labels": [
          "value"
        ]
      },
      {
        "start": 31,
        "end": 72,
        "text": "routine hazardous and non-hazardous waste",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 470,
    "created_at": "2024-11-05T11:51:07.333581Z",
    "updated_at": "2024-11-05T11:51:07.333581Z",
    "lead_time": 12.549
  },
  {
    "text": "2 Where regulatory obligations allow, excluding plastics that are critical to product discovery and development, and health and safety.",
    "id": 470,
    "annotator": 1,
    "annotation_id": 471,
    "created_at": "2024-11-05T11:54:55.676982Z",
    "updated_at": "2024-11-05T11:54:55.676982Z",
    "lead_time": 228.057
  },
  {
    "text": "21 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued Waste and materials 100% of GSK sites are now manufacturing PVC-free secondary and tertiary packaging.",
    "id": 471,
    "label": [
      {
        "start": 184,
        "end": 188,
        "text": "100%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 224,
        "end": 265,
        "text": "PVC-free secondary and tertiary packaging",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 472,
    "created_at": "2024-11-05T11:55:31.924397Z",
    "updated_at": "2024-11-05T11:55:31.924397Z",
    "lead_time": 36.021
  },
  {
    "text": "We also implemented our first pilot of The overuse of natural resources and the generation of waste and electronic patient information, to replace paper leaflets in pollution are key drivers of climate change and nature loss.",
    "id": 472,
    "annotator": 1,
    "annotation_id": 473,
    "created_at": "2024-11-05T11:55:56.108166Z",
    "updated_at": "2024-11-05T11:55:56.108166Z",
    "lead_time": 23.918
  },
  {
    "text": "Singapore.",
    "id": 473,
    "annotator": 1,
    "annotation_id": 474,
    "created_at": "2024-11-05T11:56:00.507772Z",
    "updated_at": "2024-11-05T11:56:00.507772Z",
    "lead_time": 4.123
  },
  {
    "text": "Targets A solvent reduction strategy is being rolled out across our sites Our approach to product stewardship means that we consider and key suppliers.",
    "id": 474,
    "annotator": 1,
    "annotation_id": 475,
    "created_at": "2024-11-05T11:56:05.562033Z",
    "updated_at": "2024-11-05T11:56:05.562033Z",
    "lead_time": 4.802
  },
  {
    "text": "This includes designing out solvents, using lower and aim to address impacts on nature and climate at every stage impact solvents, and improving solvent recovery rates.",
    "id": 475,
    "annotator": 1,
    "annotation_id": 476,
    "created_at": "2024-11-05T11:56:08.950066Z",
    "updated_at": "2024-11-05T11:56:08.950066Z",
    "lead_time": 3.154
  },
  {
    "text": "of the product life cycle, from discovery, design, sourcing and manufacturing through to product use and disposal.",
    "id": 476,
    "annotator": 1,
    "annotation_id": 477,
    "created_at": "2024-11-05T11:56:16.801163Z",
    "updated_at": "2024-11-05T11:56:16.801163Z",
    "lead_time": 7.61
  },
  {
    "text": "We have set Waste a target to help accelerate the adoption of this approach: In 2023, we reduced operational waste by 1% compared with   25% environmental impact reduction for our products and 2022, a total of 21% since 2020.1 We increased the amount of packaging by 2030 materials recovered by circular routes to 53%.",
    "id": 477,
    "label": [
      {
        "start": 137,
        "end": 171,
        "text": "25% environmental impact reduction",
        "labels": [
          "value"
        ]
      },
      {
        "start": 180,
        "end": 188,
        "text": "products",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 478,
    "created_at": "2024-11-05T11:56:59.707846Z",
    "updated_at": "2024-11-05T11:56:59.707846Z",
    "lead_time": 42.68
  },
  {
    "text": "We have also set targets to reduce operational and supply We have maintained zero operational waste to landfill and we chain waste: continue to build on our long-standing operational waste management programme to identify opportunities to find more   Zero operational waste,1 including eliminating single-use beneficial uses for waste.",
    "id": 478,
    "annotator": 1,
    "annotation_id": 479,
    "created_at": "2024-11-05T15:03:13.912764Z",
    "updated_at": "2024-11-05T15:03:13.912764Z",
    "lead_time": 179.538
  },
  {
    "text": "plastics2 by 2030 For example, at our wastewater treatment facility in Jurong and at   10% waste reduction from our supply chain by 2030 our site in Marburg, Germany, we are reducing the amount of Product stewardship waste incinerated.",
    "id": 479,
    "annotator": 1,
    "annotation_id": 480,
    "created_at": "2024-11-05T15:03:26.144103Z",
    "updated_at": "2024-11-05T15:03:26.144103Z",
    "lead_time": 12.017
  },
  {
    "text": "Our approach to product stewardship across both new and For our supply chain, we re working on a waste footprint existing products is built on a scientific method for environmental assessment to help with supplier engagement on waste reduction.",
    "id": 480,
    "annotator": 1,
    "annotation_id": 481,
    "created_at": "2024-11-05T15:03:32.672926Z",
    "updated_at": "2024-11-05T15:03:32.672926Z",
    "lead_time": 6.326
  },
  {
    "text": "footprinting called life cycle assessment (LCA).",
    "id": 481,
    "annotator": 1,
    "annotation_id": 482,
    "created_at": "2024-11-05T15:03:34.552556Z",
    "updated_at": "2024-11-05T15:03:34.552556Z",
    "lead_time": 1.707
  },
  {
    "text": "We worked with external specialists to co-develop an internal product carbon Investing in nature footprinting tool, building on the LCA process, that covers both Investing in nature protection and restoration is a key part of our climate and nature to inform our scientists and engineers when ambition and commitment to achieve a net zero, nature positive, they develop new products.",
    "id": 482,
    "annotator": 1,
    "annotation_id": 483,
    "created_at": "2024-11-05T15:03:56.027114Z",
    "updated_at": "2024-11-05T15:03:56.027114Z",
    "lead_time": 21.302
  },
  {
    "text": "We also use publicly available tools healthier planet.",
    "id": 483,
    "annotator": 1,
    "annotation_id": 484,
    "created_at": "2024-11-05T15:04:04.144598Z",
    "updated_at": "2024-11-05T15:04:04.144598Z",
    "lead_time": 7.935
  },
  {
    "text": "We aim to do this by making investments in when we need to share information outside of GSK.",
    "id": 484,
    "annotator": 1,
    "annotation_id": 485,
    "created_at": "2024-11-05T15:04:13.645056Z",
    "updated_at": "2024-11-05T15:04:13.645056Z",
    "lead_time": 9.332
  },
  {
    "text": "nature across our value chain.",
    "id": 485,
    "annotator": 1,
    "annotation_id": 486,
    "created_at": "2024-11-05T15:04:15.898229Z",
    "updated_at": "2024-11-05T15:04:15.898229Z",
    "lead_time": 2.087
  },
  {
    "text": "We are also prioritising nature To embed sustainability into the design of all our future products, investments for the carbon credits we are committed to securing we have developed a set of eco-design principles to help guide as part of our pathway to net zero emissions.",
    "id": 486,
    "label": [
      {
        "start": 182,
        "end": 212,
        "text": "a set of eco-design principles",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 182,
        "end": 212,
        "text": "a set of eco-design principles",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 487,
    "created_at": "2024-11-05T15:04:43.856539Z",
    "updated_at": "2024-11-05T15:04:43.856539Z",
    "lead_time": 27.786
  },
  {
    "text": "the decision-making.",
    "id": 487,
    "annotator": 1,
    "annotation_id": 488,
    "created_at": "2024-11-05T15:04:45.918517Z",
    "updated_at": "2024-11-05T15:04:45.918517Z",
    "lead_time": 1.875
  },
  {
    "text": "Our approach is to partner with expert developers, investors and We are actively working as part of a consortium of eight global NGOs to invest in early-stage nature projects for the long term.",
    "id": 488,
    "annotator": 1,
    "annotation_id": 489,
    "created_at": "2024-11-05T15:04:51.787180Z",
    "updated_at": "2024-11-05T15:04:51.787180Z",
    "lead_time": 5.685
  },
  {
    "text": "pharmaceutical that have come together via the Pharmaceutical GSK is an investor in Climate Asset Management s Nature Based Environment Group (PEG), with support from the SMI, to co- Carbon Fund, which aims to invest at a landscape scale in develop a shared way of measuring and reporting environmental grassland, agriculture, forestry, wetlands and coastal carbon product data.",
    "id": 489,
    "annotator": 1,
    "annotation_id": 490,
    "created_at": "2024-11-05T15:04:59.321195Z",
    "updated_at": "2024-11-05T15:04:59.321195Z",
    "lead_time": 7.367
  },
  {
    "text": "projects in developing economies, to provide long-lasting, verified, Since 2022, we have completed an LCA analysis for 22 products, positive impact at scale for the climate, biodiversity and local which has enabled us to identify where we need to improve communities.",
    "id": 490,
    "label": [
      {
        "start": 119,
        "end": 130,
        "text": "22 products",
        "labels": [
          "value"
        ]
      },
      {
        "start": 102,
        "end": 114,
        "text": "LCA analysis",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 491,
    "created_at": "2024-11-05T15:05:28.028397Z",
    "updated_at": "2024-11-05T15:05:28.028397Z",
    "lead_time": 28.529
  },
  {
    "text": "This is a long-term investment over the next 15 years, manufacturing design, to assess potential savings from design which aims to secure approximately a quarter of credits that we changes and to provide product-level information to key need in 2030, to meet our commitment to invest in nature-based customers on specific products.",
    "id": 491,
    "annotator": 1,
    "annotation_id": 492,
    "created_at": "2024-11-05T15:06:12.982195Z",
    "updated_at": "2024-11-05T15:06:12.982195Z",
    "lead_time": 44.754
  },
  {
    "text": "solutions for 20% of our 2020 footprint.",
    "id": 492,
    "annotator": 1,
    "annotation_id": 493,
    "created_at": "2024-11-05T15:06:20.369303Z",
    "updated_at": "2024-11-05T15:06:20.369303Z",
    "lead_time": 7.209
  },
  {
    "text": "To help ensure that human health is a key outcome of the world s drive to protect and restore nature, in September 2023, we published an open-source toolkit in partnership with Pollination, developed with input from key nature and health experts from organisations such as the Circular Bioeconomy Alliance, the Nature Climate Solutions Alliance and the London School of Hygiene and Tropical Medicine.",
    "id": 493,
    "label": [
      {
        "start": 124,
        "end": 156,
        "text": "published an open-source toolkit",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 124,
        "end": 156,
        "text": "published an open-source toolkit",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 494,
    "created_at": "2024-11-05T15:06:49.452600Z",
    "updated_at": "2024-11-05T15:06:49.452600Z",
    "lead_time": 28.899
  },
  {
    "text": "The toolkit aims to support companies, investors and developers to incorporate health considerations in the design of nature-based projects.",
    "id": 494,
    "annotator": 1,
    "annotation_id": 495,
    "created_at": "2024-11-05T15:06:54.015827Z",
    "updated_at": "2024-11-05T15:06:54.015827Z",
    "lead_time": 4.379
  },
  {
    "text": "We will be seeking to test the toolkit in some of the nature investments that we make.",
    "id": 495,
    "annotator": 1,
    "annotation_id": 496,
    "created_at": "2024-11-05T15:06:59.691549Z",
    "updated_at": "2024-11-05T15:06:59.691549Z",
    "lead_time": 5.515
  },
  {
    "text": "1 Methodology changed in 2023 to only include waste and materials leaving our sites.",
    "id": 496,
    "annotator": 1,
    "annotation_id": 497,
    "created_at": "2024-11-05T15:07:05.285915Z",
    "updated_at": "2024-11-05T15:07:05.285915Z",
    "lead_time": 5.427
  },
  {
    "text": "2 Where regulatory obligations allow, excluding plastics that are critical to product discovery and development, and health and safety.",
    "id": 497,
    "annotator": 1,
    "annotation_id": 498,
    "created_at": "2024-11-05T15:07:09.551957Z",
    "updated_at": "2024-11-05T15:07:09.551957Z",
    "lead_time": 4.093
  },
  {
    "text": "22 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued 2020 2021 2022 2023 Energy Natural gas purchased (GWh) 1,873 1,744 1,655 1,567 Electricity used (GWh) 1,102 1,008 970 958 Purchased renewable electricity (GWh) 487 631 697 782 A Purchased non-renewable electricity (GWh) 605 372 263 163 On-site renewably generated electricity (GWh) 19 13 18 17 A Exported electricity (GWh) 9 8 8 4 Coal (GWh) 0 0 0 0 Other fossil fuels (GWh) 49 58 81 60 Renewable heat (GWh) 9 8 13 12 Purchased heating and cooling (GWh) 52 52 41 39 Total energy for operations (GWh) 3,085 2,871 2,759 2,636 A % renewable electricity 46% 63% 73% 83% Carbon: Scope 1 and 2 emissions On-site fuel use (thousands of tonnes CO2e) 355 333 320 301 Sales force vehicles (thousands of tonnes CO2e) 60 52 51 46 Propellant emissions during manufacture of inhalers (thousands of tonnes CO2e) 275 237 243 220 On-site waste or wastewater treatment (thousands of tonnes CO2e) 0 0 0 0 Refrigerant gas losses (thousands of tonnes CO2e) 20 11 13 13 Total Scope 1 emissions (thousands of tonnes CO2e) 711 633 626 581 A Electricity (market-based emissions) (thousands of tonnes CO2e) 163 125 84 60 Purchased heating and cooling (thousands of tonnes CO2e) 6 6 4 4 Total Scope 2 market-based emissions (thousands of tonnes CO2e) 169 131 88 64 A Total Scope 2 location-based emissions (thousands of tonnes CO2e) 309 285 265 240 A Total Scope 1 and 2 market-based emissions (thousands of tonnes CO2e) 879 764 715 645 PR A Fermentation\/biogenic releases (thousands of tonnes CO2e) 27 10 12 12 Carbon: Scope 3 emissions1 Purchased goods and services (thousands of tonnes CO2e) 3,267 2,725 2,485   Capital goods (thousands of tonnes CO2e) 162 154 161   Fuel and energy-related activities (thousands of tonnes CO2e) 89 84 145   Transportation and distribution (upstream) (thousands of tonnes CO2e) 267 189 242   Waste generated in operations (thousands of tonnes CO2e) 20 64 51   Business travel (thousands of tonnes CO2e) 42 50 85   Employee commuting (thousands of tonnes CO2e) 37 48 60   Leased assets (upstream) (thousands of tonnes CO2e) 0 0 0   Transportation and distribution (downstream) (thousands of tonnes CO2e) 135 99 130   Processing of sold products (thousands of tonnes CO2e) 0 0 0   PR Metric contributes to our ESG Performance Rating.",
    "id": 498,
    "annotator": 1,
    "annotation_id": 499,
    "created_at": "2024-11-05T15:07:23.111132Z",
    "updated_at": "2024-11-05T15:07:23.111132Z",
    "lead_time": 13.392
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 499,
    "annotator": 1,
    "annotation_id": 500,
    "created_at": "2024-11-05T15:07:29.355790Z",
    "updated_at": "2024-11-05T15:07:29.355790Z",
    "lead_time": 6.036
  },
  {
    "text": "1 O ther than propellant emissions data (which is collected through our internal systems); we will not have an accurate picture of 2023 Scope 3 emissions until later in the year.",
    "id": 500,
    "annotator": 1,
    "annotation_id": 501,
    "created_at": "2024-11-05T15:07:31.408048Z",
    "updated_at": "2024-11-05T15:07:31.408048Z",
    "lead_time": 1.86
  },
  {
    "text": "23 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued 2020 2021 2022 2023 Use of sold products (thousands of tonnes CO2e) 5,836 5,120 5,523     Emissions from use of propellant-based inhalers by patients (thousands of tonnes CO2e) 5,631 5,039 5,429 5,039 A End of life (thousands of tonnes CO2e) 24 51 47   Leased assets (downstream) (thousands of tonnes CO2e) 0 0     Franchises (thousands of tonnes CO2e) 0 0     Investments (thousands of tonnes CO2e) 70 41 66   Total Scope 3 emissions (thousands of tonnes CO2e) 9,949 8,624 8,995   Ozone-depleting substances ODP inventory of CFC and HCFC in equipment (kg of CFC11e) 307 277 6 5 ODP calculated releases of CFC11e (kg of CFC11e) 8 8 0 0 Water use Municipal (million m3) 6.9 5.8 5.6 5.6 Ground water (million m3) 2.7 2.0 1.7 1.6 Tankers (million m3) 0.1 0.1 0.1 0.2 Total water use (million m3) 9.7 7.9 7.5 7.4 A Recycled sources (million m3) 0.2 0.3 0.2 0.3 Water use at high water risk sites (million m3) 0.3 0.3 0.3 0.3 A Water discharge Wastewater to municipal sewers (million m3) 5.7 4.0 4.0 3.9 Wastewater to surface water (million m3) 2.8 1.9 1.8 2.2 Wastewater to land (million m3) 0.1 0.1 0.1 0.1 Wastewater to other (million m3) 0.0 0.0 0.0 0.0 Total wastewater discharged (million m3) 8.6 5.9 5.9 6.2 A % of GSK sites and supplier locations used by GSK that are compliant with AMR alliance and     94% 87% PR wastewater API limits PR Metric contributes to our ESG Performance Rating.",
    "id": 501,
    "annotator": 1,
    "annotation_id": 502,
    "created_at": "2024-11-05T15:07:42.501487Z",
    "updated_at": "2024-11-05T15:07:42.501487Z",
    "lead_time": 10.929
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 502,
    "annotator": 1,
    "annotation_id": 503,
    "created_at": "2024-11-05T15:07:54.903918Z",
    "updated_at": "2024-11-05T15:07:54.903918Z",
    "lead_time": 12.224
  },
  {
    "text": "24 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Environment continued 2020 2021 2022 2023 Waste and materials1 Total waste recovered via a circular route (thousand tonnes)   21.9 21.8 26.2 Total waste disposed via a non-circular route (thousand tonnes)   33.9 28.5 23.5 Total waste and materials generated (thousand tonnes)1 63.0 55.8 50.3 49.7 PR % circular waste   39% 43% 53% Total hazardous waste recovered via a circular route (thousand tonnes)   2.9 2.9 3.6 Total hazardous waste disposed via a non-circular route (thousand tonnes)   18.3 16.3 14.7 Total hazardous waste (thousand tonnes) 25.7 21.2 19.2 18.3 Total non-hazardous waste recovered via a circular route (thousand tonnes)   19.0 18.9 22.5 Total non-hazardous waste disposed via a non-circular route (thousand tonnes)   15.6 12.1 8.9 Total non-hazardous waste (thousand tonnes) 37.3 34.6 31.0 31.4 Total hazardous waste incinerated (thousand tonnes) 21.9 14.0 13.2 13.0 Total non-hazardous waste incinerated (thousand tonnes) 14.1 13.2 8.5 8.4 Total waste incinerated (thousand tonnes) 36.0 27.2 21.7 21.4 Total hazardous waste to landfill (thousand tonnes) 0.0 0.0 0.0 0.2 Total non-hazardous waste to landfill (thousand tonnes) 0.1 0.0 0.1 0.0 Total waste to landfill (thousand tonnes) 0.1 0.0 0.1 0.2 Sustainable sourcing Percentage of paper deforestation free       86% PR Percentage of palm oil deforestation free       98% PR Compliance and remediation Number of GSK internal audits 0 0 24 20 Number of GSK sites independently certified to ISO 4001 0 0 7 9 Environmental fines ( '000s) 0 0 0.2 0 Remediation spend ($m) 2.8 3.0 2.8 3.3 PR Metric contributes to our ESG Performance Rating.",
    "id": 503,
    "annotator": 1,
    "annotation_id": 504,
    "created_at": "2024-11-05T15:08:02.902730Z",
    "updated_at": "2024-11-05T15:08:02.902730Z",
    "lead_time": 7.829
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 504,
    "annotator": 1,
    "annotation_id": 505,
    "created_at": "2024-11-05T15:08:08.035140Z",
    "updated_at": "2024-11-05T15:08:08.035140Z",
    "lead_time": 4.955
  },
  {
    "text": "1 M ethodology changed in 2023 to only include waste and materials leaving our sites.",
    "id": 505,
    "annotator": 1,
    "annotation_id": 506,
    "created_at": "2024-11-05T15:08:09.971932Z",
    "updated_at": "2024-11-05T15:08:09.971932Z",
    "lead_time": 1.783
  },
  {
    "text": "We have restated waste and materials data for 2021 and 2022 to reflect this.",
    "id": 506,
    "annotator": 1,
    "annotation_id": 507,
    "created_at": "2024-11-05T15:08:16.532582Z",
    "updated_at": "2024-11-05T15:08:16.532582Z",
    "lead_time": 6.396
  },
  {
    "text": "Please see Environmental Data Table 2023 for more detail.",
    "id": 507,
    "annotator": 1,
    "annotation_id": 508,
    "created_at": "2024-11-05T15:08:22.040779Z",
    "updated_at": "2024-11-05T15:08:22.040779Z",
    "lead_time": 5.335
  },
  {
    "text": "25 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Diversity, equity and inclusion We want to ensure all our people can thrive, foster diversity in our clinical trials and support diverse communities, as becoming a more inclusive business is central to our purpose.",
    "id": 508,
    "annotator": 1,
    "annotation_id": 509,
    "created_at": "2024-11-05T15:08:27.237428Z",
    "updated_at": "2024-11-05T15:08:27.237428Z",
    "lead_time": 5.018
  },
  {
    "text": "100% 45% 18.4% 2023 phase III trials included a VP-and-above roles held by ethnically diverse leaders at demographic plan women globally VP-and-above in the UK Our commitment Create a diverse, equitable and inclusive workplace; enhance   Update towards 2025 aspirations through fair and equitable recruitment of diverse patient populations in our clinical trials; opportunities: and support diverse communities   aspire to have women hold at least 45% of VP-and-above roles globally by the end of 2025 Our ESG Performance Rating metrics 2023   aspire to have at least 30% ethnically diverse leaders in our   100% of phase III trials initiated in 2023 will have proactive roles at VP-and-above in the US by the end of 2025, and plans in place designed to enrol appropriately diverse trial increase the percentage of Black or African American, and participants, consistent with disease epidemiology Hispanic or Latinx VP-and-above leaders year on year   Improve year-on-year spend with US-based certified   aspire to have at least 18% ethnically diverse leaders in our diverse-owned suppliers roles at VP-and-above in the UK by the end of 2025, and increase the percentage of Black VP-and-above leaders year on year Becoming a more diverse, inclusive and equitable business will Clinical trial diversity help to attract and retain outstanding talent, bringing greater Diseases and medicines can affect people differently depending opportunity to create better health outcomes for patients.",
    "id": 509,
    "annotator": 1,
    "annotation_id": 510,
    "created_at": "2024-11-05T15:08:33.028720Z",
    "updated_at": "2024-11-05T15:08:33.028720Z",
    "lead_time": 5.625
  },
  {
    "text": "on ethnicity, sex, race and age.",
    "id": 510,
    "annotator": 1,
    "annotation_id": 511,
    "created_at": "2024-11-05T15:08:34.631382Z",
    "updated_at": "2024-11-05T15:08:34.631382Z",
    "lead_time": 1.429
  },
  {
    "text": "This means it is important to We want better health outcomes for all.",
    "id": 511,
    "annotator": 1,
    "annotation_id": 512,
    "created_at": "2024-11-05T15:08:39.543138Z",
    "updated_at": "2024-11-05T15:08:39.543138Z",
    "lead_time": 4.745
  },
  {
    "text": "Our clinical trials need to ensure that the patients and people enrolled in our clinical trials reflect the populations affected by the diseases we are aiming to represent the real-world patient\/people population that will use address.",
    "id": 512,
    "annotator": 1,
    "annotation_id": 513,
    "created_at": "2024-11-05T15:08:45.426486Z",
    "updated_at": "2024-11-05T15:08:45.426486Z",
    "lead_time": 5.714
  },
  {
    "text": "Backed by the latest scientific research, we are working our medicines and vaccines and represent those affected by the to make sure we recruit participants to our clinical trials in line with disease under study.",
    "id": 513,
    "annotator": 1,
    "annotation_id": 514,
    "created_at": "2024-11-05T15:08:53.228478Z",
    "updated_at": "2024-11-05T15:08:53.228478Z",
    "lead_time": 7.635
  },
  {
    "text": "the epidemiology of the diseases in question.",
    "id": 514,
    "annotator": 1,
    "annotation_id": 515,
    "created_at": "2024-11-05T15:08:55.392459Z",
    "updated_at": "2024-11-05T15:08:55.392459Z",
    "lead_time": 1.872
  },
  {
    "text": "We continue to make progress in advancing clinical trial diversity.",
    "id": 515,
    "annotator": 1,
    "annotation_id": 516,
    "created_at": "2024-11-05T15:09:01.733890Z",
    "updated_at": "2024-11-05T15:09:01.733890Z",
    "lead_time": 6.169
  },
  {
    "text": "Being an inclusive business will make the most of our people s In addition to ensuring 100% of our phase III trials have diversity potential and increase our positive impact.",
    "id": 516,
    "annotator": 1,
    "annotation_id": 517,
    "created_at": "2024-11-05T15:09:07.364856Z",
    "updated_at": "2024-11-05T15:09:07.364856Z",
    "lead_time": 5.463
  },
  {
    "text": "Our culture should allow plans in place to enrol the groups most affected by the disease all our people to thrive, we want all our leadership to reflect our GSK being studied, based on disease epidemiology, we also are people and our people to reflect the communities we work and hire challenging ourselves to actively monitor patient recruitment in in.",
    "id": 517,
    "annotator": 1,
    "annotation_id": 518,
    "created_at": "2024-11-05T15:09:19.351793Z",
    "updated_at": "2024-11-05T15:09:19.351793Z",
    "lead_time": 11.83
  },
  {
    "text": "Diversity brings better insights and better-quality decision- real time to ensure that we reach our diversity goals.",
    "id": 518,
    "annotator": 1,
    "annotation_id": 519,
    "created_at": "2024-11-05T15:09:24.584692Z",
    "updated_at": "2024-11-05T15:09:24.584692Z",
    "lead_time": 5.069
  },
  {
    "text": "We met our making to help us perform better and understand our diverse objective of 100% of the phase III interventional trials initiated in patients.",
    "id": 519,
    "annotator": 1,
    "annotation_id": 520,
    "created_at": "2024-11-05T15:09:32.554766Z",
    "updated_at": "2024-11-05T15:09:32.554766Z",
    "lead_time": 7.805
  },
  {
    "text": "We want a truly inclusive working environment where all 2023 having proactive diversity plans.",
    "id": 520,
    "annotator": 1,
    "annotation_id": 521,
    "created_at": "2024-11-05T15:09:39.170106Z",
    "updated_at": "2024-11-05T15:09:39.170106Z",
    "lead_time": 6.454
  },
  {
    "text": "employees can be themselves and their diverse perspectives and In February 2023, we published a study of 17 years of GSK and characteristics are valued so they can thrive, perform at their best ViiV Healthcare US clinical trial diversity data.",
    "id": 521,
    "annotator": 1,
    "annotation_id": 522,
    "created_at": "2024-11-05T15:09:45.013129Z",
    "updated_at": "2024-11-05T15:09:45.013129Z",
    "lead_time": 5.685
  },
  {
    "text": "It showed that and help us get ahead of disease together.",
    "id": 522,
    "annotator": 1,
    "annotation_id": 523,
    "created_at": "2024-11-05T15:09:50.974197Z",
    "updated_at": "2024-11-05T15:09:50.974197Z",
    "lead_time": 5.794
  },
  {
    "text": "enrolling participants to clinical trials based on real-world disease To build a diverse workforce, we need a diverse pool of job epidemiology data, rather than census data, would ensure that applicants   so we are working to improve access to STEM those trials reflect the populations affected by different diseases.",
    "id": 523,
    "annotator": 1,
    "annotation_id": 524,
    "created_at": "2024-11-05T15:10:03.261240Z",
    "updated_at": "2024-11-05T15:10:03.261240Z",
    "lead_time": 12.119
  },
  {
    "text": "education among under-represented communities.",
    "id": 524,
    "annotator": 1,
    "annotation_id": 525,
    "created_at": "2024-11-05T15:10:04.581057Z",
    "updated_at": "2024-11-05T15:10:04.581057Z",
    "lead_time": 1.149
  },
  {
    "text": "These efforts As an example, US Census Bureau data indicates 13.4% of the extend from community programmes and secondary education, total US population is Black\/African American.",
    "id": 525,
    "annotator": 1,
    "annotation_id": 526,
    "created_at": "2024-11-05T15:10:11.452241Z",
    "updated_at": "2024-11-05T15:10:11.452241Z",
    "lead_time": 6.701
  },
  {
    "text": "However, through working with universities to mentoring young people epidemiology shows us that of HIV patients recently diagnosed beginning their careers.",
    "id": 526,
    "annotator": 1,
    "annotation_id": 527,
    "created_at": "2024-11-05T15:10:17.726023Z",
    "updated_at": "2024-11-05T15:10:17.726023Z",
    "lead_time": 6.104
  },
  {
    "text": "in the US, 55.3% are Black\/African American.",
    "id": 527,
    "annotator": 1,
    "annotation_id": 528,
    "created_at": "2024-11-05T15:10:20.314990Z",
    "updated_at": "2024-11-05T15:10:20.314990Z",
    "lead_time": 2.424
  },
  {
    "text": "We are using epidemiologic data to guide enrolment in our clinical trials, allowing us to set more representative trial enrolment goals.",
    "id": 528,
    "annotator": 1,
    "annotation_id": 529,
    "created_at": "2024-11-05T15:10:25.642529Z",
    "updated_at": "2024-11-05T15:10:25.642529Z",
    "lead_time": 5.145
  },
  {
    "text": "26 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Diversity, equity and inclusion continued By publicly sharing this research, we hope to advance the In the UK at the end of 2023, we had 18.4% ethnically diverse discussion around clinical trial diversity and improve how the leaders at VP-and-above, compared with 14.3% in 2022.",
    "id": 529,
    "label": [
      {
        "start": 279,
        "end": 284,
        "text": "18.4%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 285,
        "end": 346,
        "text": "ethnically diverse discussion around clinical trial diversity",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 530,
    "created_at": "2024-11-05T15:11:01.662832Z",
    "updated_at": "2024-11-05T15:11:01.662832Z",
    "lead_time": 35.841
  },
  {
    "text": "We had pharmaceutical sector approaches the issue of clinical trial 1.9% Black leaders at VP level and above compared with 1.6% in diversity.",
    "id": 530,
    "label": [
      {
        "start": 68,
        "end": 72,
        "text": "1.9%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 73,
        "end": 108,
        "text": "Black leaders at VP level and above",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 123,
        "end": 127,
        "text": "1.6%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 130,
        "end": 141,
        "text": " diversity.",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 531,
    "created_at": "2024-11-05T15:11:58.003577Z",
    "updated_at": "2024-11-05T15:11:58.003577Z",
    "lead_time": 56.142
  },
  {
    "text": "2022.",
    "id": 531,
    "annotator": 1,
    "annotation_id": 532,
    "created_at": "2024-11-05T15:11:59.444562Z",
    "updated_at": "2024-11-05T15:11:59.444562Z",
    "lead_time": 1.24
  },
  {
    "text": "In the US at the end of 2023, we had 35.7% ethnically diverse leaders at VP-and-above, compared with 31.3% in 2022.",
    "id": 532,
    "label": [
      {
        "start": 37,
        "end": 42,
        "text": "35.7%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 43,
        "end": 85,
        "text": "ethnically diverse leaders at VP-and-above",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 533,
    "created_at": "2024-11-05T15:12:40.202078Z",
    "updated_at": "2024-11-05T15:12:40.202078Z",
    "lead_time": 40.592
  },
  {
    "text": "Supporting diversity in our supply chains We had 8.1% Black or African American leaders at VP-and-above By engaging with and mentoring small and diverse-owned compared with 8.6% in 2022.",
    "id": 533,
    "label": [
      {
        "start": 48,
        "end": 53,
        "text": " 8.1%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 54,
        "end": 103,
        "text": "Black or African American leaders at VP-and-above",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 534,
    "created_at": "2024-11-05T15:13:00.311675Z",
    "updated_at": "2024-11-05T15:13:00.311675Z",
    "lead_time": 19.926
  },
  {
    "text": "We had 6.4% Hispanic or Latinx businesses in our supply chain, we can help them identify leaders at VP-and-above compared with 6.4% in 2022.",
    "id": 534,
    "label": [
      {
        "start": 7,
        "end": 11,
        "text": "6.4%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 12,
        "end": 61,
        "text": "Hispanic or Latinx businesses in our supply chain",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 535,
    "created_at": "2024-11-05T15:13:16.662150Z",
    "updated_at": "2024-11-05T15:13:16.662150Z",
    "lead_time": 16.154
  },
  {
    "text": "potential areas for growth.",
    "id": 535,
    "annotator": 1,
    "annotation_id": 536,
    "created_at": "2024-11-05T15:13:45.642442Z",
    "updated_at": "2024-11-05T15:13:45.642442Z",
    "lead_time": 28.792
  },
  {
    "text": "In 2023, we increased investments We are working to ensure that we have a representative pool with select suppliers in marketing, sales and technology.",
    "id": 536,
    "annotator": 1,
    "annotation_id": 537,
    "created_at": "2024-11-05T15:13:50.017686Z",
    "updated_at": "2024-11-05T15:13:50.017686Z",
    "lead_time": 4.206
  },
  {
    "text": "In of job applicants from which to hire.",
    "id": 537,
    "annotator": 1,
    "annotation_id": 538,
    "created_at": "2024-11-05T15:13:53.478169Z",
    "updated_at": "2024-11-05T15:13:53.478169Z",
    "lead_time": 3.29
  },
  {
    "text": "In the US, we continue to addition, we significantly increased partnerships with external engage with Historically Black Colleges and Universities, and advocacy groups, deepened relationships with key existing Hispanic Serving Institutions, and our employee alumni, to diverse suppliers, and onboarded new diverse suppliers.",
    "id": 538,
    "annotator": 1,
    "annotation_id": 539,
    "created_at": "2024-11-05T15:14:01.090196Z",
    "updated_at": "2024-11-05T15:14:01.090196Z",
    "lead_time": 7.432
  },
  {
    "text": "encourage applications for our graduate and experienced hire This year, we expanded our successful US supplier diversity positions and target recruitment campaigns to reach under- programme to the UK.",
    "id": 539,
    "annotator": 1,
    "annotation_id": 540,
    "created_at": "2024-11-05T15:14:11.398859Z",
    "updated_at": "2024-11-05T15:14:11.398859Z",
    "lead_time": 10.125
  },
  {
    "text": "This programme provides opportunities to represented groups.",
    "id": 540,
    "annotator": 1,
    "annotation_id": 541,
    "created_at": "2024-11-05T15:14:15.982768Z",
    "updated_at": "2024-11-05T15:14:15.982768Z",
    "lead_time": 4.404
  },
  {
    "text": "under-represented groups, including women, ethnic minorities, A highly talented and diverse team is essential to help us get members of the LGBTQ+ community, people with disabilities and ahead of disease together.",
    "id": 541,
    "annotator": 1,
    "annotation_id": 542,
    "created_at": "2024-11-05T15:14:22.960334Z",
    "updated_at": "2024-11-05T15:14:22.960334Z",
    "lead_time": 6.792
  },
  {
    "text": "Our fair and equitable pay practices military veterans, as well as small businesses in high- help ensure we create an environment where people feel unemployment, low-income communities.",
    "id": 542,
    "label": [
      {
        "start": 4,
        "end": 54,
        "text": "fair and equitable pay practices military veterans",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4,
        "end": 54,
        "text": "fair and equitable pay practices military veterans",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 543,
    "created_at": "2024-11-05T15:14:57.429515Z",
    "updated_at": "2024-11-05T15:14:57.429515Z",
    "lead_time": 34.263
  },
  {
    "text": "welcome, valued, included, and supported to thrive.",
    "id": 543,
    "annotator": 1,
    "annotation_id": 544,
    "created_at": "2024-11-05T15:15:02.562568Z",
    "updated_at": "2024-11-05T15:15:02.562568Z",
    "lead_time": 4.94
  },
  {
    "text": "We conduct country-based reviews and ensure all markets have Supporting an inclusive culture clear guidance, tools, and support to ensure pay equity.",
    "id": 544,
    "annotator": 1,
    "annotation_id": 545,
    "created_at": "2024-11-05T15:15:07.356510Z",
    "updated_at": "2024-11-05T15:15:07.356510Z",
    "lead_time": 4.612
  },
  {
    "text": "If Our Code requires all our people to commit to being inclusive and unexplained differences are detected, we address them through aware of their impact on others.",
    "id": 545,
    "annotator": 1,
    "annotation_id": 546,
    "created_at": "2024-11-05T15:15:13.619926Z",
    "updated_at": "2024-11-05T15:15:13.619926Z",
    "lead_time": 6.099
  },
  {
    "text": "Our annual mandatory training our compensation processes.",
    "id": 546,
    "annotator": 1,
    "annotation_id": 547,
    "created_at": "2024-11-05T15:15:17.183462Z",
    "updated_at": "2024-11-05T15:15:17.183462Z",
    "lead_time": 3.4
  },
  {
    "text": "Our focus on pay equity while on Creating an Inclusive Workplace sets out the standards we building a diverse organisation helps us to deliver strong UK expect.",
    "id": 547,
    "label": [
      {
        "start": 13,
        "end": 23,
        "text": "pay equity",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 13,
        "end": 23,
        "text": "pay equity",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 548,
    "created_at": "2024-11-05T15:15:30.375203Z",
    "updated_at": "2024-11-05T15:15:30.375203Z",
    "lead_time": 13.002
  },
  {
    "text": "pay gap results.",
    "id": 548,
    "annotator": 1,
    "annotation_id": 549,
    "created_at": "2024-11-05T15:15:31.859410Z",
    "updated_at": "2024-11-05T15:15:31.859410Z",
    "lead_time": 1.271
  },
  {
    "text": "gsk.com: The Code Our 2023 gender pay gap for all permanent UK-based GSK employees is -0.50% (mean), compared to the national average Building a diverse organisation of 13.2%.",
    "id": 549,
    "label": [
      {
        "start": 86,
        "end": 99,
        "text": "-0.50% (mean)",
        "labels": [
          "value"
        ]
      },
      {
        "start": 27,
        "end": 82,
        "text": "gender pay gap for all permanent UK-based GSK employees",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 550,
    "created_at": "2024-11-05T15:15:56.617918Z",
    "updated_at": "2024-11-05T15:16:41.552381Z",
    "lead_time": 67.17399999999999
  },
  {
    "text": "This is the second time that we re reporting our UK ethnicity pay gap comparing the average pay of our White and We are fundamentally committed to equal employment Ethnically Diverse employees.",
    "id": 550,
    "annotator": 1,
    "annotation_id": 551,
    "created_at": "2024-11-05T15:16:54.374117Z",
    "updated_at": "2024-11-05T15:16:54.374117Z",
    "lead_time": 10.088
  },
  {
    "text": "Our 2023 UK ethnicity pay gap for opportunity and non-discrimination for all employees and we all permanent UK-based GSK employees is -0.74% (mean), want all our leadership to reflect our GSK people and our people compared with 0.06% in 2022.",
    "id": 551,
    "label": [
      {
        "start": 134,
        "end": 147,
        "text": "-0.74% (mean)",
        "labels": [
          "value"
        ]
      },
      {
        "start": 0,
        "end": 130,
        "text": "Our 2023 UK ethnicity pay gap for opportunity and non-discrimination for all employees and we all permanent UK-based GSK employees",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 552,
    "created_at": "2024-11-05T15:17:39.856475Z",
    "updated_at": "2024-11-05T15:17:39.856475Z",
    "lead_time": 45.302
  },
  {
    "text": "to reflect the communities we work and hire in.",
    "id": 552,
    "annotator": 1,
    "annotation_id": 553,
    "created_at": "2024-11-05T15:17:44.323006Z",
    "updated_at": "2024-11-05T15:17:44.323006Z",
    "lead_time": 4.246
  },
  {
    "text": "That is why we have set leadership aspirations for race and ethnicity in senior In addition, within our 2023 UK ethnicity pay gap report we are positions in the US and UK and gender aspirations for senior also sharing the pay gaps comparing the average pay of our positions globally.",
    "id": 553,
    "annotator": 1,
    "annotation_id": 554,
    "created_at": "2024-11-05T15:17:51.732199Z",
    "updated_at": "2024-11-05T15:17:51.732199Z",
    "lead_time": 7.218
  },
  {
    "text": "To support this, we ensure that our recruitment White employees with those in the ethnic groupings of Black, and selection processes are fair and equitable to all.",
    "id": 554,
    "annotator": 1,
    "annotation_id": 555,
    "created_at": "2024-11-05T15:17:58.379908Z",
    "updated_at": "2024-11-05T15:17:58.379908Z",
    "lead_time": 6.479
  },
  {
    "text": "Mixed, Asian, and Other.",
    "id": 555,
    "annotator": 1,
    "annotation_id": 556,
    "created_at": "2024-11-05T15:18:00.118941Z",
    "updated_at": "2024-11-05T15:18:00.118941Z",
    "lead_time": 1.576
  },
  {
    "text": "This is with reference to the UK government s recently published guidance to provide a more For vacancies in our senior grades, we expect diverse shortlists granular view.",
    "id": 556,
    "annotator": 1,
    "annotation_id": 557,
    "created_at": "2024-11-05T15:18:06.569972Z",
    "updated_at": "2024-11-05T15:18:06.569972Z",
    "lead_time": 6.277
  },
  {
    "text": "and interview panels by gender and ethnicity.",
    "id": 557,
    "annotator": 1,
    "annotation_id": 558,
    "created_at": "2024-11-05T15:18:12.025777Z",
    "updated_at": "2024-11-05T15:18:12.025777Z",
    "lead_time": 5.277
  },
  {
    "text": "We are working with recruitment agencies, our internal Employee Resource gsk.com: Gender pay gap report   Ethnicity pay gap report Groups and specialist organisations to drive progress.",
    "id": 558,
    "annotator": 1,
    "annotation_id": 559,
    "created_at": "2024-11-05T15:18:19.678668Z",
    "updated_at": "2024-11-05T15:18:19.678668Z",
    "lead_time": 7.466
  },
  {
    "text": "Hiring managers are required to complete inclusive interview training An inclusive and accessible place to work before they start selection processes.",
    "id": 559,
    "label": [
      {
        "start": 40,
        "end": 69,
        "text": " inclusive interview training",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 41,
        "end": 69,
        "text": "inclusive interview training",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 560,
    "created_at": "2024-11-05T15:18:39.312332Z",
    "updated_at": "2024-11-05T15:18:39.312332Z",
    "lead_time": 19.472
  },
  {
    "text": "Our workplaces must be inclusive and accessible to all, with a At the end of 2023, women held 45% of VP-and-above roles culture of empathy and acceptance where we embrace each globally, compared with 42% in 2022.",
    "id": 560,
    "label": [
      {
        "start": 94,
        "end": 97,
        "text": "45%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 82,
        "end": 89,
        "text": " women ",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 561,
    "created_at": "2024-11-05T15:19:04.311182Z",
    "updated_at": "2024-11-05T15:19:04.311182Z",
    "lead_time": 24.811
  },
  {
    "text": "Women made up 48% of all other s differences and identities.",
    "id": 561,
    "annotator": 1,
    "annotation_id": 562,
    "created_at": "2024-11-05T15:19:17.665317Z",
    "updated_at": "2024-11-05T15:19:17.665317Z",
    "lead_time": 13.158
  },
  {
    "text": "Our Employee Resource Groups employees in 2023, and 50% of all management roles.",
    "id": 562,
    "label": [
      {
        "start": 52,
        "end": 78,
        "text": "50% of all management role",
        "labels": [
          "value"
        ]
      },
      {
        "start": 5,
        "end": 38,
        "text": "mployee Resource Groups employees",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4,
        "end": 5,
        "text": "E",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 563,
    "created_at": "2024-11-05T15:19:48.736721Z",
    "updated_at": "2024-11-05T15:19:48.737720Z",
    "lead_time": 30.902
  },
  {
    "text": "(ERGs) are employee-led communities that collaborate with the business in achieving their strategic priorities, in line with the In countries that meet our criteria for data confidentiality and global inclusion and diversity strategy.",
    "id": 563,
    "annotator": 1,
    "annotation_id": 564,
    "created_at": "2024-11-05T15:19:56.115120Z",
    "updated_at": "2024-11-05T15:19:56.115120Z",
    "lead_time": 7.184
  },
  {
    "text": "Alongside our Councils anonymity, we disclose the race and ethnicity of our people focused on single aspects of diversity like race or gender, this year, at each level and set aspirations for leadership representation we also created a new forum   the Intersectionality and Inclusion which reflect available talent, our employee population and Council   through which our various ERGs can provide cross- external communities.",
    "id": 564,
    "annotator": 1,
    "annotation_id": 565,
    "created_at": "2024-11-05T15:20:05.216569Z",
    "updated_at": "2024-11-05T15:20:05.216569Z",
    "lead_time": 8.921
  },
  {
    "text": "Currently, the UK and the US meet those dimensional input to our priority global initiatives that affect criteria.",
    "id": 565,
    "annotator": 1,
    "annotation_id": 566,
    "created_at": "2024-11-05T15:20:13.091232Z",
    "updated_at": "2024-11-05T15:20:13.091232Z",
    "lead_time": 7.692
  },
  {
    "text": "employees at scale.",
    "id": 566,
    "annotator": 1,
    "annotation_id": 567,
    "created_at": "2024-11-05T15:20:14.522345Z",
    "updated_at": "2024-11-05T15:20:14.522345Z",
    "lead_time": 1.241
  },
  {
    "text": "27 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Diversity, equity and inclusion continued This year, we undertook the UK s Business Disability Forum s This year, we relaunched our Mental Health Matters training.",
    "id": 567,
    "annotator": 1,
    "annotation_id": 568,
    "created_at": "2024-11-05T15:20:26.312053Z",
    "updated_at": "2024-11-05T15:20:26.312053Z",
    "lead_time": 11.597
  },
  {
    "text": "Disability Smart Assessment; it showed that we have made clear Available globally, it is designed to help our people spot the signs improvements over the last three years in making adjustments of poor mental health, know how to start a conversation with for people with disabilities, recruitment, retention, the built others, and signpost resources to support everyone s wellbeing.",
    "id": 568,
    "annotator": 1,
    "annotation_id": 569,
    "created_at": "2024-11-05T15:20:32.429311Z",
    "updated_at": "2024-11-05T15:20:32.429311Z",
    "lead_time": 5.926
  },
  {
    "text": "environment and technology.",
    "id": 569,
    "annotator": 1,
    "annotation_id": 570,
    "created_at": "2024-11-05T15:20:33.916189Z",
    "updated_at": "2024-11-05T15:20:33.916189Z",
    "lead_time": 1.32
  },
  {
    "text": "We are now developing a new three-year plan to further improve how we meet the needs of Supporting diverse innovators for the future people with disabilities.",
    "id": 570,
    "label": [
      {
        "start": 88,
        "end": 158,
        "text": "Supporting diverse innovators for the future people with disabilities.",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 88,
        "end": 157,
        "text": "Supporting diverse innovators for the future people with disabilities",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 571,
    "created_at": "2024-11-05T15:20:55.873186Z",
    "updated_at": "2024-11-05T15:20:55.873186Z",
    "lead_time": 21.786
  },
  {
    "text": "We re investing in STEM education to make it more equitable and We are taking the needs of all our people into account by using to support and inspire the next generation of diverse, talented our own Inclusive Design Standards for all new and retrofitted innovators.",
    "id": 571,
    "label": [
      {
        "start": 6,
        "end": 33,
        "text": "investing in STEM education",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 6,
        "end": 33,
        "text": "investing in STEM education",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 572,
    "created_at": "2024-11-05T15:21:10.679737Z",
    "updated_at": "2024-11-05T15:21:10.679737Z",
    "lead_time": 14.613
  },
  {
    "text": "facilities, including our new global headquarters in London.",
    "id": 572,
    "annotator": 1,
    "annotation_id": 573,
    "created_at": "2024-11-05T15:21:13.953429Z",
    "updated_at": "2024-11-05T15:21:13.953429Z",
    "lead_time": 3.088
  },
  {
    "text": "These Our GSK Science in the Summer  initiative offers free, hands-on standards aim to ensure that our workplaces are welcoming to all STEM learning in community settings to students in the US from our people.",
    "id": 573,
    "annotator": 1,
    "annotation_id": 574,
    "created_at": "2024-11-05T15:21:22.835713Z",
    "updated_at": "2024-11-05T15:21:22.835713Z",
    "lead_time": 8.712
  },
  {
    "text": "groups traditionally under-represented in STEM careers, or from We have also partnered with PurpleSpace to sponsor a series of under-resourced communities.",
    "id": 574,
    "annotator": 1,
    "annotation_id": 575,
    "created_at": "2024-11-05T15:21:28.737934Z",
    "updated_at": "2024-11-05T15:21:28.737934Z",
    "lead_time": 5.721
  },
  {
    "text": "It has reached more than 380,000  Confident Conversation  guides, available to all.",
    "id": 575,
    "label": [
      {
        "start": 25,
        "end": 32,
        "text": "380,000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 34,
        "end": 64,
        "text": "Confident Conversation guides",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 576,
    "created_at": "2024-11-05T15:21:33.308476Z",
    "updated_at": "2024-11-05T15:21:45.354236Z",
    "lead_time": 13.93
  },
  {
    "text": "These guides are children across the US since its launch in 1986.",
    "id": 576,
    "annotator": 1,
    "annotation_id": 577,
    "created_at": "2024-11-05T15:21:49.732034Z",
    "updated_at": "2024-11-05T15:21:49.732034Z",
    "lead_time": 3.037
  },
  {
    "text": "a resource for people with disabilities and health conditions to In 2020, we committed $10 million over 10 years to support the help build confidence and personal resilience.",
    "id": 577,
    "label": [
      {
        "start": 87,
        "end": 112,
        "text": "$10 million over 10 years",
        "labels": [
          "value"
        ]
      },
      {
        "start": 0,
        "end": 61,
        "text": "a resource for people with disabilities and health conditions",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 578,
    "created_at": "2024-11-05T15:22:12.898258Z",
    "updated_at": "2024-11-05T15:22:12.898258Z",
    "lead_time": 22.979
  },
  {
    "text": "They are also useful number of women and Black and Latinx students in Philadelphia for colleagues, managers and leaders to learn more about how to entering STEM careers.",
    "id": 578,
    "annotator": 1,
    "annotation_id": 579,
    "created_at": "2024-11-05T15:22:21.666140Z",
    "updated_at": "2024-11-05T15:22:21.666140Z",
    "lead_time": 8.583
  },
  {
    "text": "More than 138,000 students of all support employees with disabilities and health conditions.",
    "id": 579,
    "label": [
      {
        "start": 0,
        "end": 17,
        "text": "More than 138,000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 18,
        "end": 91,
        "text": "students of all support employees with disabilities and health conditions",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 580,
    "created_at": "2024-11-05T15:22:37.489265Z",
    "updated_at": "2024-11-05T15:22:37.489265Z",
    "lead_time": 15.657
  },
  {
    "text": "backgrounds have benefited from GSK STEM equity grants Additionally, Disability Confidence training has been added into provided to local non-profit organisations so far.",
    "id": 580,
    "label": [
      {
        "start": 69,
        "end": 99,
        "text": "Disability Confidence training",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 69,
        "end": 99,
        "text": "Disability Confidence training",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 581,
    "created_at": "2024-11-05T15:22:50.875969Z",
    "updated_at": "2024-11-05T15:22:50.875969Z",
    "lead_time": 13.184
  },
  {
    "text": "our First Line Leader training, aimed at all our people managers.",
    "id": 581,
    "annotator": 1,
    "annotation_id": 582,
    "created_at": "2024-11-05T15:22:54.978597Z",
    "updated_at": "2024-11-05T15:22:54.978597Z",
    "lead_time": 3.91
  },
  {
    "text": "In the UK, we launched a  6 million, 10-year STEM equity This training is designed to develop inclusive leaders that are able programme, targeting 11 25-year-old girls and young women, to promote disability confidence within their teams.",
    "id": 582,
    "label": [
      {
        "start": 26,
        "end": 56,
        "text": "6 million, 10-year STEM equity",
        "labels": [
          "value"
        ]
      },
      {
        "start": 26,
        "end": 56,
        "text": "6 million, 10-year STEM equity",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 583,
    "created_at": "2024-11-05T15:23:28.820611Z",
    "updated_at": "2024-11-05T15:23:28.820611Z",
    "lead_time": 33.65
  },
  {
    "text": "black people and people from low socio-economic backgrounds.",
    "id": 583,
    "annotator": 1,
    "annotation_id": 584,
    "created_at": "2024-11-05T15:23:30.778493Z",
    "updated_at": "2024-11-05T15:23:30.778493Z",
    "lead_time": 1.775
  },
  {
    "text": "We continue to work to make sure that our LGBTQ+ colleagues The programme includes nationwide STEM mentoring, delivered feel welcome, valued and included.",
    "id": 584,
    "annotator": 1,
    "annotation_id": 585,
    "created_at": "2024-11-05T15:23:36.483617Z",
    "updated_at": "2024-11-05T15:23:36.483617Z",
    "lead_time": 5.538
  },
  {
    "text": "We were once more in partnership with established mentoring organisations.",
    "id": 585,
    "annotator": 1,
    "annotation_id": 586,
    "created_at": "2024-11-05T15:23:41.627717Z",
    "updated_at": "2024-11-05T15:23:41.627717Z",
    "lead_time": 4.97
  },
  {
    "text": "In its first recognised as a Gold employer within Stonewall s Top Global three years, we aim to reach approximately 4,000 young people Employers Index.",
    "id": 586,
    "label": [
      {
        "start": 116,
        "end": 121,
        "text": "4,000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 122,
        "end": 151,
        "text": "young people Employers Index.",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 587,
    "created_at": "2024-11-05T15:24:09.925993Z",
    "updated_at": "2024-11-05T15:24:09.925993Z",
    "lead_time": 28.125
  },
  {
    "text": "through this programme.",
    "id": 587,
    "annotator": 1,
    "annotation_id": 588,
    "created_at": "2024-11-05T15:24:11.377834Z",
    "updated_at": "2024-11-05T15:24:11.377834Z",
    "lead_time": 1.247
  },
  {
    "text": "2020 2021 2022 2023 Gender diversity1 % of women (all employees) 47% 47% 47% 48% A SVP\/VP level 38% 40% 42% 45% PR A Director level 46% 48% 49% 50% A Manager level 50% 50% 51% 51% A Total women in management 48% 48% 50% 50% A % of women on the Board 42% 42% 27% 42% Share of women in STEM-related positions (as a % of total STEM positions) 44% 45% 45% 46% % of women in management positions in revenue-generating functions 41% 41% 43% 45% PR Metric contributes to our ESG Performance Rating.",
    "id": 588,
    "annotator": 1,
    "annotation_id": 589,
    "created_at": "2024-11-05T15:24:14.160116Z",
    "updated_at": "2024-11-05T15:24:14.160116Z",
    "lead_time": 2.623
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 589,
    "annotator": 1,
    "annotation_id": 590,
    "created_at": "2024-11-05T15:24:16.453398Z",
    "updated_at": "2024-11-05T15:24:16.453398Z",
    "lead_time": 2.121
  },
  {
    "text": "1 T his data represents those that actively responded to identify a gender category.",
    "id": 590,
    "annotator": 1,
    "annotation_id": 591,
    "created_at": "2024-11-05T15:24:20.267130Z",
    "updated_at": "2024-11-05T15:24:20.267130Z",
    "lead_time": 3.647
  },
  {
    "text": "In 2023, 0.2% did not actively respond and a further 0.1% indicated  I prefer not to say .",
    "id": 591,
    "annotator": 1,
    "annotation_id": 592,
    "created_at": "2024-11-05T15:24:25.858647Z",
    "updated_at": "2024-11-05T15:24:25.858647Z",
    "lead_time": 5.413
  },
  {
    "text": "28 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Diversity, equity and inclusion continued SVP\/VP Director Manager All employees 2020 2021 2022 2023 2020 2021 2022 2023 2020 2021 2022 2023 2020 2021 2022 2023 US ethnic diversity1 American    2  2  2 0.4% 0.4% 0.3% 0.3% 0.3% 0.4% 0.3% 0.2% 0.4% 0.4% 0.3% 0.3% Indian or Alaska Native Asian 10.8% 10.8% 13.3% 18.8% 13.8% 14.7% 16.2% 16.8% 15.9% 16.7% 17.8% 18.4% 12.9% 13.7% 14.9% 15.7% Black or 5.8% 7.9% 8.6% 8.1% 5.5% 5.2% 6.0% 6.5% 6.3% 7.1% 7.9% 7.8% 9.9% 9.8% 10.4% 11.0% PR African American Hispanic 5.0% 5.8% 6.4% 6.4% 4.5% 4.5% 4.5% 4.9% 5.1% 5.4% 4.4% 4.9% 5.1% 5.3% 5.3% 5.8% PR or Latinx Native    2  2  2 0.3% 0.3% 0.2% 0.2% 0.1% 0.1%  2 0.1% 0.2% 0.2% 0.2% 0.2% Hawaiian or Other Pacific Islander Two or more 1.2% 2.2% 2.1% 1.7% 0.9% 1.2% 1.5% 1.3% 1.6% 1.5% 1.7% 2.0% 1.5% 1.6% 1.9% 1.9% races Ethnically 23.2% 27.1% 31.3% 35.7% 25.3% 26.3% 28.7%30.0% 29.3% 31.1% 32.2% 33.5% 30.0% 31.0% 33.1% 34.9% PR A diverse total White total 76.8% 72.9% 68.7%64.3% 74.7% 73.7% 71.3% 70.0% 70.8% 68.9% 67.8% 66.5% 70.0%69.0% 66.9% 65.1% UK ethnic diversity1,3 Asian 5.7% 6.5% 7.4% 9.7% 11.8% 12.6% 14.2% 15.1% 16.0% 17.4% 16.5% 17.4% 13.1% 13.8% 13.3% 14.2% Black 1.6% 1.6% 1.6% 1.9% 1.8% 1.8% 1.9% 2.2% 2.3% 2.7% 3.1% 3.4% 2.5% 2.6% 2.7% 3.0% PR Mixed 1.2% 2.0% 1.6% 2.9% 1.5% 1.9% 1.7% 2.0% 1.8% 2.0% 1.8% 2.2% 1.8% 2.1% 1.9% 2.1% Other 2.5% 2.8% 3.7% 3.9% 1.6% 1.5% 1.7% 1.9% 1.6% 1.6% 1.8% 2.1% 1.3% 1.3% 1.4% 1.6% Ethnically 11.1% 12.9% 14.3% 18.4% 16.7% 17.8% 19.5% 21.3% 21.8% 23.7% 23.2%25.0% 18.7% 19.8% 19.3% 20.9% PR A diverse total White total 88.9% 87.1% 85.7% 81.6% 83.4%82.2%80.5% 78.7% 78.2% 76.3% 76.8% 75.0% 81.3% 80.2%80.7% 79.1% PR Metric contributes to our ESG Performance Rating.",
    "id": 592,
    "annotator": 1,
    "annotation_id": 593,
    "created_at": "2024-11-05T15:24:27.229607Z",
    "updated_at": "2024-11-05T15:24:27.229607Z",
    "lead_time": 1.197
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 593,
    "annotator": 1,
    "annotation_id": 594,
    "created_at": "2024-11-05T15:24:28.806487Z",
    "updated_at": "2024-11-05T15:24:28.806487Z",
    "lead_time": 1.41
  },
  {
    "text": "1 T his data represents those that responded to identify a race or ethnicity category.",
    "id": 594,
    "annotator": 1,
    "annotation_id": 595,
    "created_at": "2024-11-05T15:24:35.222874Z",
    "updated_at": "2024-11-05T15:24:35.222874Z",
    "lead_time": 6.226
  },
  {
    "text": "In the US, 4.3% of employees did not actively respond to identify a race or ethnicity category, and a further 1.9% indicated  I prefer not to say .",
    "id": 595,
    "annotator": 1,
    "annotation_id": 596,
    "created_at": "2024-11-05T15:25:01.556328Z",
    "updated_at": "2024-11-05T15:25:01.556328Z",
    "lead_time": 26.152
  },
  {
    "text": "In the UK, 9.5% did not actively respond and a further 3.2% indicated  I prefer not to say .",
    "id": 596,
    "annotator": 1,
    "annotation_id": 597,
    "created_at": "2024-11-05T15:25:06.596853Z",
    "updated_at": "2024-11-05T15:25:06.596853Z",
    "lead_time": 4.861
  },
  {
    "text": "Due to rounding, the sum of the data may be marginally different from the totals.",
    "id": 597,
    "annotator": 1,
    "annotation_id": 598,
    "created_at": "2024-11-05T15:25:12.186485Z",
    "updated_at": "2024-11-05T15:25:12.186485Z",
    "lead_time": 5.409
  },
  {
    "text": "2 I nsufficient data to report (fewer than three employees).",
    "id": 598,
    "annotator": 1,
    "annotation_id": 599,
    "created_at": "2024-11-05T15:28:21.492670Z",
    "updated_at": "2024-11-05T15:28:21.492670Z",
    "lead_time": 189.115
  },
  {
    "text": "29 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Ethical standards Our culture guides our people to behave in an ethical way, to do the right thing and Speak Up about any concerns they have.",
    "id": 599,
    "annotator": 1,
    "annotation_id": 600,
    "created_at": "2024-11-05T15:28:27.251352Z",
    "updated_at": "2024-11-05T15:28:27.251352Z",
    "lead_time": 5.568
  },
  {
    "text": "We expect everyone who works for us to live up to this, and we expect the same of our suppliers.",
    "id": 600,
    "annotator": 1,
    "annotation_id": 601,
    "created_at": "2024-11-05T15:28:31.377463Z",
    "updated_at": "2024-11-05T15:28:31.377463Z",
    "lead_time": 3.918
  },
  {
    "text": "100% 83% 89% employees completed our of employees believe they of direct high-risk suppliers mandatory training 'can and do Speak Up if achieved our minimum things don't feel right' EcoVadis score Our commitment Promote ethical behaviour across our business by supporting our   Percentage of employees who believe they  can and do Speak employees to do the right thing and working with suppliers that Up if things don t feel right  is above the general industry share our standards and operate in a responsible way benchmark1   Percentage of direct high-risk suppliers that achieve GSK s Our ESG Performance Rating metrics 2023 minimum EcoVadis score or have an improvement plan in   Percentage of employees and complementary workers place complete GSK s 2023 mandatory training Supporting GSK people to do the right thing It is important that all our people, and everyone who works on our Our approach to managing ABAC risk, and other risks relating behalf, conducts themselves in the right way.",
    "id": 601,
    "label": [
      {
        "start": 9,
        "end": 12,
        "text": "89%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 13,
        "end": 57,
        "text": "employees completed our of employees believe",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 602,
    "created_at": "2024-11-05T15:28:53.946335Z",
    "updated_at": "2024-11-05T15:28:53.946335Z",
    "lead_time": 22.369
  },
  {
    "text": "This builds trust in what to ethical standards, forms part of our well-embedded risk we do, protects our business and helps create a workplace where management framework, which is described in detail in our we all thrive.",
    "id": 602,
    "annotator": 1,
    "annotation_id": 603,
    "created_at": "2024-11-05T15:28:59.829797Z",
    "updated_at": "2024-11-05T15:28:59.829797Z",
    "lead_time": 5.685
  },
  {
    "text": "How we do things is as important as what we do.",
    "id": 603,
    "annotator": 1,
    "annotation_id": 604,
    "created_at": "2024-11-05T15:29:03.593072Z",
    "updated_at": "2024-11-05T15:29:03.593072Z",
    "lead_time": 3.587
  },
  {
    "text": "Annual Report, on pages 57-61.",
    "id": 604,
    "annotator": 1,
    "annotation_id": 605,
    "created_at": "2024-11-05T15:29:05.582950Z",
    "updated_at": "2024-11-05T15:29:05.582950Z",
    "lead_time": 1.814
  },
  {
    "text": "Our Code of Conduct (The Code) reflects our purpose to unite g sk.com: Anti-bribery and corruption policy   The Code science, technology and talent to get ahead of disease together.",
    "id": 605,
    "annotator": 1,
    "annotation_id": 606,
    "created_at": "2024-11-05T15:29:10.151935Z",
    "updated_at": "2024-11-05T15:29:10.151935Z",
    "lead_time": 4.404
  },
  {
    "text": "It sets out the commitments we make as a company and to each Reporting and investigating concerns other to deliver on our purpose and ambition.",
    "id": 606,
    "annotator": 1,
    "annotation_id": 607,
    "created_at": "2024-11-05T15:29:15.294081Z",
    "updated_at": "2024-11-05T15:29:15.294081Z",
    "lead_time": 4.952
  },
  {
    "text": "The Code is Anyone inside or outside GSK can raise concerns or speak to our supported by additional global policies and standards, which integrity lines, confidentially and anonymously, without fear of can be found in our Code Hub.",
    "id": 607,
    "annotator": 1,
    "annotation_id": 608,
    "created_at": "2024-11-05T15:29:22.457607Z",
    "updated_at": "2024-11-05T15:29:22.457607Z",
    "lead_time": 6.988
  },
  {
    "text": "We have an accompanying global retaliation.",
    "id": 608,
    "annotator": 1,
    "annotation_id": 609,
    "created_at": "2024-11-05T15:29:24.446295Z",
    "updated_at": "2024-11-05T15:29:39.095628Z",
    "lead_time": 11.283
  },
  {
    "text": "We take every concern seriously and review every mandatory learning curriculum, Living our Code, which all our report to see whether we need to investigate formally.",
    "id": 609,
    "annotator": 1,
    "annotation_id": 610,
    "created_at": "2024-11-05T15:29:49.522950Z",
    "updated_at": "2024-11-05T15:29:49.522950Z",
    "lead_time": 6.547
  },
  {
    "text": "If our people are required to complete, comprising three modules: investigations show an employee has breached our policies, The Code, Creating an Inclusive Workplace and Protecting GSK.",
    "id": 610,
    "annotator": 1,
    "annotation_id": 611,
    "created_at": "2024-11-05T15:29:53.679388Z",
    "updated_at": "2024-11-05T15:29:53.679388Z",
    "lead_time": 3.976
  },
  {
    "text": "we take action.",
    "id": 611,
    "annotator": 1,
    "annotation_id": 612,
    "created_at": "2024-11-05T15:29:54.887398Z",
    "updated_at": "2024-11-05T15:29:54.887398Z",
    "lead_time": 1.013
  },
  {
    "text": "Protecting GSK focuses on key areas such as anti-bribery and In 2023, we saw an overall decrease in the number of employees corruption (ABAC), information and cyber security, privacy, who had concerns raised against them, employees disciplined for reporting human safety information related to our products, and policy violations and open cases at year end.",
    "id": 612,
    "annotator": 1,
    "annotation_id": 613,
    "created_at": "2024-11-05T15:30:25.407513Z",
    "updated_at": "2024-11-05T15:30:25.407513Z",
    "lead_time": 30.347
  },
  {
    "text": "This is reflective of our Speak Up integrity lines.",
    "id": 613,
    "annotator": 1,
    "annotation_id": 614,
    "created_at": "2024-11-05T15:30:29.794772Z",
    "updated_at": "2024-11-05T15:30:29.794772Z",
    "lead_time": 4.176
  },
  {
    "text": "In 2023, 100% of our employees and several factors including external geopolitical and economic 99% of complementary workers completed this training where issues affecting some countries which changes the nature of due by year end.",
    "id": 614,
    "annotator": 1,
    "annotation_id": 615,
    "created_at": "2024-11-05T15:30:35.457193Z",
    "updated_at": "2024-11-05T15:30:35.457193Z",
    "lead_time": 5.477
  },
  {
    "text": "concerns raised and, internally, our continued emphasis on We have additional ABAC training for our people in certain appropriate management and closure of cases.",
    "id": 615,
    "label": [
      {
        "start": 78,
        "end": 92,
        "text": "ABAC training ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 78,
        "end": 92,
        "text": "ABAC training ",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 616,
    "created_at": "2024-11-05T15:30:50.301566Z",
    "updated_at": "2024-11-05T15:30:50.301566Z",
    "lead_time": 14.647
  },
  {
    "text": "high-risk roles or geographic regions.",
    "id": 616,
    "annotator": 1,
    "annotation_id": 617,
    "created_at": "2024-11-05T15:30:54.086905Z",
    "updated_at": "2024-11-05T15:30:54.086905Z",
    "lead_time": 3.592
  },
  {
    "text": "This helps them identify and mitigate any potential ABAC risk   especially in third-party relationships   and recognise, report and manage conflicts of interest.",
    "id": 617,
    "annotator": 1,
    "annotation_id": 618,
    "created_at": "2024-11-05T15:31:03.603562Z",
    "updated_at": "2024-11-05T15:31:03.603562Z",
    "lead_time": 9.337
  },
  {
    "text": "In 2023, 100% of employees and 99% of complementary workers completed this training where due by year end.",
    "id": 618,
    "annotator": 1,
    "annotation_id": 619,
    "created_at": "2024-11-05T15:31:11.099270Z",
    "updated_at": "2024-11-05T15:31:11.099270Z",
    "lead_time": 7.305
  },
  {
    "text": "1 T he general industry benchmark is 66% according to 2023 research by KornFerry.",
    "id": 619,
    "annotator": 1,
    "annotation_id": 620,
    "created_at": "2024-11-05T15:31:15.589496Z",
    "updated_at": "2024-11-05T15:31:15.589496Z",
    "lead_time": 4.303
  },
  {
    "text": "30 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Ethical standards continued Our commitment to human rights We are committed to respecting internationally recognised We conduct audits and site visits covering EHS and labour rights human rights wherever we do business.",
    "id": 620,
    "annotator": 1,
    "annotation_id": 621,
    "created_at": "2024-11-05T15:31:19.730265Z",
    "updated_at": "2024-11-05T15:31:19.730265Z",
    "lead_time": 3.966
  },
  {
    "text": "Our salient human rights for our priority suppliers.",
    "id": 621,
    "annotator": 1,
    "annotation_id": 622,
    "created_at": "2024-11-05T15:31:24.639664Z",
    "updated_at": "2024-11-05T15:31:24.639664Z",
    "lead_time": 4.726
  },
  {
    "text": "1 Some of the issues identified during relate to access to healthcare, research practices, patient safety, supplier visits in 2023 related to policy, wages and compliance.",
    "id": 622,
    "annotator": 1,
    "annotation_id": 623,
    "created_at": "2024-11-05T15:31:29.197502Z",
    "updated_at": "2024-11-05T15:31:29.197502Z",
    "lead_time": 4.377
  },
  {
    "text": "environment, health and safety (EHS), and privacy.",
    "id": 623,
    "annotator": 1,
    "annotation_id": 624,
    "created_at": "2024-11-05T15:31:32.311182Z",
    "updated_at": "2024-11-05T15:31:32.311182Z",
    "lead_time": 2.931
  },
  {
    "text": "We continue All observations have action plans in place to drive improvement, to make progress in integrating them within our operations and which are tracked and followed up for completion.",
    "id": 624,
    "annotator": 1,
    "annotation_id": 625,
    "created_at": "2024-11-05T15:31:39.036789Z",
    "updated_at": "2024-11-05T15:31:39.036789Z",
    "lead_time": 6.537
  },
  {
    "text": "how we conduct our business.",
    "id": 625,
    "annotator": 1,
    "annotation_id": 626,
    "created_at": "2024-11-05T15:31:42.620975Z",
    "updated_at": "2024-11-05T15:31:42.620975Z",
    "lead_time": 3.398
  },
  {
    "text": "We are committed to fair and equitable pay, ensuring that all We are signatories to the UN Global Compact and our Human employees globally receive pay that is competitive in their local Rights Position Statement lays out our commitment to the UN markets and sufficient to support a sustainable standard of living.",
    "id": 626,
    "label": [
      {
        "start": 20,
        "end": 42,
        "text": "fair and equitable pay",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 20,
        "end": 42,
        "text": "fair and equitable pay",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 627,
    "created_at": "2024-11-05T15:32:01.272988Z",
    "updated_at": "2024-11-05T15:32:01.272988Z",
    "lead_time": 18.465
  },
  {
    "text": "Guiding Principles on Business and Human Rights.",
    "id": 627,
    "annotator": 1,
    "annotation_id": 628,
    "created_at": "2024-11-05T15:32:06.813932Z",
    "updated_at": "2024-11-05T15:32:06.813932Z",
    "lead_time": 5.344
  },
  {
    "text": "We have a In 2023, the Fair Wage Network certified GSK as a Living Wage cross-business Human Rights Steering Group, which reports to employer, after it reviewed the global gap analysis we conducted the GSK Leadership Team and Board s Corporate Responsibility in 2022.",
    "id": 628,
    "annotator": 1,
    "annotation_id": 629,
    "created_at": "2024-11-05T15:32:12.535954Z",
    "updated_at": "2024-11-05T15:32:12.535954Z",
    "lead_time": 5.517
  },
  {
    "text": "It confirmed that all GSK workers are paid at or above the Committee, and drives progress on human rights impacts and living wage in their relevant markets.",
    "id": 629,
    "annotator": 1,
    "annotation_id": 630,
    "created_at": "2024-11-05T15:32:19.550307Z",
    "updated_at": "2024-11-05T15:32:19.550307Z",
    "lead_time": 6.822
  },
  {
    "text": "We have also developed a risks across the business.",
    "id": 630,
    "annotator": 1,
    "annotation_id": 631,
    "created_at": "2024-11-05T15:32:23.023770Z",
    "updated_at": "2024-11-05T15:32:23.023770Z",
    "lead_time": 3.292
  },
  {
    "text": "consistent approach to how GSK will manage global fair wage analysis annually, as well as a methodology for the Fair Wage In 2023, we carried out human rights training for priority suppliers, Network to use to continue to assess us.",
    "id": 631,
    "annotator": 1,
    "annotation_id": 632,
    "created_at": "2024-11-05T15:32:40.538741Z",
    "updated_at": "2024-11-05T15:32:40.538741Z",
    "lead_time": 17.345
  },
  {
    "text": "aimed at ensuring a good understanding of human rights and labour principles, aligned with international standards.",
    "id": 632,
    "label": [
      {
        "start": 42,
        "end": 76,
        "text": "human rights and labour principles",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 42,
        "end": 76,
        "text": "human rights and labour principles",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 633,
    "created_at": "2024-11-05T15:32:54.560217Z",
    "updated_at": "2024-11-05T15:32:54.560217Z",
    "lead_time": 13.843
  },
  {
    "text": "We also g sk.com: Our position on Human Rights   Modern Slavery Act statement continued our human rights training for procurement and third-   Our position on working with third parties party engagement leads, to better equip them to spot human rights issues when visiting suppliers.",
    "id": 633,
    "label": [
      {
        "start": 91,
        "end": 113,
        "text": " human rights training",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 92,
        "end": 113,
        "text": "human rights training",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 634,
    "created_at": "2024-11-05T15:33:07.376196Z",
    "updated_at": "2024-11-05T15:33:07.376196Z",
    "lead_time": 12.61
  },
  {
    "text": "Working with third parties Our suppliers and other third parties   including agents, We assess all our third parties to understand whether we consider distributors and affiliate companies (where we have an equity them to be low, medium or high risk.",
    "id": 634,
    "annotator": 1,
    "annotation_id": 635,
    "created_at": "2024-11-05T15:33:14.108511Z",
    "updated_at": "2024-11-05T15:33:14.108511Z",
    "lead_time": 6.543
  },
  {
    "text": "Our high-risk third parties are stake)   help us research, develop, manufacture and distribute determined by location in high-risk markets, size of spend and the medicines and vaccines that patients need.",
    "id": 635,
    "annotator": 1,
    "annotation_id": 636,
    "created_at": "2024-11-05T15:33:18.978931Z",
    "updated_at": "2024-11-05T15:33:18.978931Z",
    "lead_time": 4.694
  },
  {
    "text": "We want to work type of goods or services.",
    "id": 636,
    "annotator": 1,
    "annotation_id": 637,
    "created_at": "2024-11-05T15:33:23.778627Z",
    "updated_at": "2024-11-05T15:33:23.778627Z",
    "lead_time": 4.61
  },
  {
    "text": "They are mostly goods and services with business partners who share our commitment to high ethical providers (62%), distributors and wholesalers (3%), direct material standards and operate in a responsible way.",
    "id": 637,
    "annotator": 1,
    "annotation_id": 638,
    "created_at": "2024-11-05T15:33:28.723376Z",
    "updated_at": "2024-11-05T15:33:28.723376Z",
    "lead_time": 4.766
  },
  {
    "text": "How these third suppliers (3%) and contract manufacturers (1%).",
    "id": 638,
    "annotator": 1,
    "annotation_id": 639,
    "created_at": "2024-11-05T15:33:32.484439Z",
    "updated_at": "2024-11-05T15:33:32.484439Z",
    "lead_time": 3.584
  },
  {
    "text": "In 2023, we parties act can have a direct impact on us.",
    "id": 639,
    "annotator": 1,
    "annotation_id": 640,
    "created_at": "2024-11-05T15:33:37.219214Z",
    "updated_at": "2024-11-05T15:33:37.219214Z",
    "lead_time": 4.552
  },
  {
    "text": "It is important to assessed our high-risk third parties, totalling over 7,500 manage our relationships with them well, including the way we assessments across 17 risk areas.",
    "id": 640,
    "annotator": 1,
    "annotation_id": 641,
    "created_at": "2024-11-05T15:33:43.088428Z",
    "updated_at": "2024-11-05T15:33:43.088428Z",
    "lead_time": 5.679
  },
  {
    "text": "We also use tools to assess how choose, contract and monitor them.",
    "id": 641,
    "annotator": 1,
    "annotation_id": 642,
    "created_at": "2024-11-05T15:33:44.901869Z",
    "updated_at": "2024-11-05T15:33:44.901869Z",
    "lead_time": 1.621
  },
  {
    "text": "suppliers manage risks, including EcoVadis desktop assessments.",
    "id": 642,
    "annotator": 1,
    "annotation_id": 643,
    "created_at": "2024-11-05T15:33:45.929378Z",
    "updated_at": "2024-11-05T15:33:45.929378Z",
    "lead_time": 0.851
  },
  {
    "text": "Our third-party risk management programme provides the Additionally, to further support ongoing oversight of our third framework by which we manage and oversee risks associated parties and suppliers, we have additional controls and monitoring with the third parties we engage to provide goods or services.",
    "id": 643,
    "label": [
      {
        "start": 208,
        "end": 265,
        "text": "additional controls and monitoring with the third parties",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 208,
        "end": 265,
        "text": "additional controls and monitoring with the third parties",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 644,
    "created_at": "2024-11-05T15:34:08.782806Z",
    "updated_at": "2024-11-05T15:34:08.782806Z",
    "lead_time": 22.685
  },
  {
    "text": "programmes to ensure they meet our standards and We expect our third parties to comply with applicable laws and requirements.",
    "id": 644,
    "annotator": 1,
    "annotation_id": 645,
    "created_at": "2024-11-05T15:34:14.087689Z",
    "updated_at": "2024-11-05T15:34:14.087689Z",
    "lead_time": 5.113
  },
  {
    "text": "For example, we include controls as relevant in regulations and to adopt, at minimum, our ABAC and labour our principal risks to manage third-party risk, which differs by rights principles and, where relevant, to comply with our standards business area according to the third-party risk profiles.",
    "id": 645,
    "annotator": 1,
    "annotation_id": 646,
    "created_at": "2024-11-05T15:34:18.782062Z",
    "updated_at": "2024-11-05T15:34:18.782062Z",
    "lead_time": 4.509
  },
  {
    "text": "Teams on quality, patient safety, health and safety, and the environment.",
    "id": 646,
    "annotator": 1,
    "annotation_id": 647,
    "created_at": "2024-11-05T15:34:22.277981Z",
    "updated_at": "2024-11-05T15:34:22.277981Z",
    "lead_time": 3.316
  },
  {
    "text": "in our Global Supply Chain business are responsible for on-site All expectations are formalised in contracts and subject to supplier visits and audits, periodic business review and appropriate levels of audit and oversight.",
    "id": 647,
    "annotator": 1,
    "annotation_id": 648,
    "created_at": "2024-11-05T15:34:27.808454Z",
    "updated_at": "2024-11-05T15:34:27.808454Z",
    "lead_time": 5.357
  },
  {
    "text": "All new suppliers performance meetings, and annual or semi-annual enterprise- undergo a risk assessment and all existing suppliers are re- level governance.",
    "id": 648,
    "label": [
      {
        "start": 44,
        "end": 103,
        "text": "annual or semi-annual enterprise- undergo a risk assessment",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 44,
        "end": 103,
        "text": "annual or semi-annual enterprise- undergo a risk assessment",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 649,
    "created_at": "2024-11-05T15:34:56.153039Z",
    "updated_at": "2024-11-05T15:34:56.153039Z",
    "lead_time": 28.154
  },
  {
    "text": "In R&D, we have an established third-party assessed once every three years on average.",
    "id": 649,
    "label": [
      {
        "start": 31,
        "end": 52,
        "text": "third-party assessed ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 31,
        "end": 52,
        "text": "third-party assessed ",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 650,
    "created_at": "2024-11-05T15:35:10.499708Z",
    "updated_at": "2024-11-05T15:35:10.499708Z",
    "lead_time": 14.149
  },
  {
    "text": "Appropriate action monitoring programme to assess compliance with our policies is taken against those third parties found in breach of their and standards.",
    "id": 650,
    "annotator": 1,
    "annotation_id": 651,
    "created_at": "2024-11-05T15:35:15.493322Z",
    "updated_at": "2024-11-05T15:35:15.493322Z",
    "lead_time": 4.794
  },
  {
    "text": "In our Commercial business, we annually risk undertakings.",
    "id": 651,
    "annotator": 1,
    "annotation_id": 652,
    "created_at": "2024-11-05T15:35:19.480455Z",
    "updated_at": "2024-11-05T15:35:19.480455Z",
    "lead_time": 3.801
  },
  {
    "text": "assess key commercial third parties and prioritise independent monitoring reviews, focused on ABAC, commercial practices and scientific and patient engagement.",
    "id": 652,
    "annotator": 1,
    "annotation_id": 653,
    "created_at": "2024-11-05T15:35:23.578702Z",
    "updated_at": "2024-11-05T15:35:23.578702Z",
    "lead_time": 3.929
  },
  {
    "text": "We monitor the actions we require them to complete and the reasons for doing so.",
    "id": 653,
    "annotator": 1,
    "annotation_id": 654,
    "created_at": "2024-11-05T15:35:27.932459Z",
    "updated_at": "2024-11-05T15:35:27.932459Z",
    "lead_time": 4.17
  },
  {
    "text": "1 O ur largest suppliers, including those who supply globally medically critical products, are critical to our R&D, and those largest by spend.",
    "id": 654,
    "annotator": 1,
    "annotation_id": 655,
    "created_at": "2024-11-05T15:35:34.031713Z",
    "updated_at": "2024-11-05T15:35:34.031713Z",
    "lead_time": 5.92
  },
  {
    "text": "31 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Ethical standards continued Helping our suppliers to manage environment, We conducted 47 supplier audits following industry standard Pharmaceutical Supply Chain Initiative guidelines.",
    "id": 655,
    "label": [
      {
        "start": 228,
        "end": 230,
        "text": "47",
        "labels": [
          "value"
        ]
      },
      {
        "start": 231,
        "end": 274,
        "text": "supplier audits following industry standard",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 656,
    "created_at": "2024-11-05T15:36:08.072851Z",
    "updated_at": "2024-11-05T15:36:08.072851Z",
    "lead_time": 33.852
  },
  {
    "text": "We trained health and safety risks more than 1,000 supplier employees on EHS and ESG Across the organisation, we give additional support on EHS risks fundamentals this year, strengthened EHS contractual obligations to our largest suppliers, including those who supply globally and have worked with suppliers to help them improve their medically critical products, those critical to our R&D, and those EcoVadis scores.",
    "id": 656,
    "label": [
      {
        "start": 35,
        "end": 69,
        "text": "more than 1,000 supplier employees",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3,
        "end": 34,
        "text": "trained health and safety risks",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 657,
    "created_at": "2024-11-05T15:36:41.373680Z",
    "updated_at": "2024-11-05T15:36:41.374686Z",
    "lead_time": 33.094
  },
  {
    "text": "We introduced a process to pause supply if a largest by spend.",
    "id": 657,
    "annotator": 1,
    "annotation_id": 658,
    "created_at": "2024-11-05T15:36:45.850268Z",
    "updated_at": "2024-11-05T15:36:45.850268Z",
    "lead_time": 4.266
  },
  {
    "text": "1 We help suppliers improve safety management third party has a significant EHS incident, and the decision on systems and build overall EHS capability, focusing on active whether to restart or discontinue work with the third party pharmaceutical ingredients manufacturers and contract depends on completion of an improvement plan and trajectory.",
    "id": 658,
    "annotator": 1,
    "annotation_id": 659,
    "created_at": "2024-11-05T15:36:56.319733Z",
    "updated_at": "2024-11-05T15:36:56.319733Z",
    "lead_time": 10.264
  },
  {
    "text": "manufacturing suppliers.",
    "id": 659,
    "annotator": 1,
    "annotation_id": 660,
    "created_at": "2024-11-05T15:36:57.647661Z",
    "updated_at": "2024-11-05T15:36:57.647661Z",
    "lead_time": 1.151
  },
  {
    "text": "We also introduced an EHS risk app-based questionnaire for GSK We set EHS requirements and review performance as part of our visitors to a third party as part of our monitoring activities, which internal EHS governance and oversight.",
    "id": 660,
    "label": [
      {
        "start": 22,
        "end": 54,
        "text": "EHS risk app-based questionnaire",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 22,
        "end": 54,
        "text": "EHS risk app-based questionnaire",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 661,
    "created_at": "2024-11-05T15:37:17.837449Z",
    "updated_at": "2024-11-05T15:37:17.837449Z",
    "lead_time": 19.984
  },
  {
    "text": "We visit sites, in person generate improvement actions that we track through to or virtually, to help suppliers better understand and control their completion.",
    "id": 661,
    "annotator": 1,
    "annotation_id": 662,
    "created_at": "2024-11-05T15:37:23.250615Z",
    "updated_at": "2024-11-05T15:37:23.250615Z",
    "lead_time": 5.213
  },
  {
    "text": "risks.",
    "id": 662,
    "annotator": 1,
    "annotation_id": 663,
    "created_at": "2024-11-05T15:37:24.524566Z",
    "updated_at": "2024-11-05T15:37:24.524566Z",
    "lead_time": 1.076
  },
  {
    "text": "This year, we conducted 73 physical visits across 63 priority suppliers.",
    "id": 663,
    "label": [
      {
        "start": 24,
        "end": 26,
        "text": "73",
        "labels": [
          "value"
        ]
      },
      {
        "start": 27,
        "end": 71,
        "text": "physical visits across 63 priority suppliers",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 664,
    "created_at": "2024-11-05T15:37:36.730110Z",
    "updated_at": "2024-11-05T15:37:36.730110Z",
    "lead_time": 12.025
  },
  {
    "text": "2 g sk.com: Our position on working with third parties   Annual Report 2023   Principal risks and uncertainties pages 230-240 Using data and AI responsibly Data is an essential foundation to realising our ambitions for In 2023, we created cross-functional AI Governance Council to patients.",
    "id": 664,
    "annotator": 1,
    "annotation_id": 665,
    "created_at": "2024-11-05T15:37:43.578284Z",
    "updated_at": "2024-11-05T15:37:43.578284Z",
    "lead_time": 6.651
  },
  {
    "text": "Advances in artificial intelligence (AI) and machine oversee our AI strategy and to ensure responsible adoption of learning (ML) technologies present tremendous opportunities, but AI\/ML.",
    "id": 665,
    "annotator": 1,
    "annotation_id": 666,
    "created_at": "2024-11-05T15:37:49.339103Z",
    "updated_at": "2024-11-05T15:37:49.339103Z",
    "lead_time": 5.576
  },
  {
    "text": "This is complemented by an internal policy to ensure that the technologies must be approached correctly, responsibly and AI\/ML adoption is safe and aligned with GSK s culture by ethically.",
    "id": 666,
    "label": [
      {
        "start": 24,
        "end": 103,
        "text": "an internal policy to ensure that the technologies must be approached correctly",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 24,
        "end": 103,
        "text": "an internal policy to ensure that the technologies must be approached correctly",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 667,
    "created_at": "2024-11-05T15:38:56.414531Z",
    "updated_at": "2024-11-05T15:38:56.414531Z",
    "lead_time": 66.89
  },
  {
    "text": "Increases in the volume of data processed through AI\/ establishing AI Principles, which are underpinned by the ethical ML use have resulted in a greater focus on data governance and standards set out in the GSK Code.",
    "id": 667,
    "annotator": 1,
    "annotation_id": 668,
    "created_at": "2024-11-05T15:39:02.639397Z",
    "updated_at": "2024-11-05T15:39:02.639397Z",
    "lead_time": 6.014
  },
  {
    "text": "The AI Governance Council is the ethical use of personal information, over and above responsible for enforcing our AI Principles and monitoring the compliance with data privacy laws.",
    "id": 668,
    "label": [
      {
        "start": 4,
        "end": 25,
        "text": "AI Governance Council",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4,
        "end": 25,
        "text": "AI Governance Council",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 669,
    "created_at": "2024-11-05T15:39:16.829293Z",
    "updated_at": "2024-11-05T15:39:16.829293Z",
    "lead_time": 13.996
  },
  {
    "text": "external AI\/ML landscape to anticipate potential risks to GSK.",
    "id": 669,
    "annotator": 1,
    "annotation_id": 670,
    "created_at": "2024-11-05T15:39:21.327100Z",
    "updated_at": "2024-11-05T15:39:21.327100Z",
    "lead_time": 4.28
  },
  {
    "text": "We take our responsibility for data privacy seriously and we We have also published a public policy position on responsible AI exercise high standards of integrity in dealing with the personal to set out our views, commitments and asks of policymakers.",
    "id": 670,
    "label": [
      {
        "start": 12,
        "end": 53,
        "text": "responsibility for data privacy seriously",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 12,
        "end": 53,
        "text": "responsibility for data privacy seriously",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 671,
    "created_at": "2024-11-05T15:39:47.038418Z",
    "updated_at": "2024-11-05T15:39:47.038418Z",
    "lead_time": 25.511
  },
  {
    "text": "Our information of our employees, patients, clinical research new operating model for AI governance is scalable and flexible to participants, healthcare providers and other stakeholders.",
    "id": 671,
    "annotator": 1,
    "annotation_id": 672,
    "created_at": "2024-11-05T15:39:51.891575Z",
    "updated_at": "2024-11-05T15:39:51.891575Z",
    "lead_time": 4.649
  },
  {
    "text": "adapt to the upcoming regulations.",
    "id": 672,
    "annotator": 1,
    "annotation_id": 673,
    "created_at": "2024-11-05T15:39:54.756908Z",
    "updated_at": "2024-11-05T15:39:54.756908Z",
    "lead_time": 2.678
  },
  {
    "text": "We are engaging with policymakers about the most appropriate regulatory approaches Our Digital and Privacy Governance Board oversees our overall that foster innovation while preserving safety and trust.",
    "id": 673,
    "annotator": 1,
    "annotation_id": 674,
    "created_at": "2024-11-05T15:40:01.500261Z",
    "updated_at": "2024-11-05T15:40:01.500261Z",
    "lead_time": 6.564
  },
  {
    "text": "data ethics and privacy operating model, supported by digital and privacy legal experts and compliance professionals.",
    "id": 674,
    "annotator": 1,
    "annotation_id": 675,
    "created_at": "2024-11-05T15:40:06.233174Z",
    "updated_at": "2024-11-05T15:40:06.233174Z",
    "lead_time": 4.552
  },
  {
    "text": "We monitor g sk.com: Annual Report, pages 57-61   Annual Report, R&D pages and mitigate new and emerging cyber threats to protect GSK 27-29   Our position on Responsible AI from cyber security risks.",
    "id": 675,
    "annotator": 1,
    "annotation_id": 676,
    "created_at": "2024-11-05T15:40:10.943308Z",
    "updated_at": "2024-11-05T15:40:10.943308Z",
    "lead_time": 4.53
  },
  {
    "text": "We have additional governance boards that oversee the use of our data in the research, development, manufacture and supply of our products to ensure we follow regulations and meet ethical obligations.",
    "id": 676,
    "label": [
      {
        "start": 8,
        "end": 36,
        "text": "additional governance boards",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 8,
        "end": 36,
        "text": "additional governance boards",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 677,
    "created_at": "2024-11-05T15:40:17.337983Z",
    "updated_at": "2024-11-05T15:40:30.803786Z",
    "lead_time": 17.18
  },
  {
    "text": "Political engagement Our industry is heavily regulated, meaning that our business We are committed to the highest ethical standards and legislative model and market are influenced by legislation and regulation.",
    "id": 677,
    "annotator": 1,
    "annotation_id": 678,
    "created_at": "2024-11-05T15:40:35.905579Z",
    "updated_at": "2024-11-05T15:40:35.905579Z",
    "lead_time": 3.817
  },
  {
    "text": "At requirements in all of our political engagements.",
    "id": 678,
    "annotator": 1,
    "annotation_id": 679,
    "created_at": "2024-11-05T15:40:40.450966Z",
    "updated_at": "2024-11-05T15:40:40.450966Z",
    "lead_time": 4.357
  },
  {
    "text": "We do not make GSK, we seek to contribute to public policy debate, especially in corporate political contributions, nor do we sponsor party political relation to life sciences and healthcare.",
    "id": 679,
    "annotator": 1,
    "annotation_id": 680,
    "created_at": "2024-11-05T15:40:45.841992Z",
    "updated_at": "2024-11-05T15:40:45.841992Z",
    "lead_time": 5.206
  },
  {
    "text": "As a major multinational meetings anywhere around the world.",
    "id": 680,
    "annotator": 1,
    "annotation_id": 681,
    "created_at": "2024-11-05T15:40:48.948669Z",
    "updated_at": "2024-11-05T15:40:48.948669Z",
    "lead_time": 2.926
  },
  {
    "text": "company, we are frequently invited by governments to give our g sk.com: Our position on political advocacy   Political advocacy views on the development of new policies, along with other disclosure stakeholders such as non-governmental organisations, scientists, healthcare professionals, patients and industry groups.",
    "id": 681,
    "annotator": 1,
    "annotation_id": 682,
    "created_at": "2024-11-05T15:40:53.751865Z",
    "updated_at": "2024-11-05T15:40:53.751865Z",
    "lead_time": 4.613
  },
  {
    "text": "1 G SK maintains a list of globally medically critical products.",
    "id": 682,
    "annotator": 1,
    "annotation_id": 683,
    "created_at": "2024-11-05T15:40:56.169113Z",
    "updated_at": "2024-11-05T15:40:56.169113Z",
    "lead_time": 2.233
  },
  {
    "text": "These are drug products approved to treat a life-threatening disease or medical condition for which there is no other adequately available alternative and of which GSK is the only provider.",
    "id": 683,
    "annotator": 1,
    "annotation_id": 684,
    "created_at": "2024-11-05T15:41:03.037123Z",
    "updated_at": "2024-11-05T15:41:03.037123Z",
    "lead_time": 6.655
  },
  {
    "text": "2 Our EHS priority suppliers are API suppliers who are, or will be, medically-, R&D-, or revenue-critical to GSK, or are high-spend suppliers.",
    "id": 684,
    "annotator": 1,
    "annotation_id": 685,
    "created_at": "2024-11-05T15:41:07.020189Z",
    "updated_at": "2024-11-05T15:41:07.020189Z",
    "lead_time": 3.795
  },
  {
    "text": "32 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix EEtthhiiccaall ssttaannddaarrddss ccoonnttiinnuueedd 2020 2021 2022 2023 Ethical conduct1 Employees who had concerns raised against them (including current year and prior year 2,105 2,534 2,191 1,960 A open cases) Employees disciplined for policy violations 553 910 850 798 A Breakdown of types of policy violation2 Employee conduct3 268 555 367 304 A Sales and marketing 63 166 168 122 A Product quality 85 65 48 76 A Safeguarding people and information and assets 60 78 140 177 A Employee relations and HR policies 18 20 42 994 A R&D and medical practices 7 13 13 7 A Anti-bribery and corruption 8 22 12 394 A Cyber security 27 9 14 245 A EHS and sustainability 9 16 152 646 A Other 17 5 4 4 A Employees who were dismissed or agreed to leave the company voluntarily as a result of 103 177 290 256 A misconduct Documented warnings 455 740 566 553 A Open cases awaiting investigation or a disciplinary decision at year end 617 636 457 297 A Mandatory training7 % of employees and complementary workers that complete GSK s mandatory training8     99% 100% PR A % of employees that complete GSK s mandatory training   The Code: Living our Values and 100% 99% 100% 100% Expectations (2019, 2020); Working at GSK (2021) % of complementary workers that complete GSK s mandatory training   The Code: Living our 97% 93% 98% 99% Values and Expectations (2019, 2020); Working at GSK (2021) % of employees that complete GSK s mandatory training   ABAC 100% 100% 100% 100% % of complementary workers that complete GSK s mandatory training   ABAC 100% 99% 96% 99% Reporting concerns % of employees who believe they  can and do Speak Up if things don t feel right    87% 87% 83% PR A Suppliers % of direct high-risk suppliers that achieve GSK s minimum EcoVadis score or have an 53% 80% 82% 89% PR A improvement plan in place PR Metric contributes to our ESG Performance Rating.",
    "id": 685,
    "annotator": 1,
    "annotation_id": 686,
    "created_at": "2024-11-05T15:41:09.154813Z",
    "updated_at": "2024-11-05T15:41:09.154813Z",
    "lead_time": 1.947
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 686,
    "annotator": 1,
    "annotation_id": 687,
    "created_at": "2024-11-05T15:41:10.823637Z",
    "updated_at": "2024-11-05T15:41:10.823637Z",
    "lead_time": 1.488
  },
  {
    "text": "1 In 2023, we enhanced our analytics of types of discipline taken and identified additional cases from prior years where disciplinary action was not reported.",
    "id": 687,
    "label": [
      {
        "start": 14,
        "end": 59,
        "text": "enhanced our analytics of types of discipline",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 14,
        "end": 59,
        "text": "enhanced our analytics of types of discipline",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 688,
    "created_at": "2024-11-05T15:41:11.503493Z",
    "updated_at": "2024-11-05T15:41:37.827382Z",
    "lead_time": 20.165999999999997
  },
  {
    "text": "As a result, we restated some prior years metrics with the following net increase changes in employees disciplined for policy violations from prior reporting: 2020 (1); 2021 (3) and 2022 (3).",
    "id": 688,
    "annotator": 1,
    "annotation_id": 689,
    "created_at": "2024-11-05T15:41:42.486464Z",
    "updated_at": "2024-11-05T15:41:42.486464Z",
    "lead_time": 3.397
  },
  {
    "text": "Disciplinary action was taken within the year.",
    "id": 689,
    "annotator": 1,
    "annotation_id": 690,
    "created_at": "2024-11-05T15:41:44.483594Z",
    "updated_at": "2024-11-05T15:41:44.483594Z",
    "lead_time": 1.811
  },
  {
    "text": "2 I n 2022, we updated the reporting methodology for the breakdown of types of policy violation to provide more granularity by case class as there was a broader distribution from the top five policy area categories historically reported under 'other'.",
    "id": 690,
    "annotator": 1,
    "annotation_id": 691,
    "created_at": "2024-11-05T15:41:49.311917Z",
    "updated_at": "2024-11-05T15:41:49.311917Z",
    "lead_time": 4.648
  },
  {
    "text": "To enable comparison, prior year data has been restated using the new reporting methodology.",
    "id": 691,
    "annotator": 1,
    "annotation_id": 692,
    "created_at": "2024-11-05T15:41:53.376197Z",
    "updated_at": "2024-11-05T15:41:53.376197Z",
    "lead_time": 3.881
  },
  {
    "text": "3 I n 2022, we changed our process for the circumstances that trigger discipline for late completion of mandatory training, now reported under employee conduct.",
    "id": 692,
    "annotator": 1,
    "annotation_id": 693,
    "created_at": "2024-11-05T15:42:21.638284Z",
    "updated_at": "2024-11-05T15:42:21.638284Z",
    "lead_time": 28.072
  },
  {
    "text": "As a result, we saw fewer disciplinary cases in 2022 compared to prior years.",
    "id": 693,
    "annotator": 1,
    "annotation_id": 694,
    "created_at": "2024-11-05T15:42:25.853196Z",
    "updated_at": "2024-11-05T15:42:25.853196Z",
    "lead_time": 4.032
  },
  {
    "text": "4 I n 2023 changes from prior years are reflective of several factors including external geopolitical and economic issues affecting some countries which changes the nature of concerns raised and, internally, our continued emphasis on appropriate management and closure of cases, correlating in an increase in these areas.",
    "id": 694,
    "annotator": 1,
    "annotation_id": 695,
    "created_at": "2024-11-05T15:42:29.797968Z",
    "updated_at": "2024-11-05T15:42:29.797968Z",
    "lead_time": 3.752
  },
  {
    "text": "5 I n 2023, policy violation class type name changed from Computer and data-breach security to Cyber Security, content\/classification remains the same and therefore data is comparable year on year.",
    "id": 695,
    "annotator": 1,
    "annotation_id": 696,
    "created_at": "2024-11-05T15:42:33.791511Z",
    "updated_at": "2024-11-05T15:42:33.791511Z",
    "lead_time": 3.8
  },
  {
    "text": "6 T he majority of EHS and sustainability category increases in 2022 were written warnings related to compliance with the company's COVID-19 vaccination mandate, safety or testing requirements, to ensure the health, safety and wellbeing of our workforce, which were subsequently lifted in April 2023, correlating in a decrease in 2023.",
    "id": 696,
    "annotator": 1,
    "annotation_id": 697,
    "created_at": "2024-11-05T15:42:40.312243Z",
    "updated_at": "2024-11-05T15:42:40.312243Z",
    "lead_time": 6.314
  },
  {
    "text": "7 T hese figures are based on active employees and complementary workers at year end.",
    "id": 697,
    "annotator": 1,
    "annotation_id": 698,
    "created_at": "2024-11-05T15:42:45.442138Z",
    "updated_at": "2024-11-05T15:42:45.442138Z",
    "lead_time": 4.945
  },
  {
    "text": "Data from 2020-21 is split between employees and complementary workers, as disclosed in our prior ESG reports, and rounded to the nearest whole number.",
    "id": 698,
    "annotator": 1,
    "annotation_id": 699,
    "created_at": "2024-11-05T15:42:48.952948Z",
    "updated_at": "2024-11-05T15:42:48.952948Z",
    "lead_time": 3.32
  },
  {
    "text": "2020-21 also includes data from our previous Consumer Healthcare business; due to attrition over the last three years, restating completion rates would not provide a comparable metric.",
    "id": 699,
    "annotator": 1,
    "annotation_id": 700,
    "created_at": "2024-11-05T15:42:54.067531Z",
    "updated_at": "2024-11-05T15:42:54.067531Z",
    "lead_time": 4.924
  },
  {
    "text": "8 In 2022, we updated the way in which we report completion of mandatory training by combining metrics for employees and complementary workers across the mandatory trainings into a single metric, rounded to the nearest whole number.",
    "id": 700,
    "annotator": 1,
    "annotation_id": 701,
    "created_at": "2024-11-05T15:42:58.977244Z",
    "updated_at": "2024-11-05T15:42:58.977244Z",
    "lead_time": 4.717
  },
  {
    "text": "33 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Ethical standards continued 2020 2021 2022 2023 Supplier spend by region Asia-Pacific     8.6% 8% Europe, Middle East and Africa     58.5% 55% Latin America     1.5% 2% North America     31.3% 35% US political engagement Spend on federal lobbying activities ($m) 3.80 5.30 4.46 5.10 Trade association membership spend ($m) 21.5 20.3 20.6 20.6 Corporate political contributions ($)1 0 0 0 0 Political action committee contributions from US employees to state and federal candidates ($'000) 366.8 298.0 360.5 325.8 European political engagement Trade association membership spend ( m)3 2.28 2.08 1.91 2.00 Corporate political contributions ( )1 0 0 0 0 Cost of representing our interests to EU institutions ( m)2 1.82 1.18 1.22 0.70 PR Metric contributes to our ESG Performance Rating.",
    "id": 701,
    "annotator": 1,
    "annotation_id": 702,
    "created_at": "2024-11-05T15:43:05.007109Z",
    "updated_at": "2024-11-05T15:43:05.007109Z",
    "lead_time": 5.832
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 702,
    "annotator": 1,
    "annotation_id": 703,
    "created_at": "2024-11-05T15:43:06.630086Z",
    "updated_at": "2024-11-05T15:43:06.630086Z",
    "lead_time": 1.403
  },
  {
    "text": "1 G SK does not make corporate political contributions, nor do we sponsor political meetings anywhere around the world.",
    "id": 703,
    "annotator": 1,
    "annotation_id": 704,
    "created_at": "2024-11-05T15:43:16.042284Z",
    "updated_at": "2024-11-05T15:43:16.043286Z",
    "lead_time": 9.222
  },
  {
    "text": "2 T his includes the latest available figures from the previous year.",
    "id": 704,
    "annotator": 1,
    "annotation_id": 705,
    "created_at": "2024-11-05T15:43:17.452468Z",
    "updated_at": "2024-11-05T15:43:17.452468Z",
    "lead_time": 1.199
  },
  {
    "text": "Figures from the reporting year are published annually in March, after publication of this document.",
    "id": 705,
    "annotator": 1,
    "annotation_id": 706,
    "created_at": "2024-11-05T15:43:24.301379Z",
    "updated_at": "2024-11-05T15:43:24.301379Z",
    "lead_time": 6.651
  },
  {
    "text": "3 E uropean political memberships included here are EFPIA (European Federation of Pharmaceutical Industries and Associations) and ABPI (Association of the British Pharmaceutical Industry) 34 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Product governance To protect our patients, it is critically important to ensure the quality, safety and reliable supply of our products.",
    "id": 706,
    "annotator": 1,
    "annotation_id": 707,
    "created_at": "2024-11-05T15:43:25.863030Z",
    "updated_at": "2024-11-05T15:43:25.863030Z",
    "lead_time": 1.361
  },
  {
    "text": "1,081 114 7,988 quality audits of our regulatory inspections at our clinical trial protocol contract manufacturers manufacturing sites and local summaries registered and and suppliers operating companies 6,734 summaries of results Our commitment We commit to maintaining robust quality and safety processes,   Number of FDA warning letters and using data and new technologies responsibly   Total number of Class I\/II external product recalls across all markets Our ESG Performance Rating metrics 2023   Register and disclose all human subject research of GSK   Average number of critical and major findings per inspection products.",
    "id": 707,
    "annotator": 1,
    "annotation_id": 708,
    "created_at": "2024-11-05T23:23:39.606790Z",
    "updated_at": "2024-11-05T23:23:39.606790Z",
    "lead_time": 8.514
  },
  {
    "text": "Specifically, register protocol summaries for studies by FDA\/MHRA\/EMA regulators1 initiated in 2023; and disclose results summaries for studies   Percentage of inspections from all regulators with no critical with results due in 2023 findings or official action indicated Product quality and patient safety are critically important to GSK.",
    "id": 708,
    "annotator": 1,
    "annotation_id": 709,
    "created_at": "2024-11-05T23:23:49.593123Z",
    "updated_at": "2024-11-05T23:23:49.593123Z",
    "lead_time": 9.77
  },
  {
    "text": "These systems enable us to deliver a safe and reliable supply of We have systems in place across the company that ensure we high-quality medicines and vaccines.",
    "id": 709,
    "annotator": 1,
    "annotation_id": 710,
    "created_at": "2024-11-05T23:24:36.421290Z",
    "updated_at": "2024-11-05T23:24:36.421290Z",
    "lead_time": 2.645
  },
  {
    "text": "When issues arise, our meet the high standards we set ourselves, and those that are quality systems, in line with our values-driven culture, ensure they expected of us externally.",
    "id": 710,
    "annotator": 1,
    "annotation_id": 711,
    "created_at": "2024-11-05T23:24:42.537716Z",
    "updated_at": "2024-11-05T23:24:42.537716Z",
    "lead_time": 5.905
  },
  {
    "text": "are responded to swiftly and transparently.",
    "id": 711,
    "annotator": 1,
    "annotation_id": 712,
    "created_at": "2024-11-05T23:24:45.398944Z",
    "updated_at": "2024-11-05T23:24:45.398944Z",
    "lead_time": 2.685
  },
  {
    "text": "Maintaining quality across GSK We have a detailed and specific quality framework that describes Inspections, recalls and audit how we comply with regulatory requirements and other standards We are subject to frequent regulatory inspections in markets across our markets.",
    "id": 712,
    "label": [
      {
        "start": 41,
        "end": 80,
        "text": "detailed and specific quality framework",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 41,
        "end": 80,
        "text": "detailed and specific quality framework",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 713,
    "created_at": "2024-11-05T23:25:10.755471Z",
    "updated_at": "2024-11-05T23:25:10.755471Z",
    "lead_time": 25.17
  },
  {
    "text": "This addresses global and local regulations where we supply our medicines and vaccines.",
    "id": 713,
    "annotator": 1,
    "annotation_id": 714,
    "created_at": "2024-11-05T23:25:20.933758Z",
    "updated_at": "2024-11-05T23:25:20.933758Z",
    "lead_time": 9.945
  },
  {
    "text": "These inspections across manufacturing and distribution processes, and is based on provide independent assurance that our development, principles defined by the International Council for Harmonisation manufacturing and distribution processes adhere to the required of Technical Requirements for Pharmaceuticals for Human Use.",
    "id": 714,
    "annotator": 1,
    "annotation_id": 715,
    "created_at": "2024-11-05T23:25:29.533988Z",
    "updated_at": "2024-11-05T23:25:29.533988Z",
    "lead_time": 8.373
  },
  {
    "text": "high quality standards and expectations.",
    "id": 715,
    "annotator": 1,
    "annotation_id": 716,
    "created_at": "2024-11-05T23:25:33.391155Z",
    "updated_at": "2024-11-05T23:25:33.391155Z",
    "lead_time": 3.658
  },
  {
    "text": "We work to ensure we Our GSK quality function is responsible for managing quality are inspection ready at all times.",
    "id": 716,
    "annotator": 1,
    "annotation_id": 717,
    "created_at": "2024-11-05T23:25:38.636575Z",
    "updated_at": "2024-11-05T23:25:38.636575Z",
    "lead_time": 5.067
  },
  {
    "text": "and for ensuring a quality mindset is embedded throughout the In 2023, we had 114 regulatory inspections at our manufacturing organisation at all levels.",
    "id": 717,
    "label": [
      {
        "start": 82,
        "end": 138,
        "text": "regulatory inspections at our manufacturing organisation",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 78,
        "end": 81,
        "text": "114",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 718,
    "created_at": "2024-11-05T23:25:59.360263Z",
    "updated_at": "2024-11-05T23:25:59.360263Z",
    "lead_time": 20.537
  },
  {
    "text": "It brings together an extensive global sites and local operating companies, compared with 122 in 2022.",
    "id": 718,
    "annotator": 1,
    "annotation_id": 719,
    "created_at": "2024-11-05T23:26:38.732414Z",
    "updated_at": "2024-11-05T23:26:38.732414Z",
    "lead_time": 39.157
  },
  {
    "text": "network of quality and compliance professionals within each of We received zero warning letters from the United States Food and our business units, from site level to senior management.",
    "id": 719,
    "label": [
      {
        "start": 74,
        "end": 95,
        "text": " zero warning letters",
        "labels": [
          "value"
        ]
      },
      {
        "start": 96,
        "end": 146,
        "text": "from the United States Food and our business units",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 720,
    "created_at": "2024-11-05T23:27:08.770823Z",
    "updated_at": "2024-11-05T23:27:08.770823Z",
    "lead_time": 29.852
  },
  {
    "text": "Drug Administration (FDA) or critical findings from the Medicines Our Quality Management System provides the standards required and Healthcare products Regulatory Agency (MHRA) and to be followed by GSK people to support good distribution and European Medicines Agency (EMA) in 2023.",
    "id": 720,
    "annotator": 1,
    "annotation_id": 721,
    "created_at": "2024-11-05T23:28:01.229832Z",
    "updated_at": "2024-11-05T23:28:01.229832Z",
    "lead_time": 52.209
  },
  {
    "text": "We respond to and manufacturing practice and to maintain a standardised and learn from all inspection findings, taking the necessary actions to compliant approach to all our quality activities, aligned to address them.",
    "id": 721,
    "annotator": 1,
    "annotation_id": 722,
    "created_at": "2024-11-05T23:28:17.827340Z",
    "updated_at": "2024-11-05T23:28:17.827340Z",
    "lead_time": 16.389
  },
  {
    "text": "the regulatory expectations of the markets that we supply to.",
    "id": 722,
    "annotator": 1,
    "annotation_id": 723,
    "created_at": "2024-11-05T23:28:22.018669Z",
    "updated_at": "2024-11-05T23:28:22.018669Z",
    "lead_time": 4.004
  },
  {
    "text": "Throughout 2023, we had two Class I product recalls.",
    "id": 723,
    "label": [
      {
        "start": 24,
        "end": 27,
        "text": "two",
        "labels": [
          "value"
        ]
      },
      {
        "start": 28,
        "end": 51,
        "text": "Class I product recalls",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 724,
    "created_at": "2024-11-05T23:28:40.078846Z",
    "updated_at": "2024-11-05T23:28:40.078846Z",
    "lead_time": 17.884
  },
  {
    "text": "In these instances, we engaged with regulators and acted quickly to prioritise patient safety.",
    "id": 724,
    "annotator": 1,
    "annotation_id": 725,
    "created_at": "2024-11-05T23:28:47.447647Z",
    "updated_at": "2024-11-05T23:28:47.447647Z",
    "lead_time": 7.151
  },
  {
    "text": "There were fewer Class II recalls compared with 2022.",
    "id": 725,
    "annotator": 1,
    "annotation_id": 726,
    "created_at": "2024-11-05T23:28:49.509197Z",
    "updated_at": "2024-11-05T23:28:49.509197Z",
    "lead_time": 1.868
  },
  {
    "text": "If necessary to protect patients, we will not hesitate to recall products voluntarily.",
    "id": 726,
    "annotator": 1,
    "annotation_id": 727,
    "created_at": "2024-11-05T23:28:54.615013Z",
    "updated_at": "2024-11-05T23:28:54.615013Z",
    "lead_time": 4.92
  },
  {
    "text": "1 We consider any observations from the US FDA as major.",
    "id": 727,
    "annotator": 1,
    "annotation_id": 728,
    "created_at": "2024-11-05T23:29:01.026252Z",
    "updated_at": "2024-11-05T23:29:01.026252Z",
    "lead_time": 6.242
  },
  {
    "text": "35 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Product governance continued Quality management along our supply chains We have a comprehensive quality oversight model for suppliers that is aligned to our Quality Management System.",
    "id": 728,
    "label": [
      {
        "start": 224,
        "end": 275,
        "text": "comprehensive quality oversight model for suppliers",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 224,
        "end": 275,
        "text": "comprehensive quality oversight model for suppliers",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 729,
    "created_at": "2024-11-05T23:29:21.430814Z",
    "updated_at": "2024-11-05T23:29:21.430814Z",
    "lead_time": 20.106
  },
  {
    "text": "It uses a We expect all our contract manufacturers and suppliers to risk-based approach to assess, qualify, manage and monitor our comply with GSK standards.",
    "id": 729,
    "annotator": 1,
    "annotation_id": 730,
    "created_at": "2024-11-05T23:29:26.460216Z",
    "updated_at": "2024-11-05T23:29:26.460216Z",
    "lead_time": 4.819
  },
  {
    "text": "In 2023, we conducted 1,081 quality third-party suppliers on an ongoing basis, driving continuous audits of contract manufacturers and suppliers to verify that they performance.",
    "id": 730,
    "label": [
      {
        "start": 22,
        "end": 27,
        "text": "1,081",
        "labels": [
          "value"
        ]
      },
      {
        "start": 28,
        "end": 77,
        "text": "quality third-party suppliers on an ongoing basis",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 731,
    "created_at": "2024-11-05T23:30:58.748976Z",
    "updated_at": "2024-11-05T23:30:58.748976Z",
    "lead_time": 92.076
  },
  {
    "text": "do so.",
    "id": 731,
    "annotator": 1,
    "annotation_id": 732,
    "created_at": "2024-11-05T23:31:00.382972Z",
    "updated_at": "2024-11-05T23:31:00.382972Z",
    "lead_time": 1.415
  },
  {
    "text": "Pharmacovigilance We have a well-established and rigorous worldwide system to Tackling counterfeit medicines and vaccines monitor and review the safety of our products throughout clinical Falsified products put the health of patients at risk and threaten development and after regulatory approval.",
    "id": 732,
    "annotator": 1,
    "annotation_id": 733,
    "created_at": "2024-11-05T23:31:08.260842Z",
    "updated_at": "2024-11-05T23:31:08.260842Z",
    "lead_time": 7.677
  },
  {
    "text": "Through this our brand and reputation.",
    "id": 733,
    "annotator": 1,
    "annotation_id": 734,
    "created_at": "2024-11-05T23:31:10.015546Z",
    "updated_at": "2024-11-05T23:31:10.015546Z",
    "lead_time": 1.563
  },
  {
    "text": "We report all cases of confirmed pharmacovigilance system, we aim to enhance patient care and counterfeit products to the WHO and to relevant regulatory safety when using our marketed and investigational medicines authorities.",
    "id": 734,
    "annotator": 1,
    "annotation_id": 735,
    "created_at": "2024-11-05T23:31:16.243099Z",
    "updated_at": "2024-11-05T23:31:16.243099Z",
    "lead_time": 6.041
  },
  {
    "text": "We actively participate in legal proceedings against and vaccines.",
    "id": 735,
    "annotator": 1,
    "annotation_id": 736,
    "created_at": "2024-11-05T23:31:21.190633Z",
    "updated_at": "2024-11-05T23:31:21.190633Z",
    "lead_time": 4.763
  },
  {
    "text": "We also support public health programmes by illegal actors, and support customs and local authorities with using this system to provide reliable, comprehensive information regular training.",
    "id": 736,
    "label": [
      {
        "start": 8,
        "end": 58,
        "text": "support public health programmes by illegal actors",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 8,
        "end": 58,
        "text": "support public health programmes by illegal actors",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 737,
    "created_at": "2024-11-05T23:31:51.854891Z",
    "updated_at": "2024-11-05T23:31:51.854891Z",
    "lead_time": 30.471
  },
  {
    "text": "We also monitor online marketplaces and social on our products  overall benefit-risk balance.",
    "id": 737,
    "annotator": 1,
    "annotation_id": 738,
    "created_at": "2024-11-05T23:31:56.881593Z",
    "updated_at": "2024-11-05T23:31:56.881593Z",
    "lead_time": 4.803
  },
  {
    "text": "media to request takedowns of sites illicitly selling prescription- We expect our partners to meet the same high standards of only medicines.",
    "id": 738,
    "annotator": 1,
    "annotation_id": 739,
    "created_at": "2024-11-05T23:32:05.313298Z",
    "updated_at": "2024-11-05T23:32:05.313298Z",
    "lead_time": 8.232
  },
  {
    "text": "safety governance.",
    "id": 739,
    "annotator": 1,
    "annotation_id": 740,
    "created_at": "2024-11-05T23:32:06.530377Z",
    "updated_at": "2024-11-05T23:32:06.530377Z",
    "lead_time": 1.024
  },
  {
    "text": "We conduct reviews of third-party safety g sk.com: Our position on falsified and substandard healthcare products systems, monitoring of contractual obligations and fostering collaboration through the life cycle of the relationship.",
    "id": 740,
    "annotator": 1,
    "annotation_id": 741,
    "created_at": "2024-11-05T23:32:13.670775Z",
    "updated_at": "2024-11-05T23:32:13.670775Z",
    "lead_time": 6.952
  },
  {
    "text": "g sk.com: Our position on pharmacovigilance Clinical data transparency We are committed to transparency of data from clinical studies As part of our commitment to transparency, we have made 7,988 that evaluate our medicines and vaccines.",
    "id": 741,
    "label": [
      {
        "start": 189,
        "end": 195,
        "text": " 7,988",
        "labels": [
          "value"
        ]
      },
      {
        "start": 201,
        "end": 236,
        "text": "evaluate our medicines and vaccines",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 742,
    "created_at": "2024-11-05T23:32:41.157244Z",
    "updated_at": "2024-11-05T23:32:41.157244Z",
    "lead_time": 27.285
  },
  {
    "text": "This is because we want protocol summaries and 6,734 summaries of results available since to enable access to information about our research to study the GSK trial register was set up in 2004.",
    "id": 742,
    "annotator": 1,
    "annotation_id": 743,
    "created_at": "2024-11-05T23:32:56.882075Z",
    "updated_at": "2024-11-05T23:32:56.882075Z",
    "lead_time": 15.497
  },
  {
    "text": "We have also listed 2,669 participants, patients, healthcare providers and the wider public.",
    "id": 743,
    "annotator": 1,
    "annotation_id": 744,
    "created_at": "2024-11-05T23:33:06.383812Z",
    "updated_at": "2024-11-05T23:33:06.383812Z",
    "lead_time": 9.31
  },
  {
    "text": "clinical trials for data sharing via www.",
    "id": 744,
    "annotator": 1,
    "annotation_id": 745,
    "created_at": "2024-11-05T23:33:07.831428Z",
    "updated_at": "2024-11-05T23:33:07.831428Z",
    "lead_time": 1.269
  },
  {
    "text": "vivli.org.",
    "id": 745,
    "annotator": 1,
    "annotation_id": 746,
    "created_at": "2024-11-05T23:33:09.053014Z",
    "updated_at": "2024-11-05T23:33:09.053014Z",
    "lead_time": 1.036
  },
  {
    "text": "It also allows us to acknowledge the invaluable contribution of the people who take part in our clinical research.",
    "id": 746,
    "annotator": 1,
    "annotation_id": 747,
    "created_at": "2024-11-05T23:33:14.482099Z",
    "updated_at": "2024-11-05T23:33:14.482099Z",
    "lead_time": 5.225
  },
  {
    "text": "2020 2021 2022 2023 Regulatory inspections and audits Audits of our third parties  quality processes 1,451 1,044 1,0891 1,081 Total regulatory inspections from all health authorities 86 111 122 114 PR A % of inspections from all regulators with no critical findings or official action indicated 100% 100% 99% 100% PR A Total regulatory inspections from FDA\/MHRA\/EMA regulators 27 35 36 32 PR A Number of critical\/major findings by FDA\/MHRA\/EMA regulators 11 4 26 11 PR A Total FDA regulatory inspections 7 2 8 5 PR A Number of FDA observations 3 1 16 8 PR A Number of FDA warning letters 0 0 0 0 PR A Product recalls Total number of Class I external product recalls 0 0 0 2 PR A Total number of Class II external product recalls 4 6 5 3 PR A Total number of Class III external product recalls 16 12 7 11 PR A Total product recalls 20 18 12 16 A PR Metric contributes to our ESG Performance Rating.",
    "id": 747,
    "annotator": 1,
    "annotation_id": 748,
    "created_at": "2024-11-05T23:33:16.982597Z",
    "updated_at": "2024-11-05T23:33:16.982597Z",
    "lead_time": 2.326
  },
  {
    "text": "A Metric s 2023 data has been externally assured.",
    "id": 748,
    "annotator": 1,
    "annotation_id": 749,
    "created_at": "2024-11-05T23:33:18.070935Z",
    "updated_at": "2024-11-05T23:33:18.070935Z",
    "lead_time": 0.892
  },
  {
    "text": "1 2022 figure has been restated.",
    "id": 749,
    "annotator": 1,
    "annotation_id": 750,
    "created_at": "2024-11-05T23:33:20.093916Z",
    "updated_at": "2024-11-05T23:33:20.093916Z",
    "lead_time": 1.828
  },
  {
    "text": "36 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Product governance continued 2020 2021 2022 2023 FDA product recalls by business and class1 Pharmaceuticals business Class I product recalls 0 0 0 0 PR A Class II product recalls 0 0 0 0 PR A Class III product recalls 0 0 1 1 A Vaccines business Class I product recalls 0 0 0 1 PR A Class II product recalls 0 1 0 0 PR A Class III product recalls 0 1 0 1 A Clinical trial management, pharmacovigiliance and transparency Clinical trial audits (on our own trials and those conducted by third parties on our behalf) 223 294 339 286 Number of FDA sponsor inspections related to clinical trial management and pharmacovigilance   0 0 0 that resulted in voluntary action indicated (VAI) Number of FDA sponsor inspections related to clinical trial management and pharmacovigilance   0 0 0 that resulted in official action indicated (OAI) Clinical study reports\/study report synopsis on GSK and ViiV study register4 60 48 35 99 Trials for which anonymised data will be made available upon meeting defined eligibility criteria4 77 51 40 111 Research proposals approved for access to GSK and ViiV clinical trial data4 23 16 34 22 Human subject research of GSK products: percentage of protocol summaries initiated in current     100% 100% PR year registered and results disclosed in the current year2,3 Publicly available trial protocol summaries (register)4 7,178 7,290 7,377 7,988 PR Publicly available trial result summaries (disclose)4 6,160 6,239 6,295 6,734 PR PR Metric contributes to our ESG Performance Rating.",
    "id": 750,
    "annotator": 1,
    "annotation_id": 751,
    "created_at": "2024-11-05T23:33:21.002217Z",
    "updated_at": "2024-11-05T23:33:21.002217Z",
    "lead_time": 0.7
  },
  {
    "text": "A Metric s 2023 data has been independently assured.",
    "id": 751,
    "annotator": 1,
    "annotation_id": 752,
    "created_at": "2024-11-05T23:33:22.173793Z",
    "updated_at": "2024-11-05T23:33:22.173793Z",
    "lead_time": 0.977
  },
  {
    "text": "1 T his data includes recalls in the US market which may be initiated voluntarily by GSK, requested by the US FDA or mandated by the US FDA under its statutory authority.",
    "id": 752,
    "annotator": 1,
    "annotation_id": 753,
    "created_at": "2024-11-05T23:33:28.644075Z",
    "updated_at": "2024-11-05T23:33:28.644075Z",
    "lead_time": 6.26
  },
  {
    "text": "2 From 2023 includes ViiV Healthcare in addition to GSK.",
    "id": 753,
    "annotator": 1,
    "annotation_id": 754,
    "created_at": "2024-11-05T23:33:29.861151Z",
    "updated_at": "2024-11-05T23:33:29.861151Z",
    "lead_time": 1.038
  },
  {
    "text": "3 T his metric created and first reported in 2022; for 2023, the number of all protocol summaries registered (103) and results summaries disclosed (98) was independently assured.",
    "id": 754,
    "annotator": 1,
    "annotation_id": 755,
    "created_at": "2024-11-05T23:33:37.716429Z",
    "updated_at": "2024-11-05T23:33:37.716429Z",
    "lead_time": 7.679
  },
  {
    "text": "4 C umulative summaries for GSK from 2004 and from 2023 cumulative for ViiV Healthcare from 2009.",
    "id": 755,
    "annotator": 1,
    "annotation_id": 756,
    "created_at": "2024-11-05T23:33:39.775508Z",
    "updated_at": "2024-11-05T23:33:39.775508Z",
    "lead_time": 1.872
  },
  {
    "text": "37 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix Materiality assessment In 2021-22, GSK conducted a materiality assessment, a process Through this process, 16 issues were identified as most material of engagement and analysis that identifies and prioritises the to our business and our external stakeholders, illustrated in the ESG issues that pose the most significant risks and opportunities matrix below.",
    "id": 756,
    "annotator": 1,
    "annotation_id": 757,
    "created_at": "2024-11-05T23:33:48.804618Z",
    "updated_at": "2024-11-05T23:33:48.804618Z",
    "lead_time": 8.834
  },
  {
    "text": "The issues identified through this process helped to the business, and where GSK has the most significant impact.",
    "id": 757,
    "annotator": 1,
    "annotation_id": 758,
    "created_at": "2024-11-05T23:34:03.246428Z",
    "updated_at": "2024-11-05T23:34:03.246428Z",
    "lead_time": 14.216
  },
  {
    "text": "confirm our six ESG focus areas: Access, Global health and health The materiality assessment is used to inform strategic decision- security, Environment, Diversity, equity and inclusion, Ethical making and helps us to prioritise issues covered in public reporting.",
    "id": 758,
    "annotator": 1,
    "annotation_id": 759,
    "created_at": "2024-11-05T23:34:10.203262Z",
    "updated_at": "2024-11-05T23:34:10.203262Z",
    "lead_time": 6.761
  },
  {
    "text": "standards and Product governance.",
    "id": 759,
    "annotator": 1,
    "annotation_id": 760,
    "created_at": "2024-11-05T23:34:13.617613Z",
    "updated_at": "2024-11-05T23:34:13.617613Z",
    "lead_time": 3.225
  },
  {
    "text": "We used Datamaran s data analytics platform to conduct To read more about our materiality methodology, process and the assessment.",
    "id": 760,
    "label": [
      {
        "start": 8,
        "end": 43,
        "text": "Datamaran s data analytics platform",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 8,
        "end": 43,
        "text": "Datamaran s data analytics platform",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 761,
    "created_at": "2024-11-05T23:34:38.320311Z",
    "updated_at": "2024-11-05T23:34:38.320311Z",
    "lead_time": 24.507
  },
  {
    "text": "The software monitors external ESG risks by key observations please see our materiality overview on gsk.com.",
    "id": 761,
    "annotator": 1,
    "annotation_id": 762,
    "created_at": "2024-11-05T23:34:44.436129Z",
    "updated_at": "2024-11-05T23:34:44.436129Z",
    "lead_time": 5.895
  },
  {
    "text": "assessing the coverage of issues within peer annual and g sk.com: Materiality assessment sustainability reports, regulatory and legislative documents, media and social media.",
    "id": 762,
    "annotator": 1,
    "annotation_id": 763,
    "created_at": "2024-11-05T23:34:54.297999Z",
    "updated_at": "2024-11-05T23:34:54.297999Z",
    "lead_time": 9.672
  },
  {
    "text": "We also conducted stakeholder engagement, through internal and external interviews and analysis of investor ratings, rankings and reports.",
    "id": 763,
    "annotator": 1,
    "annotation_id": 764,
    "created_at": "2024-11-05T23:35:00.896171Z",
    "updated_at": "2024-11-05T23:35:00.896171Z",
    "lead_time": 6.404
  },
  {
    "text": "MEDIUM HIGH Importance to the business 38 GSK ESG Performance Report 2023 March 2024 sredlohekats lanretxe ot ecnatropmI Materiality matrix VERY HIGH Product quality Privacy and and patient safety data security Supply chain management Product innovation Global health security Labour rights Healthcare access and affordability Ethical business conduct Employee health, safety and wellbeing Clinical trial conduct Climate change Talent attraction and retention Nature and environmental protection Waste and hazardous materials management Diversity, equity Water and wastewater management and inclusion KEY Access Environment Ethical standards Global health Diversity, equity Product governance and health security and inclusion People and culture Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued People disclosures A positive experience at work is critical to attract, retain and Keeping our people safe motivate the best people.",
    "id": 764,
    "annotator": 1,
    "annotation_id": 765,
    "created_at": "2024-11-05T23:37:50.720516Z",
    "updated_at": "2024-11-05T23:37:50.720516Z",
    "lead_time": 169.634
  },
  {
    "text": "We want our workplace to embrace We care deeply about the health and safety of our employees, everyone s unique differences and encourage growth and complementary workers and everyone that works at or visits our development in a safe environment so that people can perform sites.",
    "id": 765,
    "annotator": 1,
    "annotation_id": 766,
    "created_at": "2024-11-05T23:40:42.660158Z",
    "updated_at": "2024-11-05T23:40:42.660158Z",
    "lead_time": 171.748
  },
  {
    "text": "Our commitment is that everyone goes home safely.",
    "id": 766,
    "annotator": 1,
    "annotation_id": 767,
    "created_at": "2024-11-05T23:40:47.585466Z",
    "updated_at": "2024-11-05T23:40:47.585466Z",
    "lead_time": 4.74
  },
  {
    "text": "Our 12 at their best at work.",
    "id": 767,
    "annotator": 1,
    "annotation_id": 768,
    "created_at": "2024-11-05T23:40:49.230596Z",
    "updated_at": "2024-11-05T23:40:49.230596Z",
    "lead_time": 1.473
  },
  {
    "text": "For more information around how we put Life Saving Rules have been embedded throughout our company.",
    "id": 768,
    "annotator": 1,
    "annotation_id": 769,
    "created_at": "2024-11-05T23:40:54.139431Z",
    "updated_at": "2024-11-05T23:40:54.139431Z",
    "lead_time": 4.731
  },
  {
    "text": "our people at the heart of our success, please see page 8, and These rules are simple, standardised and easy to remember.",
    "id": 769,
    "annotator": 1,
    "annotation_id": 770,
    "created_at": "2024-11-05T23:45:57.633349Z",
    "updated_at": "2024-11-05T23:45:57.633349Z",
    "lead_time": 302.991
  },
  {
    "text": "for further detail on our focus on Diversity, equity and inclusion, Responsibilities for safety as leaders and as individuals have see page 26.",
    "id": 770,
    "annotator": 1,
    "annotation_id": 771,
    "created_at": "2024-11-05T23:46:00.822748Z",
    "updated_at": "2024-11-05T23:46:00.822748Z",
    "lead_time": 2.982
  },
  {
    "text": "been reviewed at all levels of the organisation.",
    "id": 771,
    "annotator": 1,
    "annotation_id": 772,
    "created_at": "2024-11-05T23:46:02.714311Z",
    "updated_at": "2024-11-05T23:46:02.714311Z",
    "lead_time": 1.705
  },
  {
    "text": "Risk assessments are a key part of the environment, health and safety control Freedom of association framework that governs our approach to identifying and We are respectful of the right of colleagues to join an controlling hazards.",
    "id": 772,
    "annotator": 1,
    "annotation_id": 773,
    "created_at": "2024-11-05T23:51:46.162513Z",
    "updated_at": "2024-11-05T23:51:46.162513Z",
    "lead_time": 342.923
  },
  {
    "text": "We conduct health and safety training for independent trade union, to collectively bargain and to freedom our people, specific to whether they are working from an office, of association.",
    "id": 773,
    "label": [
      {
        "start": 3,
        "end": 65,
        "text": "conduct health and safety training for independent trade union",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3,
        "end": 65,
        "text": "conduct health and safety training for independent trade union",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 774,
    "created_at": "2024-11-06T00:32:19.709305Z",
    "updated_at": "2024-11-06T00:32:19.709305Z",
    "lead_time": 2433.366
  },
  {
    "text": "Of our global employee population, 35% are a lab, at a manufacturing site or in our commercial operations.",
    "id": 774,
    "annotator": 1,
    "annotation_id": 775,
    "created_at": "2024-11-06T00:32:25.562703Z",
    "updated_at": "2024-11-06T00:32:25.562703Z",
    "lead_time": 5.617
  },
  {
    "text": "covered by collective bargaining arrangements and 15% have Recent key initiatives have included safety leadership, warehouse declared that they are a member of a union.",
    "id": 775,
    "annotator": 1,
    "annotation_id": 776,
    "created_at": "2024-11-06T00:32:29.652883Z",
    "updated_at": "2024-11-06T00:32:29.652883Z",
    "lead_time": 3.906
  },
  {
    "text": "1 We also invest safety and driver safety.",
    "id": 776,
    "annotator": 1,
    "annotation_id": 777,
    "created_at": "2024-11-06T00:32:31.667734Z",
    "updated_at": "2024-11-06T00:32:31.667734Z",
    "lead_time": 1.837
  },
  {
    "text": "In 2023, we improved our reporting heavily in formal information and consultation arrangements, processes and systems and carried out increased training in which actively involve and provide additional Employee Voice to Safety and Incident Reporting which has contributed to an uplift a higher proportion of our colleagues.",
    "id": 777,
    "annotator": 1,
    "annotation_id": 778,
    "created_at": "2024-11-06T00:32:42.808826Z",
    "updated_at": "2024-11-06T00:32:42.808826Z",
    "lead_time": 10.962
  },
  {
    "text": "in reported injuries and illnesses with lost time.",
    "id": 778,
    "annotator": 1,
    "annotation_id": 779,
    "created_at": "2024-11-06T00:32:45.164218Z",
    "updated_at": "2024-11-06T00:32:45.164218Z",
    "lead_time": 2.141
  },
  {
    "text": "g sk.com Policy on environment, health and safety 2020 2021 2022 2023 Hiring Total number of new hires 9,305 11,110 12,513 10,730 % of open positions filled by internal candidates 30.0% 34.0% 31.4% 29.9% Employee turnover Overall turnover 10.3% 15.2% 13.3% 10.0% A Turnover of voluntary leavers2 5.5% 7.8% 7.3% 5.5% % of all permanent leavers that were male3 56.9% 49.0% 54.1% 56.7% % of all permanent leavers that were female3 42.9% 50.9% 45.6% 42.9% Workforce breakdown by age (permanent employees) < 30 years old 13.8% 13.0% 13.1% 12.8% 30-50 years old 61.0% 61.3% 60.9% 63.2% > 50 years old 25.2% 25.7% 26.0% 23.8% Engagement Employee surveys engagement score 84% 78% 81% 81%4 Talent and leadership development Number of graduates recruited through our Future Leaders programme 176 139 161 162 Number of postgraduates recruited through our Esprit programme 14 6 13 4 Number of apprentices recruited 85 68 67 57 A Metric s 2023 data has been independently assured.",
    "id": 779,
    "annotator": 1,
    "annotation_id": 780,
    "created_at": "2024-11-06T00:32:52.511162Z",
    "updated_at": "2024-11-06T00:32:52.511162Z",
    "lead_time": 7.147
  },
  {
    "text": "1 I n certain markets, data is unavailable due to privacy reasons.",
    "id": 780,
    "annotator": 1,
    "annotation_id": 781,
    "created_at": "2024-11-06T00:32:57.500057Z",
    "updated_at": "2024-11-06T00:32:57.500057Z",
    "lead_time": 4.802
  },
  {
    "text": "2 C alculated as the number of permanent employees that voluntarily left GSK divided by the average permanent headcount in the reporting year.",
    "id": 781,
    "annotator": 1,
    "annotation_id": 782,
    "created_at": "2024-11-06T00:33:01.080836Z",
    "updated_at": "2024-11-06T00:33:01.080836Z",
    "lead_time": 3.396
  },
  {
    "text": "3 C alculated as the number of permanent employees that left GSK for any reason within the period that were male or female, divided by the total number of permanent leavers that left for any reason within the period.",
    "id": 782,
    "annotator": 1,
    "annotation_id": 783,
    "created_at": "2024-11-06T00:35:21.824616Z",
    "updated_at": "2024-11-06T00:35:21.824616Z",
    "lead_time": 140.552
  },
  {
    "text": "4 E mployee surveys response rate was 79% in 2023.",
    "id": 783,
    "label": [
      {
        "start": 38,
        "end": 41,
        "text": "79%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2,
        "end": 33,
        "text": "E mployee surveys response rate",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 784,
    "created_at": "2024-11-06T00:35:34.894204Z",
    "updated_at": "2024-11-06T00:35:34.894204Z",
    "lead_time": 12.871
  },
  {
    "text": "39 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued 2020 2021 2022 2023 Health and safety Number of fatalities (employees and complementary workers under GSK direct supervision) 1 0 0 0 A Number of fatalities (contractors not under GSK direct supervision) 1 0 0 0 A Reportable injuries with lost time 137 133 144 195 A Reportable illnesses with lost time 8 5 8 301 A Lost time reportable injury rate (per 100,000 hours worked) 0.09 0.09 0.10 0.13 A Lost time reportable illness rate (per 100,000 hours worked) 0.01 0 0.01 0.02 A Reportable injuries with and without lost time 205 190 214 292 A Reportable illnesses with and without lost time 31 42 32 65 A Reportable injury rate (per 100,000 hours worked) 0.13 0.13 0.15 0.19 A Reportable illness rate (per 100,000 hours worked) 0.02 0.03 0.02 0.04 A Reportable injury and illness rate (per 100,000 hours worked)1 0.15 0.15 0.17 0.24 A Hours worked (m) 156 151 147 151 A A Metric s 2023 data has been independently assured.",
    "id": 784,
    "annotator": 1,
    "annotation_id": 785,
    "created_at": "2024-11-06T00:35:36.395901Z",
    "updated_at": "2024-11-06T00:35:36.395901Z",
    "lead_time": 1.272
  },
  {
    "text": "1 In 2023, there were two illness-related incidents that involved multiple workers; these were promptly investigated and corrected.",
    "id": 785,
    "label": [
      {
        "start": 22,
        "end": 26,
        "text": "two ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 26,
        "end": 51,
        "text": "illness-related incidents",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 786,
    "created_at": "2024-11-06T00:35:55.181782Z",
    "updated_at": "2024-11-06T00:35:55.181782Z",
    "lead_time": 18.563
  },
  {
    "text": "1 Totals may not equal the exact sum of the constituents due to rounding.",
    "id": 786,
    "annotator": 1,
    "annotation_id": 787,
    "created_at": "2024-11-06T00:35:57.307521Z",
    "updated_at": "2024-11-06T00:35:57.307521Z",
    "lead_time": 1.905
  },
  {
    "text": "40 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued GRI guidelines and SASB index GRI indicator Description Where to find the information General disclosures 2-1 Organisational details Legal name: GSK plc Ownership: Annual Report   Share capital and share price, page 268 HQ address: Brentford, Middlesex, TW8 9GS, UK Operations: Annual Report   Business model, pages 8-9 2-2 Entities included in the organisation s sustainability reporting GSK plc 2-3 Reporting period, frequency and contact point Sustainability and financial annual reporting period: 1 January 2023 to 31 December 2023 Report publication: 1 March 2024 Contact: csr.",
    "id": 787,
    "annotator": 1,
    "annotation_id": 788,
    "created_at": "2024-11-06T00:35:58.177703Z",
    "updated_at": "2024-11-06T00:35:58.177703Z",
    "lead_time": 0.679
  },
  {
    "text": "contact@gsk.com 2-4 Restatements of information Demerger: 2019-21 comparative results restated to reflect the demerger of our Consumer Healthcare business, unless otherwise specified.",
    "id": 788,
    "annotator": 1,
    "annotation_id": 789,
    "created_at": "2024-11-06T00:36:03.353182Z",
    "updated_at": "2024-11-06T00:36:03.353182Z",
    "lead_time": 4.975
  },
  {
    "text": "Other restatements of information are detailed where relevant for specific data points throughout the report.",
    "id": 789,
    "annotator": 1,
    "annotation_id": 790,
    "created_at": "2024-11-06T00:48:06.883056Z",
    "updated_at": "2024-11-06T00:48:06.883056Z",
    "lead_time": 723.008
  },
  {
    "text": "2-5 External assurance Independent limited assurance statements, pages 55-62 2-6 Activities, value chain and other business relationships Sector: Healthcare, Pharmaceuticals Annual report, Business model, pages 8-9 Changes compared to the previous reporting period: Following the demerger of our Consumer Healthcare business to form Haleon in July 2022, we are now a fully focused biopharma company.",
    "id": 790,
    "annotator": 1,
    "annotation_id": 791,
    "created_at": "2024-11-06T00:48:12.879017Z",
    "updated_at": "2024-11-06T00:48:12.879017Z",
    "lead_time": 5.801
  },
  {
    "text": "2-7 Employees Full-time employees (FTEs) as of 31 December 2023, page 8 Annual Report   Employees by gender, page 75.",
    "id": 791,
    "annotator": 1,
    "annotation_id": 792,
    "created_at": "2024-11-06T00:48:17.799842Z",
    "updated_at": "2024-11-06T00:48:17.799842Z",
    "lead_time": 4.723
  },
  {
    "text": "Changes compared to previous reporting period: Following the demerger of our Consumer Healthcare business to form Haleon in July 2022, we are now a fully-focused biopharma company.",
    "id": 792,
    "annotator": 1,
    "annotation_id": 793,
    "created_at": "2024-11-06T00:48:21.944540Z",
    "updated_at": "2024-11-06T00:48:21.944540Z",
    "lead_time": 3.959
  },
  {
    "text": "2-8 Workers who are not employees Not reported 2-9 Governance structure and composition Annual Report   The Board and GSK Leadership team, page 108 Annual Report   Corporate governance architecture, page 116 Annual Report   Nominations & Corporate Governance 2-10 Nomination and selection of the highest governance body Committee report, pages 131-132 2-11 Chair of the highest governance body GSK has an independent non-executive Chair of the Board 2-12 Role of the highest governance body in overseeing the Annual Report   Corporate Responsibility Committee report, management of impacts page 128-129 2-13 Delegation of responsibility for managing impacts Annual Report   Corporate Responsibility Committee report, page 128-129 2-14 Role of the highest governance body in sustainability reporting Our ESG Performance Report is reviewed by both GSK Leadership Team and the Board 2-15 Conflicts of interest Annual Report   Directors  conflicts of interest, page 161 2-16 Communication of critical concerns Annual Report   Board committee reports, page 128 2-17 Collective knowledge of the highest governance body Annual Report   The Board, page 108 2-18 Evaluation of the performance of the highest governance body Annual Report   Board performance, page 120 2-19 Remuneration policies Annual Report   Annual report on remuneration, pages 139-160 2-20 Process to determine remuneration Annual Report   Annual report on remuneration, pages 139-160 2-21 Annual total compensation ratio Annual Report   Annual report on remuneration, page 151 2-22 Statement on sustainable development strategy Annual Report   CEO's statement, page 7 2-23 Policy commitments Policy positions, including on human rights.",
    "id": 793,
    "annotator": 1,
    "annotation_id": 794,
    "created_at": "2024-11-06T00:48:28.855532Z",
    "updated_at": "2024-11-06T00:48:28.856536Z",
    "lead_time": 6.705
  },
  {
    "text": "Policies are approved at GSK Leadership Team level and apply at Group-level.",
    "id": 794,
    "annotator": 1,
    "annotation_id": 795,
    "created_at": "2024-11-06T00:48:36.215194Z",
    "updated_at": "2024-11-06T00:48:36.215194Z",
    "lead_time": 7.167
  },
  {
    "text": "2-24 Embedding policy commitments Corporate responsibility committee 2-25 Processes to remediate negative impacts Annual Report   Principal risks and uncertainties, page 230 Ethical standards, page 30 Ethics and compliance grievance mechanisms 41 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued GRI indicator Description Where to find the information 2-26 Mechanisms for seeking advice and raising concerns Ethical standards, ESG Performance Report 2023, page 30 Grievance mechanisms 2-27 Compliance with laws and regulations Annual Report   Audit & Risk Committee report, page 133-138 2-28 Membership associations Trade association memberships 2-29 Approach to stakeholder engagement ESG Performance Report, Stakeholder engagement, page 4 2-30 Collective bargaining agreements People disclosures, page 39 Position on human rights 3-1 Process to determine material topics Materiality Assessment, ESG Performance Report 2023, page 38 3-2 List of material topics Materiality Assessment, ESG Performance Report 2023, page 38 3-3 Management of material topics Materiality Assessment, ESG Performance Report 2023, page 38 Economic performance 201-1 Direct economic value generated and distributed Annual Report   Financial statements, page 163 201-2 Financial implications and other risks and opportunities due to Annual Report   Risk management, page 58 climate change Annual Report   TCFD, page 62 201-3 Defined benefit plan obligations and other retirement plans Annual Report   Annual report on remuneration, page 139-160 201-4 Financial assistance received from government Annual Report   Financial statements, page 163 Annual Report   Share capital and control, page 268 Anti-corruption 205-1 Operations assessed for risks related to corruption Annual Report   Risk management, page 57 205-2 Communication and training about anti-corruption policies Ethical standards, ESG Performance Report 2023, pages 30-33 and procedures 205-3 Confirmed incidents of corruption and actions taken Ethical standards, ESG Performance Report 2023, pages 30-33 Tax 207-1 Approach to tax GSK Tax strategy 207-2 Tax governance, control, and risk management GSK Tax strategy 207-3 Stakeholder engagement and management of concerns GSK Tax strategy related to tax 207-4 Country-by-country reporting GSK Tax strategy Energy 302-1 Energy consumption within the organisation Environment, ESG Performance Report 2023, page 23 Environment, Basis of reporting, Environmental Data 2023 302-2 Energy consumption outside of the organisation Environment, ESG Performance Report 2023, page 23 Environment, Basis of reporting 302-3 Energy intensity Annual Report, TCFD, pages 69-70 Environment, Basis of reporting 302-4 Reduction of energy consumption Environment, ESG Performance Report 2023, pages 18-23 Environment, Basis of reporting 302-5 Reductions in energy requirements of products and services Environment, ESG Performance Report 2023, pages 18-23 Environment, Basis of reporting Water 303-1 Interactions with water as a shared resource Environment, ESG Performance Report 2023, Pages 18-25, Annual Report, TNFD, page 70 303-2 Management of water discharge-related impacts Environment, Basis of reporting 303-3 Water withdrawal Environment, ESG Performance Report 2023, Pages 18-25, Annual Report, TNFD, page 70 Environment, Basis of reporting 303-4 Water discharge Environment, ESG Performance Report 2023, Pages 18-25, Annual Report, TNFD, page 70 Environment, Basis of reporting 303-5 Water consumption Environment, ESG Performance Report 2023, Pages 18-25, Annual Report, TNFD, page 70 Environment, Basis of reporting 42 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued GRI indicator Description Where to find the information Biodiversity 3-3 Management of material topics Materiality assessment, ESG Performance Report 2023, page 38 304-1 Operational sites owned, leased, managed in, or adjacent to, Annual Report, TNFD, page 71 protected areas and areas of high biodiversity value outside protected areas 304-2 Significant impacts of activities, products and services on Environment, ESG Performance Report 2023, pages 20-22, biodiversity Annual Report, TNFD, pages 70-74 304-3 Habitats protected or restored Environment, ESG Performance Report 2023, pages 20-22, Annual Report, TNFD, pages 70-74 304-4 IUCN Red List species and national conservation list species Not reported with habitats in areas affected by operations Emissions 305-1 Direct (Scope 1) GHG emissions Environment, ESG Performance Report 2023, page 23 Environment, Basis of reporting, Environmental Data 2023 305-2 Energy indirect (Scope 2) GHG emissions Environment, ESG Performance Report 2023, page 23 Environment, Basis of reporting, Environmental Data 2023 305-3 Other indirect (Scope 3) GHG emissions Environment, ESG Performance Report 2023, page 23-24 Environment, Basis of reporting, Environmental Data 2023 305-4 GHG emissions intensity Annual Report, TCFD, page 70 Environment, Basis of reporting, Environmental Data 2023 305-5 Reduction of GHG emissions Environment, ESG Performance Report 2023, pages 18-24 Environment, Basis of reporting, Environmental Data 2023 305-6 Emissions of ozone-depleting substances (ODS) Environment, ESG Performance Report, page 24 Environment, Basis of reporting, Environmental Data 2023 305-7 Nitrogen oxides (NOx), sulfur oxides (SOx), and other significant Not reported air emissions Waste 306-1 Waste generation and significant waste-related impacts Environment, ESG Performance Report, pages 22-25 306-2 Management of significant waste-related impacts Environment, ESG Performance Report, pages 22-25 Environment, Basis of reporting 306-3 Waste generated Environment, ESG Performance Report, pages 22-25 Environment, Basis of reporting 306-4 Waste diverted from disposal Environment, ESG Performance Report, pages 22-25 Environment, Basis of reporting 306-5 Waste directed to disposal Environment, ESG Performance Report, pages 22-25 Supplier environmental assessment 308-1 New suppliers that were screened using environmental Ethical standards, ESG Performance Report, pages 30-32 criteria 308-2 Negative environmental impacts in the supply chain and Ethical standards, ESG Performance Report, pages 30-32 actions taken Employment 401-1 New employee hires and employee turnover People disclosures, ESG Performance Report, pages 39-40 401-2 Benefits provided to full-time employees that are not Life at GSK provided to temporary or part-time employees 401-3 Parental leave Not reported Occupational health and safety 403-1 Occupational health and safety management system GSK EHS policy 403-2 Hazard identification, risk assessment, and incident GSK EHS policy investigation 403-3 Occupational health services GSK EHS policy 403-4 Worker participation, consultation, and communication on GSK EHS policy occupational health and safety 403-5 Worker training on occupational health and safety GSK EHS policy 403-6 Promotion of worker health GSK EHS policy 403-7 Prevention and mitigation of occupational health and safety GSK EHS policy impacts directly linked by business relationships 43 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued GRI indicator Description Where to find the information 403-8 Workers covered by an occupational health and safety GSK EHS policy management system 403-9 Work-related injuries People disclosures, ESG Performance Report, pages 29-30 GSK EHS policy 403-10 Work-related ill health Diversity and equal opportunity 405-1 Diversity of governance bodies and employees Diversity, equity and inclusion.",
    "id": 795,
    "annotator": 1,
    "annotation_id": 796,
    "created_at": "2024-11-06T00:48:54.822576Z",
    "updated_at": "2024-11-06T00:48:54.822576Z",
    "lead_time": 18.404
  },
  {
    "text": "People disclosures, ESG Performance Report 2023, pages 26-29, 39-40 405-2 Ratio of basic salary and remuneration of women to men Gender pay gap report Diversity, equity and inclusion Non-discrimination 3-3 Management of material topics Materiality assessment, ESG Performance Report 2023, page 36 Human rights and labour rights 407-1 Operations and suppliers in which the right to freedom GSK position on human rights of association and collective bargaining may be at risk 408-1 Operations and suppliers at significant risk for incidents GSK position on human rights of child labour Modern Slavery Act statement 409-1 Operations and suppliers at significant risk for incidents GSK position on human rights of forced or compulsory labour Modern Slavery Act statement 414-1 New suppliers that were screened using social criteria Ethical standards, ESG Performance Report 2023, pages 30-34 414-2 Negative social impacts in the supply chain and actions Ethical standards, ESG Performance Report 2023, pages 30-34 taken Public policy 415-1 Political contributions Political advocacy disclosure Customer health and safety 416-1 Assessment of the health and safety impacts of product and Product governance, ESG Performance Report 2023, service categories pages 35-37 416-2 Incidents of non-compliance concerning the health and Product governance, ESG Performance Report 2023, safety impacts of products and services pages 35-37 Customer privacy 3-3 Management of material topics Materiality assessment, Materiality Assessment, ESG Performance Report 2023, page 36 Marketing and labelling 417-1 Requirements for product and service information and Our code of practice labelling 417-2 Incidents of non-compliance concerning product and service Product governance, ESG Performance Report 2023, information and labelling pages 35-37 417-3 Incidents of non-compliance concerning marketing Product governance, ESG Performance Report 2023, communications pages 35-37 SASB indicator Description Where to find the information Safety of clinical trial participants HC-BP-210a.",
    "id": 796,
    "annotator": 1,
    "annotation_id": 797,
    "created_at": "2024-11-06T00:49:21.908635Z",
    "updated_at": "2024-11-06T00:49:21.908635Z",
    "lead_time": 26.868
  },
  {
    "text": "1 Discussion, by region, of management process for ensuring \"Our position on \"Approach to Clinical Trials\" quality and patient safety during clinical trials HC-BP-210a.",
    "id": 797,
    "annotator": 1,
    "annotation_id": 798,
    "created_at": "2024-11-06T00:49:26.817744Z",
    "updated_at": "2024-11-06T00:49:26.817744Z",
    "lead_time": 4.681
  },
  {
    "text": "2 Number of inspections related to clinical trial management Clinical data transparency, ESG performance report 2023, and pharmacovigilance that resulted in: (1) entity voluntary pages 36-37 remediation or (2) regulatory or administrative actions taken Available via the FDA Inspection Citation page against the entity Access to medicines HC-BP-240a.",
    "id": 798,
    "annotator": 1,
    "annotation_id": 799,
    "created_at": "2024-11-06T00:49:31.732294Z",
    "updated_at": "2024-11-06T00:49:31.732294Z",
    "lead_time": 4.729
  },
  {
    "text": "1 Description of actions and initiatives to promote access to Access, ESG Performance Report 2023 pages 10-14 health care products for priority diseases and in priority countries as defined by the Access to Medicine Index HC-BP-240a.",
    "id": 799,
    "annotator": 1,
    "annotation_id": 800,
    "created_at": "2024-11-06T00:49:35.643546Z",
    "updated_at": "2024-11-06T00:49:35.643546Z",
    "lead_time": 3.738
  },
  {
    "text": "2 List of products on the WHO List of Prequalified Medicinal List of products, ESG Performance Report 2023 page 46 Products as part of its Prequalification of Medicines Global health and health security, ESG Performance Report Programme (PQP) 2023 pages 15-17 44 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued SASB indicator Description Where to find the information Affordability and pricing HC-BP-240b.",
    "id": 800,
    "annotator": 1,
    "annotation_id": 801,
    "created_at": "2024-11-06T00:49:41.965307Z",
    "updated_at": "2024-11-06T00:49:41.965307Z",
    "lead_time": 6.152
  },
  {
    "text": "2 Percentage change in: (1) weighted average list price and (2) Access, ESG Performance Report 2023, page 12 weighted average net price across product portfolio compared to previous reporting period HC-BP-240b.",
    "id": 801,
    "annotator": 1,
    "annotation_id": 802,
    "created_at": "2024-11-06T00:49:46.316596Z",
    "updated_at": "2024-11-06T00:49:46.316596Z",
    "lead_time": 4.142
  },
  {
    "text": "3 Percentage change in: (1) list price and (2) net price of Access, ESG Performance Report 2023, pages 10, 13 product with largest increase compared to previous reporting period Drug safety HC-BP-250a.",
    "id": 802,
    "annotator": 1,
    "annotation_id": 803,
    "created_at": "2024-11-06T00:49:52.693617Z",
    "updated_at": "2024-11-06T00:49:52.693617Z",
    "lead_time": 6.196
  },
  {
    "text": "1 Products listed in public medical product safety or adverse Available via the FDA event alert databases HC-BP-250a.",
    "id": 803,
    "annotator": 1,
    "annotation_id": 804,
    "created_at": "2024-11-06T00:49:55.056843Z",
    "updated_at": "2024-11-06T00:49:55.056843Z",
    "lead_time": 2.185
  },
  {
    "text": "2 Number of fatalities associated with products Available via the FDA HC-BP-250a.",
    "id": 804,
    "annotator": 1,
    "annotation_id": 805,
    "created_at": "2024-11-06T00:50:00.534617Z",
    "updated_at": "2024-11-06T00:50:00.534617Z",
    "lead_time": 5.281
  },
  {
    "text": "3 (1) Number of recalls issued, (2) total units recalled Product governance, ESG Performance Report 2023, pages 35-37 HC-BP-250a.",
    "id": 805,
    "annotator": 1,
    "annotation_id": 806,
    "created_at": "2024-11-06T00:50:02.372360Z",
    "updated_at": "2024-11-06T00:50:02.372360Z",
    "lead_time": 1.658
  },
  {
    "text": "4 Total amount of product accepted for takeback, reuse, or Not reported disposal HC-BP-250a.",
    "id": 806,
    "annotator": 1,
    "annotation_id": 807,
    "created_at": "2024-11-06T00:50:20.977073Z",
    "updated_at": "2024-11-06T00:50:20.977073Z",
    "lead_time": 18.432
  },
  {
    "text": "5 Number of enforcement actions taken in response to ESG Performance Report 2023, Inspections, recalls and audit, violations of good manufacturing practices (GMP) or page 34 equivalent standards, by type Counterfeit drugs HC-BP-260a.",
    "id": 807,
    "annotator": 1,
    "annotation_id": 808,
    "created_at": "2024-11-06T00:50:31.867217Z",
    "updated_at": "2024-11-06T00:50:31.867217Z",
    "lead_time": 10.691
  },
  {
    "text": "1 Description of methods and technologies used to maintain Product governance, ESG Performance Report 2023, traceability of products throughout the supply chain and pages 35-36 prevent counterfeiting Position on falsified and substandard healthcare products HC-BP-260a.",
    "id": 808,
    "annotator": 1,
    "annotation_id": 809,
    "created_at": "2024-11-06T00:50:42.042265Z",
    "updated_at": "2024-11-06T00:50:42.042265Z",
    "lead_time": 9.958
  },
  {
    "text": "2 Discussion of process for alerting customers and business Product governance, ESG Performance Report 2023, partners of potential or known risks associated with pages 35-36 counterfeit products Position on falsified and substandard healthcare products HC-BP-260a.",
    "id": 809,
    "annotator": 1,
    "annotation_id": 810,
    "created_at": "2024-11-06T00:50:50.023598Z",
    "updated_at": "2024-11-06T00:50:50.023598Z",
    "lead_time": 7.762
  },
  {
    "text": "3 Number of actions that led to raids, seizure, arrests, and\/or Not reported filing of criminal charges related to counterfeit products Ethical marketing HC-BP-270a.",
    "id": 810,
    "annotator": 1,
    "annotation_id": 811,
    "created_at": "2024-11-06T00:50:55.227118Z",
    "updated_at": "2024-11-06T00:50:55.227118Z",
    "lead_time": 4.976
  },
  {
    "text": "1 Total amount of monetary losses as a result of legal Not reported proceedings associated with false marketing claims HC-BP-270a.",
    "id": 811,
    "annotator": 1,
    "annotation_id": 812,
    "created_at": "2024-11-06T00:50:58.560446Z",
    "updated_at": "2024-11-06T00:50:58.560446Z",
    "lead_time": 3.136
  },
  {
    "text": "2 Description of code of ethics governing promotion of Code of practice for promotional and non-promotional external off-label use of products interactions Employee recruitment, development and retention HC-BP-330a.",
    "id": 812,
    "annotator": 1,
    "annotation_id": 813,
    "created_at": "2024-11-06T00:51:03.035086Z",
    "updated_at": "2024-11-06T00:51:03.035086Z",
    "lead_time": 4.265
  },
  {
    "text": "1 Discussion of talent recruitment and retention efforts for Our culture and people, ESG Performance Report, page 8 scientists and research and development personnel HC-BP-330a.",
    "id": 813,
    "annotator": 1,
    "annotation_id": 814,
    "created_at": "2024-11-06T00:51:14.146192Z",
    "updated_at": "2024-11-06T00:51:14.146192Z",
    "lead_time": 10.921
  },
  {
    "text": "2 (1) Voluntary and (2) involuntary turnover rate for: People disclosures, ESG Performance Report, page 39 (a) executives\/senior managers, (b) mid-level managers, (c) professionals, and (d) all others Supply chain management HC-BP-430a.",
    "id": 814,
    "annotator": 1,
    "annotation_id": 815,
    "created_at": "2024-11-06T00:51:22.432679Z",
    "updated_at": "2024-11-06T00:51:22.433678Z",
    "lead_time": 8.092
  },
  {
    "text": "1 Percentage of (1) entity s facilities and (2) Tier I suppliers  GSK is a member of Rx 360 and also conducts audits of third facilities participating in the Rx-360 International parties Pharmaceutical Supply Chain Consortium audit programme Working with third parties, ESG Performance Report 2023, or equivalent third-party audit programmes for integrity of page 31 supply chain and ingredients Business ethics HC-BP-510a.",
    "id": 815,
    "annotator": 1,
    "annotation_id": 816,
    "created_at": "2024-11-06T00:54:52.667900Z",
    "updated_at": "2024-11-06T00:54:52.667900Z",
    "lead_time": 210.022
  },
  {
    "text": "1 Total amount of monetary losses as a result of legal Not reported proceedings associated with corruption and bribery HC-BP-510a.",
    "id": 816,
    "annotator": 1,
    "annotation_id": 817,
    "created_at": "2024-11-06T00:54:58.720140Z",
    "updated_at": "2024-11-06T00:54:58.720140Z",
    "lead_time": 5.831
  },
  {
    "text": "2 Description of code of ethics governing interactions with Engagement with healthcare professionals healthcare professionals Activity metrics HC-BP-000.",
    "id": 817,
    "annotator": 1,
    "annotation_id": 818,
    "created_at": "2024-11-06T00:55:04.989277Z",
    "updated_at": "2024-11-06T00:55:04.989277Z",
    "lead_time": 6.053
  },
  {
    "text": "A Number of patients treated Access, ESG Performance Report 2023, pages 10-14 (patients reached through our access strategies) HC-BP-000.",
    "id": 818,
    "annotator": 1,
    "annotation_id": 819,
    "created_at": "2024-11-06T00:55:10.890263Z",
    "updated_at": "2024-11-06T00:55:10.890263Z",
    "lead_time": 5.704
  },
  {
    "text": "B Number of drugs (1) in portfolio and (2) in research and Annual Report   Product development pipeline, page 250 development (Phases 1-3) 45 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued List of products on the WHO List of Prequalified Medicinal Products and Vaccines as part of its Prequalification of Medicines Programme (PQP) Type, form and presentation Date of prequalification Vaccines Engerix Hepatitis B   Liquid: ready to use vial (one dose) Thursday, 1 January 1987 Engerix Hepatitis B   Liquid: ready to use vial (10 doses) Thursday, 1 January 1987 Engerix Hepatitis B   Liquid: ready to use vial (20 doses) Thursday, 1 January 1987 Priorix Measles, Mumps and Rubella   Lyophilised active component to be reconstituted Friday, 9 March 2001 with excipient diluent before use vial (one dose) Rotarix Rotavirus   Liquid: ready to use plastic tube (one dose) Thursday, 12 March 2009 Rotarix Rotavirus   Liquid: ready to use applicator (one dose) Thursday, 12 March 2009 Cervarix Human Papillomavirus (Bivalent)   Liquid: ready to use vial (one dose) Wednesday, 8 July 2009 Cervarix Human Papillomavirus (Bivalent)   Liquid: ready to use vial (two doses) Wednesday, 8 July 2009 Polio Sabin Mono T1 Polio Vaccine   Oral (OPV) Monovalent Type 1   Liquid: ready to use vial (10 doses) Thursday, 29 October 2009 Polio Sabin Mono T1 Polio Vaccine   Oral (OPV) Monovalent Type 1   Liquid: ready to use vial (20 doses) Thursday, 29 October 2009 Polio Sabin One and Three Polio Vaccine   Oral (OPV) Bivalent Types 1 and 3   Liquid: ready to use vial (10 doses) Thursday, 29 October 2009 Polio Sabin One and Three Polio Vaccine   Oral (OPV) Bivalent Types 1 and 3   Liquid: ready to use vial (20 doses) Thursday, 29 October 2009 Synflorix Pneumococcal (conjugate)   Liquid: ready to use vial (one dose) Friday, 30 October 2009 Synflorix Pneumococcal (conjugate)   Liquid: ready to use vial (two doses) Friday, 19 March 2010 Polio Sabin Mono Three (oral) Polio Vaccine   Oral (OPV) Monovalent Type 3   Liquid: ready to use vial (10 doses) Tuesday, 5 October 2010 Polio Sabin Mono Three (oral) Polio Vaccine   Oral (OPV) Monovalent Type 3   Liquid: ready to use vial (20 doses) Tuesday, 5 October 2010 Polio Sabin Mono Two (oral) Polio Vaccine   Oral (OPV) Monovalent Type 2   Liquid: ready to use vial (20 doses) Wednesday, 11 May 2011 Polio Sabin Mono Two (oral) Polio Vaccine   Oral (OPV) Monovalent Type 2   Liquid: ready to use vial (10 doses) Wednesday, 11 May 2011 Priorix Measles, Mumps and Rubella   Lyophilised active component to be reconstituted with Wednesday, 21 December 2011 excipient diluent before use vial (two doses) Hepatitis A (Human Diploid Cell), Inactivated (Adult)   Liquid: ready to use vial Havrix 1440 Adult Friday, 19 July 2013 (one dose) Havrix 720 Junior Hepatitis A (Human Diploid Cell), Inactivated (Paediatric)   Liquid: ready to use vial Friday, 19 July 2013 (one dose) Boostrix Diphtheria-Tetanus-Pertussis (acellular)   Liquid: ready to use vial (one dose) Tuesday, 9 July 2013 Menveo Meningococcal ACYW-135 (conjugate vaccine)   Lyophilised active component to be Wednesday, 31 July 2013 reconstituted with liquid active component before use.",
    "id": 819,
    "annotator": 1,
    "annotation_id": 820,
    "created_at": "2024-11-06T00:55:28.222011Z",
    "updated_at": "2024-11-06T00:55:28.222011Z",
    "lead_time": 17.125
  },
  {
    "text": "Two vial set (one dose) Synflorix Pneumococcal (conjugate)   Liquid: ready to use vial (four doses) Monday, 16 October 2017 Rotarix Rotavirus   Liquid: ready to use plastic tube (five doses) Thursday, 14 February 2019 Mosquirix Plasmodium falciparum (Malaria) and Hepatitis B (recombinant, adjuvanted)   Friday, 15 July 2022 Liquid active component to be mixed with second component before use.",
    "id": 820,
    "annotator": 1,
    "annotation_id": 821,
    "created_at": "2024-11-06T00:55:36.327795Z",
    "updated_at": "2024-11-06T00:55:36.327795Z",
    "lead_time": 7.874
  },
  {
    "text": "Two vial set (two doses) Pharmaceuticals Abacavir (sulfate) HIV   ViiV Healthcare   HA106 (a) 20 March 2002 Abacavir (sulfate) HIV   ViiV Healthcare   HA107 (a) 20 March 2002 Zidovudine HIV   ViiV Healthcare   HA108 (a) 29 May 2002 Zidovudine HIV   ViiV Healthcare   HA109 (a) 29 May 2002 Lamivudine\/Zidovudine HIV   ViiV Healthcare   HA110 (a) 20 March 2002 Zidovudine HIV   ViiV Healthcare   HA114 (a) 20 March 2002 Zidovudine HIV   ViiV Healthcare   HA115 (a) 20 March 2002 Lamivudine HIV   ViiV Healthcare   HA117 (a) 20 March 2002 Lamivudine HIV   ViiV Healthcare   HA128 (a) 20 March 2002 Dolutegravir (Sodium) HIV   ViiV Healthcare   HA634 (a) 14 October 2014 Abacavir (sulfate)\/Lamivudine HIV   ViiV Healthcare   HA706 (a) 19 June 2018 Dolutegravir (Sodium) HIV   ViiV Healthcare   HA768 (a) 1 July 2021 Cabotegravir (Sodium) HIV   ViiV Healthcare   HA788 (a) 22 December 2023 Cabotegravir (Sodium) HIV   ViiV Healthcare   HA789 (a) 22 December 2023 Zanamivir Influenza   GSK   IN007 (a) 22 September 2009 46 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued ESG reporting criteria Unless stated otherwise, the data reflects the reporting period of 1 January 2023 to 31 December 2023.",
    "id": 821,
    "annotator": 1,
    "annotation_id": 822,
    "created_at": "2024-11-06T00:55:46.277527Z",
    "updated_at": "2024-11-06T00:55:46.277527Z",
    "lead_time": 9.763
  },
  {
    "text": "KPI Definition Method Access Total community All donations made by GSK globally for Donations are only included if they are voluntary and charitable in purpose.",
    "id": 822,
    "annotator": 1,
    "annotation_id": 823,
    "created_at": "2024-11-06T00:55:51.005584Z",
    "updated_at": "2024-11-06T00:55:51.005584Z",
    "lead_time": 4.518
  },
  {
    "text": "investment ( m) charitable purposes including cash, product, in Donations are valued in GBP at year end exchange rates.",
    "id": 823,
    "annotator": 1,
    "annotation_id": 824,
    "created_at": "2024-11-06T00:55:55.900608Z",
    "updated_at": "2024-11-06T00:55:55.900608Z",
    "lead_time": 4.69
  },
  {
    "text": "kind donations, the value of time donated via Product donations are valued at global average cost of goods as reported volunteering and the management costs in year-end results.",
    "id": 824,
    "annotator": 1,
    "annotation_id": 825,
    "created_at": "2024-11-06T00:55:58.762954Z",
    "updated_at": "2024-11-06T00:55:58.762954Z",
    "lead_time": 2.674
  },
  {
    "text": "associated with charitable programmes.",
    "id": 825,
    "annotator": 1,
    "annotation_id": 826,
    "created_at": "2024-11-06T00:56:00.417968Z",
    "updated_at": "2024-11-06T00:56:00.417968Z",
    "lead_time": 1.448
  },
  {
    "text": "In-kind donations are valued at the value or cost of the item to GSK not the current external purchase price.",
    "id": 826,
    "annotator": 1,
    "annotation_id": 827,
    "created_at": "2024-11-06T00:56:04.692934Z",
    "updated_at": "2024-11-06T00:56:04.692934Z",
    "lead_time": 4.087
  },
  {
    "text": "Previous years  data is included for comparison but not restated for inflation or exchange rate changes.",
    "id": 827,
    "annotator": 1,
    "annotation_id": 828,
    "created_at": "2024-11-06T00:56:11.993290Z",
    "updated_at": "2024-11-06T00:56:11.993290Z",
    "lead_time": 7.124
  },
  {
    "text": "The methodology used follows the B4SI (formerly LBG) Framework for Corporate Community Investment.",
    "id": 828,
    "annotator": 1,
    "annotation_id": 829,
    "created_at": "2024-11-06T00:56:16.882575Z",
    "updated_at": "2024-11-06T00:56:16.882575Z",
    "lead_time": 4.71
  },
  {
    "text": "Value of GSK medicine The value of medicine and vaccines provided The GSK and ViiV Patient Assistance Programs Foundation administers 13 and vaccines provided through the GSK and ViiV Healthcare Patient Patient Assistance Programs for patients in the US, Puerto Rico and the US through our US Patient Assistance Programs Foundation which provides Virgin Islands.",
    "id": 829,
    "annotator": 1,
    "annotation_id": 830,
    "created_at": "2024-11-06T00:56:23.321345Z",
    "updated_at": "2024-11-06T00:56:23.321345Z",
    "lead_time": 6.257
  },
  {
    "text": "Assistance Program medication at no charge to eligible individuals.",
    "id": 830,
    "annotator": 1,
    "annotation_id": 831,
    "created_at": "2024-11-06T00:56:26.153674Z",
    "updated_at": "2024-11-06T00:56:26.153674Z",
    "lead_time": 2.637
  },
  {
    "text": "We capture Patient Assistance Program orders for GSK and ViiV (COGS in million USD) Patients who receive medications through the Healthcare products through an internal ordering database.",
    "id": 831,
    "annotator": 1,
    "annotation_id": 832,
    "created_at": "2024-11-06T00:56:33.064762Z",
    "updated_at": "2024-11-06T00:56:33.064762Z",
    "lead_time": 6.69
  },
  {
    "text": "The data is Patient Assistance Programs must meet captured according to the Wholesale Acquisition Cost of the medicine or eligibility requirements.",
    "id": 832,
    "annotator": 1,
    "annotation_id": 833,
    "created_at": "2024-11-06T00:56:39.530973Z",
    "updated_at": "2024-11-06T00:56:39.530973Z",
    "lead_time": 6.28
  },
  {
    "text": "These requirements vaccine and is coded as  Free Good Charitable Orders .",
    "id": 833,
    "annotator": 1,
    "annotation_id": 834,
    "created_at": "2024-11-06T01:08:12.343079Z",
    "updated_at": "2024-11-06T01:08:12.343079Z",
    "lead_time": 692.282
  },
  {
    "text": "This amount is include insurance status, a financial component converted to a  Cost of Goods Sold  amount for reporting purposes.",
    "id": 834,
    "annotator": 1,
    "annotation_id": 835,
    "created_at": "2024-11-06T01:08:17.415651Z",
    "updated_at": "2024-11-06T01:08:17.415651Z",
    "lead_time": 4.886
  },
  {
    "text": "based on the Federal Poverty Level, being a Patient participation varies annually based on current program eligibility resident of the US, Puerto Rico or the US Virgin criteria, overall healthcare environmental factors and products included in Islands and being treated by a US-licensed the programs.",
    "id": 835,
    "annotator": 1,
    "annotation_id": 836,
    "created_at": "2024-11-06T01:08:22.947016Z",
    "updated_at": "2024-11-06T01:08:22.947016Z",
    "lead_time": 5.352
  },
  {
    "text": "healthcare provider.",
    "id": 836,
    "annotator": 1,
    "annotation_id": 837,
    "created_at": "2024-11-06T01:08:24.284518Z",
    "updated_at": "2024-11-06T01:08:24.284518Z",
    "lead_time": 1.132
  },
  {
    "text": "Doses of Rotarix, The number of doses of the Rotarix, Synflorix and To calculate the number of doses supplied, we use the number of GSK Synflorix and Cervarix Cervarix vaccine that are supplied to Gavi, the doses shipped to Gavi supported countries.",
    "id": 837,
    "annotator": 1,
    "annotation_id": 838,
    "created_at": "2024-11-06T01:08:30.185527Z",
    "updated_at": "2024-11-06T01:08:30.185527Z",
    "lead_time": 5.715
  },
  {
    "text": "vaccines supplied to Vaccine Alliance.",
    "id": 838,
    "annotator": 1,
    "annotation_id": 839,
    "created_at": "2024-11-06T01:08:32.742220Z",
    "updated_at": "2024-11-06T01:08:32.742220Z",
    "lead_time": 2.362
  },
  {
    "text": "GSK has been a Gavi supplier since Gavi s inception in 2000.",
    "id": 839,
    "annotator": 1,
    "annotation_id": 840,
    "created_at": "2024-11-06T01:08:38.494201Z",
    "updated_at": "2024-11-06T01:08:38.494201Z",
    "lead_time": 5.568
  },
  {
    "text": "Gavi (millions) Doses of Mosquirix The number of doses of the Mosquirix (RTS,S\/ To calculate the number of doses supplied, we use the number of GSK (RTS,S\/AS01 E) AS01 E) vaccine GSK donated to the Malaria doses procured by UNICEF for MVIP and Gavi funded supply.",
    "id": 840,
    "annotator": 1,
    "annotation_id": 841,
    "created_at": "2024-11-06T01:08:46.933953Z",
    "updated_at": "2024-11-06T01:08:46.933953Z",
    "lead_time": 8.262
  },
  {
    "text": "vaccines supplied Vaccine Implementation Programme (MVIP) GSK has supplied\/donated 10 million Mosquirix (RTS,S\/AS01 E), since the (millions) and number of Gavi funded doses supplied beginning of the MVIP in 2019 and has supplied the first Gavi funded doses through Gavi-Unicef from Q4-2023.",
    "id": 841,
    "annotator": 1,
    "annotation_id": 842,
    "created_at": "2024-11-06T01:08:50.981099Z",
    "updated_at": "2024-11-06T01:08:50.981099Z",
    "lead_time": 3.872
  },
  {
    "text": "Doses of OPV The number of doses of the OPV vaccine that To calculate the number of doses in the OPV stockpile, we use the number vaccines ready-to- are ready-to-ship stockpile for outbreak of mOPV2 doses stored in GSK warehouse for outbreak responses.",
    "id": 842,
    "annotator": 1,
    "annotation_id": 843,
    "created_at": "2024-11-06T01:08:56.807214Z",
    "updated_at": "2024-11-06T01:08:56.807214Z",
    "lead_time": 5.647
  },
  {
    "text": "ship stockpile for responses to UNICEF.",
    "id": 843,
    "annotator": 1,
    "annotation_id": 844,
    "created_at": "2024-11-06T01:08:58.233780Z",
    "updated_at": "2024-11-06T01:08:58.233780Z",
    "lead_time": 1.225
  },
  {
    "text": "outbreak responses to UNICEF (millions) Doses of OPV The number of doses of the OPV vaccine that To calculate the number of doses supplied, we use the total number of GSK vaccines supplied to are supplied to UNICEF.",
    "id": 844,
    "label": [
      {
        "start": 167,
        "end": 214,
        "text": "GSK vaccines supplied to are supplied to UNICEF",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 167,
        "end": 214,
        "text": "GSK vaccines supplied to are supplied to UNICEF",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 845,
    "created_at": "2024-11-06T01:09:40.587319Z",
    "updated_at": "2024-11-06T01:09:40.587319Z",
    "lead_time": 42.13
  },
  {
    "text": "doses shipped to countries procuring via UNICEF for both routine UNICEF (millions) vaccination campaigns and outbreak responses.",
    "id": 845,
    "annotator": 1,
    "annotation_id": 846,
    "created_at": "2024-11-06T01:09:47.555188Z",
    "updated_at": "2024-11-06T01:09:47.555188Z",
    "lead_time": 6.735
  },
  {
    "text": "People with access to The total number of people living with HIV As a chronic and ongoing treatment, we capture the cumulative number of a generic dolutegravir currently accessing generic dolutegravir-based people with access to dolutegravir, rather than annual data, to avoid product through products through ViiV Healthcare s voluntary duplication.",
    "id": 846,
    "annotator": 1,
    "annotation_id": 847,
    "created_at": "2024-11-06T01:09:53.847520Z",
    "updated_at": "2024-11-06T01:09:53.847520Z",
    "lead_time": 6.105
  },
  {
    "text": "The indicator therefore represents the total number of people voluntary licensing licensing agreements with the Medicines Patent living with HIV accessing the treatment at the time of measurement.",
    "id": 847,
    "annotator": 1,
    "annotation_id": 848,
    "created_at": "2024-11-06T01:09:57.755765Z",
    "updated_at": "2024-11-06T01:09:57.755765Z",
    "lead_time": 3.71
  },
  {
    "text": "As a agreements ( 000) Pool and directly with Aurobindo Pharma.",
    "id": 848,
    "annotator": 1,
    "annotation_id": 849,
    "created_at": "2024-11-06T01:10:01.385075Z",
    "updated_at": "2024-11-06T01:10:01.385075Z",
    "lead_time": 3.456
  },
  {
    "text": "life-long treatment, this number incorporates people that have been receiving ongoing treatment for multiple years.",
    "id": 849,
    "annotator": 1,
    "annotation_id": 850,
    "created_at": "2024-11-06T01:10:06.011032Z",
    "updated_at": "2024-11-06T01:10:06.011032Z",
    "lead_time": 4.437
  },
  {
    "text": "For adults living with HIV, the number is calculated by adding the total number of packs of all generic dolutegravir-based products (indicated for adults) sold over the previous four quarters.",
    "id": 850,
    "annotator": 1,
    "annotation_id": 851,
    "created_at": "2024-11-06T01:10:12.119284Z",
    "updated_at": "2024-11-06T01:10:12.119284Z",
    "lead_time": 5.918
  },
  {
    "text": "This is then divided by twelve to obtain average monthly sales and estimate the number of adults on treatment.",
    "id": 851,
    "annotator": 1,
    "annotation_id": 852,
    "created_at": "2024-11-06T01:10:18.632018Z",
    "updated_at": "2024-11-06T01:10:18.632018Z",
    "lead_time": 6.331
  },
  {
    "text": "For children living with HIV, this is done by calculating the total number of paediatric DTG 10mg tablets sold over the previous four quarters and dividing this by 365 to calculate average number of tablets sold per day.",
    "id": 852,
    "annotator": 1,
    "annotation_id": 853,
    "created_at": "2024-11-06T01:10:23.995728Z",
    "updated_at": "2024-11-06T01:10:23.995728Z",
    "lead_time": 5.156
  },
  {
    "text": "This is then divided by 2.056 (the average daily number of tablets taken across different paediatric weight bands) to estimate the number of children on treatment.",
    "id": 853,
    "annotator": 1,
    "annotation_id": 854,
    "created_at": "2024-11-06T01:10:25.367787Z",
    "updated_at": "2024-11-06T01:10:25.367787Z",
    "lead_time": 1.195
  },
  {
    "text": "In both cases, packs of 90 and 60 are converted to 30 pack equivalents (i.e. monthly equivalents for a daily treatment).",
    "id": 854,
    "annotator": 1,
    "annotation_id": 855,
    "created_at": "2024-11-06T01:10:31.707465Z",
    "updated_at": "2024-11-06T01:10:31.707465Z",
    "lead_time": 6.165
  },
  {
    "text": "Data is provided by the Medicines Patent Pool and Aurobindo, through which ViiV s DTG patents are (sub-)licensed.",
    "id": 855,
    "annotator": 1,
    "annotation_id": 856,
    "created_at": "2024-11-06T01:10:34.602185Z",
    "updated_at": "2024-11-06T01:10:34.602185Z",
    "lead_time": 2.708
  },
  {
    "text": "47 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Access Estimated children The estimated number of children who have To calculate the estimated number of children reached, we use the number reached with Synflorix received the Synflorix vaccine (for the prevention of GSK doses shipped to Gavi supported countries, and divide this by the through Gavi ( 000) of pneumococcal infection) through Gavi, the number of doses needed to complete a full schedule, with Gavi estimated Vaccine Alliance.",
    "id": 856,
    "annotator": 1,
    "annotation_id": 857,
    "created_at": "2024-11-06T01:10:42.375408Z",
    "updated_at": "2024-11-06T01:10:42.375408Z",
    "lead_time": 7.568
  },
  {
    "text": "vaccine wastage rates factored in.",
    "id": 857,
    "annotator": 1,
    "annotation_id": 858,
    "created_at": "2024-11-06T01:10:43.478815Z",
    "updated_at": "2024-11-06T01:10:43.478815Z",
    "lead_time": 0.909
  },
  {
    "text": "For Synflorix a full schedule is three All children receiving Synflorix are under five doses, and Gavi estimates wastage of 10% in 2017 and 2018, 8% in years of age.",
    "id": 858,
    "annotator": 1,
    "annotation_id": 859,
    "created_at": "2024-11-06T01:10:51.864936Z",
    "updated_at": "2024-11-06T01:10:51.864936Z",
    "lead_time": 8.187
  },
  {
    "text": "2019-2023.",
    "id": 859,
    "annotator": 1,
    "annotation_id": 860,
    "created_at": "2024-11-06T01:10:53.099757Z",
    "updated_at": "2024-11-06T01:10:53.099757Z",
    "lead_time": 1.015
  },
  {
    "text": "See: Detailed-product-profiles.",
    "id": 860,
    "annotator": 1,
    "annotation_id": 861,
    "created_at": "2024-11-06T01:10:57.223935Z",
    "updated_at": "2024-11-06T01:10:57.223935Z",
    "lead_time": 3.926
  },
  {
    "text": "xlsx (live.com) Estimated children The estimated number of children who have To calculate the estimated number of children reached, we use the number reached with Rotarix received the Rotarix vaccine (for the prevention of GSK doses shipped to Gavi supported countries, and divide this by the through Gavi ( 000) of rotavirus) through Gavi, the Vaccine Alliance.",
    "id": 861,
    "annotator": 1,
    "annotation_id": 862,
    "created_at": "2024-11-06T01:16:23.579850Z",
    "updated_at": "2024-11-06T01:16:23.579850Z",
    "lead_time": 325.839
  },
  {
    "text": "number of doses needed to complete a full schedule, with Gavi estimated vaccine wastage rates factored in.",
    "id": 862,
    "annotator": 1,
    "annotation_id": 863,
    "created_at": "2024-11-06T01:16:28.089862Z",
    "updated_at": "2024-11-06T01:16:28.089862Z",
    "lead_time": 4.301
  },
  {
    "text": "For Rotarix a full schedule is two doses All children receiving Rotarix are under five and Gavi estimates wastage of 5% in 2017 and 2018, 4% in 2019-2023.",
    "id": 863,
    "annotator": 1,
    "annotation_id": 864,
    "created_at": "2024-11-06T01:16:32.380722Z",
    "updated_at": "2024-11-06T01:16:32.380722Z",
    "lead_time": 4.08
  },
  {
    "text": "years of age.",
    "id": 864,
    "annotator": 1,
    "annotation_id": 865,
    "created_at": "2024-11-06T01:16:33.550741Z",
    "updated_at": "2024-11-06T01:16:33.550741Z",
    "lead_time": 0.965
  },
  {
    "text": "See: Detailed-product-profiles.",
    "id": 865,
    "annotator": 1,
    "annotation_id": 866,
    "created_at": "2024-11-06T01:16:34.256735Z",
    "updated_at": "2024-11-06T01:16:34.256735Z",
    "lead_time": 0.506
  },
  {
    "text": "xlsx (live.com) Estimated girls The estimated number of girls who have To calculate the estimated number of girls reached, we use the number of GSK reached with Cervarix received the Cervarix vaccine (for the prevention doses shipped to Gavi supported countries, and divide this by the number of through Gavi ( 000) of cervical cancer) through Gavi, the Vaccine doses needed to complete a full schedule, with Gavi estimated vaccine Alliance.",
    "id": 866,
    "annotator": 1,
    "annotation_id": 867,
    "created_at": "2024-11-06T01:16:41.852262Z",
    "updated_at": "2024-11-06T01:16:41.852262Z",
    "lead_time": 7.389
  },
  {
    "text": "wastage rates factored in.",
    "id": 867,
    "annotator": 1,
    "annotation_id": 868,
    "created_at": "2024-11-06T01:16:43.448303Z",
    "updated_at": "2024-11-06T01:16:43.448303Z",
    "lead_time": 1.393
  },
  {
    "text": "For Cervarix a full schedule is either one dose or two doses and Gavi estimates 10% wastage in 2023.",
    "id": 868,
    "annotator": 1,
    "annotation_id": 869,
    "created_at": "2024-11-06T01:16:44.533069Z",
    "updated_at": "2024-11-06T01:16:44.533069Z",
    "lead_time": 0.886
  },
  {
    "text": "See: Detailed-product- profiles.",
    "id": 869,
    "annotator": 1,
    "annotation_id": 870,
    "created_at": "2024-11-06T01:16:45.841264Z",
    "updated_at": "2024-11-06T01:16:45.841264Z",
    "lead_time": 1.1
  },
  {
    "text": "xlsx (live.com) Estimated people The estimated number of people who have To calculate the estimated number of people reached, we use the number reached with the Oral received the OPV vaccine for polio procured of bivalent OPV (bOPV) and monovalent OPV (mOPV) doses shipped to Polio Vaccine (OPV) through UNICEF.",
    "id": 870,
    "annotator": 1,
    "annotation_id": 871,
    "created_at": "2024-11-06T01:16:51.100935Z",
    "updated_at": "2024-11-06T01:16:51.100935Z",
    "lead_time": 5.052
  },
  {
    "text": "UNICEF, divided by the number of doses needed to complete a full ( 000) schedule, with WHO estimated vaccine wastage rates factored in.",
    "id": 871,
    "annotator": 1,
    "annotation_id": 872,
    "created_at": "2024-11-06T01:16:55.829755Z",
    "updated_at": "2024-11-06T01:16:55.829755Z",
    "lead_time": 4.538
  },
  {
    "text": "In outbreak situations, which is where GSK OPV volumes are often used, 1 dose is usually given to each child.",
    "id": 872,
    "annotator": 1,
    "annotation_id": 873,
    "created_at": "2024-11-06T01:16:58.151726Z",
    "updated_at": "2024-11-06T01:16:58.151726Z",
    "lead_time": 2.125
  },
  {
    "text": "However, as the primary schedule is 4 doses and children may receive more than one dose through subsequent outbreak campaigns, we use 4 doses for the calculation in order to be conservative.",
    "id": 873,
    "annotator": 1,
    "annotation_id": 874,
    "created_at": "2024-11-06T01:17:03.620134Z",
    "updated_at": "2024-11-06T01:17:03.620134Z",
    "lead_time": 5.272
  },
  {
    "text": "WHO estimates 20% wastage given that we supply 10 and 20 dose vials, vials are mainly used in campaigns and vials may or may not be used or discarded after vial is opened at the end of the session.",
    "id": 874,
    "annotator": 1,
    "annotation_id": 875,
    "created_at": "2024-11-06T01:17:10.644759Z",
    "updated_at": "2024-11-06T01:17:10.644759Z",
    "lead_time": 6.829
  },
  {
    "text": "See WHO indicative vaccine wastage rates: OPV Supply: revising-wastage-concept- note.",
    "id": 875,
    "annotator": 1,
    "annotation_id": 876,
    "created_at": "2024-11-06T01:17:11.624294Z",
    "updated_at": "2024-11-06T01:17:11.624294Z",
    "lead_time": 0.778
  },
  {
    "text": "pdf (who.",
    "id": 876,
    "annotator": 1,
    "annotation_id": 877,
    "created_at": "2024-11-06T01:17:12.304434Z",
    "updated_at": "2024-11-06T01:17:12.304434Z",
    "lead_time": 0.497
  },
  {
    "text": "int) Estimated people The estimated number of children who have To calculate the estimated number of children reached, we use the number of reached with received the RTS,S vaccine through the Malaria GSK doses shipped and divide this by the number of doses needed to Mosquirix (RTS,S\/AS01 Vaccine Implementation Programme (MVIP) complete a full schedule (4 doses), with WHO estimated vaccine wastage E) ('000) and through Gavi-Unicef.",
    "id": 877,
    "annotator": 1,
    "annotation_id": 878,
    "created_at": "2024-11-06T01:17:37.430140Z",
    "updated_at": "2024-11-06T01:17:37.430140Z",
    "lead_time": 24.949
  },
  {
    "text": "rates (10% for 2 dose vials used in routine immunisation) factored in.",
    "id": 878,
    "annotator": 1,
    "annotation_id": 879,
    "created_at": "2024-11-06T01:17:41.959075Z",
    "updated_at": "2024-11-06T01:17:41.959075Z",
    "lead_time": 4.311
  },
  {
    "text": "See: Detailed-product-profiles.",
    "id": 879,
    "annotator": 1,
    "annotation_id": 880,
    "created_at": "2024-11-06T01:17:43.759285Z",
    "updated_at": "2024-11-06T01:17:43.759285Z",
    "lead_time": 1.599
  },
  {
    "text": "xlsx (live.com) Albendazole tablets The number of albendazole tablets donated to Albendazole tablet shipments are sent from GSK s manufacturing facility to donated to help the World Health Organization to support endemic countries.",
    "id": 880,
    "annotator": 1,
    "annotation_id": 881,
    "created_at": "2024-11-06T01:17:48.862399Z",
    "updated_at": "2024-11-06T01:17:48.862399Z",
    "lead_time": 4.902
  },
  {
    "text": "These shipments are entered into a real-time database of eliminate lymphatic endemic country efforts to eliminate lymphatic donated medicines for Neglected Tropical Diseases.",
    "id": 881,
    "annotator": 1,
    "annotation_id": 882,
    "created_at": "2024-11-06T01:19:01.203341Z",
    "updated_at": "2024-11-06T01:19:01.203341Z",
    "lead_time": 72.139
  },
  {
    "text": "Albendazole tablet filariasis (millions) filariasis (LF).",
    "id": 882,
    "annotator": 1,
    "annotation_id": 883,
    "created_at": "2024-11-06T01:19:04.492245Z",
    "updated_at": "2024-11-06T01:19:04.492245Z",
    "lead_time": 3.089
  },
  {
    "text": "donation figures for LF are aggregated and reported annually through data pulled from this system.",
    "id": 883,
    "annotator": 1,
    "annotation_id": 884,
    "created_at": "2024-11-06T01:19:08.262566Z",
    "updated_at": "2024-11-06T01:19:08.262566Z",
    "lead_time": 3.553
  },
  {
    "text": "Albendazole tablets The number of albendazole tablets donated to Albendazole tablet shipments are sent from GSK s manufacturing facility to donated to help treat the World Health Organization to support endemic countries.",
    "id": 884,
    "annotator": 1,
    "annotation_id": 885,
    "created_at": "2024-11-06T01:19:14.092458Z",
    "updated_at": "2024-11-06T01:19:14.092458Z",
    "lead_time": 5.59
  },
  {
    "text": "These shipments are entered into a real-time database of intestinal worms endemic country efforts to treat soil- donated medicines for Neglected Tropical Diseases.",
    "id": 885,
    "annotator": 1,
    "annotation_id": 886,
    "created_at": "2024-11-06T01:19:18.072096Z",
    "updated_at": "2024-11-06T01:19:18.072096Z",
    "lead_time": 3.781
  },
  {
    "text": "Albendazole tablet (millions) transmitted helminthiasis (intestinal worms) in donation figures for soil-transmitted helminthiasis control are aggregated school-age children.",
    "id": 886,
    "annotator": 1,
    "annotation_id": 887,
    "created_at": "2024-11-06T01:19:27.371068Z",
    "updated_at": "2024-11-06T01:19:27.371068Z",
    "lead_time": 2.413
  },
  {
    "text": "and reported annually through data pulled from this system.",
    "id": 887,
    "annotator": 1,
    "annotation_id": 888,
    "created_at": "2024-11-06T01:19:29.408374Z",
    "updated_at": "2024-11-06T01:19:29.408374Z",
    "lead_time": 1.86
  },
  {
    "text": "People reached The total number of unique individuals that The GSK and ViiV Patient Assistance Programs Foundation administers 13 through the US Patient received GSK and ViiV Healthcare product Patient Assistance Programs for patients in the US, Puerto Rico and the US Assistance Program through all our Patient Assistance Programs.",
    "id": 888,
    "annotator": 1,
    "annotation_id": 889,
    "created_at": "2024-11-06T01:19:34.761671Z",
    "updated_at": "2024-11-06T01:19:34.761671Z",
    "lead_time": 5.167
  },
  {
    "text": "Virgin Islands.",
    "id": 889,
    "annotator": 1,
    "annotation_id": 890,
    "created_at": "2024-11-06T01:19:36.441679Z",
    "updated_at": "2024-11-06T01:19:36.441679Z",
    "lead_time": 1.482
  },
  {
    "text": "( 000) Patients who receive medications through the Each of the 13 US Patient Assistance Programs provides a report at year-end, Patient Assistance Programs must meet eligibility which enables us to consolidate the number of unique patients that received requirements.",
    "id": 890,
    "annotator": 1,
    "annotation_id": 891,
    "created_at": "2024-11-06T01:19:40.942303Z",
    "updated_at": "2024-11-06T01:19:40.942303Z",
    "lead_time": 4.325
  },
  {
    "text": "These requirements include GSK and ViiV Healthcare products throughout the year.",
    "id": 891,
    "annotator": 1,
    "annotation_id": 892,
    "created_at": "2024-11-06T01:19:44.591885Z",
    "updated_at": "2024-11-06T01:19:44.591885Z",
    "lead_time": 3.453
  },
  {
    "text": "insurance status, a financial component based Patient participation varies annually based on current programme eligibility on the Federal Poverty Level, being a resident of criteria, overall healthcare environmental conditions and products included in the US, Puerto Rico or the US Virgin Islands and the programmes.",
    "id": 892,
    "annotator": 1,
    "annotation_id": 893,
    "created_at": "2024-11-06T01:20:13.452186Z",
    "updated_at": "2024-11-06T01:20:13.452186Z",
    "lead_time": 28.665
  },
  {
    "text": "being treated by a US-licensed healthcare provider.",
    "id": 893,
    "annotator": 1,
    "annotation_id": 894,
    "created_at": "2024-11-06T01:20:15.055125Z",
    "updated_at": "2024-11-06T01:20:15.055125Z",
    "lead_time": 1.397
  },
  {
    "text": "48 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Global health and health security Number of assets The number of assets progressed through the  Pipeline progression  is defined as the movement of a Global Health asset progressed through Global Health pipeline to address priority WHO from one phase to another.",
    "id": 894,
    "annotator": 1,
    "annotation_id": 895,
    "created_at": "2024-11-06T01:20:20.510795Z",
    "updated_at": "2024-11-06T01:20:20.510795Z",
    "lead_time": 5.252
  },
  {
    "text": "GSK recognises progression through the the Global Health diseases across GSK s two Global Health hubs following four categories: pipeline to address   Tres Cantos (Spain), which focuses on   Senior leadership endorsement of business plan for progression priority WHO diseases therapeutics, and the GSK Vaccines Institute for   Clinical trial starts ( First Subject, First Visit\/Dose ) Global Health (GVGH in Sienna), which focuses   Business development\/in-licensing on preventative treatment.",
    "id": 895,
    "annotator": 1,
    "annotation_id": 896,
    "created_at": "2024-11-06T01:20:26.565458Z",
    "updated_at": "2024-11-06T01:20:26.565458Z",
    "lead_time": 5.872
  },
  {
    "text": "Regulatory milestone (ie   submission, approval, or launch) Priority WHO diseases are defined as diseases 2023 ESG achievements consider GSK s internal 2-week grace period to and pathogens prioritized for R&D in public ensure that any asset progressed through 15 January will not be double health emergency contexts, which distinguishes counted for the metric in 2024.",
    "id": 896,
    "annotator": 1,
    "annotation_id": 897,
    "created_at": "2024-11-06T01:20:31.826732Z",
    "updated_at": "2024-11-06T01:20:31.826732Z",
    "lead_time": 5.07
  },
  {
    "text": "diseases to the degree they pose the greatest public health risk due to their epidemic potential and\/or whether there is no or insufficient countermeasures.",
    "id": 897,
    "annotator": 1,
    "annotation_id": 898,
    "created_at": "2024-11-06T01:20:36.466668Z",
    "updated_at": "2024-11-06T01:20:36.466668Z",
    "lead_time": 4.443
  },
  {
    "text": "GSK uses the following lists:   WHO Priority Pathogen List*   WHO Emergency Diseases List*   WHO Blueprint for Prioritized Disease List*   WHO Essential Medicines List*   UN Sustainable Development Goals * WHO reviews and updates these lists as needs arise and methodologies change.",
    "id": 898,
    "annotator": 1,
    "annotation_id": 899,
    "created_at": "2024-11-06T01:20:41.165907Z",
    "updated_at": "2024-11-06T01:20:41.165907Z",
    "lead_time": 4.5
  },
  {
    "text": "Number of active R&D The number of active R&D projects that address Active R&D projects include projects in discovery, preclinical, phase I, projects that address pathogens prioritised by the WHO and CDC as phase II, phase III, and open label trials.",
    "id": 899,
    "annotator": 1,
    "annotation_id": 900,
    "created_at": "2024-11-06T01:20:45.715986Z",
    "updated_at": "2024-11-06T01:20:45.715986Z",
    "lead_time": 4.346
  },
  {
    "text": "pathogens prioritised posing the highest level of concern due to drug   The global infectious disease and vaccines team maintain an internal by the WHO and CDC resistance (critical and\/or urgent threats).",
    "id": 900,
    "annotator": 1,
    "annotation_id": 901,
    "created_at": "2024-11-06T01:20:51.087583Z",
    "updated_at": "2024-11-06T01:20:51.087583Z",
    "lead_time": 5.17
  },
  {
    "text": "** tracker with active projects being run exclusively by GSK.",
    "id": 901,
    "annotator": 1,
    "annotation_id": 902,
    "created_at": "2024-11-06T01:20:55.328847Z",
    "updated_at": "2024-11-06T01:20:55.328847Z",
    "lead_time": 4.032
  },
  {
    "text": "Additional as posing the highest GSK uses the following lists to define critical projects being run with partner companies are added to the list.",
    "id": 902,
    "annotator": 1,
    "annotation_id": 903,
    "created_at": "2024-11-06T01:20:59.607170Z",
    "updated_at": "2024-11-06T01:20:59.607170Z",
    "lead_time": 4.082
  },
  {
    "text": "level of concern due to and\/or urgent threats:   Accuracy is validated by key subject matter experts identified in the drug resistance (critical and\/or urgent   Bacterial pathogens categorized as a controls document.",
    "id": 903,
    "annotator": 1,
    "annotation_id": 904,
    "created_at": "2024-11-06T01:21:04.713803Z",
    "updated_at": "2024-11-06T01:21:04.713803Z",
    "lead_time": 4.907
  },
  {
    "text": "threats) Critical Threats by the WHO (updated 2017)   Fungal pathogens categorized as a Critical Threats by the WHO (added 2022)   Pathogens listed as Urgent Threats on the CDC (Updated 2019) Active R&D Projects include R&D projects from ID therapeutics and Vaccines team.",
    "id": 904,
    "annotator": 1,
    "annotation_id": 905,
    "created_at": "2024-11-06T01:21:09.465362Z",
    "updated_at": "2024-11-06T01:21:09.465362Z",
    "lead_time": 4.566
  },
  {
    "text": "Includes active R&D projects in Discovery, preclinical, or phase I, phase II, phase III, and open label trials.",
    "id": 905,
    "annotator": 1,
    "annotation_id": 906,
    "created_at": "2024-11-06T01:21:14.475091Z",
    "updated_at": "2024-11-06T01:21:14.475091Z",
    "lead_time": 4.827
  },
  {
    "text": "Note that projects on clinical hold, and low priority\/Tier 3 projects are NOT included in the count.",
    "id": 906,
    "annotator": 1,
    "annotation_id": 907,
    "created_at": "2024-11-06T01:21:17.074180Z",
    "updated_at": "2024-11-06T01:21:17.074180Z",
    "lead_time": 2.409
  },
  {
    "text": "** Currently, WHO and CDC designated critical and\/or urgent threats include carbapenem- resistant (CR) Acinetobacter spp.",
    "id": 907,
    "annotator": 1,
    "annotation_id": 908,
    "created_at": "2024-11-06T01:21:22.866185Z",
    "updated_at": "2024-11-06T01:21:22.866185Z",
    "lead_time": 5.608
  },
  {
    "text": ", C. difficile, CR or ESBL+ Enterobacteriaceae, Drug-resistant N. gonorrhoeae and carbapenem-resistant P. aeruginosa, Candida auris, Candida albicans, Aspergillis fumigatus and Cryptococcus neoformans.",
    "id": 908,
    "annotator": 1,
    "annotation_id": 909,
    "created_at": "2024-11-06T01:21:29.134718Z",
    "updated_at": "2024-11-06T01:21:29.134718Z",
    "lead_time": 6.077
  },
  {
    "text": "Environment For a full list of our environment reporting criteria, please see our Basis of reporting, including full definitions and methodologies.",
    "id": 909,
    "annotator": 1,
    "annotation_id": 910,
    "created_at": "2024-11-06T01:21:34.334232Z",
    "updated_at": "2024-11-06T01:21:34.334232Z",
    "lead_time": 5.018
  },
  {
    "text": "Diversity, equity and inclusion Ethnically diverse total Total percentage of ethnically diverse The data covers the total number of employees salaried in our internal HR (%) employees for GSK in the US and UK employee system, both active (including Full-time\/Part-time, Regular\/Temporary population across SVP\/VP level, Director level, employees) and non-active (ie, on Maternity Leave, Paternity Leave, Manager level and across all employees.",
    "id": 910,
    "annotator": 1,
    "annotation_id": 911,
    "created_at": "2024-11-06T01:21:40.424620Z",
    "updated_at": "2024-11-06T01:21:40.424620Z",
    "lead_time": 5.907
  },
  {
    "text": "Due Adoption Leave, etc.",
    "id": 911,
    "annotator": 1,
    "annotation_id": 912,
    "created_at": "2024-11-06T01:21:42.311022Z",
    "updated_at": "2024-11-06T01:21:42.311022Z",
    "lead_time": 1.706
  },
  {
    "text": ").",
    "id": 912,
    "annotator": 1,
    "annotation_id": 913,
    "created_at": "2024-11-06T01:21:43.150986Z",
    "updated_at": "2024-11-06T01:21:43.150986Z",
    "lead_time": 0.677
  },
  {
    "text": "It excludes Puerto Rico-based employees, Agency to differing ethnic groups across the UK and Temporary Workers ( Contingent Workers  defined as those payrolled via US employee population, race\/ethnic recruitment agencies) and employees with blank ethnicity and  Prefer not to categories are defined according to UK say .",
    "id": 913,
    "annotator": 1,
    "annotation_id": 914,
    "created_at": "2024-11-06T01:21:48.640759Z",
    "updated_at": "2024-11-06T01:21:48.640759Z",
    "lead_time": 5.316
  },
  {
    "text": "The US figures exclude Puerto Rico-based employees given significant Census and US Federal reporting guidelines.",
    "id": 914,
    "annotator": 1,
    "annotation_id": 915,
    "created_at": "2024-11-06T01:21:55.872382Z",
    "updated_at": "2024-11-06T01:21:55.872382Z",
    "lead_time": 7.063
  },
  {
    "text": "differences in ethnic composition of the territory s population relative to the rest of the US.",
    "id": 915,
    "annotator": 1,
    "annotation_id": 916,
    "created_at": "2024-11-06T01:22:02.432650Z",
    "updated_at": "2024-11-06T01:22:02.432650Z",
    "lead_time": 6.39
  },
  {
    "text": "The percentage is calculated using employee numbers as of 31 December of the current year.",
    "id": 916,
    "annotator": 1,
    "annotation_id": 917,
    "created_at": "2024-11-06T01:22:12.839855Z",
    "updated_at": "2024-11-06T01:22:12.839855Z",
    "lead_time": 10.223
  },
  {
    "text": "This is calculated as the number of salaried employees at 31 December of the current year recorded in our internal HR system who self-identified as Ethnically Diverse, divided by total salaried employees in the system.",
    "id": 917,
    "annotator": 1,
    "annotation_id": 918,
    "created_at": "2024-11-06T01:22:15.696869Z",
    "updated_at": "2024-11-06T01:22:15.696869Z",
    "lead_time": 2.641
  },
  {
    "text": "49 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Diversity, equity and inclusion Total women in The total percentage of women in a The data covers the total number of salaried employees who identify as management (%) management role.",
    "id": 918,
    "annotator": 1,
    "annotation_id": 919,
    "created_at": "2024-11-06T01:22:21.432328Z",
    "updated_at": "2024-11-06T01:22:21.432328Z",
    "lead_time": 5.546
  },
  {
    "text": "Management  is classed as women within our HR system, including active (Full-time\/Part-time, an employee in grade bands 0-6 which includes Regular\/Temporary employees) and non-active (i.e., on Maternity Leave, Managers, Directors, VPs and SVPs.",
    "id": 919,
    "annotator": 1,
    "annotation_id": 920,
    "created_at": "2024-11-06T01:22:26.955643Z",
    "updated_at": "2024-11-06T01:22:26.955643Z",
    "lead_time": 5.355
  },
  {
    "text": "Paternity Leave, Adoption Leave, etc.",
    "id": 920,
    "annotator": 1,
    "annotation_id": 921,
    "created_at": "2024-11-06T01:22:28.421978Z",
    "updated_at": "2024-11-06T01:22:28.421978Z",
    "lead_time": 1.294
  },
  {
    "text": ").",
    "id": 921,
    "annotator": 1,
    "annotation_id": 922,
    "created_at": "2024-11-06T01:22:29.080844Z",
    "updated_at": "2024-11-06T01:22:29.080844Z",
    "lead_time": 0.48
  },
  {
    "text": "It excludes Agency Temporary Workers ( Contingent Workers  defined as those payrolled via recruitment agencies) and employees with no gender recorded, or if they have indicated  Prefer not to say .",
    "id": 922,
    "annotator": 1,
    "annotation_id": 923,
    "created_at": "2024-11-06T01:22:35.730498Z",
    "updated_at": "2024-11-06T01:22:35.730498Z",
    "lead_time": 6.474
  },
  {
    "text": "The percentage is calculated using employee numbers as of 31 December of the current year.",
    "id": 923,
    "annotator": 1,
    "annotation_id": 924,
    "created_at": "2024-11-06T01:22:39.864950Z",
    "updated_at": "2024-11-06T01:22:39.864950Z",
    "lead_time": 3.958
  },
  {
    "text": "This is calculated as the number of salaried employees (at 31 December) recorded in our HR system with Gender specified as female, within grades 0-6, divided by the total payrolled employees recorded in the HR system.",
    "id": 924,
    "annotator": 1,
    "annotation_id": 925,
    "created_at": "2024-11-06T01:23:04.639206Z",
    "updated_at": "2024-11-06T01:23:04.639206Z",
    "lead_time": 24.571
  },
  {
    "text": "% of phase III trials The total percentage of clinical trials that have The number of (and status of) actual protocol approvals is recorded in initiated in the current achieved First Subject First Visit (FSFV) and GSK s electronic Trial Master File (Veeva CDMS) database.",
    "id": 925,
    "annotator": 1,
    "annotation_id": 926,
    "created_at": "2024-11-06T01:23:09.604141Z",
    "updated_at": "2024-11-06T01:23:09.604141Z",
    "lead_time": 4.745
  },
  {
    "text": "reporting year with have a Study Diversity Plan recorded at time of proactive plans   FSFV.",
    "id": 926,
    "annotator": 1,
    "annotation_id": 927,
    "created_at": "2024-11-06T01:23:13.905052Z",
    "updated_at": "2024-11-06T01:23:13.905052Z",
    "lead_time": 4.12
  },
  {
    "text": "Diversity Ethical standards Employees who had The number of distinct employees with a Anyone inside or outside GSK can raise concerns or speak to an concerns raised disciplinary concern raised against them.",
    "id": 927,
    "annotator": 1,
    "annotation_id": 928,
    "created_at": "2024-11-06T01:23:18.202122Z",
    "updated_at": "2024-11-06T01:23:18.202122Z",
    "lead_time": 4.127
  },
  {
    "text": "independent third party through our integrity lines, confidentially or against them anonymously.",
    "id": 928,
    "annotator": 1,
    "annotation_id": 929,
    "created_at": "2024-11-06T01:25:04.759299Z",
    "updated_at": "2024-11-06T01:25:04.759299Z",
    "lead_time": 106.382
  },
  {
    "text": "Concerns can also be raised internally by employees, management, or internal monitoring.",
    "id": 929,
    "annotator": 1,
    "annotation_id": 930,
    "created_at": "2024-11-06T01:25:09.007465Z",
    "updated_at": "2024-11-06T01:25:09.007465Z",
    "lead_time": 4.048
  },
  {
    "text": "This data comprises all regular employees and excludes contractors and contingent workers.",
    "id": 930,
    "annotator": 1,
    "annotation_id": 931,
    "created_at": "2024-11-06T01:25:12.758865Z",
    "updated_at": "2024-11-06T01:25:12.758865Z",
    "lead_time": 3.545
  },
  {
    "text": "The data includes the total number of distinct employees with a disciplinary concern raised against them during the reporting period and those employees with disciplinary concerns raised against them from prior year s open cases.",
    "id": 931,
    "annotator": 1,
    "annotation_id": 932,
    "created_at": "2024-11-06T01:25:17.442132Z",
    "updated_at": "2024-11-06T01:25:17.442132Z",
    "lead_time": 4.485
  },
  {
    "text": "Employees disciplined The number of distinct employees where the This data comprises all regular employees and excludes contractors and for policy violations outcome of a concern raised resulted in contingent workers.",
    "id": 932,
    "annotator": 1,
    "annotation_id": 933,
    "created_at": "2024-11-06T01:25:24.622287Z",
    "updated_at": "2024-11-06T01:25:24.622287Z",
    "lead_time": 6.989
  },
  {
    "text": "disciplinary action.",
    "id": 933,
    "annotator": 1,
    "annotation_id": 934,
    "created_at": "2024-11-06T01:25:26.061590Z",
    "updated_at": "2024-11-06T01:25:26.061590Z",
    "lead_time": 1.236
  },
  {
    "text": "The data represents cases closed during the reporting period.",
    "id": 934,
    "annotator": 1,
    "annotation_id": 935,
    "created_at": "2024-11-06T01:25:27.872876Z",
    "updated_at": "2024-11-06T01:25:27.872876Z",
    "lead_time": 1.611
  },
  {
    "text": "In 2022, we also included three open cases where disciplinary decisions were made and action taken at year end; however, the cases had not yet been closed in the source system by the reporting criteria end date range due to timing.",
    "id": 935,
    "annotator": 1,
    "annotation_id": 936,
    "created_at": "2024-11-06T01:25:33.680269Z",
    "updated_at": "2024-11-06T01:25:33.680269Z",
    "lead_time": 5.615
  },
  {
    "text": "Disciplinary action includes a documented warning, termination, or resignation.",
    "id": 936,
    "annotator": 1,
    "annotation_id": 937,
    "created_at": "2024-11-06T01:25:34.959747Z",
    "updated_at": "2024-11-06T01:25:34.959747Z",
    "lead_time": 1.085
  },
  {
    "text": "Employees who were The number of distinct employees where the This data comprises all regular employees and excludes contractors and dismissed or agreed to outcome of a disciplinary concern resulted in contingent workers.",
    "id": 937,
    "annotator": 1,
    "annotation_id": 938,
    "created_at": "2024-11-06T01:25:39.783869Z",
    "updated_at": "2024-11-06T01:25:39.783869Z",
    "lead_time": 4.629
  },
  {
    "text": "leave the company termination of employment or voluntary The data represents cases closed during the reporting period.",
    "id": 938,
    "annotator": 1,
    "annotation_id": 939,
    "created_at": "2024-11-06T01:25:41.190607Z",
    "updated_at": "2024-11-06T01:25:41.190607Z",
    "lead_time": 1.216
  },
  {
    "text": "In 2022, we also voluntarily resignation of the employee.",
    "id": 939,
    "annotator": 1,
    "annotation_id": 940,
    "created_at": "2024-11-06T01:25:42.798043Z",
    "updated_at": "2024-11-06T01:25:42.798043Z",
    "lead_time": 1.415
  },
  {
    "text": "included three open cases where disciplinary decisions were made and action taken at year end; however, the cases had not yet been closed in the source system by the reporting criteria end date range due to timing.",
    "id": 940,
    "annotator": 1,
    "annotation_id": 941,
    "created_at": "2024-11-06T01:25:49.226045Z",
    "updated_at": "2024-11-06T01:25:49.226045Z",
    "lead_time": 6.01
  },
  {
    "text": "Includes termination of employment or resignation.",
    "id": 941,
    "annotator": 1,
    "annotation_id": 942,
    "created_at": "2024-11-06T01:25:53.049124Z",
    "updated_at": "2024-11-06T01:25:53.049124Z",
    "lead_time": 3.643
  },
  {
    "text": "Documented The number of distinct employees where the This data comprises all regular employees and excludes contractors and warnings outcome of a disciplinary concern resulted in a contingent workers.",
    "id": 942,
    "annotator": 1,
    "annotation_id": 943,
    "created_at": "2024-11-06T01:25:58.191583Z",
    "updated_at": "2024-11-06T01:25:58.191583Z",
    "lead_time": 4.937
  },
  {
    "text": "documented warning.",
    "id": 943,
    "annotator": 1,
    "annotation_id": 944,
    "created_at": "2024-11-06T01:25:58.987559Z",
    "updated_at": "2024-11-06T01:25:58.987559Z",
    "lead_time": 0.619
  },
  {
    "text": "The data represents cases closed during the reporting period.",
    "id": 944,
    "annotator": 1,
    "annotation_id": 945,
    "created_at": "2024-11-06T01:26:01.290802Z",
    "updated_at": "2024-11-06T01:26:01.290802Z",
    "lead_time": 2.109
  },
  {
    "text": "In 2022, we also included three open cases where disciplinary decisions were made and action taken at year end; however, the cases had not yet been closed in the source system by the reporting criteria end date range due to timing.",
    "id": 945,
    "annotator": 1,
    "annotation_id": 946,
    "created_at": "2024-11-06T01:38:55.286311Z",
    "updated_at": "2024-11-06T01:38:55.286311Z",
    "lead_time": 773.487
  },
  {
    "text": "Disciplinary action includes a documented warning (Level 1, 2, 3 sanction or final warning).",
    "id": 946,
    "annotator": 1,
    "annotation_id": 947,
    "created_at": "2024-11-06T01:39:00.305823Z",
    "updated_at": "2024-11-06T01:39:00.305823Z",
    "lead_time": 4.818
  },
  {
    "text": "Open cases awaiting The number of distinct employees involved in This data comprises all regular employees and excludes contractors and investigation or a an investigation or a disciplinary decision that contingent workers disciplinary decision is still open and pending an outcome at the This data represents employees that are involved in a disciplinary case that at year end end of the reporting period.",
    "id": 947,
    "annotator": 1,
    "annotation_id": 948,
    "created_at": "2024-11-06T01:39:04.841252Z",
    "updated_at": "2024-11-06T01:39:04.841252Z",
    "lead_time": 4.343
  },
  {
    "text": "remain open at the end of the reporting period.",
    "id": 948,
    "annotator": 1,
    "annotation_id": 949,
    "created_at": "2024-11-06T01:39:05.607690Z",
    "updated_at": "2024-11-06T01:39:05.607690Z",
    "lead_time": 0.565
  },
  {
    "text": "In 2022, we also included three open cases where disciplinary decisions were made and action taken at year end; however, the cases had not yet been closed in the source system by the reporting criteria end date range due to timing.",
    "id": 949,
    "annotator": 1,
    "annotation_id": 950,
    "created_at": "2024-11-06T01:39:07.350416Z",
    "updated_at": "2024-11-06T01:39:07.350416Z",
    "lead_time": 1.534
  },
  {
    "text": "The outcome of investigations that are still open or awaiting disciplinary action at year end are captured during the subsequent reporting period, and correlating, this metric will be updated accordingly for the prior year.",
    "id": 950,
    "annotator": 1,
    "annotation_id": 951,
    "created_at": "2024-11-06T01:39:12.787668Z",
    "updated_at": "2024-11-06T01:39:12.787668Z",
    "lead_time": 5.233
  },
  {
    "text": "50 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Ethical standards Compliance   The breakdown of the types of policy violations This data comprises all regular employees and excludes contractors and Breakdown of types of that employees have been disciplined for contingent workers.",
    "id": 951,
    "annotator": 1,
    "annotation_id": 952,
    "created_at": "2024-11-06T01:39:17.723041Z",
    "updated_at": "2024-11-06T01:39:17.723041Z",
    "lead_time": 4.724
  },
  {
    "text": "policy violation (%) during the year.",
    "id": 952,
    "annotator": 1,
    "annotation_id": 953,
    "created_at": "2024-11-06T01:39:18.464944Z",
    "updated_at": "2024-11-06T01:39:18.464944Z",
    "lead_time": 0.543
  },
  {
    "text": "Individual employees can be subject to multiple allegations resulting in Policy violations categories are defined as: disciplinary action.",
    "id": 953,
    "annotator": 1,
    "annotation_id": 954,
    "created_at": "2024-11-06T01:39:24.752994Z",
    "updated_at": "2024-11-06T01:39:24.752994Z",
    "lead_time": 6.095
  },
  {
    "text": "Where this is the case, an individual is counted once   Anti-Bribery and Corruption   Anti-Bribery and against each unique category.",
    "id": 954,
    "annotator": 1,
    "annotation_id": 955,
    "created_at": "2024-11-06T01:39:29.585865Z",
    "updated_at": "2024-11-06T01:39:29.585865Z",
    "lead_time": 4.647
  },
  {
    "text": "Corruption Employee discipline results from policy violation, and includes Level 1   Cyber Security   Cyber Security (CSIR) Sanction, Level 2 Sanction, Level 3 Sanction, Final Warning, Termination, or   Continuity of Supply Chain   Supply Chain Resignation and is categorised as appropriate.",
    "id": 955,
    "annotator": 1,
    "annotation_id": 956,
    "created_at": "2024-11-06T01:39:33.972106Z",
    "updated_at": "2024-11-06T01:39:33.972106Z",
    "lead_time": 4.205
  },
  {
    "text": "Outcomes for employees Continuity including mediation, demotion and settlement are not included in counts   EHS and Sustainability   Environment Health and or percentages within categories.",
    "id": 956,
    "annotator": 1,
    "annotation_id": 957,
    "created_at": "2024-11-06T01:39:37.906939Z",
    "updated_at": "2024-11-06T01:39:37.907936Z",
    "lead_time": 3.757
  },
  {
    "text": "These outcome types are not considered Safety and Sustainability disciplinary action and they represent situations in which employees and   Employee Conduct   Conflict of Interest; the company work together towards a solution.",
    "id": 957,
    "annotator": 1,
    "annotation_id": 958,
    "created_at": "2024-11-06T01:39:39.551599Z",
    "updated_at": "2024-11-06T01:39:39.551599Z",
    "lead_time": 1.457
  },
  {
    "text": "Discrimination; Expenses; Harassment; All markets, except Germany, utilise a case management system to Inappropriate behaviour, Mandatory training manage cases and data retention.",
    "id": 958,
    "annotator": 1,
    "annotation_id": 959,
    "created_at": "2024-11-06T01:39:45.090593Z",
    "updated_at": "2024-11-06T01:39:45.090593Z",
    "lead_time": 5.36
  },
  {
    "text": "The German market maintains its own   Employee Relations & HR Policies   case list which is submitted to the global employee relations team at year Appeal; Attendance at Work; Capability (Health); end for consolidation and analysis.",
    "id": 959,
    "annotator": 1,
    "annotation_id": 960,
    "created_at": "2024-11-06T01:39:52.437017Z",
    "updated_at": "2024-11-06T01:39:52.437017Z",
    "lead_time": 7.167
  },
  {
    "text": "Capability (Performance); External Litigation; GSK Performance System; Recruitment and Selection; Case owners regularly utilise published data quality reports to assist in Restructuring Programmes; Settlement\/Mutual data accuracy regularly.",
    "id": 960,
    "annotator": 1,
    "annotation_id": 961,
    "created_at": "2024-11-06T01:40:08.716089Z",
    "updated_at": "2024-11-06T01:40:08.716089Z",
    "lead_time": 16.104
  },
  {
    "text": "Quarterly internal audits are conducted to Agreement; Working arrangements address any outstanding data discrepancies.",
    "id": 961,
    "annotator": 1,
    "annotation_id": 962,
    "created_at": "2024-11-06T01:40:14.714709Z",
    "updated_at": "2024-11-06T01:40:14.714709Z",
    "lead_time": 5.794
  },
  {
    "text": "Government Trade Restrictions   Sanctions and Export Controls   Product Quality   Good Manufacturing Practice; Manufacturing Site Resilience; Supply Chain Quality Assurance   Research and Development and Medical Practices   Care and Welfare and Treatment of Animals; Data Integrity (nonGxP); Good Laboratory Practices\/Good Clinical Practice; Human Biological Sample Management (HBSM); Non-Promotional Engagement; Non-Promotional Engagement; Patient Safety; Public Disclosure; Regulatory Filings   Safeguard People and Information and Assets   Communications; Corporate or Financial information, reporting and disclosure; Crisis and Continuity Management; Fraud; Intellectual Property; Privacy   Loss of data; Privacy   Unauthorized Access; Privacy   Unsecured data disclosure; Protection of Physical Assets and Security; Security   People; Security   Places\/ Sites; Security - Products\/Supply Chain   Sales and Marketing   Antitrust; Commercial Practices Funding; Contract Sales Organisation; External Experts; HCP\/HCI Transfer of Value; Inappropriate Managerial Direction; Interactions with PAGs\/Consumer\/Payer groups; Product Promotion; Samples; Speaker Programme   Tax and Treasury   Tax; Treasury   Other   Any other policy violation types that do not fit into the above categories specified.",
    "id": 962,
    "annotator": 1,
    "annotation_id": 963,
    "created_at": "2024-11-06T01:40:22.310016Z",
    "updated_at": "2024-11-06T01:40:22.310016Z",
    "lead_time": 7.414
  },
  {
    "text": "% of employees and The percentage of active employees and All active employees (Full-time\/Part-time, Regular\/Temporary) and complementary complementary workers who have been complementary workers (ie, Agency workers, Statement of Work workers, workers that complete assigned the mandatory training curriculum Outsourced workers, etc.",
    "id": 963,
    "annotator": 1,
    "annotation_id": 964,
    "created_at": "2024-11-06T01:40:28.354332Z",
    "updated_at": "2024-11-06T01:40:28.354332Z",
    "lead_time": 5.837
  },
  {
    "text": ") are required to complete our global mandatory GSK s mandatory and completed all training modules.",
    "id": 964,
    "annotator": 1,
    "annotation_id": 965,
    "created_at": "2024-11-06T01:40:29.654964Z",
    "updated_at": "2024-11-06T01:40:29.654964Z",
    "lead_time": 1.123
  },
  {
    "text": "learning curriculum called Living our Code which comprises two modules: training The Code, Living our Code.",
    "id": 965,
    "label": [
      {
        "start": 0,
        "end": 42,
        "text": "learning curriculum called Living our Code",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 0,
        "end": 42,
        "text": "learning curriculum called Living our Code",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 966,
    "created_at": "2024-11-06T01:40:35.206645Z",
    "updated_at": "2024-11-06T01:41:29.805963Z",
    "lead_time": 26.971
  },
  {
    "text": "Additionally, those in high-risk roles or geographic regions complete an additional module: Effectively managing high ABAC risk.",
    "id": 966,
    "label": [
      {
        "start": 92,
        "end": 128,
        "text": "Effectively managing high ABAC risk.",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 92,
        "end": 128,
        "text": "Effectively managing high ABAC risk.",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 967,
    "created_at": "2024-11-06T01:42:05.731052Z",
    "updated_at": "2024-11-06T01:42:05.731052Z",
    "lead_time": 59.266
  },
  {
    "text": "The percentage is calculated by using training data as of 31 December 2023 (ie, training due on or before 31 December 2023).",
    "id": 967,
    "annotator": 1,
    "annotation_id": 968,
    "created_at": "2024-11-06T01:42:16.264983Z",
    "updated_at": "2024-11-06T01:42:16.264983Z",
    "lead_time": 7.313
  },
  {
    "text": "This is calculated as the total number of active employees and complementary workers who have been assigned the Living our Code mandatory training and have completed all modules divided by the total population of active employees and complementary workers who have been assigned the Living our Code mandatory training.",
    "id": 968,
    "annotator": 1,
    "annotation_id": 969,
    "created_at": "2024-11-06T01:42:21.256060Z",
    "updated_at": "2024-11-06T01:42:21.256060Z",
    "lead_time": 4.795
  },
  {
    "text": "51 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Ethical standards % of employees who The percentage of employees that strongly The question is included in the Annual Engagement and Culture Survey believe they \"can and agreed or agreed with the question  I can and which is sent annually.",
    "id": 969,
    "annotator": 1,
    "annotation_id": 970,
    "created_at": "2024-11-06T01:42:28.327925Z",
    "updated_at": "2024-11-06T01:42:28.327925Z",
    "lead_time": 6.891
  },
  {
    "text": "do Speak Up if things do speak up if things don t feel right  in the GSK The survey is issued to all regular full-time and fixed term contract don't feel right\" Annual Engagement and Culture Survey.",
    "id": 970,
    "annotator": 1,
    "annotation_id": 971,
    "created_at": "2024-11-06T01:42:33.338017Z",
    "updated_at": "2024-11-06T01:42:33.338017Z",
    "lead_time": 4.832
  },
  {
    "text": "employees in all countries in which GSK operates (excluding Russia due to the sanctions).",
    "id": 971,
    "annotator": 1,
    "annotation_id": 972,
    "created_at": "2024-11-06T01:42:36.688730Z",
    "updated_at": "2024-11-06T01:42:36.688730Z",
    "lead_time": 3.163
  },
  {
    "text": "Questions are translated by professional service partners into 23 languages (excluding English).",
    "id": 972,
    "annotator": 1,
    "annotation_id": 973,
    "created_at": "2024-11-06T01:42:43.777717Z",
    "updated_at": "2024-11-06T01:42:43.777717Z",
    "lead_time": 6.896
  },
  {
    "text": "In 2023, the  Annual Engagement and Culture Survey  replaced the quarterly Pulse surveys, therefore the percentage of employees for this metric is the result of a single annual data point instead of an average score across quarterly surveys.",
    "id": 973,
    "annotator": 1,
    "annotation_id": 974,
    "created_at": "2024-11-06T01:42:49.072349Z",
    "updated_at": "2024-11-06T01:42:49.072349Z",
    "lead_time": 5.115
  },
  {
    "text": "80% of direct high-risk Direct high-risk suppliers are identified on a Through our EcoVadis Programme, we work with direct high-risk suppliers suppliers achieve yearly basis through a combination of spend, to help them improve their operations and support their sustainability GSK s minimum category and high-risk countries.",
    "id": 974,
    "label": [
      {
        "start": 83,
        "end": 101,
        "text": "EcoVadis Programme",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 83,
        "end": 101,
        "text": "EcoVadis Programme",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 975,
    "created_at": "2024-11-06T01:43:18.798135Z",
    "updated_at": "2024-11-06T01:43:18.798135Z",
    "lead_time": 29.547
  },
  {
    "text": "Direct journey.",
    "id": 975,
    "annotator": 1,
    "annotation_id": 976,
    "created_at": "2024-11-06T01:43:20.332744Z",
    "updated_at": "2024-11-06T01:43:20.332744Z",
    "lead_time": 1.309
  },
  {
    "text": "EcoVadis score or procurement involves the purchasing of EcoVadis is an external ratings provider and assesses organisations across have an improvement materials directly associated with the four themes: Environment & Community, Labour & Human Rights, Ethics plan in place production of goods.",
    "id": 976,
    "annotator": 1,
    "annotation_id": 977,
    "created_at": "2024-11-06T01:43:31.463807Z",
    "updated_at": "2024-11-06T01:43:31.463807Z",
    "lead_time": 10.928
  },
  {
    "text": "and Sustainable Procurement.",
    "id": 977,
    "annotator": 1,
    "annotation_id": 978,
    "created_at": "2024-11-06T01:43:36.827952Z",
    "updated_at": "2024-11-06T01:43:36.827952Z",
    "lead_time": 5.143
  },
  {
    "text": "Out of the total number of 4,414 direct A supplier may not have an improvement plan in place because the suppliers, 122 are high-risk and managed assessment is in progress, the supplier has committed to participate in the through GSK s EcoVadis Programme.",
    "id": 978,
    "annotator": 1,
    "annotation_id": 979,
    "created_at": "2024-11-06T01:43:46.307330Z",
    "updated_at": "2024-11-06T01:43:46.307330Z",
    "lead_time": 9.256
  },
  {
    "text": "programme but hasn t commenced yet or the supplier hasn t accepted the An improvement plan in place is defined as an improvement plan.",
    "id": 979,
    "annotator": 1,
    "annotation_id": 980,
    "created_at": "2024-11-06T01:43:50.308620Z",
    "updated_at": "2024-11-06T01:43:50.308620Z",
    "lead_time": 3.774
  },
  {
    "text": "Where the improvement plan has been implemented ongoing improvement plan.",
    "id": 980,
    "annotator": 1,
    "annotation_id": 981,
    "created_at": "2024-11-06T01:43:53.792862Z",
    "updated_at": "2024-11-06T01:43:53.792862Z",
    "lead_time": 3.262
  },
  {
    "text": "and the supplier awaits reassessment to reflect improved score, this is reported as the supplier not having an improvement plan in place.",
    "id": 981,
    "annotator": 1,
    "annotation_id": 982,
    "created_at": "2024-11-06T01:43:58.043912Z",
    "updated_at": "2024-11-06T01:43:58.043912Z",
    "lead_time": 4.045
  },
  {
    "text": "GSK requires suppliers to have a minimum An improvement plan is initiated by the supplier or any of its partners, EcoVadis score of 45.",
    "id": 982,
    "annotator": 1,
    "annotation_id": 983,
    "created_at": "2024-11-06T01:44:03.388051Z",
    "updated_at": "2024-11-06T01:44:03.388051Z",
    "lead_time": 5.13
  },
  {
    "text": "including GSK, and tracked on the EcoVadis platform.",
    "id": 983,
    "annotator": 1,
    "annotation_id": 984,
    "created_at": "2024-11-06T06:50:00.203622Z",
    "updated_at": "2024-11-06T06:50:00.203622Z",
    "lead_time": 7.172
  },
  {
    "text": "Where required, GSK interacts directly with the supplier to ensure corrective actions are implemented.",
    "id": 984,
    "annotator": 1,
    "annotation_id": 985,
    "created_at": "2024-11-06T06:50:05.311550Z",
    "updated_at": "2024-11-06T06:50:05.311550Z",
    "lead_time": 4.832
  },
  {
    "text": "EcoVadis scorecard data is exported from the EcoVadis platform.",
    "id": 985,
    "annotator": 1,
    "annotation_id": 986,
    "created_at": "2024-11-06T06:50:11.077970Z",
    "updated_at": "2024-11-06T06:50:11.077970Z",
    "lead_time": 5.557
  },
  {
    "text": "Direct high-risk suppliers are identified on a yearly basis through a combination of spend, category and high-risk countries.",
    "id": 986,
    "annotator": 1,
    "annotation_id": 987,
    "created_at": "2024-11-06T06:50:19.496163Z",
    "updated_at": "2024-11-06T06:50:19.496163Z",
    "lead_time": 8.218
  },
  {
    "text": "Direct procurement involves the urchasing of material directly associated with the production of goods.",
    "id": 987,
    "annotator": 1,
    "annotation_id": 988,
    "created_at": "2024-11-06T06:50:23.447370Z",
    "updated_at": "2024-11-06T06:50:23.447370Z",
    "lead_time": 3.733
  },
  {
    "text": "Suppliers reaching the minimum score for a given year are considered to have met the minimum for the entire three-year grace period even if the desired minimum score increases in that period.",
    "id": 988,
    "annotator": 1,
    "annotation_id": 989,
    "created_at": "2024-11-06T06:50:28.413828Z",
    "updated_at": "2024-11-06T06:50:28.415002Z",
    "lead_time": 4.728
  },
  {
    "text": "Product governance Total regulatory The number of regulatory inspections of GSK The data represents Good Manufacturing Practice (GMP)\/Good inspections from all entities from all health authorities.",
    "id": 989,
    "label": [
      {
        "start": 105,
        "end": 150,
        "text": "Manufacturing Practice (GMP)\/Good inspections",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 105,
        "end": 150,
        "text": "Manufacturing Practice (GMP)\/Good inspections",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 990,
    "created_at": "2024-11-06T06:50:33.124709Z",
    "updated_at": "2024-11-06T06:51:05.395803Z",
    "lead_time": 19.039
  },
  {
    "text": "Distribution Practice (GDP) inspections where results have been confirmed.",
    "id": 990,
    "label": [
      {
        "start": 0,
        "end": 39,
        "text": "Distribution Practice (GDP) inspections",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 0,
        "end": 39,
        "text": "Distribution Practice (GDP) inspections",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 991,
    "created_at": "2024-11-06T06:50:49.110369Z",
    "updated_at": "2024-11-06T06:50:49.110369Z",
    "lead_time": 15.753
  },
  {
    "text": "health authorities % of inspections from The percentage of the number of regulatory Percentage across GMP\/ GDP for the where results have been confirmed.",
    "id": 991,
    "annotator": 1,
    "annotation_id": 992,
    "created_at": "2024-11-06T06:51:24.134844Z",
    "updated_at": "2024-11-06T06:51:24.134844Z",
    "lead_time": 17.346
  },
  {
    "text": "all regulators with no inspections of GSK entities with no critical The percentage is calculate by the total number of inspections from all critical findings or findings or official action.",
    "id": 992,
    "annotator": 1,
    "annotation_id": 993,
    "created_at": "2024-11-06T06:51:43.829097Z",
    "updated_at": "2024-11-06T06:51:43.829097Z",
    "lead_time": 19.499
  },
  {
    "text": "regulators with no critical findings or official action indicated divided by the official action total number of inspections from all regulators multiplied by 100.",
    "id": 993,
    "annotator": 1,
    "annotation_id": 994,
    "created_at": "2024-11-06T06:51:50.327533Z",
    "updated_at": "2024-11-06T06:51:50.327533Z",
    "lead_time": 6.294
  },
  {
    "text": "indicated Total regulatory The number of regulatory inspections by the The number of regulatory inspections across GMP\/GDP based on FDA, inspections from FDA\/ following regulators of GSK entities: United MHRA and European regulators* that are inspecting on behalf of EMA MHRA\/EMA States (US) Federal Drugs Agency (FDA); where results have been confirmed.",
    "id": 994,
    "annotator": 1,
    "annotation_id": 995,
    "created_at": "2024-11-06T06:51:56.268663Z",
    "updated_at": "2024-11-06T06:51:56.268663Z",
    "lead_time": 5.724
  },
  {
    "text": "regulators United Kingdom (UK) Medicines Healthcare *National Competent Authorities Regulatory Agency (MHRA); and European Medicines Agency (EMA) National Competent Authority in the EEA.",
    "id": 995,
    "annotator": 1,
    "annotation_id": 996,
    "created_at": "2024-11-06T06:52:00.371071Z",
    "updated_at": "2024-11-06T06:52:00.371071Z",
    "lead_time": 3.933
  },
  {
    "text": "Number of critical\/ The number of critical and major 483 findings The number of critical and major 483 findings across GMP\/GDP on major 483 findings per from regulatory inspections of GSK entities by business and products based on FDA, MHRA and European regulators that inspection by FDA\/ US FDA, UK MHRA and EMA regulators are inspecting on behalf of EMA where results have been confirmed.",
    "id": 996,
    "annotator": 1,
    "annotation_id": 997,
    "created_at": "2024-11-06T06:52:13.380490Z",
    "updated_at": "2024-11-06T06:52:13.380490Z",
    "lead_time": 12.802
  },
  {
    "text": "MHRA\/EMA regulators Total FDA regulatory The total number of regulatory inspections of The number of regulatory inspections across GMP\/ GDP on the business inspections GSK entities by US FDA.",
    "id": 997,
    "annotator": 1,
    "annotation_id": 998,
    "created_at": "2024-11-06T06:52:19.846559Z",
    "updated_at": "2024-11-06T06:52:19.846559Z",
    "lead_time": 6.265
  },
  {
    "text": "and products based on US FDA regulatory inspections where results have been confirmed.",
    "id": 998,
    "annotator": 1,
    "annotation_id": 999,
    "created_at": "2024-11-06T06:52:36.372677Z",
    "updated_at": "2024-11-06T06:52:36.372677Z",
    "lead_time": 16.32
  },
  {
    "text": "Number of FDA The number of 483 observations issued by the The number of 483 observations across GMP\/GDP on the business and observations US FDA to GSK entities.",
    "id": 999,
    "annotator": 1,
    "annotation_id": 1000,
    "created_at": "2024-11-06T06:52:44.430967Z",
    "updated_at": "2024-11-06T06:52:44.430967Z",
    "lead_time": 7.86
  },
  {
    "text": "products based on US FDA regulatory inspections where results have been confirmed.",
    "id": 1000,
    "annotator": 1,
    "annotation_id": 1001,
    "created_at": "2024-11-06T06:52:48.537258Z",
    "updated_at": "2024-11-06T06:52:48.537258Z",
    "lead_time": 3.894
  },
  {
    "text": "Number of FDA The number of warning letters issued by the The number of enforceable GMP\/GDP warning letters.",
    "id": 1001,
    "annotator": 1,
    "annotation_id": 1002,
    "created_at": "2024-11-06T06:52:53.348426Z",
    "updated_at": "2024-11-06T06:52:53.348426Z",
    "lead_time": 4.628
  },
  {
    "text": "warning letters US FDA to GSK entities, which led to enforced regulatory actions being required.",
    "id": 1002,
    "annotator": 1,
    "annotation_id": 1003,
    "created_at": "2024-11-06T06:52:59.388135Z",
    "updated_at": "2024-11-06T06:52:59.388135Z",
    "lead_time": 5.713
  },
  {
    "text": "52 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method Product governance Total number of The number of external Class I\/II\/III recalls of The number of external Class I\/II\/III recalls across GMP\/ GDP.",
    "id": 1003,
    "annotator": 1,
    "annotation_id": 1004,
    "created_at": "2024-11-06T06:53:30.365816Z",
    "updated_at": "2024-11-06T06:53:30.365816Z",
    "lead_time": 30.787
  },
  {
    "text": "Class I\/II\/III external product broken down by recall type: product recalls   Class I recall: Reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.",
    "id": 1004,
    "annotator": 1,
    "annotation_id": 1005,
    "created_at": "2024-11-06T06:53:35.088615Z",
    "updated_at": "2024-11-06T06:53:35.088615Z",
    "lead_time": 4.534
  },
  {
    "text": "Class II recall: Use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.",
    "id": 1005,
    "annotator": 1,
    "annotation_id": 1006,
    "created_at": "2024-11-06T06:53:50.449743Z",
    "updated_at": "2024-11-06T06:53:50.449743Z",
    "lead_time": 15.185
  },
  {
    "text": "Class III recall: Use of or exposure to a violative product is not likely to cause adverse health consequences.",
    "id": 1006,
    "annotator": 1,
    "annotation_id": 1007,
    "created_at": "2024-11-06T06:53:59.329498Z",
    "updated_at": "2024-11-06T06:53:59.329498Z",
    "lead_time": 8.684
  },
  {
    "text": "FDA product recalls by The number of US FDA recalls of product from Business units track recall data in an electronic system.",
    "id": 1007,
    "annotator": 1,
    "annotation_id": 1008,
    "created_at": "2024-11-06T06:54:04.641964Z",
    "updated_at": "2024-11-06T06:54:04.641964Z",
    "lead_time": 5.118
  },
  {
    "text": "business and class the US market.",
    "id": 1008,
    "annotator": 1,
    "annotation_id": 1009,
    "created_at": "2024-11-06T06:54:06.647708Z",
    "updated_at": "2024-11-06T06:54:06.647708Z",
    "lead_time": 1.809
  },
  {
    "text": "We categorise the data according to which of our businesses it relates to (pharmaceutical or vaccine) and according to recall type.",
    "id": 1009,
    "annotator": 1,
    "annotation_id": 1010,
    "created_at": "2024-11-06T06:54:25.651723Z",
    "updated_at": "2024-11-06T06:54:25.651723Z",
    "lead_time": 18.816
  },
  {
    "text": "Publicly available trial The number of trial protocol summaries Studies for which protocol summaries were registered on the GSK trial protocol summaries registered and results summaries disclosed on register (www.",
    "id": 1010,
    "annotator": 1,
    "annotation_id": 1011,
    "created_at": "2024-11-06T06:54:31.091310Z",
    "updated_at": "2024-11-06T06:54:31.091310Z",
    "lead_time": 5.244
  },
  {
    "text": "gsk-studyregister.com) or on ViiV register (www.",
    "id": 1011,
    "annotator": 1,
    "annotation_id": 1012,
    "created_at": "2024-11-06T06:54:35.741479Z",
    "updated_at": "2024-11-06T06:54:35.741479Z",
    "lead_time": 4.482
  },
  {
    "text": "viiv- (register) and result the external facing GSK trial register or ViiV studyregister.com).",
    "id": 1012,
    "annotator": 1,
    "annotation_id": 1013,
    "created_at": "2024-11-06T06:54:39.890677Z",
    "updated_at": "2024-11-06T06:54:39.890677Z",
    "lead_time": 3.957
  },
  {
    "text": "The numbers represent the studies which were initiated summaries (disclose) register as part of GSK s internal policy in the current year for which protocol summaries were registered.",
    "id": 1013,
    "annotator": 1,
    "annotation_id": 1014,
    "created_at": "2024-11-06T06:54:45.722489Z",
    "updated_at": "2024-11-06T06:54:45.722489Z",
    "lead_time": 5.666
  },
  {
    "text": "commitment to disclosure of human subject For cumulative values: The numbers represent the studies for which research.",
    "id": 1014,
    "annotator": 1,
    "annotation_id": 1015,
    "created_at": "2024-11-06T06:54:51.508235Z",
    "updated_at": "2024-11-06T06:54:51.508235Z",
    "lead_time": 5.587
  },
  {
    "text": "This is in addition to the mandatory protocol summaries were registered on the GSK register between 2004 and requirements by regulators for disclosure of 2023; and those registered on ViiV study register between 2009 and 2023.",
    "id": 1015,
    "annotator": 1,
    "annotation_id": 1016,
    "created_at": "2024-11-06T06:55:09.189185Z",
    "updated_at": "2024-11-06T06:55:09.189185Z",
    "lead_time": 17.508
  },
  {
    "text": "protocol registrations.",
    "id": 1016,
    "annotator": 1,
    "annotation_id": 1017,
    "created_at": "2024-11-06T06:55:09.989751Z",
    "updated_at": "2024-11-06T06:55:09.989751Z",
    "lead_time": 0.605
  },
  {
    "text": "These numbers are generated through the Transparency report which derives the data from the disclosure system used by the business.",
    "id": 1017,
    "annotator": 1,
    "annotation_id": 1018,
    "created_at": "2024-11-06T06:55:15.192982Z",
    "updated_at": "2024-11-06T06:55:15.192982Z",
    "lead_time": 5.024
  },
  {
    "text": "People disclosures Overall turnover (%) Overall turnover is a measure of GSK We calculate the number of leavers during the year as a percentage of the employees leaving GSK and does not include average reporting year s permanent headcount.",
    "id": 1018,
    "annotator": 1,
    "annotation_id": 1019,
    "created_at": "2024-11-06T06:55:22.738034Z",
    "updated_at": "2024-11-06T06:55:22.738034Z",
    "lead_time": 7.359
  },
  {
    "text": "internal moves within GSK.",
    "id": 1019,
    "annotator": 1,
    "annotation_id": 1020,
    "created_at": "2024-11-06T06:55:24.322063Z",
    "updated_at": "2024-11-06T06:55:24.322063Z",
    "lead_time": 1.389
  },
  {
    "text": "The employee turnover rate includes employees who left the company both voluntarily and involuntarily during the year.",
    "id": 1020,
    "annotator": 1,
    "annotation_id": 1021,
    "created_at": "2024-11-06T06:55:28.645475Z",
    "updated_at": "2024-11-06T06:55:28.645475Z",
    "lead_time": 4.143
  },
  {
    "text": "The data is updated daily and extracted from our GSK-wide HR platform.",
    "id": 1021,
    "annotator": 1,
    "annotation_id": 1022,
    "created_at": "2024-11-06T06:55:36.301836Z",
    "updated_at": "2024-11-06T06:55:36.301836Z",
    "lead_time": 7.466
  },
  {
    "text": "The data is based on the effective date of termination and not the termination date.",
    "id": 1022,
    "annotator": 1,
    "annotation_id": 1023,
    "created_at": "2024-11-06T06:55:41.173255Z",
    "updated_at": "2024-11-06T06:55:41.173255Z",
    "lead_time": 4.693
  },
  {
    "text": "The termination date is the last day of work and the effective date of termination is the first day of termination, ie the following day.",
    "id": 1023,
    "annotator": 1,
    "annotation_id": 1024,
    "created_at": "2024-11-06T06:55:46.900337Z",
    "updated_at": "2024-11-06T06:55:46.900337Z",
    "lead_time": 5.549
  },
  {
    "text": "Therefore, employees with termination dates of 31 December of reporting year are not included in this dataset.",
    "id": 1024,
    "annotator": 1,
    "annotation_id": 1025,
    "created_at": "2024-11-06T06:55:52.551393Z",
    "updated_at": "2024-11-06T06:55:52.551393Z",
    "lead_time": 5.477
  },
  {
    "text": "Reportable  injury or A GSK reportable injury or illness meets the Assessed and reviewed by EHS site team during approval\/closure of record illness following criteria: in EHS One system.",
    "id": 1025,
    "annotator": 1,
    "annotation_id": 1026,
    "created_at": "2024-11-06T06:55:57.824498Z",
    "updated_at": "2024-11-06T06:55:57.824498Z",
    "lead_time": 5.102
  },
  {
    "text": "as part of the reporting process.",
    "id": 1026,
    "annotator": 1,
    "annotation_id": 1027,
    "created_at": "2024-11-06T06:55:58.939168Z",
    "updated_at": "2024-11-06T06:55:58.939168Z",
    "lead_time": 0.926
  },
  {
    "text": "1.",
    "id": 1027,
    "annotator": 1,
    "annotation_id": 1028,
    "created_at": "2024-11-06T06:55:59.560867Z",
    "updated_at": "2024-11-06T06:55:59.560867Z",
    "lead_time": 0.446
  },
  {
    "text": "M ust be an employee or GSK-supervised worker 2.",
    "id": 1028,
    "annotator": 1,
    "annotation_id": 1029,
    "created_at": "2024-11-06T06:56:01.720336Z",
    "updated_at": "2024-11-06T06:56:01.720336Z",
    "lead_time": 1.987
  },
  {
    "text": "Must be GSK work-related 3.",
    "id": 1029,
    "annotator": 1,
    "annotation_id": 1030,
    "created_at": "2024-11-06T06:56:02.452226Z",
    "updated_at": "2024-11-06T06:56:02.452226Z",
    "lead_time": 0.537
  },
  {
    "text": "M ust meet one or more of the general criteria: a. Medical treatment beyond first aid b. Restricted days\/job transfer\/days away from work c. Loss of consciousness d. A significant occupational injury or occupational illness diagnosed by a physician or other licensed healthcare professional e. Fatality 4.",
    "id": 1030,
    "annotator": 1,
    "annotation_id": 1031,
    "created_at": "2024-11-06T06:56:09.216602Z",
    "updated_at": "2024-11-06T06:56:09.216602Z",
    "lead_time": 6.569
  },
  {
    "text": "M ust be a  new case  53 GSK ESG Performance Report 2023 March 2024 Our approach Access Global health Environment DEI Ethical standards Product governance Appendix Appendix continued KPI Definition Method People disclosures Fatalities Work-related fatalities of employees and As per GSK standard, all work-related incidents are required to be reported complementary workers under GSK direct into GSK s EHS One system.",
    "id": 1031,
    "annotator": 1,
    "annotation_id": 1032,
    "created_at": "2024-11-06T06:56:21.958547Z",
    "updated_at": "2024-11-06T06:56:21.958547Z",
    "lead_time": 12.548
  },
  {
    "text": "supervision.",
    "id": 1032,
    "annotator": 1,
    "annotation_id": 1033,
    "created_at": "2024-11-06T06:56:23.405437Z",
    "updated_at": "2024-11-06T06:56:23.405437Z",
    "lead_time": 1.249
  },
  {
    "text": "Fatalities - contractors Fatalities of contractors not under GSK direct As per GSK standard, all work-related incidents are required to be reported supervision but related to work at GSK.",
    "id": 1033,
    "annotator": 1,
    "annotation_id": 1034,
    "created_at": "2024-11-06T06:56:58.868256Z",
    "updated_at": "2024-11-06T06:56:58.868256Z",
    "lead_time": 35.251
  },
  {
    "text": "into GSK s EHS One system.",
    "id": 1034,
    "annotator": 1,
    "annotation_id": 1035,
    "created_at": "2024-11-06T06:57:01.090462Z",
    "updated_at": "2024-11-06T06:57:01.090462Z",
    "lead_time": 1.998
  },
  {
    "text": "Reportable injuries Injuries at the global GSK site level meeting the As per GSK standard, all work-related incidents are required to be reported with lost time criteria of GSK reportable and resulted in lost into GSK s EHS One system.",
    "id": 1035,
    "label": [
      {
        "start": 220,
        "end": 235,
        "text": "EHS One system.",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 220,
        "end": 235,
        "text": "EHS One system.",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1036,
    "created_at": "2024-11-06T06:57:19.160028Z",
    "updated_at": "2024-11-06T06:57:19.160028Z",
    "lead_time": 17.858
  },
  {
    "text": "time.",
    "id": 1036,
    "annotator": 1,
    "annotation_id": 1037,
    "created_at": "2024-11-06T06:57:20.468746Z",
    "updated_at": "2024-11-06T06:57:20.468746Z",
    "lead_time": 1.088
  },
  {
    "text": "Lost time includes work-related incidents that have resulted in lost days, restricted time, or a job transfer.",
    "id": 1037,
    "annotator": 1,
    "annotation_id": 1038,
    "created_at": "2024-11-06T06:57:25.866364Z",
    "updated_at": "2024-11-06T06:57:25.866364Z",
    "lead_time": 5.185
  },
  {
    "text": "Reportable illnesses Number of illnesses at the global GSK site level As per GSK standard, all work-related incidents are required to be reported with lost time meeting the criteria of GSK reportable and into GSK s EHS One system.",
    "id": 1038,
    "annotator": 1,
    "annotation_id": 1039,
    "created_at": "2024-11-06T06:57:30.508637Z",
    "updated_at": "2024-11-06T06:57:30.508637Z",
    "lead_time": 4.463
  },
  {
    "text": "resulted in lost time.",
    "id": 1039,
    "annotator": 1,
    "annotation_id": 1040,
    "created_at": "2024-11-06T06:57:35.460679Z",
    "updated_at": "2024-11-06T06:57:35.460679Z",
    "lead_time": 4.756
  },
  {
    "text": "Lost time includes work related incidents that have resulted in lost days, restricted time or a job transfer.",
    "id": 1040,
    "annotator": 1,
    "annotation_id": 1041,
    "created_at": "2024-11-06T06:58:25.875097Z",
    "updated_at": "2024-11-06T06:58:25.875097Z",
    "lead_time": 50.187
  },
  {
    "text": "Lost time reportable The number of reportable injuries with lost (# of reportable lost time injuries)   100,000 divided by Total hours worked injury rate (per days, restricted work or job transfers rated per for GSK employees\/GSK supervised workers.",
    "id": 1041,
    "annotator": 1,
    "annotation_id": 1042,
    "created_at": "2024-11-06T06:58:30.043970Z",
    "updated_at": "2024-11-06T06:58:30.043970Z",
    "lead_time": 3.95
  },
  {
    "text": "100,000 hours 100,000 hours worked.",
    "id": 1042,
    "annotator": 1,
    "annotation_id": 1043,
    "created_at": "2024-11-06T06:58:32.590408Z",
    "updated_at": "2024-11-06T06:58:32.590408Z",
    "lead_time": 2.342
  },
  {
    "text": "worked) Lost time reportable The number of reportable illnesses with lost (# of reportable lost time illnesses)   100,000 divided by Total hours worked illness rate (per days, restricted work or job transfers rated per for GSK employees\/GSK supervised workers.",
    "id": 1043,
    "annotator": 1,
    "annotation_id": 1044,
    "created_at": "2024-11-06T06:58:38.944107Z",
    "updated_at": "2024-11-06T06:58:38.944107Z",
    "lead_time": 6.164
  },
  {
    "text": "100,000 hours 100,000 hours worked.",
    "id": 1044,
    "annotator": 1,
    "annotation_id": 1045,
    "created_at": "2024-11-06T06:58:42.970239Z",
    "updated_at": "2024-11-06T06:58:42.970239Z",
    "lead_time": 3.828
  },
  {
    "text": "worked) Reportable injuries Total number of injuries that meet the criteria As per GSK standard, all work-related incidents are required to be reported with and without lost of being  reportable .",
    "id": 1045,
    "annotator": 1,
    "annotation_id": 1046,
    "created_at": "2024-11-06T06:58:48.975542Z",
    "updated_at": "2024-11-06T06:58:48.975542Z",
    "lead_time": 5.816
  },
  {
    "text": "into GSK s EHS One system.",
    "id": 1046,
    "annotator": 1,
    "annotation_id": 1047,
    "created_at": "2024-11-06T06:58:50.093749Z",
    "updated_at": "2024-11-06T06:58:50.093749Z",
    "lead_time": 0.934
  },
  {
    "text": "time Reportable illnesses Total number of illnesses that meet the criteria As per GSK standard, all work-related incidents are required to be reported with and without lost of being  reportable .",
    "id": 1047,
    "annotator": 1,
    "annotation_id": 1048,
    "created_at": "2024-11-06T06:58:54.930868Z",
    "updated_at": "2024-11-06T06:58:54.930868Z",
    "lead_time": 4.627
  },
  {
    "text": "into GSK s EHS One system.",
    "id": 1048,
    "annotator": 1,
    "annotation_id": 1049,
    "created_at": "2024-11-06T06:58:56.321315Z",
    "updated_at": "2024-11-06T06:58:56.321315Z",
    "lead_time": 1.215
  },
  {
    "text": "time Reportable injury rate The number of reportable injuries rated per (# of reportable injuries*100,000) divided by 'total hours worked for GSK (per 100,000 hours 100,000 hours worked.",
    "id": 1049,
    "annotator": 1,
    "annotation_id": 1050,
    "created_at": "2024-11-06T07:00:05.646616Z",
    "updated_at": "2024-11-06T07:00:05.646616Z",
    "lead_time": 69.12
  },
  {
    "text": "employees\/supervised workers.",
    "id": 1050,
    "annotator": 1,
    "annotation_id": 1051,
    "created_at": "2024-11-06T07:00:06.938250Z",
    "updated_at": "2024-11-06T07:00:06.938250Z",
    "lead_time": 1.08
  },
  {
    "text": "worked) Reportable illness rate The number of reportable illnesses rated per (# of reportable illnesses*100,000) divided by 'total hours worked for GSK (per 100,000 hours 100,000 hours worked.",
    "id": 1051,
    "annotator": 1,
    "annotation_id": 1052,
    "created_at": "2024-11-06T07:00:13.122443Z",
    "updated_at": "2024-11-06T07:00:13.122443Z",
    "lead_time": 5.998
  },
  {
    "text": "employees\/supervised workers.",
    "id": 1052,
    "annotator": 1,
    "annotation_id": 1053,
    "created_at": "2024-11-06T07:00:13.933753Z",
    "updated_at": "2024-11-06T07:00:13.933753Z",
    "lead_time": 0.599
  },
  {
    "text": "worked) Reportable injury and The number of reportable injuries and illnesses (# of GSK reportable illnesses+ # of GSK reportable injuries*100,000) illness rate (per rated per 100,000 hours worked.",
    "id": 1053,
    "annotator": 1,
    "annotation_id": 1054,
    "created_at": "2024-11-06T07:00:18.486959Z",
    "updated_at": "2024-11-06T07:00:18.486959Z",
    "lead_time": 4.359
  },
  {
    "text": "divided by 'total hours worked for GSK employees\/supervised workers.",
    "id": 1054,
    "annotator": 1,
    "annotation_id": 1055,
    "created_at": "2024-11-06T07:00:22.853999Z",
    "updated_at": "2024-11-06T07:00:22.853999Z",
    "lead_time": 4.179
  },
  {
    "text": "100,000 hours worked) Hours worked HR System Report of the hours worked.",
    "id": 1055,
    "annotator": 1,
    "annotation_id": 1056,
    "created_at": "2024-11-06T07:00:27.526219Z",
    "updated_at": "2024-11-06T07:00:27.526219Z",
    "lead_time": 4.5
  },
  {
    "text": "Hours worked is based on multiplying headcount on the 15th of the month per site by 150 hours in the EHS One system each month.",
    "id": 1056,
    "annotator": 1,
    "annotation_id": 1057,
    "created_at": "2024-11-06T07:00:32.396976Z",
    "updated_at": "2024-11-06T07:00:32.396976Z",
    "lead_time": 4.7
  },
  {
    "text": "The total number of employees in active status with specified employee type codes for each location (site) and multiply that number by 150.",
    "id": 1057,
    "annotator": 1,
    "annotation_id": 1058,
    "created_at": "2024-11-06T07:00:40.602571Z",
    "updated_at": "2024-11-06T07:00:40.602571Z",
    "lead_time": 8.001
  },
  {
    "text": "This will provide the number of hours for that location (site).",
    "id": 1058,
    "annotator": 1,
    "annotation_id": 1059,
    "created_at": "2024-11-06T07:00:44.907477Z",
    "updated_at": "2024-11-06T07:00:44.907477Z",
    "lead_time": 4.087
  },
  {
    "text": "54 GSK ESG Performance Report 2023 March 2024 Independent Limited Assurance Report to the Directors of GSK plc DNV Business Assurance Services UK Limited ( DNV ,  us  or  we ) were commissioned by GSK Services Unlimited to provide limited assurance to GSK plc ( GSK ) over Selected Information presented in the ESG Performance Report 2023 (the  Report ) for the reporting year ended 31 December 2023.",
    "id": 1059,
    "annotator": 1,
    "annotation_id": 1060,
    "created_at": "2024-11-06T07:01:07.812644Z",
    "updated_at": "2024-11-06T07:01:07.812644Z",
    "lead_time": 22.717
  },
  {
    "text": "Our Conclusion: On the basis of the work undertaken, nothing came to our attention to suggest that the Selected Information is not fairly stated and has not been prepared, in all material respects, in accordance with the Criteria.",
    "id": 1060,
    "annotator": 1,
    "annotation_id": 1061,
    "created_at": "2024-11-06T07:01:12.978519Z",
    "updated_at": "2024-11-06T07:01:12.978519Z",
    "lead_time": 4.963
  },
  {
    "text": "This conclusion relates only to the Selected Information, and is to be read in the context of this Independent Limited Assurance Report, in particular the inherent limitations explained overleaf.",
    "id": 1061,
    "annotator": 1,
    "annotation_id": 1062,
    "created_at": "2024-11-06T07:01:17.618416Z",
    "updated_at": "2024-11-06T07:01:17.618416Z",
    "lead_time": 4.464
  },
  {
    "text": "Our observations and areas for improvement will be raised in a separate report to GSK s Management.",
    "id": 1062,
    "annotator": 1,
    "annotation_id": 1063,
    "created_at": "2024-11-06T07:01:22.202255Z",
    "updated_at": "2024-11-06T07:01:22.202255Z",
    "lead_time": 4.403
  },
  {
    "text": "These observations do not affect our conclusion set out above.",
    "id": 1063,
    "annotator": 1,
    "annotation_id": 1064,
    "created_at": "2024-11-06T07:01:26.712805Z",
    "updated_at": "2024-11-06T07:01:26.712805Z",
    "lead_time": 4.336
  },
  {
    "text": "SelectedInformation The scope and boundary of our work is restricted to the metrics included within the Report for the current reporting year (the  Selected Information ), listed below and in the Appendix:   The Environmental Social and Governance (ESG) performance data listed in the Appendix of this document.",
    "id": 1064,
    "annotator": 1,
    "annotation_id": 1065,
    "created_at": "2024-11-06T07:01:40.972731Z",
    "updated_at": "2024-11-06T07:01:40.972731Z",
    "lead_time": 14.051
  },
  {
    "text": "The overall 2023 ESG Performance Rating score of  on track  relating to GSK s performance against the 2023 Performance Rating metrics listed on pages 6 and 7 of the Report.",
    "id": 1065,
    "annotator": 1,
    "annotation_id": 1066,
    "created_at": "2024-11-06T07:01:46.143985Z",
    "updated_at": "2024-11-06T07:01:46.143985Z",
    "lead_time": 4.962
  },
  {
    "text": "To assess the Selected Information, which includes an assessment of the risk of material misstatement in the Report, we have used GSK s ESG Data Collection Process and Controls Documents which are summarised in the ESG reporting criteria (the  Criteria ), which can be found from pages 47 to 54 of the Report.",
    "id": 1066,
    "annotator": 1,
    "annotation_id": 1067,
    "created_at": "2024-11-06T07:01:52.812030Z",
    "updated_at": "2024-11-06T07:01:52.812030Z",
    "lead_time": 6.464
  },
  {
    "text": "We have not performed any work, and do not express any conclusion, on any other information that may be published in the Report or on GSK s website for the current reporting period or for previous periods.",
    "id": 1067,
    "annotator": 1,
    "annotation_id": 1068,
    "created_at": "2024-11-06T07:02:25.601134Z",
    "updated_at": "2024-11-06T07:02:25.601134Z",
    "lead_time": 32.579
  },
  {
    "text": "Standard and level of assurance Our competence, independence We performed a limited assurance engagement of specified data and information using DNV s assurance methodology VerisustainTM, which is based on our professional and quality control experience and international assurance best practice including the International Standard on Assurance Engagements (ISAE) 3000    Assurance Engagements other than DNV established policies and procedures are Audits and Reviews of Historical Financial Information  (revised) issued by the designed to ensure that DNV, its personnel and, where applicable, others are subject to International Auditing and Assurance Standards Board.",
    "id": 1068,
    "annotator": 1,
    "annotation_id": 1069,
    "created_at": "2024-11-06T07:05:04.531689Z",
    "updated_at": "2024-11-06T07:05:04.531689Z",
    "lead_time": 158.693
  },
  {
    "text": "This methodology ensures independence requirements (including compliance with ethical requirements and mandates planning and execution of the personnel of other entities of DNV) and assurance engagement to obtain a limited level of assurance.",
    "id": 1069,
    "annotator": 1,
    "annotation_id": 1070,
    "created_at": "2024-11-06T07:05:41.076231Z",
    "updated_at": "2024-11-06T07:05:41.076231Z",
    "lead_time": 36.326
  },
  {
    "text": "maintain independence where required by relevant ethical requirements.",
    "id": 1070,
    "annotator": 1,
    "annotation_id": 1071,
    "created_at": "2024-11-06T07:05:45.264182Z",
    "updated_at": "2024-11-06T07:05:45.264182Z",
    "lead_time": 4.005
  },
  {
    "text": "This DNV applies its own management standards and compliance policies for quality control, engagement work was carried out by an which are based on the principles enclosed within ISO IEC 17029:2019 - Conformity independent team of sustainability Assessment - General principles and requirements for validation and verification bodies, assurance professionals.",
    "id": 1071,
    "annotator": 1,
    "annotation_id": 1072,
    "created_at": "2024-11-06T07:05:49.842682Z",
    "updated_at": "2024-11-06T07:05:49.842682Z",
    "lead_time": 4.409
  },
  {
    "text": "DNV did not provide any services to GSK in 2023 that and accordingly maintains a comprehensive system of quality control including could compromise the independence or documented policies and procedures regarding compliance with ethical requirements, impartiality of our work.",
    "id": 1072,
    "annotator": 1,
    "annotation_id": 1073,
    "created_at": "2024-11-06T07:05:53.983512Z",
    "updated_at": "2024-11-06T07:05:53.983512Z",
    "lead_time": 3.934
  },
  {
    "text": "Our multi- professional standards, and applicable legal and regulatory requirements.",
    "id": 1073,
    "annotator": 1,
    "annotation_id": 1074,
    "created_at": "2024-11-06T07:05:57.991225Z",
    "updated_at": "2024-11-06T07:05:57.991225Z",
    "lead_time": 3.804
  },
  {
    "text": "disciplinary team consisted of professionals with a combination of environmental and The procedures performed in a limited assurance engagement vary in nature and are sustainability assurance experience.",
    "id": 1074,
    "annotator": 1,
    "annotation_id": 1075,
    "created_at": "2024-11-06T07:06:02.985677Z",
    "updated_at": "2024-11-06T07:06:02.985677Z",
    "lead_time": 4.813
  },
  {
    "text": "shorter in extent than for a reasonable assurance engagement.",
    "id": 1075,
    "annotator": 1,
    "annotation_id": 1076,
    "created_at": "2024-11-06T07:06:07.700537Z",
    "updated_at": "2024-11-06T07:06:07.700537Z",
    "lead_time": 4.528
  },
  {
    "text": "Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained if a reasonable assurance engagement had been performed.",
    "id": 1076,
    "annotator": 1,
    "annotation_id": 1077,
    "created_at": "2024-11-06T07:06:12.335833Z",
    "updated_at": "2024-11-06T07:06:12.335833Z",
    "lead_time": 4.453
  },
  {
    "text": "55 GSK ESG Performance Report 2023 March 2024 Basis of our conclusion Inherent limitations We are required to plan and perform our work in order to consider the risk of material DNV s assurance engagements are based on misstatement of the Selected Information; our work included, but was not restricted to: the assumption that the data and information provided by GSK to us as part of   Conducting interviews with GSK s management to obtain an understanding of the key our review have been provided in good processes, systems and controls in place to generate, aggregate and report the faith, is true, complete, sufficient, and Selected Information; authentic, and is free from material misstatements.",
    "id": 1077,
    "annotator": 1,
    "annotation_id": 1078,
    "created_at": "2024-11-06T07:07:07.130978Z",
    "updated_at": "2024-11-06T07:07:07.130978Z",
    "lead_time": 54.564
  },
  {
    "text": "Because of the selected   Remote site visits to Evreux (France), Ste.",
    "id": 1078,
    "annotator": 1,
    "annotation_id": 1079,
    "created_at": "2024-11-06T07:07:13.865594Z",
    "updated_at": "2024-11-06T07:07:13.865594Z",
    "lead_time": 6.518
  },
  {
    "text": "Foy (Canada) and Stevenage (UK) to review nature (sampling) and other inherent the processes and systems for preparing site level Health and Safety data limitations of both procedures and systems consolidated at Company level.",
    "id": 1079,
    "annotator": 1,
    "annotation_id": 1080,
    "created_at": "2024-11-06T07:07:28.367388Z",
    "updated_at": "2024-11-06T07:07:28.367388Z",
    "lead_time": 14.315
  },
  {
    "text": "DNV were free to choose sites based on materiality; of internal control, there remains the unavoidable risk that errors or irregularities,   Performing limited substantive testing on a selective basis of the Selected Information possibly significant, may not have been to check that data had been appropriately measured, recorded, collated and detected.",
    "id": 1080,
    "annotator": 1,
    "annotation_id": 1081,
    "created_at": "2024-11-06T07:07:56.353080Z",
    "updated_at": "2024-11-06T07:07:56.353080Z",
    "lead_time": 8.191
  },
  {
    "text": "The engagement excludes the sustainability management, performance, reported; and reporting practices of the Company s   Reviewing that the evidence, measurements and their scope provided to us by GSK for suppliers, contractors, and any third parties mentioned in the Report.",
    "id": 1081,
    "annotator": 1,
    "annotation_id": 1082,
    "created_at": "2024-11-06T07:08:02.165682Z",
    "updated_at": "2024-11-06T07:08:02.165682Z",
    "lead_time": 5.611
  },
  {
    "text": "We understand the Selected Information is prepared in line with the Criteria; that the reported financial data, governance   Assessing the appropriateness of the Criteria for the Selected Information; and and related information are based on statutory disclosures and Audited Financial   Reading the Report and narrative accompanying the Selected Information within it Statements, which are subject to a separate with regard to the Criteria.",
    "id": 1082,
    "annotator": 1,
    "annotation_id": 1083,
    "created_at": "2024-11-06T07:08:20.058774Z",
    "updated_at": "2024-11-06T07:08:20.058774Z",
    "lead_time": 17.683
  },
  {
    "text": "independent statutory audit process.",
    "id": 1083,
    "annotator": 1,
    "annotation_id": 1084,
    "created_at": "2024-11-06T07:08:21.488356Z",
    "updated_at": "2024-11-06T07:08:21.488356Z",
    "lead_time": 1.215
  },
  {
    "text": "We did not review financial disclosures and data During the assurance process, we did not come across limitations to the scope of the as they are not within the scope of our agreed assurance engagement.",
    "id": 1084,
    "annotator": 1,
    "annotation_id": 1085,
    "created_at": "2024-11-06T07:08:47.887485Z",
    "updated_at": "2024-11-06T07:08:47.887485Z",
    "lead_time": 26.192
  },
  {
    "text": "assurance engagement.",
    "id": 1085,
    "annotator": 1,
    "annotation_id": 1086,
    "created_at": "2024-11-06T07:08:49.062635Z",
    "updated_at": "2024-11-06T07:08:49.062635Z",
    "lead_time": 0.95
  },
  {
    "text": "Disclaimers Responsibilities of the Directors of The assurance provided by DNV is limited to the selected indicators and information GSK and DNV specified in the scope of the engagement.",
    "id": 1086,
    "annotator": 1,
    "annotation_id": 1087,
    "created_at": "2024-11-06T07:08:54.708743Z",
    "updated_at": "2024-11-06T07:08:54.708743Z",
    "lead_time": 5.438
  },
  {
    "text": "DNV has not conducted an assessment of the reporting organisation's overall adherence to reporting principles or the preparation of The Directors of GSK have sole responsibility the report.",
    "id": 1087,
    "annotator": 1,
    "annotation_id": 1088,
    "created_at": "2024-11-06T07:09:01.881830Z",
    "updated_at": "2024-11-06T07:09:01.881830Z",
    "lead_time": 6.956
  },
  {
    "text": "Therefore, no conclusions should be drawn regarding the reporting for: organization's compliance with reporting principles or the quality of the overall report.",
    "id": 1088,
    "annotator": 1,
    "annotation_id": 1089,
    "created_at": "2024-11-06T07:09:07.270151Z",
    "updated_at": "2024-11-06T07:09:07.270151Z",
    "lead_time": 5.184
  },
  {
    "text": "Preparing and presenting the Selected The assurance provided by DNV is based on the selected indicators and information information in accordance with the made available to us at the time of the engagement.",
    "id": 1089,
    "annotator": 1,
    "annotation_id": 1090,
    "created_at": "2024-11-06T07:09:12.383618Z",
    "updated_at": "2024-11-06T07:09:12.383618Z",
    "lead_time": 4.904
  },
  {
    "text": "DNV assumes no responsibility for Criteria; any changes or updates made to the indicators or information after the completion of   Designing, implementing and the assurance engagement.",
    "id": 1090,
    "annotator": 1,
    "annotation_id": 1091,
    "created_at": "2024-11-06T07:09:17.089740Z",
    "updated_at": "2024-11-06T07:09:17.089740Z",
    "lead_time": 4.514
  },
  {
    "text": "maintaining effective internal controls over the information and data, resulting Use and distribution of our Independent Limited Assurance Report in the preparation of the Selected Information that is free from material misstatements; This report is intended solely for the information and use of the Directors of GSK and is not intended to be and should not be used by anyone other than these specified parties.",
    "id": 1091,
    "annotator": 1,
    "annotation_id": 1092,
    "created_at": "2024-11-06T07:09:29.642834Z",
    "updated_at": "2024-11-06T07:09:29.642834Z",
    "lead_time": 12.351
  },
  {
    "text": "Measuring and reporting the Selected DNV expressly disclaims any liability or co-responsibility for any decision a person or an Information based on their established Criteria; and entity may make based on this Independent Limited Assurance Report.",
    "id": 1092,
    "annotator": 1,
    "annotation_id": 1093,
    "created_at": "2024-11-06T07:09:35.554828Z",
    "updated_at": "2024-11-06T07:09:35.554828Z",
    "lead_time": 5.716
  },
  {
    "text": "Contents and statements contained within the Report and the Criteria.",
    "id": 1093,
    "annotator": 1,
    "annotation_id": 1094,
    "created_at": "2024-11-06T07:09:39.759996Z",
    "updated_at": "2024-11-06T07:09:39.759996Z",
    "lead_time": 4.035
  },
  {
    "text": "for DNV Business Assurance Services UK Limited Our responsibility is to plan and perform our work to obtain limited assurance about London, UK whether the Selected Information has been 01 March 2024 prepared in accordance with the Criteria and to report to GSK in the form of an independent limited assurance conclusion, Wallis- Digitally signed WaldenDigitally signed by based on the work performed and the C Ho op llyley, b C D 21y o a : p t 3W el 9e :a :2y 5ll , 0 9i s H 2 - Z4o .",
    "id": 1094,
    "annotator": 1,
    "annotation_id": 1095,
    "created_at": "2024-11-06T07:09:45.024116Z",
    "updated_at": "2024-11-06T07:09:45.024116Z",
    "lead_time": 5.088
  },
  {
    "text": "l 0ly 2 .",
    "id": 1095,
    "annotator": 1,
    "annotation_id": 1096,
    "created_at": "2024-11-06T07:09:46.487879Z",
    "updated_at": "2024-11-06T07:09:46.487879Z",
    "lead_time": 1.269
  },
  {
    "text": "28 , Shaun W D 11aa :t 4l ed 8:e :2 5n 0 6, 2 S Z4h .",
    "id": 1096,
    "annotator": 1,
    "annotation_id": 1097,
    "created_at": "2024-11-06T07:09:47.381259Z",
    "updated_at": "2024-11-06T07:09:47.381259Z",
    "lead_time": 0.702
  },
  {
    "text": "a 0u 2n .",
    "id": 1097,
    "annotator": 1,
    "annotation_id": 1098,
    "created_at": "2024-11-06T07:09:47.992288Z",
    "updated_at": "2024-11-06T07:09:47.992288Z",
    "lead_time": 0.416
  },
  {
    "text": "2 9 e r Rev esi pd p oe o rn n tc .",
    "id": 1098,
    "annotator": 1,
    "annotation_id": 1099,
    "created_at": "2024-11-06T07:09:48.609378Z",
    "updated_at": "2024-11-06T07:09:48.609378Z",
    "lead_time": 0.435
  },
  {
    "text": "s e ib o leb t foai rn te hd e. pW ree p h aa rv ae ti on no t o b f e the en Holly Wallis-Copley Shaun Walden Lead Verifier Technical Reviewer DNV Supply Chain and Product DNV Business Assurance Services UK DNV Business Assurance Services UK Assurance Limited Limited DNV Business Assurance Services UK Limited is part of DNV   Supply Chain and Product Assurance, a global provider of certification, verification, assessment and training services, enabling customers and stakeholders to make critical decisions with confidence.",
    "id": 1099,
    "annotator": 1,
    "annotation_id": 1100,
    "created_at": "2024-11-06T07:10:07.025632Z",
    "updated_at": "2024-11-06T07:10:07.025632Z",
    "lead_time": 18.241
  },
  {
    "text": "www.",
    "id": 1100,
    "annotator": 1,
    "annotation_id": 1101,
    "created_at": "2024-11-06T07:10:08.594749Z",
    "updated_at": "2024-11-06T07:10:08.594749Z",
    "lead_time": 1.373
  },
  {
    "text": "dnv.",
    "id": 1101,
    "annotator": 1,
    "annotation_id": 1102,
    "created_at": "2024-11-06T07:10:09.301109Z",
    "updated_at": "2024-11-06T07:10:09.301109Z",
    "lead_time": 0.505
  },
  {
    "text": "co.",
    "id": 1102,
    "annotator": 1,
    "annotation_id": 1103,
    "created_at": "2024-11-06T07:10:09.909563Z",
    "updated_at": "2024-11-06T07:10:09.909563Z",
    "lead_time": 0.403
  },
  {
    "text": "uk\/BetterAssurance DNV-2024-ASR-C672898 56 GSK ESG Performance Report 2023 March 2024 Appendix: SelectedInformation The scope and boundary of our work is restricted to the Selected Information, including the ESG Performance data listed below and continued overleaf.",
    "id": 1103,
    "annotator": 1,
    "annotation_id": 1104,
    "created_at": "2024-11-06T07:10:17.241685Z",
    "updated_at": "2024-11-06T07:10:17.241685Z",
    "lead_time": 7.133
  },
  {
    "text": "ESG Performance data Reported value Unit Access Cash 80  m Product and in-kind 198  m Time 3  m Management costs 23  m Total community investment 304  m Value of GSK medicine and vaccines provided through our US Patient Assistance Programs Foundation 224 $m Doses of Synflorixvaccines supplied to Gavi 41 m Doses of Rotarixvaccines supplied to Gavi 43 m Doses of Cervarixvaccines supplied to Gavi 5 m Doses of OPV vaccines supplied to UNICEF 130 m Doses of OPV vaccines supplied and in ready-to-ship stockpile to UNICEF 149 m Doses of Mosquirix (RTS,S\/AS01 E) vaccines supplied 6 m Albendazole tablets donated to help eliminate lymphatic filariasis 462 m Albendazole tablets donated to help treat intestinal worms 153 m Total doses supplied 989 m People with access to a generic dolutegravir product through voluntary licensing agreements 24,058  000 Estimated children reached with Synflorixthrough Gavi 12,573  000 Estimated children reached with Rotarixthrough Gavi 20,570  000 Estimated girls reached with Cervarixthrough Gavi 4,307  000 Estimated people reached with OPV through UNICEF 26,032  000 Estimated people reached with Mosquirix (RTS,S\/AS01 E) 1,383  000 Total people reached 88,923  000 People reached through our US Patient Assistance Programs 71  000 Global health and health security Number of assets progressed through the Global Health pipeline to address priority WHO diseases 11 # Environment Percentage of carbon offset volume in project pipeline (Percentage of 2.1MtCO2offsetting volume in 2030 project 35 % pipeline) Diversity, equity and inclusion Percentage of Phase III trials initiated in 2023 that have proactive plans in place designed to enrol appropriately 100 % diverse trial participants, consistent with the disease epidemiology US ethnic diversity: Ethnically diverse total of: -SVP\/VP 35.7 % -Director 30.0 % -Manager 33.5 % -All employees 34.9 % UK ethnic diversity: Ethnically diverse total of: -SVP\/VP 18.4 % -Director 21.3 % -Manager 25.0 % -All employees 20.9 % % of women (all employees): 48 % -SVP\/VP 45 % -Director 50 % -Manager 51 % Total women in management 50 % Ethical standards Employees who had concerns raised against them (including current year and prior year open cases) 1,960 # Employees disciplined for policy violations 798 # 57 GSK ESG Performance Report 2023 March 2024 Appendix: SelectedInformation continued ESG Performance data Reported value Unit Breakdown of types of policy violation: -Employee conduct 304 # -Sales and marketing 122 # -Product quality 76 # -Safeguarding people and information and assets 177 # -Employee relations 99 # -Research and development and medical practices 7 # -Anti-bribery and corruption 39 # -Cyber security 24 # -EHS and sustainability 64 # -Other 4 # Employees who were dismissed or agreed to leave the company voluntarily as a result ofmisconduct 256 # Documented warnings 553 # Open cases awaiting investigation or a disciplinary decision at year end 297 # % of employees and complementary workers that complete GSK s mandatory training 100 % % of employees who believe they  can and do Speak Up if things don't feel right  83 % % of direct high-risk suppliers that achieve GSK s minimum EcoVadis score or have an improvement plan in place 89 % Product governance Total regulatory inspections from all health authorities 114 # % of inspections from all regulators with no critical findings or official action indicated 100 % Total regulatory inspections from FDA\/MHRA\/EMA regulators 32 # Number of critical\/major findings from FDA\/MHRA\/EMA regulators 11 # Total FDA regulatory inspections 5 # Number of FDA observations 8 # Number of FDA warning letters 0 # Total product recalls 16 # -Total number of Class I external product recalls 2 # -Total number of Class II external product recalls 3 # -Total number of Class III external product recalls 11 # Pharmaceuticals business -Class product I recalls 0 # Pharmaceuticals business -Class product II recalls 0 # Pharmaceuticals business -Class product III recalls 1 # Vaccines business -Class product I recalls 1 # Vaccines business -Class product II recalls 0 # Vaccines business -Class product III recalls 1 # Publicly available trial protocol summaries (register) 103 # Publicly available trial result summaries (disclose) 98 # People disclosures Overall turnover 10 % Number of fatalities (employees and complementary workers under GSK direct supervision) 0 # Fatalities (contractors not under GSK direct supervision) 0 # Reportable injuries with lost time 195 # Reportable illnesses with lost time 30 # Lost time reportable injury rate 0.13 per 100,000 hours worked Lost time reportable illness rate 0.02 per 100,000 hours worked Reportable injuries with and without lost time 292 # Reportable illnesses with and without lost time 65 # Reportable injury rate 0.19 per 100,000 hours worked Reportable illness rate 0.04 per 100,000 hours worked Reportable injury and illness rate 0.24 per 100,000 hours worked Hours worked 151 m 58 GSK ESG Performance Report 2023 March 2024 IInnddeeppeennddeenntt LLiimmiitteedd AAssssuurraannccee RReeppoorrtt ttoo tthhee DDiirreeccttoorrss ooff GGSSKK PPLLCC Independent limited Assurance Report by Deloitte LLP to the Directors of GSK PLC on selected Environmental, Social and Governance ( ESG ) metrics (the  Selected Information ) within the Annual Report and Accounts and the ESG Performance Report for the reporting year ended 31 December 2023.",
    "id": 1104,
    "label": [
      {
        "start": 119,
        "end": 145,
        "text": "Total community investment",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 146,
        "end": 152,
        "text": "304 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 153,
        "end": 250,
        "text": "Value of GSK medicine and vaccines provided through our US Patient Assistance Programs Foundation",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 251,
        "end": 257,
        "text": "224 $m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 258,
        "end": 301,
        "text": "Doses of Synflorixvaccines supplied to Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 302,
        "end": 306,
        "text": "41 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 307,
        "end": 348,
        "text": "Doses of Rotarixvaccines supplied to Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 349,
        "end": 353,
        "text": "43 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 354,
        "end": 396,
        "text": "Doses of Cervarixvaccines supplied to Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 397,
        "end": 400,
        "text": "5 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 401,
        "end": 441,
        "text": "Doses of OPV vaccines supplied to UNICEF",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 442,
        "end": 447,
        "text": "130 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 448,
        "end": 520,
        "text": "Doses of OPV vaccines supplied and in ready-to-ship stockpile to UNICEF ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 520,
        "end": 525,
        "text": "149 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 526,
        "end": 577,
        "text": "Doses of Mosquirix (RTS,S\/AS01 E) vaccines supplied",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 578,
        "end": 581,
        "text": "6 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 582,
        "end": 648,
        "text": "Albendazole tablets donated to help eliminate lymphatic filariasis",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 649,
        "end": 654,
        "text": "462 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 655,
        "end": 713,
        "text": "Albendazole tablets donated to help treat intestinal worms",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 714,
        "end": 719,
        "text": "153 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 720,
        "end": 740,
        "text": "Total doses supplied",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 741,
        "end": 746,
        "text": "989 m",
        "labels": [
          "value"
        ]
      },
      {
        "start": 747,
        "end": 838,
        "text": "People with access to a generic dolutegravir product through voluntary licensing agreements",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 839,
        "end": 850,
        "text": "24,058 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 851,
        "end": 904,
        "text": "Estimated children reached with Synflorixthrough Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 905,
        "end": 916,
        "text": "12,573 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 917,
        "end": 968,
        "text": "Estimated children reached with Rotarixthrough Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 969,
        "end": 980,
        "text": "20,570 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 981,
        "end": 1030,
        "text": "Estimated girls reached with Cervarixthrough Gavi",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1031,
        "end": 1042,
        "text": "4,307 000 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1042,
        "end": 1091,
        "text": "Estimated people reached with OPV through UNICEF ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1091,
        "end": 1102,
        "text": "26,032 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1103,
        "end": 1157,
        "text": "Estimated people reached with Mosquirix (RTS,S\/AS01 E)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1158,
        "end": 1168,
        "text": "1,383 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1169,
        "end": 1189,
        "text": "Total people reached",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1190,
        "end": 1202,
        "text": "88,923 000 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1202,
        "end": 1259,
        "text": "People reached through our US Patient Assistance Programs",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1260,
        "end": 1267,
        "text": "71 000",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1267,
        "end": 1397,
        "text": " Global health and health security Number of assets progressed through the Global Health pipeline to address priority WHO diseases",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1398,
        "end": 1402,
        "text": "11 #",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1765,
        "end": 1813,
        "text": "US ethnic diversity: Ethnically diverse total of",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1814,
        "end": 1884,
        "text": " -SVP\/VP 35.7 % -Director 30.0 % -Manager 33.5 % -All employees 34.9 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 1885,
        "end": 1933,
        "text": "UK ethnic diversity: Ethnically diverse total of",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 1935,
        "end": 2004,
        "text": "-SVP\/VP 18.4 % -Director 21.3 % -Manager 25.0 % -All employees 20.9 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2010,
        "end": 2016,
        "text": "women ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2016,
        "end": 2079,
        "text": "(all employees): 48 % -SVP\/VP 45 % -Director 50 % -Manager 51 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2129,
        "end": 2226,
        "text": "Employees who had concerns raised against them (including current year and prior year open cases)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2227,
        "end": 2232,
        "text": "1,960",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2235,
        "end": 2278,
        "text": "Employees disciplined for policy violations",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2279,
        "end": 2282,
        "text": "798",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2657,
        "end": 2684,
        "text": "Anti-bribery and corruption",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2685,
        "end": 2688,
        "text": "39 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2691,
        "end": 2705,
        "text": "Cyber security",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2706,
        "end": 2708,
        "text": "24",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2712,
        "end": 2734,
        "text": "EHS and sustainability",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2735,
        "end": 2737,
        "text": "64",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2580,
        "end": 2598,
        "text": "Employee relations",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2599,
        "end": 2601,
        "text": "99",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2605,
        "end": 2651,
        "text": "Research and development and medical practices",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2652,
        "end": 2653,
        "text": "7",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2751,
        "end": 2847,
        "text": "Employees who were dismissed or agreed to leave the company voluntarily as a result ofmisconduct",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2848,
        "end": 2851,
        "text": "256",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2854,
        "end": 2873,
        "text": "Documented warnings",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2874,
        "end": 2877,
        "text": "553",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2880,
        "end": 2952,
        "text": "Open cases awaiting investigation or a disciplinary decision at year end",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 2953,
        "end": 2956,
        "text": "297",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3050,
        "end": 3124,
        "text": "employees who believe they can and do Speak Up if things don't feel right",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3126,
        "end": 3130,
        "text": "83 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 2964,
        "end": 3038,
        "text": "employees and complementary workers that complete GSK s mandatory training",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3039,
        "end": 3044,
        "text": "100 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3136,
        "end": 3241,
        "text": "direct high-risk suppliers that achieve GSK s minimum EcoVadis score or have an improvement plan in place",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3242,
        "end": 3246,
        "text": "89 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3247,
        "end": 3322,
        "text": "Product governance Total regulatory inspections from all health authorities",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3323,
        "end": 3326,
        "text": "114",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3334,
        "end": 3420,
        "text": "inspections from all regulators with no critical findings or official action indicated",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3421,
        "end": 3426,
        "text": "100 %",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3427,
        "end": 3484,
        "text": "Total regulatory inspections from FDA\/MHRA\/EMA regulators",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3485,
        "end": 3487,
        "text": "32",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3490,
        "end": 3552,
        "text": "Number of critical\/major findings from FDA\/MHRA\/EMA regulators",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3553,
        "end": 3555,
        "text": "11",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3558,
        "end": 3590,
        "text": "Total FDA regulatory inspections",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3591,
        "end": 3592,
        "text": "5",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3595,
        "end": 3620,
        "text": "Number of FDA observation",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3622,
        "end": 3623,
        "text": "8",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3626,
        "end": 3655,
        "text": "Number of FDA warning letters",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3656,
        "end": 3657,
        "text": "0",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3660,
        "end": 3681,
        "text": "Total product recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3682,
        "end": 3684,
        "text": "16",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3688,
        "end": 3736,
        "text": "Total number of Class I external product recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3737,
        "end": 3738,
        "text": "2",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3742,
        "end": 3791,
        "text": "Total number of Class II external product recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3792,
        "end": 3793,
        "text": "3",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3797,
        "end": 3847,
        "text": "Total number of Class III external product recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3848,
        "end": 3850,
        "text": "11",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3852,
        "end": 3903,
        "text": " Pharmaceuticals business -Class product I recalls ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3903,
        "end": 3905,
        "text": "0 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3907,
        "end": 3957,
        "text": "Pharmaceuticals business -Class product II recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 3957,
        "end": 3959,
        "text": " 0",
        "labels": [
          "value"
        ]
      },
      {
        "start": 3962,
        "end": 4013,
        "text": "Pharmaceuticals business -Class product III recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4014,
        "end": 4015,
        "text": "1",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4018,
        "end": 4060,
        "text": "Vaccines business -Class product I recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4061,
        "end": 4062,
        "text": "1",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4065,
        "end": 4108,
        "text": "Vaccines business -Class product II recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4108,
        "end": 4110,
        "text": " 0",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4113,
        "end": 4157,
        "text": "Vaccines business -Class product III recalls",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4158,
        "end": 4160,
        "text": "1 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4162,
        "end": 4217,
        "text": "Publicly available trial protocol summaries (register) ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4217,
        "end": 4220,
        "text": "103",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4223,
        "end": 4275,
        "text": "Publicly available trial result summaries (disclose)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4276,
        "end": 4278,
        "text": "98",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4281,
        "end": 4409,
        "text": "People disclosures Overall turnover 10 % Number of fatalities (employees and complementary workers under GSK direct supervision)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4410,
        "end": 4411,
        "text": "0",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4415,
        "end": 4471,
        "text": "atalities (contractors not under GSK direct supervision)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4472,
        "end": 4473,
        "text": "0",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4476,
        "end": 4552,
        "text": "Reportable injuries with lost time 195 # Reportable illnesses with lost time",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4553,
        "end": 4555,
        "text": "30",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4558,
        "end": 4731,
        "text": "Lost time reportable injury rate 0.13 per 100,000 hours worked Lost time reportable illness rate 0.02 per 100,000 hours worked Reportable injuries with and without lost time",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4732,
        "end": 4735,
        "text": "292",
        "labels": [
          "value"
        ]
      },
      {
        "start": 4738,
        "end": 4785,
        "text": "Reportable illnesses with and without lost time",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 4786,
        "end": 4788,
        "text": "65",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1105,
    "created_at": "2024-11-06T07:29:43.296139Z",
    "updated_at": "2024-11-06T07:29:43.296139Z",
    "lead_time": 1165.777
  },
  {
    "text": "OOuurr aassssuurraannccee ccoonncclluussiioonn Based on our procedures described in this report, and evidence we have obtained, nothing has come to our attention that causes us to believe that the Selected Information, as presented on page 70 of the Annual Report and Accounts and pages 23-24 of the ESG Performance Report for the year ended 31 December 2023, and as listed below and indicated with an (A) in the Annual Report and Accounts and the ESG Performance Report has not been prepared, in all material respects, in accordance with the Basis of Reporting defined by the directors.",
    "id": 1105,
    "annotator": 1,
    "annotation_id": 1106,
    "created_at": "2024-11-06T07:29:55.796778Z",
    "updated_at": "2024-11-06T07:29:55.796778Z",
    "lead_time": 12.279
  },
  {
    "text": "SSccooppee ooff oouurr wwoorrkk GSK PLC has engaged us to perform an independent limited assurance engagement in accordance with International Standard on Assurance Engagements 3000 (Revised) Assurance Engagements Other than Audits or Reviews of Historical Financial Information ( ISAE 3000 (Revised) and the International Standard on Assurance Engagements 3410 Assurance engagements on greenhouse gas statements (ISAE 3410), issued by the International Auditing and Assurance Standards Board ( IAASB ) and our agreed terms of engagement.",
    "id": 1106,
    "annotator": 1,
    "annotation_id": 1107,
    "created_at": "2024-11-06T07:30:18.947722Z",
    "updated_at": "2024-11-06T07:30:18.947722Z",
    "lead_time": 22.926
  },
  {
    "text": "The Selected Information in scope of our engagement, as presented on page 70 of the Annual Report and Accounts and pages 23-24 of the ESG Performance Report for the year ended 31 December 2023, and as listed below and indicated with an (A) in the Annual Report and Accounts and ESG Performance Report, is as follows: SSeelleecctteedd IInnffoorrmmaattiioonn AAssssuurreedd VVaalluuee Scope 1 emissions (thousand tonnes CO2e) 581 Scope 2 emissions   Market Based   (thousand tonnes CO2e) 64 Scope 2 emissions   Location Based   (thousand tonnes 240 CO2e) Total scope 1 and 2 market-based emissions (thousand 645 tonnes CO2e) Total energy for operations (GWh) 2,636 Purchased Renewable electricity (GWh) 782 Onsite renewably generated electricity (GWh) 17 Emissions from use of propellant based inhalers by patients 5,039 (thousand tonnes CO2e) Total water use at high water risk sites (million m3) 0.3 Total wastewater discharged (million m3) 6.2 Total water use (million m3) 7.4 The Basis of Reporting (defined by GSK PLC); the nature of the Selected Information, and absence of consistent external standards allow for different, but acceptable, measurement methodologies to be adopted which may result in variances between entities.",
    "id": 1107,
    "label": [
      {
        "start": 383,
        "end": 423,
        "text": "Scope 1 emissions (thousand tonnes CO2e)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 424,
        "end": 427,
        "text": "581",
        "labels": [
          "value"
        ]
      },
      {
        "start": 428,
        "end": 485,
        "text": "Scope 2 emissions Market Based (thousand tonnes CO2e)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 486,
        "end": 488,
        "text": "64",
        "labels": [
          "value"
        ]
      },
      {
        "start": 553,
        "end": 595,
        "text": "Total scope 1 and 2 market-based emissions",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 597,
        "end": 621,
        "text": "thousand 645 tonnes CO2e",
        "labels": [
          "value"
        ]
      },
      {
        "start": 623,
        "end": 656,
        "text": "Total energy for operations (GWh)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 657,
        "end": 662,
        "text": "2,636",
        "labels": [
          "value"
        ]
      },
      {
        "start": 663,
        "end": 700,
        "text": "Purchased Renewable electricity (GWh)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 701,
        "end": 704,
        "text": "782",
        "labels": [
          "value"
        ]
      },
      {
        "start": 705,
        "end": 749,
        "text": "Onsite renewably generated electricity (GWh)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 750,
        "end": 752,
        "text": "17",
        "labels": [
          "value"
        ]
      },
      {
        "start": 753,
        "end": 812,
        "text": "Emissions from use of propellant based inhalers by patients",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 813,
        "end": 841,
        "text": "5,039 (thousand tonnes CO2e)",
        "labels": [
          "value"
        ]
      },
      {
        "start": 842,
        "end": 882,
        "text": "Total water use at high water risk sites",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 883,
        "end": 899,
        "text": "(million m3) 0.3",
        "labels": [
          "value"
        ]
      },
      {
        "start": 900,
        "end": 940,
        "text": "Total wastewater discharged (million m3)",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 941,
        "end": 944,
        "text": "6.2",
        "labels": [
          "value"
        ]
      },
      {
        "start": 945,
        "end": 960,
        "text": "Total water use",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 961,
        "end": 977,
        "text": "(million m3) 7.4",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1108,
    "created_at": "2024-11-06T07:33:29.837887Z",
    "updated_at": "2024-11-06T07:33:29.837887Z",
    "lead_time": 190.66
  },
  {
    "text": "The adopted measurement methodologies may also impact comparability of the Selected Information reported by different organisations and from year to year within an organisation as methodologies develop.",
    "id": 1108,
    "annotator": 1,
    "annotation_id": 1109,
    "created_at": "2024-11-06T07:33:38.981293Z",
    "updated_at": "2024-11-06T07:33:38.981293Z",
    "lead_time": 8.881
  },
  {
    "text": "The Selected Information, as listed in the above table, needs to be read and understood together with the Basis of Reporting prepared and published by GSK PLC at ESG resources | GSK.",
    "id": 1109,
    "annotator": 1,
    "annotation_id": 1110,
    "created_at": "2024-11-06T07:33:42.880446Z",
    "updated_at": "2024-11-06T07:33:42.880446Z",
    "lead_time": 3.707
  },
  {
    "text": "IInnhheerreenntt lliimmiittaattiioonnss ooff tthhee SSeelleecctteedd IInnffoorrmmaattiioonn We obtained limited assurance over the preparation of the Selected Information in accordance with the Applicable Criteria.",
    "id": 1110,
    "annotator": 1,
    "annotation_id": 1111,
    "created_at": "2024-11-06T07:33:46.540024Z",
    "updated_at": "2024-11-06T07:33:46.540024Z",
    "lead_time": 3.488
  },
  {
    "text": "Inherent limitations exist in all assurance engagements.",
    "id": 1111,
    "annotator": 1,
    "annotation_id": 1112,
    "created_at": "2024-11-06T07:33:47.168593Z",
    "updated_at": "2024-11-06T07:33:47.168593Z",
    "lead_time": 0.454
  },
  {
    "text": "Any internal control structure, no matter how effective, cannot eliminate the possibility that fraud, errors or irregularities may occur and remain undetected and because we use selective testing in our engagement, we cannot guarantee that errors or irregularities, if present, will be detected.",
    "id": 1112,
    "annotator": 1,
    "annotation_id": 1113,
    "created_at": "2024-11-06T07:33:53.200754Z",
    "updated_at": "2024-11-06T07:33:53.200754Z",
    "lead_time": 5.843
  },
  {
    "text": "The self-defined Basis of Reporting, the nature of the Selected Information, and absence of consistent external standards allow for different, but acceptable, measurement methodologies to be adopted which may result in variances between entities.",
    "id": 1113,
    "annotator": 1,
    "annotation_id": 1114,
    "created_at": "2024-11-06T07:33:57.338324Z",
    "updated_at": "2024-11-06T07:33:57.338324Z",
    "lead_time": 3.938
  },
  {
    "text": "The adopted measurement methodologies may also impact comparability of the Selected Information reported by different organisations and from year to year within an organisation as methodologies develop.",
    "id": 1114,
    "annotator": 1,
    "annotation_id": 1115,
    "created_at": "2024-11-06T07:33:58.737459Z",
    "updated_at": "2024-11-06T07:33:58.737459Z",
    "lead_time": 1.212
  },
  {
    "text": "Inherent limitations exist in all assurance engagements due to the selective enquiry of the information being examined.",
    "id": 1115,
    "annotator": 1,
    "annotation_id": 1116,
    "created_at": "2024-11-06T07:33:59.904551Z",
    "updated_at": "2024-11-06T07:33:59.904551Z",
    "lead_time": 0.974
  },
  {
    "text": "Therefore fraud, error or non-compliance may occur and not be detected.",
    "id": 1116,
    "annotator": 1,
    "annotation_id": 1117,
    "created_at": "2024-11-06T07:34:05.491203Z",
    "updated_at": "2024-11-06T07:34:05.491203Z",
    "lead_time": 5.384
  },
  {
    "text": "Our work does not involve testing the operating effectiveness of controls over the underlying data, nor have we sought to review systems and controls beyond those relevant to the selected ESG metrics.",
    "id": 1117,
    "annotator": 1,
    "annotation_id": 1118,
    "created_at": "2024-11-06T07:34:09.112065Z",
    "updated_at": "2024-11-06T07:34:09.112065Z",
    "lead_time": 3.436
  },
  {
    "text": "DDiirreeccttoorrss  rreessppoonnssiibbiilliittiieess The Directors are responsible for preparing an Annual Report and Accounts which complies with the requirements of the Companies Act 2006 and for being satisfied that the Annual Report and Accounts and ESG Performance Report, taken as a whole, is fair, balanced and understandable.",
    "id": 1118,
    "annotator": 1,
    "annotation_id": 1119,
    "created_at": "2024-11-06T07:34:13.421584Z",
    "updated_at": "2024-11-06T07:34:13.422584Z",
    "lead_time": 4.107
  },
  {
    "text": "The Directors are also responsible for:   Selecting and establishing the Basis of Reporting.",
    "id": 1119,
    "annotator": 1,
    "annotation_id": 1120,
    "created_at": "2024-11-06T07:34:18.273691Z",
    "updated_at": "2024-11-06T07:34:18.273691Z",
    "lead_time": 4.668
  },
  {
    "text": "Preparing, measuring, presenting and reporting the Selected Information in accordance with the Basis of Reporting.",
    "id": 1120,
    "annotator": 1,
    "annotation_id": 1121,
    "created_at": "2024-11-06T07:34:23.781993Z",
    "updated_at": "2024-11-06T07:34:23.781993Z",
    "lead_time": 5.329
  },
  {
    "text": "Publishing the Basis of Reporting publicly in advance of, or at the same time as, the publication of the Selected Information   Designing, implementing, and maintaining internal processes and controls over information relevant to the preparation of the Selected Information to ensure that they are free from material misstatement, including whether due to fraud or error.",
    "id": 1121,
    "annotator": 1,
    "annotation_id": 1122,
    "created_at": "2024-11-06T07:34:29.214781Z",
    "updated_at": "2024-11-06T07:34:29.214781Z",
    "lead_time": 5.254
  },
  {
    "text": "Providing sufficient access and making available all necessary records, correspondence, information and explanations to allow the successful completion of the Services.",
    "id": 1122,
    "annotator": 1,
    "annotation_id": 1123,
    "created_at": "2024-11-06T07:34:33.861899Z",
    "updated_at": "2024-11-06T07:34:33.861899Z",
    "lead_time": 4.425
  },
  {
    "text": "Confirming to us through written representations that they have provided us with all information relevant to our Services of which they are aware, and that the measurement or evaluation of the underlying subject matter against the Basis of Reporting, including that all relevant matters, are reflected in the Selected Information.",
    "id": 1123,
    "annotator": 1,
    "annotation_id": 1124,
    "created_at": "2024-11-06T07:34:38.741616Z",
    "updated_at": "2024-11-06T07:34:38.741616Z",
    "lead_time": 4.689
  },
  {
    "text": "60 GSK ESG Performance Report 2023 March 2024 OOuurr rreessppoonnssiibbiilliittiieess We are responsible for:   Planning and performing procedures to obtain sufficient appropriate evidence in order to express an independent limited assurance conclusion on the Selected Information.",
    "id": 1124,
    "annotator": 1,
    "annotation_id": 1125,
    "created_at": "2024-11-06T07:34:44.711874Z",
    "updated_at": "2024-11-06T07:34:44.711874Z",
    "lead_time": 5.788
  },
  {
    "text": "Communicating matters that may be relevant to the Selected Information to the appropriate party including identified or suspected non-compliance with laws and regulations, fraud or suspected fraud, and bias in the preparation of the Selected Information.",
    "id": 1125,
    "annotator": 1,
    "annotation_id": 1126,
    "created_at": "2024-11-06T07:34:48.470223Z",
    "updated_at": "2024-11-06T07:34:48.470223Z",
    "lead_time": 3.553
  },
  {
    "text": "Reporting our conclusion in the form of an independent limited Assurance Report to the Directors.",
    "id": 1126,
    "annotator": 1,
    "annotation_id": 1127,
    "created_at": "2024-11-06T07:34:49.808691Z",
    "updated_at": "2024-11-06T07:34:49.808691Z",
    "lead_time": 1.159
  },
  {
    "text": "OOuurr iinnddeeppeennddeennccee aanndd ccoommppeetteennccee In conducting our engagement, we complied with the independence requirements of the FRC s Ethical Standard and the ICAEW Code of Ethics.",
    "id": 1127,
    "label": [
      {
        "start": 144,
        "end": 166,
        "text": "FRC s Ethical Standard",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 144,
        "end": 166,
        "text": "FRC s Ethical Standard",
        "labels": [
          "value"
        ]
      },
      {
        "start": 175,
        "end": 196,
        "text": "ICAEW Code of Ethics.",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 175,
        "end": 196,
        "text": "ICAEW Code of Ethics.",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1128,
    "created_at": "2024-11-06T07:35:09.118147Z",
    "updated_at": "2024-11-06T07:35:09.118147Z",
    "lead_time": 19.131
  },
  {
    "text": "The ICAEW Code is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behaviour.",
    "id": 1128,
    "annotator": 1,
    "annotation_id": 1129,
    "created_at": "2024-11-06T07:35:11.653240Z",
    "updated_at": "2024-11-06T07:35:11.653240Z",
    "lead_time": 2.295
  },
  {
    "text": "We applied the International Standard on Quality Management 1 ( ISQM 1 ) issued by the International Auditing and Assurance Standards Board.",
    "id": 1129,
    "label": [
      {
        "start": 15,
        "end": 71,
        "text": "International Standard on Quality Management 1 ( ISQM 1 ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 15,
        "end": 72,
        "text": "International Standard on Quality Management 1 ( ISQM 1 )",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1130,
    "created_at": "2024-11-06T07:35:17.346593Z",
    "updated_at": "2024-11-06T07:35:31.362703Z",
    "lead_time": 13.649
  },
  {
    "text": "Accordingly, we maintained a comprehensive system of quality management including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.",
    "id": 1130,
    "annotator": 1,
    "annotation_id": 1131,
    "created_at": "2024-11-06T07:35:33.277769Z",
    "updated_at": "2024-11-06T07:35:33.277769Z",
    "lead_time": 0.703
  },
  {
    "text": "KKeeyy pprroocceedduurreess ppeerrffoorrmmeedd We are required to plan and perform our work to address the areas where we have identified that a material misstatement in respect of the Selected Information is likely to arise.",
    "id": 1131,
    "annotator": 1,
    "annotation_id": 1132,
    "created_at": "2024-11-06T07:35:37.827688Z",
    "updated_at": "2024-11-06T07:35:37.827688Z",
    "lead_time": 4.336
  },
  {
    "text": "The procedures we performed were based on our professional judgment.",
    "id": 1132,
    "annotator": 1,
    "annotation_id": 1133,
    "created_at": "2024-11-06T07:35:41.386330Z",
    "updated_at": "2024-11-06T07:35:41.386330Z",
    "lead_time": 3.34
  },
  {
    "text": "In carrying out our limited assurance engagement in respect of the Selected Information, we performed the following procedures:   Performed analytical review procedures and considered the risks of material misstatement of the Selected Information.",
    "id": 1133,
    "annotator": 1,
    "annotation_id": 1134,
    "created_at": "2024-11-06T07:35:48.396600Z",
    "updated_at": "2024-11-06T07:35:48.396600Z",
    "lead_time": 6.831
  },
  {
    "text": "Through inquiries of management, obtained an understanding of the Company, its environment, processes and information systems relevant to the preparation of the Selected Information sufficient to identify and assess risks of material misstatement in the Selected Information, and provide a basis for designing and performing procedures to respond to assessed risks and to obtain limited assurance to support a conclusion.",
    "id": 1134,
    "annotator": 1,
    "annotation_id": 1135,
    "created_at": "2024-11-06T07:35:51.522133Z",
    "updated_at": "2024-11-06T07:35:51.522133Z",
    "lead_time": 2.933
  },
  {
    "text": "Through inquiries of management, obtained an understanding of internal controls relevant to the Selected Information, the quantification process and data used in preparing the Selected Information, the methodology for gathering qualitative information, and the process for preparing and reporting the Selected Information.",
    "id": 1135,
    "annotator": 1,
    "annotation_id": 1136,
    "created_at": "2024-11-06T07:36:11.699110Z",
    "updated_at": "2024-11-06T07:36:11.699110Z",
    "lead_time": 19.987
  },
  {
    "text": "We did not evaluate the design of particular internal control activities, obtain evidence about their implementation or test their operating effectiveness.",
    "id": 1136,
    "annotator": 1,
    "annotation_id": 1137,
    "created_at": "2024-11-06T07:36:15.497079Z",
    "updated_at": "2024-11-06T07:36:15.497079Z",
    "lead_time": 3.588
  },
  {
    "text": "Inspected documents relating to the Selected Information, including Sustainability Council minutes and where applicable internal audit outputs to understand the level of management awareness and oversight of the Selected Information.",
    "id": 1137,
    "annotator": 1,
    "annotation_id": 1138,
    "created_at": "2024-11-06T07:36:19.376132Z",
    "updated_at": "2024-11-06T07:36:19.376132Z",
    "lead_time": 3.685
  },
  {
    "text": "Performed procedures over the Selected Information, including recalculation of relevant formulae used in manual calculations and assessment whether the data was appropriately consolidated.",
    "id": 1138,
    "annotator": 1,
    "annotation_id": 1139,
    "created_at": "2024-11-06T07:36:23.364829Z",
    "updated_at": "2024-11-06T07:36:23.364829Z",
    "lead_time": 3.812
  },
  {
    "text": "Performed procedures over underlying data on a statistical sample basis to assess whether the data was collected and reported in accordance with the Basis of Reporting, including verifying to source documentation.",
    "id": 1139,
    "annotator": 1,
    "annotation_id": 1140,
    "created_at": "2024-11-06T07:36:28.955034Z",
    "updated_at": "2024-11-06T07:36:28.955034Z",
    "lead_time": 5.404
  },
  {
    "text": "Conducted site visits at a sample of sites, selected on a judgemental basis to determine consistency in understanding and application of the Basis of Reporting.",
    "id": 1140,
    "annotator": 1,
    "annotation_id": 1141,
    "created_at": "2024-11-06T07:36:32.792678Z",
    "updated_at": "2024-11-06T07:36:32.792678Z",
    "lead_time": 3.629
  },
  {
    "text": "61 GSK ESG Performance Report 2023 March 2024   Performed procedures over the Selected Information including assessing management s assumptions and estimates (if applicable).",
    "id": 1141,
    "annotator": 1,
    "annotation_id": 1142,
    "created_at": "2024-11-06T07:36:36.735823Z",
    "updated_at": "2024-11-06T07:36:36.735823Z",
    "lead_time": 3.753
  },
  {
    "text": "Accumulated misstatements and control deficiencies identified, assessing whether material.",
    "id": 1142,
    "annotator": 1,
    "annotation_id": 1143,
    "created_at": "2024-11-06T07:36:39.212991Z",
    "updated_at": "2024-11-06T07:36:39.212991Z",
    "lead_time": 2.278
  },
  {
    "text": "Read the narrative accompanying the Selected Information with regard to the Basis of Reporting, and for consistency with our findings.",
    "id": 1143,
    "annotator": 1,
    "annotation_id": 1144,
    "created_at": "2024-11-06T07:36:54.967135Z",
    "updated_at": "2024-11-06T07:36:54.967135Z",
    "lead_time": 15.573
  },
  {
    "text": "The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement.",
    "id": 1144,
    "annotator": 1,
    "annotation_id": 1145,
    "created_at": "2024-11-06T07:36:56.545256Z",
    "updated_at": "2024-11-06T07:36:56.545256Z",
    "lead_time": 1.4
  },
  {
    "text": "Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.",
    "id": 1145,
    "annotator": 1,
    "annotation_id": 1146,
    "created_at": "2024-11-06T07:37:01.551257Z",
    "updated_at": "2024-11-06T07:37:01.551257Z",
    "lead_time": 4.797
  },
  {
    "text": "UUssee ooff oouurr rreeppoorrtt This report is made solely to the Directors of GSK PLC in accordance with ISAE 3000 (Revised) and ISAE 3410 and our agreed terms of engagement.",
    "id": 1146,
    "annotator": 1,
    "annotation_id": 1147,
    "created_at": "2024-11-06T07:37:08.107943Z",
    "updated_at": "2024-11-06T07:37:08.107943Z",
    "lead_time": 6.333
  },
  {
    "text": "Our work has been undertaken so that we might state to the Directors of GSK PLC those matters we have agreed to state to them in this report and for no other purpose.",
    "id": 1147,
    "annotator": 1,
    "annotation_id": 1148,
    "created_at": "2024-11-06T07:37:10.170236Z",
    "updated_at": "2024-11-06T07:37:10.170236Z",
    "lead_time": 1.886
  },
  {
    "text": "Without assuming or accepting any responsibility or liability in respect of this report to any party other than GSK PLC and the Directors of GSK PLC, we acknowledge that the Directors of GSK PLC may choose to make this report publicly available for others wishing to have access to it, which does not and will not affect or extend for any purpose or on any basis our responsibilities.",
    "id": 1148,
    "annotator": 1,
    "annotation_id": 1149,
    "created_at": "2024-11-06T07:37:14.706920Z",
    "updated_at": "2024-11-06T07:37:14.706920Z",
    "lead_time": 4.336
  },
  {
    "text": "To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than GSK PLC and the Directors of GSK PLC as a body, for our work, for this report, or for the conclusions we have formed.",
    "id": 1149,
    "annotator": 1,
    "annotation_id": 1150,
    "created_at": "2024-11-06T07:37:20.575371Z",
    "updated_at": "2024-11-06T07:37:20.575371Z",
    "lead_time": 5.662
  },
  {
    "text": "DDeellooiittttee LLLLPP London, UK 27 February 2024 62 GSK ESG Performance Report 2023 March 2024",
    "id": 1150,
    "annotator": 1,
    "annotation_id": 1151,
    "created_at": "2024-11-06T07:37:22.075927Z",
    "updated_at": "2024-11-06T07:37:22.075927Z",
    "lead_time": 1.319
  },
  {
    "text": "12 BIOLIDICS LIMITED SUSTAINABILITY REPORT ANNUAL REPORT 2023 13 CONTENTS 14 BOARD STATEMENT 15 ABOUT THIS REPORT 16 MATERIALITY ASSESSMENT 17 STAKEHOLDER ENGAGEMENT 18 ECONOMIC 18 Economic Performance 18 ENVIRONMENTAL 18 Climate Change Mitigation and Adaptation 20 SOCIAL AND ENVIRONMENTAL 20 Occupational Health and Safety (including Effluents and Waste) 21 SOCIAL 21 Talent Retention (including Training and Education) 24 Diversity, Equal Opportunity and Non-discrimination 25 Research and Development\/Innovation 25 Customer Privacy 26 Product Quality and Safety 27 SOCIAL AND GOVERNANCE 27 Anti-corruption 28 GOVERNANCE 28 Environmental and Socioeconomic Compliance 29 SGX CONTENT INDEX 29 GRI CONTENT INDEX 14 BIOLIDICS LIMITED SUSTAINABILITY REPORT BOARD STATEMENT The board (\"Board\") of directors (\"Directors\") of Biolidics Limited (\"Biolidics\" or the \"Company\", and together with its subsidiaries, the \"Group\") is pleased to present the Group's sustainability report (the \"Report\") for the financial year ended 31 December 2023 (\"FY2023\").",
    "id": 1151,
    "annotator": 1,
    "annotation_id": 1152,
    "created_at": "2024-11-06T07:38:04.508227Z",
    "updated_at": "2024-11-06T07:38:04.508227Z",
    "lead_time": 16.453
  },
  {
    "text": "With the aim of lowering healthcare costs and improving clinical outcomes, Biolidics started its journey by pioneering of minimally invasive cancer diagnostics solutions since its initial public offering in December 2018.",
    "id": 1152,
    "annotator": 1,
    "annotation_id": 1153,
    "created_at": "2024-11-06T07:38:10.338054Z",
    "updated_at": "2024-11-06T07:38:10.338054Z",
    "lead_time": 5.618
  },
  {
    "text": "In 2020, the Group ventured into the area of diagnostic solutions for infectious diseases and provision of laboratory testing service.",
    "id": 1153,
    "annotator": 1,
    "annotation_id": 1154,
    "created_at": "2024-11-06T14:03:47.530843Z",
    "updated_at": "2024-11-06T14:03:47.530843Z",
    "lead_time": 20.915
  },
  {
    "text": "To provide additional and recurrent revenue streams for the Group, with the approval of shareholders in the Extraordinary General Meeting (\"EGM\") held in February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming (\"New Businesses\").",
    "id": 1154,
    "annotator": 1,
    "annotation_id": 1155,
    "created_at": "2024-11-06T14:03:54.123428Z",
    "updated_at": "2024-11-06T14:03:54.123428Z",
    "lead_time": 6.396
  },
  {
    "text": "This will allow the Group to reduce its reliance on the Group's existing business in cancer, infectious disease and laboratory services.",
    "id": 1155,
    "annotator": 1,
    "annotation_id": 1156,
    "created_at": "2024-11-06T14:03:59.336974Z",
    "updated_at": "2024-11-06T14:03:59.336974Z",
    "lead_time": 5.018
  },
  {
    "text": "The Board recognises the importance of sustainability and considers environmental, social and governance (\"ESG\") factors in its decision making, while focusing on areas which are most relevant to its business.",
    "id": 1156,
    "annotator": 1,
    "annotation_id": 1157,
    "created_at": "2024-11-06T14:04:08.243937Z",
    "updated_at": "2024-11-06T14:04:08.243937Z",
    "lead_time": 8.716
  },
  {
    "text": "For FY2023, the Group has continued its sustainability approach by reviewing its materiality assessment, performance indicators and targets that will guide its sustainability efforts.",
    "id": 1157,
    "annotator": 1,
    "annotation_id": 1158,
    "created_at": "2024-11-06T14:04:16.334430Z",
    "updated_at": "2024-11-06T14:04:16.334430Z",
    "lead_time": 7.903
  },
  {
    "text": "Regarding the governance of sustainability issues, the Board has overall responsibility for the ESG issues of the Group, including determining material ESG factors, formulating necessary strategies, ensuring the Group has appropriate and effective internal control and risk management systems, monitoring the Group's ESG performance, ensuring the Group's compliance with relevant external requirements, and reviewing and approving sustainability reports.",
    "id": 1158,
    "annotator": 1,
    "annotation_id": 1159,
    "created_at": "2024-11-06T14:06:39.602254Z",
    "updated_at": "2024-11-06T14:06:39.602254Z",
    "lead_time": 143.064
  },
  {
    "text": "Assisting the Board to fulfil its responsibility in ESG issues, the management (\"Management\") of Biolidics, including the Group's senior executives, are responsible for monitoring the implementation of relevant policies and measures in accordance with the Group's strategy, managing the Group's material ESG factors, and evaluating the Group's performance in various aspects of ESG.",
    "id": 1159,
    "annotator": 1,
    "annotation_id": 1160,
    "created_at": "2024-11-06T14:06:46.117598Z",
    "updated_at": "2024-11-06T14:06:46.117598Z",
    "lead_time": 6.341
  },
  {
    "text": "In support of the Management, the members of the sustainability reporting task force (\"SR Task Force\") are responsible for implementing relevant policies, evaluating and collecting ESG data, and keeping abreast of current sustainability trends through regular training.",
    "id": 1160,
    "label": [
      {
        "start": 45,
        "end": 84,
        "text": "the sustainability reporting task force",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 45,
        "end": 84,
        "text": "the sustainability reporting task force",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1161,
    "created_at": "2024-11-06T14:07:07.430757Z",
    "updated_at": "2024-11-06T14:07:07.430757Z",
    "lead_time": 21.13
  },
  {
    "text": "The Management and SR Task Force members report to the Board at least twice a year on the progress of ESG-related work, including the results of the materiality assessment of ESG factors and its targets in a timely manner, and provide advice to the Board on relevant issues to continuously improve the Group's ESG performance.",
    "id": 1161,
    "annotator": 1,
    "annotation_id": 1162,
    "created_at": "2024-11-06T14:07:14.049437Z",
    "updated_at": "2024-11-06T14:07:14.049437Z",
    "lead_time": 6.416
  },
  {
    "text": "The Board will at least annually review the Group's ESG performance and the effectiveness of the Group's policies and procedures in managing its material ESG factors.",
    "id": 1162,
    "annotator": 1,
    "annotation_id": 1163,
    "created_at": "2024-11-06T14:08:14.084577Z",
    "updated_at": "2024-11-06T14:08:14.084577Z",
    "lead_time": 59.852
  },
  {
    "text": "In addition, all Directors have attended the mandatory sustainability training courses to equip themselves with basic knowledge on sustainability matters.",
    "id": 1163,
    "label": [
      {
        "start": 45,
        "end": 87,
        "text": "mandatory sustainability training courses ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 45,
        "end": 86,
        "text": "mandatory sustainability training courses",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1164,
    "created_at": "2024-11-06T14:08:32.005667Z",
    "updated_at": "2024-11-06T14:08:32.005667Z",
    "lead_time": 17.741
  },
  {
    "text": "The Group is committed to growing sustainably as a forward-looking company covering its approach and performance in sustainability as the Group continues to actively explore expanding into New Businesses.",
    "id": 1164,
    "annotator": 1,
    "annotation_id": 1165,
    "created_at": "2024-11-06T14:08:37.801770Z",
    "updated_at": "2024-11-06T14:08:37.801770Z",
    "lead_time": 5.594
  },
  {
    "text": "This Report is prepared in accordance with the Listing Manual Section B: Rules of Catalist of the SGX-ST (\"Catalist Rules\") and with reference to the Global Reporting Initiative (\"GRI\") Standards.",
    "id": 1165,
    "annotator": 1,
    "annotation_id": 1166,
    "created_at": "2024-11-06T14:08:42.494594Z",
    "updated_at": "2024-11-06T14:08:42.494594Z",
    "lead_time": 4.513
  },
  {
    "text": "This Report serves as a platform for Biolidics to formally communicate its sustainability approach on its practices, performance and targets in relation to its sustainability efforts for FY2023 with its stakeholders.",
    "id": 1166,
    "annotator": 1,
    "annotation_id": 1167,
    "created_at": "2024-11-06T14:08:49.305662Z",
    "updated_at": "2024-11-06T14:08:49.305662Z",
    "lead_time": 6.635
  },
  {
    "text": "For target setting, the Group categorises targets set for the next year as \"short-term targets\", targets set for a period of two to five years as \"medium-term targets\", and targets set beyond five years as \"long-term targets\", with these time horizons being applied to the identified material ESG factors in target setting within its planning and strategy.",
    "id": 1167,
    "annotator": 1,
    "annotation_id": 1168,
    "created_at": "2024-11-06T14:08:55.305002Z",
    "updated_at": "2024-11-06T14:08:55.305002Z",
    "lead_time": 5.818
  },
  {
    "text": "Board of Directors Biolidics Limited ANNUAL REPORT 2023 15 SUSTAINABILITY REPORT ABOUT THIS REPORT This is Biolidics' fifth sustainability report.",
    "id": 1168,
    "annotator": 1,
    "annotation_id": 1169,
    "created_at": "2024-11-06T14:09:00.791439Z",
    "updated_at": "2024-11-06T14:09:00.791439Z",
    "lead_time": 5.317
  },
  {
    "text": "The scope of this Report focuses on the Group's key business operations in Singapore, including offices and laboratories located in Singapore, which is consistent with the scope of the Group's annual report for FY2023 and the same as the scope of the sustainability report for the financial year ended 31 December 2022 (\"FY2022\").",
    "id": 1169,
    "annotator": 1,
    "annotation_id": 1170,
    "created_at": "2024-11-06T14:09:06.755572Z",
    "updated_at": "2024-11-06T14:09:06.755572Z",
    "lead_time": 5.791
  },
  {
    "text": "Information disclosed in this Report reflects the Group's ESG efforts and encapsulates its commitment to grow sustainably as a forward-looking company covering its approach and performance in sustainability for FY2023.",
    "id": 1170,
    "annotator": 1,
    "annotation_id": 1171,
    "created_at": "2024-11-06T14:09:12.694761Z",
    "updated_at": "2024-11-06T14:09:12.694761Z",
    "lead_time": 5.766
  },
  {
    "text": "The Group will continue to assess the major ESG aspects of different businesses and extend the scope of disclosures when and where applicable.",
    "id": 1171,
    "annotator": 1,
    "annotation_id": 1172,
    "created_at": "2024-11-06T14:09:17.068849Z",
    "updated_at": "2024-11-06T14:09:17.068849Z",
    "lead_time": 4.196
  },
  {
    "text": "This Report is prepared in accordance with the requirements of Practice Note 7F: Sustainability Reporting Guide of the Catalist Rules and with reference to the GRI Standards.",
    "id": 1172,
    "annotator": 1,
    "annotation_id": 1173,
    "created_at": "2024-11-06T14:09:21.553800Z",
    "updated_at": "2024-11-06T14:09:21.553800Z",
    "lead_time": 4.308
  },
  {
    "text": "The GRI standards were chosen because they are one of the most commonly used frameworks, and therefore, familiar to readers.",
    "id": 1173,
    "annotator": 1,
    "annotation_id": 1174,
    "created_at": "2024-11-06T14:09:27.637760Z",
    "updated_at": "2024-11-06T14:09:27.637760Z",
    "lead_time": 5.907
  },
  {
    "text": "Throughout the preparation of the Report, the Group has applied the reporting principles of the GRI, which include accuracy, balance, clarity, comparability, completeness, sustainability context, timeliness, and verifiability.",
    "id": 1174,
    "label": [
      {
        "start": 96,
        "end": 100,
        "text": "GRI,",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 96,
        "end": 100,
        "text": "GRI,",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1175,
    "created_at": "2024-11-06T14:09:40.989342Z",
    "updated_at": "2024-11-06T14:09:40.989342Z",
    "lead_time": 13.166
  },
  {
    "text": "In addition, the climate-related disclosures in this Report include material information with reference to the recommendations provided by the Task Force on Climate-Related Financial Disclosures (\"TCFD\").",
    "id": 1175,
    "label": [
      {
        "start": 143,
        "end": 202,
        "text": "Task Force on Climate-Related Financial Disclosures (\"TCFD\"",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 143,
        "end": 202,
        "text": "Task Force on Climate-Related Financial Disclosures (\"TCFD\"",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1176,
    "created_at": "2024-11-06T14:09:57.973846Z",
    "updated_at": "2024-11-06T14:09:57.973846Z",
    "lead_time": 16.763
  },
  {
    "text": "This Report references the following Universal Standards and Topic Standards: GRI 1: Foundation 2021 GRI 2: General Disclosures 2021 GRI 3: Material Topics 2021 GRI 201: Economic Performance 2016 GRI 205: Anti-corruption 2016 GRI 305: Emissions 2016 GRI 306: Waste 2020 GRI 401: Employment 2016 GRI 403: Occupational Health and Safety 2018 GRI 404: Training and Education 2016 GRI 405: Diversity and Equal Opportunity 2016 GRI 406: Non-discrimination 2016 GRI 418: Customer Privacy 2016 This Report has undergone the internal review process of the Group, and was reviewed by the Board.",
    "id": 1176,
    "annotator": 1,
    "annotation_id": 1177,
    "created_at": "2024-11-06T14:11:19.710613Z",
    "updated_at": "2024-11-06T14:11:19.710613Z",
    "lead_time": 81.534
  },
  {
    "text": "The Group has engaged its internal auditors to perform an internal review of its sustainability reporting process.",
    "id": 1177,
    "annotator": 1,
    "annotation_id": 1178,
    "created_at": "2024-11-06T14:11:24.117082Z",
    "updated_at": "2024-11-06T14:11:24.117082Z",
    "lead_time": 4.207
  },
  {
    "text": "The Group has not sought external assurance for this Report for FY2023, and may consider undertaking it in the future.",
    "id": 1178,
    "annotator": 1,
    "annotation_id": 1179,
    "created_at": "2024-11-06T14:11:29.772886Z",
    "updated_at": "2024-11-06T14:11:29.773886Z",
    "lead_time": 5.472
  },
  {
    "text": "The Group strives to continuously refine its sustainability strategy and practices.",
    "id": 1179,
    "annotator": 1,
    "annotation_id": 1180,
    "created_at": "2024-11-06T14:11:33.534548Z",
    "updated_at": "2024-11-06T14:11:33.534548Z",
    "lead_time": 3.576
  },
  {
    "text": "The Group greatly welcomes your feedback and comments regarding this Report.",
    "id": 1180,
    "annotator": 1,
    "annotation_id": 1181,
    "created_at": "2024-11-06T14:11:37.296433Z",
    "updated_at": "2024-11-06T14:11:37.296433Z",
    "lead_time": 3.586
  },
  {
    "text": "You can reach us at support@biolidics.com.",
    "id": 1181,
    "annotator": 1,
    "annotation_id": 1182,
    "created_at": "2024-11-06T14:11:38.804548Z",
    "updated_at": "2024-11-06T14:11:38.804548Z",
    "lead_time": 1.348
  },
  {
    "text": "16 BIOLIDICS LIMITED SUSTAINABILITY REPORT MATERIALITY ASSESSMENT The Group conducted a materiality assessment exercise, referencing the GRI Standards   GRI 3: Material Topics 2021.",
    "id": 1182,
    "annotator": 1,
    "annotation_id": 1183,
    "created_at": "2024-11-06T14:11:44.367716Z",
    "updated_at": "2024-11-06T14:11:44.367716Z",
    "lead_time": 5.4
  },
  {
    "text": "The objective of the exercise was to identify, prioritise and validate ESG factors that are significant to business operations and of interest to the Group's key stakeholders.",
    "id": 1183,
    "annotator": 1,
    "annotation_id": 1184,
    "created_at": "2024-11-06T14:11:50.330132Z",
    "updated_at": "2024-11-06T14:11:50.330132Z",
    "lead_time": 5.781
  },
  {
    "text": "With the facilitation of an external consultant and by considering trends and current themes of concern in the healthcare industry as well as the sustainability trends in Singapore and globally, the Group has shortlisted and identified 10 material ESG factors.",
    "id": 1184,
    "annotator": 1,
    "annotation_id": 1185,
    "created_at": "2024-11-06T14:11:55.359734Z",
    "updated_at": "2024-11-06T14:11:55.359734Z",
    "lead_time": 4.84
  },
  {
    "text": "Then, the Group conducted a materiality assessment in the form of questionnaires.",
    "id": 1185,
    "annotator": 1,
    "annotation_id": 1186,
    "created_at": "2024-11-06T14:11:58.964735Z",
    "updated_at": "2024-11-06T14:11:58.964735Z",
    "lead_time": 3.429
  },
  {
    "text": "Shareholders, customers and employees from different business units across the Group were involved in completing the materiality survey and rated the relative importance of these factors according to the significance of their impacts on the economy, environment, and people, including impacts on the human rights, as well as their influence on business strategy, financial planning, and the overall business model.",
    "id": 1186,
    "annotator": 1,
    "annotation_id": 1187,
    "created_at": "2024-11-06T14:12:04.261270Z",
    "updated_at": "2024-11-06T14:12:04.261270Z",
    "lead_time": 5.129
  },
  {
    "text": "Based on the results of the materiality survey, the priority of different material ESG factors was identified and disclosed in the table below.",
    "id": 1187,
    "annotator": 1,
    "annotation_id": 1188,
    "created_at": "2024-11-06T14:12:09.725090Z",
    "updated_at": "2024-11-06T14:12:09.725090Z",
    "lead_time": 5.175
  },
  {
    "text": "The results of the materiality assessment has been reviewed and approved by the Management and the Board.",
    "id": 1188,
    "annotator": 1,
    "annotation_id": 1189,
    "created_at": "2024-11-06T14:12:14.483517Z",
    "updated_at": "2024-11-06T14:12:14.483517Z",
    "lead_time": 4.595
  },
  {
    "text": "The following table depicts the relative importance of the Group's material factors for FY2023.",
    "id": 1189,
    "annotator": 1,
    "annotation_id": 1190,
    "created_at": "2024-11-06T14:12:17.769631Z",
    "updated_at": "2024-11-06T14:12:17.769631Z",
    "lead_time": 3.129
  },
  {
    "text": "Material Factors Rating Sustainability Aspects For Detailed Information Economic Performance 2   Operations & Financial Review, pages 4 to 6   Financial Statements, pages 65 to 113   Sustainability Report, page 18 Climate Change Mitigation and 10 Sustainability Report, Adaptation page 18 to 19 Occupational Health and Safety 7 Sustainability Report, (including Effluents and Waste) page 20 to 21 Talent Retention (including Training 4 Sustainability Report, and Education) pages 21 to 23 Diversity, Equal Opportunity and 8 Sustainability Report, Non-discrimination pages 24 to 25 Research and Development\/ 5 Sustainability Report, Innovation pages 25 Customer Privacy 1 Sustainability Report, page 25 Product Quality and Safety 2 Sustainability Report, page 26 Anti-corruption 5 Sustainability Report, page 27 Environmental and Socioeconomic 9 Sustainability Report, Compliance page 28 Legend: Economic Environmental Social Governance ANNUAL REPORT 2023 17 SUSTAINABILITY REPORT STAKEHOLDER ENGAGEMENT The Group recognises that communicating with its stakeholders allows it to further develop and refine its business strategies and respond quickly and effectively to their concerns and needs.",
    "id": 1190,
    "annotator": 1,
    "annotation_id": 1191,
    "created_at": "2024-11-06T14:12:28.037692Z",
    "updated_at": "2024-11-06T14:12:28.037692Z",
    "lead_time": 10.083
  },
  {
    "text": "Stakeholders' engagement is carried out through various communication channels and methods as depicted in the table below: Frequency of Stakeholders Key Topics and Concerns Engagement Methods Engagement Customers   Quality of products and   Contact form on the When applicable services Group s website   User experience   Product promotions   Customer and technical support Strategic partners   Market and industry trends   Regular meetings and Throughout the year   Long-term partnership follow-ups   The Group s financial   Partner support channel performance   Technical updates   Business growth plans   Good corporate governance Employees   Training and development   Regular meetings and Throughout the year of employees briefings   Recruitment and retention   Employee performance of skilled employees review   Well-being of employees   Training programmes Governments and   Compliance with laws and   Meetings and consultations Throughout the year regulators regulations   License applications and regulatory filings   Responding to requests for information (e.g. through surveys) Shareholders   The Group s financial   Annual general meetings Periodically performance   Announcements of material   Good corporate governance information, including   Sustainable business financial performance, growth through SGXNET and the Group s website 18 BIOLIDICS LIMITED SUSTAINABILITY REPORT ECONOMIC Economic Performance The Group has consistently demonstrated a commitment to growth and financial stability by actively seeking opportunities to expand its business activities.",
    "id": 1191,
    "annotator": 1,
    "annotation_id": 1192,
    "created_at": "2024-11-06T14:12:37.549622Z",
    "updated_at": "2024-11-06T14:12:37.549622Z",
    "lead_time": 9.336
  },
  {
    "text": "In addition to pursuing growth avenues, the Group strives to optimise its cost structure, ensuring prudent management of expenses and preserving cashflows.",
    "id": 1192,
    "annotator": 1,
    "annotation_id": 1193,
    "created_at": "2024-11-06T14:12:44.652859Z",
    "updated_at": "2024-11-06T14:12:44.652859Z",
    "lead_time": 6.912
  },
  {
    "text": "For the financial year ending 31 December 2024 (\"FY2024\"), the Group has set targets for both the short-term and long-term, including achieving an improvement in revenue through New Businesses, maintaining the practice of disclosing the Group's financial statements in alignment with recognised financial reporting standards with zero instances of non-compliance and continuing the pursuit of opportunities for business diversification.",
    "id": 1193,
    "annotator": 1,
    "annotation_id": 1194,
    "created_at": "2024-11-06T14:12:51.794432Z",
    "updated_at": "2024-11-06T14:12:51.794432Z",
    "lead_time": 6.942
  },
  {
    "text": "The Group is cognizant of the importance of linking executive remuneration to sustainability performance.",
    "id": 1194,
    "annotator": 1,
    "annotation_id": 1195,
    "created_at": "2024-11-06T14:12:58.603360Z",
    "updated_at": "2024-11-06T14:12:58.603360Z",
    "lead_time": 6.621
  },
  {
    "text": "However, as the Group has incurred losses since incorporation, it will only be feasible to reward executives for achieving sustainability targets when the Group becomes profitable.",
    "id": 1195,
    "annotator": 1,
    "annotation_id": 1196,
    "created_at": "2024-11-06T14:13:02.959162Z",
    "updated_at": "2024-11-06T14:13:02.959162Z",
    "lead_time": 4.167
  },
  {
    "text": "For more information regarding the Group's economic performance for FY2023, please refer to the Operations & Financial Review section and Financial Statements section of this annual report.",
    "id": 1196,
    "annotator": 1,
    "annotation_id": 1197,
    "created_at": "2024-11-06T14:13:07.822029Z",
    "updated_at": "2024-11-06T14:13:07.822029Z",
    "lead_time": 4.675
  },
  {
    "text": "ENVIRONMENTAL Climate Change Mitigation and Adaptation FY2023 Performance In FY2023, the Group's greenhouse gas (\"GHG\") emissions intensity is 0.06 tCO e\/thousand revenue (S$).",
    "id": 1197,
    "label": [
      {
        "start": 85,
        "end": 139,
        "text": "the Group's greenhouse gas (\"GHG\") emissions intensity",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 143,
        "end": 147,
        "text": "0.06",
        "labels": [
          "value"
        ]
      },
      {
        "start": 148,
        "end": 175,
        "text": "tCO e\/thousand revenue (S$)",
        "labels": [
          "unit"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1198,
    "created_at": "2024-11-06T14:13:31.615667Z",
    "updated_at": "2024-11-06T14:13:31.615667Z",
    "lead_time": 23.608
  },
  {
    "text": "Despite 2 a decrease in electricity consumption, the target of maintaining or reducing GHG emissions intensity, based on the baseline of 0.03 tCO e\/thousand revenue from FY2022, was not successfully achieved due to a significant decline in 2 revenue.",
    "id": 1198,
    "annotator": 1,
    "annotation_id": 1199,
    "created_at": "2024-11-06T14:13:38.478893Z",
    "updated_at": "2024-11-06T14:13:38.478893Z",
    "lead_time": 6.626
  },
  {
    "text": "The Group has organised at least one activity each year to raise awareness among employees on climate change.",
    "id": 1199,
    "annotator": 1,
    "annotation_id": 1200,
    "created_at": "2024-11-06T14:13:43.619913Z",
    "updated_at": "2024-11-06T14:13:43.619913Z",
    "lead_time": 4.948
  },
  {
    "text": "FY2024 Target Short-term target: Organise at least one activity each year to raise awareness among employees on climate change.",
    "id": 1200,
    "annotator": 1,
    "annotation_id": 1201,
    "created_at": "2024-11-06T14:13:57.230399Z",
    "updated_at": "2024-11-06T14:13:57.230399Z",
    "lead_time": 13.421
  },
  {
    "text": "Medium-term target: Maintain or reduce GHG emissions intensity by the financial year ending 31 December 2028 (\"FY2028\"), using baseline of FY2023 GHG emissions intensity.",
    "id": 1201,
    "annotator": 1,
    "annotation_id": 1202,
    "created_at": "2024-11-06T14:14:05.858284Z",
    "updated_at": "2024-11-06T14:14:05.858284Z",
    "lead_time": 8.44
  },
  {
    "text": "The Group understands the importance of developing a strategy and risk management framework that sets the foundation for the Group's climate resilience.",
    "id": 1202,
    "annotator": 1,
    "annotation_id": 1203,
    "created_at": "2024-11-06T14:14:12.240256Z",
    "updated_at": "2024-11-06T14:14:12.240256Z",
    "lead_time": 6.17
  },
  {
    "text": "The Group acknowledges that the TCFD provides recommendations regarding the disclosure of climate-related financial information.",
    "id": 1203,
    "annotator": 1,
    "annotation_id": 1204,
    "created_at": "2024-11-06T14:14:17.521914Z",
    "updated_at": "2024-11-06T14:14:17.521914Z",
    "lead_time": 5.108
  },
  {
    "text": "TCFD has four overarching elements, including governance, strategy, risk management and metrics and targets, to assess the impact of key climate-related risks and opportunities.",
    "id": 1204,
    "annotator": 1,
    "annotation_id": 1205,
    "created_at": "2024-11-06T14:14:23.342405Z",
    "updated_at": "2024-11-06T14:14:23.342405Z",
    "lead_time": 5.634
  },
  {
    "text": "The Group will continue to strengthen its disclosure with reference to TCFD.",
    "id": 1205,
    "annotator": 1,
    "annotation_id": 1206,
    "created_at": "2024-11-06T14:14:27.603466Z",
    "updated_at": "2024-11-06T14:14:27.603466Z",
    "lead_time": 4.086
  },
  {
    "text": "Governance The Board has oversight of the Group's sustainability strategy including its formulation and reviews disclosures relating to climate-related risk and opportunities and its actions to enhance climate resilience.",
    "id": 1206,
    "annotator": 1,
    "annotation_id": 1207,
    "created_at": "2024-11-06T14:14:32.464841Z",
    "updated_at": "2024-11-06T14:14:32.464841Z",
    "lead_time": 4.672
  },
  {
    "text": "The Management is responsible for developing objectives, plans and performance metrics, managing and monitoring the overall climate-related sustainability performance, and driving the implementation of relevant initiatives across different departments and business units.",
    "id": 1207,
    "annotator": 1,
    "annotation_id": 1208,
    "created_at": "2024-11-06T14:14:52.233182Z",
    "updated_at": "2024-11-06T14:14:52.233182Z",
    "lead_time": 19.578
  },
  {
    "text": "In collaboration with the Management, the SR Task Force will maintain and implement climate-related policies, conduct necessary climate risk assessments, and gather pertinent information.",
    "id": 1208,
    "annotator": 1,
    "annotation_id": 1209,
    "created_at": "2024-11-06T14:15:10.324141Z",
    "updated_at": "2024-11-06T14:15:10.324141Z",
    "lead_time": 17.904
  },
  {
    "text": "The Management and SR Task Force will report to and provide suggestions to the Board, where appropriate, regarding the material sustainability issues, including climate- related matters.",
    "id": 1209,
    "annotator": 1,
    "annotation_id": 1210,
    "created_at": "2024-11-06T14:15:17.186919Z",
    "updated_at": "2024-11-06T14:15:17.186919Z",
    "lead_time": 6.679
  },
  {
    "text": "ANNUAL REPORT 2023 19 SUSTAINABILITY REPORT Strategy The Group continuously updates itself on climate-related risks, including physical risks and transition risks, and climatic events affecting its business, strategy and financial planning.",
    "id": 1210,
    "annotator": 1,
    "annotation_id": 1211,
    "created_at": "2024-11-06T14:15:27.708446Z",
    "updated_at": "2024-11-06T14:15:27.708446Z",
    "lead_time": 10.339
  },
  {
    "text": "The Group has identified that the transition risks are more material to the Group's business and operation.",
    "id": 1211,
    "annotator": 1,
    "annotation_id": 1212,
    "created_at": "2024-11-06T14:15:31.918940Z",
    "updated_at": "2024-11-06T14:15:31.918940Z",
    "lead_time": 4.008
  },
  {
    "text": "The Group expects that the laws and regulations related to climate change will become more stringent and more demanding, with developments such as more aggressive government policies and measures to limit GHG emissions, in addition to carbon taxes.",
    "id": 1212,
    "annotator": 1,
    "annotation_id": 1213,
    "created_at": "2024-11-06T14:15:37.598417Z",
    "updated_at": "2024-11-06T14:15:37.598417Z",
    "lead_time": 5.473
  },
  {
    "text": "As a result, the Group may be exposed to legal risks and compliance requirements which in turn may lead to higher operating costs.",
    "id": 1213,
    "annotator": 1,
    "annotation_id": 1214,
    "created_at": "2024-11-06T14:15:43.347846Z",
    "updated_at": "2024-11-06T14:15:43.347846Z",
    "lead_time": 5.56
  },
  {
    "text": "While physical risks generally remain low, the Group still faces extreme weather events such as heavy rainfall and extreme heat, which might disrupt the Group's business operations and pose threat to the health and safety of its employees.",
    "id": 1214,
    "annotator": 1,
    "annotation_id": 1215,
    "created_at": "2024-11-06T14:15:53.608945Z",
    "updated_at": "2024-11-06T14:15:53.608945Z",
    "lead_time": 10.053
  },
  {
    "text": "With the increased awareness of climate change, the Group's stakeholders may prefer products and services that are less damaging to the climate.",
    "id": 1215,
    "annotator": 1,
    "annotation_id": 1216,
    "created_at": "2024-11-06T15:11:44.040954Z",
    "updated_at": "2024-11-06T15:11:44.040954Z",
    "lead_time": 3349.932
  },
  {
    "text": "As a result, the transition to a low-carbon business model can bring opportunities.",
    "id": 1216,
    "annotator": 1,
    "annotation_id": 1217,
    "created_at": "2024-11-06T15:11:51.692982Z",
    "updated_at": "2024-11-06T15:11:51.692982Z",
    "lead_time": 7.447
  },
  {
    "text": "If the Group is able to adopt more environmentally-friendly practices in its operations, the Group may be able to seize more business opportunities from business customers who recognise the Group's environmental initiatives.",
    "id": 1217,
    "annotator": 1,
    "annotation_id": 1218,
    "created_at": "2024-11-06T15:12:00.308056Z",
    "updated_at": "2024-11-06T15:12:00.308056Z",
    "lead_time": 8.429
  },
  {
    "text": "In addition, the Group will explore and implement climate scenario analysis to strengthen its resilience against the potential impact of climate change on its operations in the future.",
    "id": 1218,
    "annotator": 1,
    "annotation_id": 1219,
    "created_at": "2024-11-06T15:12:14.982681Z",
    "updated_at": "2024-11-06T15:12:14.982681Z",
    "lead_time": 14.48
  },
  {
    "text": "Risk Management The Board, with the assistance from the audit committee of the Company, is responsible for risk governance and ensuring that the Management maintains a sound system of risk management and internal controls.",
    "id": 1219,
    "annotator": 1,
    "annotation_id": 1220,
    "created_at": "2024-11-06T15:12:37.296939Z",
    "updated_at": "2024-11-06T15:12:37.296939Z",
    "lead_time": 22.132
  },
  {
    "text": "Recognising the climate-related risks, along with other ESG risks that affect or will affect its businesses, the Group will include climate change risks into the enterprise risk management process of the Group.",
    "id": 1220,
    "annotator": 1,
    "annotation_id": 1221,
    "created_at": "2024-11-07T01:05:03.316961Z",
    "updated_at": "2024-11-07T01:05:03.316961Z",
    "lead_time": 27.446
  },
  {
    "text": "To mitigate the identified risks, the Group has adopted the Climate Change Policy.",
    "id": 1221,
    "annotator": 1,
    "annotation_id": 1222,
    "created_at": "2024-11-07T01:05:07.265931Z",
    "updated_at": "2024-11-07T01:05:07.265931Z",
    "lead_time": 3.751
  },
  {
    "text": "The Group regularly monitors existing and emerging trends, policies and regulations related to climate change, and reminds the Management when necessary to avoid violations or reputation risks due to delayed response.",
    "id": 1222,
    "annotator": 1,
    "annotation_id": 1223,
    "created_at": "2024-11-07T01:05:14.144436Z",
    "updated_at": "2024-11-07T01:05:14.144436Z",
    "lead_time": 6.676
  },
  {
    "text": "As the Group goes beyond compliance to strive to improve the environmental performance of its operations, the Group can quickly adapt to the more stringent regulations that may arise.",
    "id": 1223,
    "annotator": 1,
    "annotation_id": 1224,
    "created_at": "2024-11-07T01:05:19.038350Z",
    "updated_at": "2024-11-07T01:05:19.038350Z",
    "lead_time": 4.701
  },
  {
    "text": "Metrics and Targets The Group is aware that its businesses involve emissions and recognises that reduction of emission is essential.",
    "id": 1224,
    "annotator": 1,
    "annotation_id": 1225,
    "created_at": "2024-11-07T01:05:24.121160Z",
    "updated_at": "2024-11-07T01:05:24.121160Z",
    "lead_time": 4.896
  },
  {
    "text": "The Group's major sources of GHG emissions is energy indirect GHG emissions from purchased electricity (Scope 2), no direct GHG emissions (Scope 1) were generated.",
    "id": 1225,
    "annotator": 1,
    "annotation_id": 1226,
    "created_at": "2024-11-07T01:05:42.255940Z",
    "updated_at": "2024-11-07T01:05:42.255940Z",
    "lead_time": 17.94
  },
  {
    "text": "In FY2023, the Group generated a total of 74.45 tCOe of GHG emissions, 2 which is equivalent to 0.06 tCO e\/thousand revenue (S$).",
    "id": 1226,
    "label": [
      {
        "start": 42,
        "end": 47,
        "text": "74.45",
        "labels": [
          "value"
        ]
      },
      {
        "start": 56,
        "end": 69,
        "text": "GHG emissions",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 48,
        "end": 52,
        "text": "tCOe",
        "labels": [
          "unit"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1227,
    "created_at": "2024-11-07T01:06:10.203103Z",
    "updated_at": "2024-11-07T01:06:10.203103Z",
    "lead_time": 27.746
  },
  {
    "text": "GHG emissions data is calculated based on, including but 2 not limited to, \"The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standards\" issued by the World Resources Institute and the World Business Council for Sustainable Development and the 2022 grid emission factor issued by the Energy Market Authority of Singapore.",
    "id": 1227,
    "annotator": 1,
    "annotation_id": 1228,
    "created_at": "2024-11-07T01:06:18.898004Z",
    "updated_at": "2024-11-07T01:06:18.898004Z",
    "lead_time": 8.475
  },
  {
    "text": "The Group has striven to mitigate its GHG emissions and has set a GHG emissions reduction target, as mentioned earlier in this section.",
    "id": 1228,
    "annotator": 1,
    "annotation_id": 1229,
    "created_at": "2024-11-07T01:06:33.874744Z",
    "updated_at": "2024-11-07T01:06:33.874744Z",
    "lead_time": 14.772
  },
  {
    "text": "Moving forward, the Group will continue to devote its efforts and ensure that its strategies align with its commitment.",
    "id": 1229,
    "annotator": 1,
    "annotation_id": 1230,
    "created_at": "2024-11-07T01:07:15.528681Z",
    "updated_at": "2024-11-07T01:07:15.528681Z",
    "lead_time": 41.453
  },
  {
    "text": "Energy and Water Consumption In FY2023, the Group consumed approximately 178,617.00 kWh of electricity and 51.99 cubic metres of water.",
    "id": 1230,
    "label": [
      {
        "start": 73,
        "end": 83,
        "text": "178,617.00",
        "labels": [
          "value"
        ]
      },
      {
        "start": 84,
        "end": 87,
        "text": "kWh",
        "labels": [
          "unit"
        ]
      },
      {
        "start": 91,
        "end": 102,
        "text": "electricity",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 129,
        "end": 134,
        "text": "water",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 107,
        "end": 112,
        "text": "51.99",
        "labels": [
          "value"
        ]
      },
      {
        "start": 113,
        "end": 125,
        "text": "cubic metres",
        "labels": [
          "unit"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1231,
    "created_at": "2024-11-07T01:07:53.097751Z",
    "updated_at": "2024-11-07T01:07:53.097751Z",
    "lead_time": 37.356
  },
  {
    "text": "The Group aims to minimise its environmental footprint and promote sustainable practices to reduce water consumption and increase energy efficiency.",
    "id": 1231,
    "annotator": 1,
    "annotation_id": 1232,
    "created_at": "2024-11-07T01:08:01.005977Z",
    "updated_at": "2024-11-07T01:08:01.005977Z",
    "lead_time": 7.656
  },
  {
    "text": "20 BIOLIDICS LIMITED SUSTAINABILITY REPORT SOCIAL AND ENVIRONMENTAL Occupational Health and Safety (including Effluents and Waste) FY2023 Performance In FY2023, there were no fatalities or workplace injuries.",
    "id": 1232,
    "annotator": 1,
    "annotation_id": 1233,
    "created_at": "2024-11-07T01:08:07.075294Z",
    "updated_at": "2024-11-07T01:08:07.075294Z",
    "lead_time": 5.871
  },
  {
    "text": "The target of maintaining zero fatalities and workplace injuries was successfully achieved.",
    "id": 1233,
    "label": [
      {
        "start": 26,
        "end": 30,
        "text": "zero",
        "labels": [
          "value"
        ]
      },
      {
        "start": 31,
        "end": 64,
        "text": "fatalities and workplace injuries",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1234,
    "created_at": "2024-11-07T01:10:49.073077Z",
    "updated_at": "2024-11-07T01:10:49.073077Z",
    "lead_time": 161.773
  },
  {
    "text": "FY2024 Target Short-term target: Maintain zero fatalities and workplace injuries.",
    "id": 1234,
    "annotator": 1,
    "annotation_id": 1235,
    "created_at": "2024-11-07T01:10:54.618263Z",
    "updated_at": "2024-11-07T01:10:54.618263Z",
    "lead_time": 5.339
  },
  {
    "text": "Medium-term target: Conduct periodic safety audits and inspections to identify potential hazards and ensure compliance with safety standards.",
    "id": 1235,
    "annotator": 1,
    "annotation_id": 1236,
    "created_at": "2024-11-07T01:11:31.869738Z",
    "updated_at": "2024-11-07T01:11:31.869738Z",
    "lead_time": 37.042
  },
  {
    "text": "Occupational Health and Safety The Group recognises that a workplace that fosters a safety and healthy environment is important in ensuring that employees are safe, healthy, satisfied and engaged at work.",
    "id": 1236,
    "annotator": 1,
    "annotation_id": 1237,
    "created_at": "2024-11-07T01:11:37.880882Z",
    "updated_at": "2024-11-07T01:11:37.880882Z",
    "lead_time": 5.797
  },
  {
    "text": "Committed employees are imperative for the Group to achieve its growth objectives; and hence, the Group engages with its workforce to continuously innovate and improve its technology.",
    "id": 1237,
    "annotator": 1,
    "annotation_id": 1238,
    "created_at": "2024-11-07T01:12:05.970086Z",
    "updated_at": "2024-11-07T01:12:05.970086Z",
    "lead_time": 27.879
  },
  {
    "text": "Safety is of utmost importance to the Group.",
    "id": 1238,
    "annotator": 1,
    "annotation_id": 1239,
    "created_at": "2024-11-07T01:12:09.583802Z",
    "updated_at": "2024-11-07T01:12:09.583802Z",
    "lead_time": 3.421
  },
  {
    "text": "The Group's activities currently require the controlled use of potentially harmful biological materials and chemicals such as cancer cell lines and formaldehyde.",
    "id": 1239,
    "annotator": 1,
    "annotation_id": 1240,
    "created_at": "2024-11-07T01:12:16.027851Z",
    "updated_at": "2024-11-07T01:12:16.027851Z",
    "lead_time": 6.262
  },
  {
    "text": "There is a risk of accidental contamination or injury to employees or third parties from the handling, use and disposal of these materials and chemicals.",
    "id": 1240,
    "annotator": 1,
    "annotation_id": 1241,
    "created_at": "2024-11-07T01:12:19.975914Z",
    "updated_at": "2024-11-07T01:12:19.975914Z",
    "lead_time": 3.754
  },
  {
    "text": "Therefore, the Group has established the Maintenance of Work Environment and Laboratory Safety Manual to specify different types of potential hazards in the workplace and implement corresponding measures based on the seriousness of different types of hazardous, so as to minimise potential risks for all employees.",
    "id": 1241,
    "annotator": 1,
    "annotation_id": 1242,
    "created_at": "2024-11-07T01:32:31.164309Z",
    "updated_at": "2024-11-07T01:32:31.164309Z",
    "lead_time": 1210.687
  },
  {
    "text": "The minimisation of safety-related issues will not only ensure a safe and conducive working environment, but also translate to a reduction in business disruption and protect the reputation of the Group.",
    "id": 1242,
    "annotator": 1,
    "annotation_id": 1243,
    "created_at": "2024-11-07T01:32:38.575944Z",
    "updated_at": "2024-11-07T01:32:38.575944Z",
    "lead_time": 7.204
  },
  {
    "text": "Employees of the Group are provided the opportunity to participate in and are consulted during the development, implementation, and evaluation of the occupational health and safety management system.",
    "id": 1243,
    "annotator": 1,
    "annotation_id": 1244,
    "created_at": "2024-11-07T01:33:04.409223Z",
    "updated_at": "2024-11-07T01:33:04.409223Z",
    "lead_time": 25.634
  },
  {
    "text": "The employees are allowed to report work-related hazards, hazardous situations and incidents, however minor, to responsible personnel.",
    "id": 1244,
    "annotator": 1,
    "annotation_id": 1245,
    "created_at": "2024-11-07T01:33:09.281293Z",
    "updated_at": "2024-11-07T01:33:09.281293Z",
    "lead_time": 4.689
  },
  {
    "text": "Upon receiving relevant report, investigation will be carried out to identify the hazards and risks associated with the case reported, and corrective actions will be made to ensure similar issues would not occur again.",
    "id": 1245,
    "annotator": 1,
    "annotation_id": 1246,
    "created_at": "2024-11-07T03:18:32.831413Z",
    "updated_at": "2024-11-07T03:18:32.831413Z",
    "lead_time": 23.799
  },
  {
    "text": "Proper treatment and disposal of biological waste is also essential to the Group to prevent any potential contamination or injury to employees or third parties.",
    "id": 1246,
    "annotator": 1,
    "annotation_id": 1247,
    "created_at": "2024-11-07T03:18:38.639004Z",
    "updated_at": "2024-11-07T03:18:38.639004Z",
    "lead_time": 5.602
  },
  {
    "text": "Hence, the Group has implemented occupational health and safety management system in accordance with the following policies and processes: Guidelines from Ministry of Health (\"MOH\"), Singapore; Workplace Safety and Health Act, Chapter 354A of Singapore and the regulations thereunder; Environmental Public Health Act, Chapter 95 of Singapore (the \"Environmental Public Health Act (Toxic Industrial Waste) Regulations\") and the regulations thereunder; Guidelines from MOH: Biosafety and Biosecurity Manual, Housekeeping and General Maintenance, Decontamination and Waste Management; and The Group's internal risk assessment management standards and health and safety guidelines.",
    "id": 1247,
    "label": [
      {
        "start": 138,
        "end": 181,
        "text": " Guidelines from Ministry of Health (\"MOH\")",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 139,
        "end": 181,
        "text": "Guidelines from Ministry of Health (\"MOH\")",
        "labels": [
          "value"
        ]
      },
      {
        "start": 183,
        "end": 225,
        "text": "Singapore; Workplace Safety and Health Act",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 182,
        "end": 225,
        "text": " Singapore; Workplace Safety and Health Act",
        "labels": [
          "value"
        ]
      },
      {
        "start": 227,
        "end": 283,
        "text": "Chapter 354A of Singapore and the regulations thereunder",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 227,
        "end": 283,
        "text": "Chapter 354A of Singapore and the regulations thereunder",
        "labels": [
          "value"
        ]
      },
      {
        "start": 285,
        "end": 316,
        "text": "Environmental Public Health Act",
        "labels": [
          "value"
        ]
      },
      {
        "start": 285,
        "end": 316,
        "text": "Environmental Public Health Act",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 451,
        "end": 470,
        "text": "Guidelines from MOH",
        "labels": [
          "value"
        ]
      },
      {
        "start": 451,
        "end": 470,
        "text": "Guidelines from MOH",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 544,
        "end": 580,
        "text": "Decontamination and Waste Management",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 544,
        "end": 580,
        "text": "Decontamination and Waste Management",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1248,
    "created_at": "2024-11-07T03:20:48.014011Z",
    "updated_at": "2024-11-07T03:20:48.014011Z",
    "lead_time": 129.179
  },
  {
    "text": "The Group also provides regular training to educate its employees on the potential health and safety hazards in the work environment, and the proper precautions to prevent any accidents.",
    "id": 1248,
    "annotator": 1,
    "annotation_id": 1249,
    "created_at": "2024-11-07T03:20:52.410864Z",
    "updated_at": "2024-11-07T03:20:52.410864Z",
    "lead_time": 4.146
  },
  {
    "text": "In addition, the Group provides medical and dental benefits to its employees.",
    "id": 1249,
    "annotator": 1,
    "annotation_id": 1250,
    "created_at": "2024-11-07T03:20:55.806065Z",
    "updated_at": "2024-11-07T03:20:55.806065Z",
    "lead_time": 3.215
  },
  {
    "text": "ANNUAL REPORT 2023 21 SUSTAINABILITY REPORT In FY2023, there were no cases of work-related injuries and fatalities for all employees.",
    "id": 1250,
    "annotator": 1,
    "annotation_id": 1251,
    "created_at": "2024-11-07T03:20:59.537712Z",
    "updated_at": "2024-11-07T03:21:30.171709Z",
    "lead_time": 10.452
  },
  {
    "text": "Therefore, the absenteeism rates for employees were at an average of zero days per annum.",
    "id": 1251,
    "label": [
      {
        "start": 69,
        "end": 78,
        "text": "zero days",
        "labels": [
          "value"
        ]
      },
      {
        "start": 15,
        "end": 46,
        "text": "absenteeism rates for employees",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1252,
    "created_at": "2024-11-07T03:21:19.651633Z",
    "updated_at": "2024-11-07T03:21:19.651633Z",
    "lead_time": 19.925
  },
  {
    "text": "Effluents and Waste At Biolidics, it maintains its duty to dispose of its waste responsibly, especially toxic waste due to its potential for causing harm to the environment and endangering the health and safety of individuals.",
    "id": 1252,
    "annotator": 1,
    "annotation_id": 1253,
    "created_at": "2024-11-07T03:21:38.579274Z",
    "updated_at": "2024-11-07T03:21:38.579274Z",
    "lead_time": 6.715
  },
  {
    "text": "The Group has implemented the Laboratory Safety Manual and adheres to the Environmental Public Health Act (Toxic Industrial Waste) Regulations which require all its authorised waste collectors to be licensed.",
    "id": 1253,
    "annotator": 1,
    "annotation_id": 1254,
    "created_at": "2024-11-07T03:21:42.537641Z",
    "updated_at": "2024-11-07T03:21:42.537641Z",
    "lead_time": 3.783
  },
  {
    "text": "The license will be granted on the condition that: The toxic waste treatment, storage and disposal facility owned by the collector is in a suitable industrial area outside water catchment; The types and quantities of toxic waste are commensurate with the treatment processes and disposal facilities; and Adequate measures such as containment areas, leak detection and warning devices, proper emergency action plans, neutralising agents, handling gear, absorbent material, etc.",
    "id": 1254,
    "annotator": 1,
    "annotation_id": 1255,
    "created_at": "2024-11-07T03:21:52.982452Z",
    "updated_at": "2024-11-07T03:21:52.982452Z",
    "lead_time": 10.261
  },
  {
    "text": "are provided to prevent and mitigate any accidental release of toxic waste.",
    "id": 1255,
    "annotator": 1,
    "annotation_id": 1256,
    "created_at": "2024-11-07T03:22:05.530871Z",
    "updated_at": "2024-11-07T03:22:05.530871Z",
    "lead_time": 1.519
  },
  {
    "text": "In FY2023, the Group disposed 9,160.00 litres of waste to its authorised waste collectors.",
    "id": 1256,
    "label": [
      {
        "start": 30,
        "end": 38,
        "text": "9,160.00",
        "labels": [
          "value"
        ]
      },
      {
        "start": 39,
        "end": 45,
        "text": "litres",
        "labels": [
          "unit"
        ]
      },
      {
        "start": 49,
        "end": 54,
        "text": "waste",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1257,
    "created_at": "2024-11-07T03:22:25.742225Z",
    "updated_at": "2024-11-07T03:22:25.742225Z",
    "lead_time": 20.023
  },
  {
    "text": "SOCIAL Talent Retention (including Training and Education) FY2023 Performance In FY2023, the permanent employees of the Group achieved an average of approximately 23 training hours.",
    "id": 1257,
    "label": [
      {
        "start": 163,
        "end": 165,
        "text": "23",
        "labels": [
          "value"
        ]
      },
      {
        "start": 165,
        "end": 180,
        "text": " training hours",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1258,
    "created_at": "2024-11-07T03:22:41.740186Z",
    "updated_at": "2024-11-07T03:22:41.740186Z",
    "lead_time": 15.769
  },
  {
    "text": "The target of achieving an average of at least 20 training hours for all permanent employees was successfully achieved.",
    "id": 1258,
    "label": [
      {
        "start": 47,
        "end": 49,
        "text": "20",
        "labels": [
          "value"
        ]
      },
      {
        "start": 50,
        "end": 92,
        "text": "training hours for all permanent employees",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1259,
    "created_at": "2024-11-07T03:22:56.215699Z",
    "updated_at": "2024-11-07T03:22:56.215699Z",
    "lead_time": 14.257
  },
  {
    "text": "FY2024 Target Short-term target: All permanent employees complete at least 20 hours of training per year, in order to achieve the adequate level of training for their scope of work.",
    "id": 1259,
    "annotator": 1,
    "annotation_id": 1260,
    "created_at": "2024-11-07T03:23:00.498453Z",
    "updated_at": "2024-11-07T03:23:00.498453Z",
    "lead_time": 4.055
  },
  {
    "text": "Medium-term target: Establish and execute internal training programmes aimed at enhancing employee skills and expertise.",
    "id": 1260,
    "annotator": 1,
    "annotation_id": 1261,
    "created_at": "2024-11-07T03:23:03.329843Z",
    "updated_at": "2024-11-07T03:23:03.329843Z",
    "lead_time": 2.646
  },
  {
    "text": "At Biolidics, the Group believes that technically skilled professionals are central and crucial for its business to remain relevant in today's changing landscape.",
    "id": 1261,
    "annotator": 1,
    "annotation_id": 1262,
    "created_at": "2024-11-07T03:23:09.833779Z",
    "updated_at": "2024-11-07T03:23:09.833779Z",
    "lead_time": 6.308
  },
  {
    "text": "To achieve this, the Group aims to develop and retain competent employees and provide an inclusive and nurturing work culture to ensure the quality of its business operations.",
    "id": 1262,
    "annotator": 1,
    "annotation_id": 1263,
    "created_at": "2024-11-07T03:23:15.318923Z",
    "updated_at": "2024-11-07T03:23:15.318923Z",
    "lead_time": 5.305
  },
  {
    "text": "The Group has regular town hall meetings for its leadership team to provide updates to its employees as well as to understand its employees' needs.",
    "id": 1263,
    "annotator": 1,
    "annotation_id": 1264,
    "created_at": "2024-11-07T03:23:21.944266Z",
    "updated_at": "2024-11-07T03:23:21.944266Z",
    "lead_time": 6.43
  },
  {
    "text": "The Group also demonstrates care for its employees through comprehensive welfare and benefits schemes, including, but not limited to, healthcare, dental, disability and invalidity coverage as well as retirement provision for full-time employee.",
    "id": 1264,
    "label": [
      {
        "start": 59,
        "end": 101,
        "text": "comprehensive welfare and benefits schemes",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 59,
        "end": 101,
        "text": "comprehensive welfare and benefits schemes",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1265,
    "created_at": "2024-11-07T03:23:37.766742Z",
    "updated_at": "2024-11-07T03:23:37.766742Z",
    "lead_time": 15.647
  },
  {
    "text": "Full-time employees are also entitled to different leave types, such as annual leave, parental leave, childcare leave, medical and hospitalisation leave, etc.",
    "id": 1265,
    "annotator": 1,
    "annotation_id": 1266,
    "created_at": "2024-11-07T03:23:44.852338Z",
    "updated_at": "2024-11-07T03:23:44.852338Z",
    "lead_time": 6.875
  },
  {
    "text": "In FY2023, 2 female employees took parental leave.",
    "id": 1266,
    "label": [
      {
        "start": 13,
        "end": 49,
        "text": "female employees took parental leave",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 11,
        "end": 12,
        "text": "2",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1267,
    "created_at": "2024-11-07T03:24:00.605019Z",
    "updated_at": "2024-11-07T03:24:00.605019Z",
    "lead_time": 15.543
  },
  {
    "text": "All of these employees returned to work in FY2023 after their parental leave had ended.",
    "id": 1267,
    "annotator": 1,
    "annotation_id": 1268,
    "created_at": "2024-11-07T03:24:08.397950Z",
    "updated_at": "2024-11-07T03:24:08.397950Z",
    "lead_time": 7.568
  },
  {
    "text": "Therefore, the return-to-work rate is 100% in FY2023.",
    "id": 1268,
    "label": [
      {
        "start": 38,
        "end": 42,
        "text": "100%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 15,
        "end": 34,
        "text": "return-to-work rate",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1269,
    "created_at": "2024-11-07T03:24:12.422703Z",
    "updated_at": "2024-11-07T03:24:22.756124Z",
    "lead_time": 11.759
  },
  {
    "text": "2 female employees that returned to work after their parental leave had ended in FY2022 were still employed by the Group 12 months after their return to work.",
    "id": 1269,
    "annotator": 1,
    "annotation_id": 1270,
    "created_at": "2024-11-07T03:24:29.432110Z",
    "updated_at": "2024-11-07T03:24:29.432110Z",
    "lead_time": 5.187
  },
  {
    "text": "Furthermore, the Group has the Biolidics Performance Share Plan (the \"Plan\") where the primary objective of the Plan is to retain employees whose contributions are essential to the well-being and success of the Group, and to give recognition to outstanding employees who have contributed to the growth of the Group.",
    "id": 1270,
    "label": [
      {
        "start": 31,
        "end": 76,
        "text": "Biolidics Performance Share Plan (the \"Plan\")",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 31,
        "end": 76,
        "text": "Biolidics Performance Share Plan (the \"Plan\")",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1271,
    "created_at": "2024-11-07T03:24:34.449643Z",
    "updated_at": "2024-11-07T03:24:45.876883Z",
    "lead_time": 13.828
  },
  {
    "text": "Eligible participants under the Plan will have the opportunity to participate in the equity of the Group, therefore inculcating a stronger sense of identity with its long-term success.",
    "id": 1271,
    "annotator": 1,
    "annotation_id": 1272,
    "created_at": "2024-11-07T03:24:51.433956Z",
    "updated_at": "2024-11-07T03:24:51.433956Z",
    "lead_time": 4.534
  },
  {
    "text": "This will help promote organisational commitment, dedication and loyalty of these employees to the Group.",
    "id": 1272,
    "annotator": 1,
    "annotation_id": 1273,
    "created_at": "2024-11-07T03:24:56.624470Z",
    "updated_at": "2024-11-07T03:24:56.624470Z",
    "lead_time": 5.014
  },
  {
    "text": "22 BIOLIDICS LIMITED SUSTAINABILITY REPORT For FY2023, all employees of the Group are located in Singapore.",
    "id": 1273,
    "annotator": 1,
    "annotation_id": 1274,
    "created_at": "2024-11-07T03:25:03.474004Z",
    "updated_at": "2024-11-07T03:25:03.474004Z",
    "lead_time": 6.661
  },
  {
    "text": "The new employee hiring rate1 and the employee turnover rate2 were at 9% and 70% respectively.",
    "id": 1274,
    "label": [
      {
        "start": 0,
        "end": 28,
        "text": "The new employee hiring rate",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 76,
        "end": 80,
        "text": " 70%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 70,
        "end": 72,
        "text": "9%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 38,
        "end": 60,
        "text": "employee turnover rate",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1275,
    "created_at": "2024-11-07T03:26:40.077904Z",
    "updated_at": "2024-11-07T03:26:40.077904Z",
    "lead_time": 96.408
  },
  {
    "text": "The breakdown of the new employees hired and turnover of the Group by age group and gender in FY2023 is as follows: New employee hire   by age group New employee hire   by gender FY2023 FY2023 1 1 1 1 <30 years old 30-50 years old >50 years old Male Female Turnover   by age group Turnover   by gender 3 5 6 FY2023 FY2023 10 6 <30 years old 30-50 years old >50 years old Male Female 1 The methodology for calculating the new employee hiring rate has been revised to ensure accuracy.",
    "id": 1275,
    "annotator": 1,
    "annotation_id": 1276,
    "created_at": "2024-11-07T03:26:46.193523Z",
    "updated_at": "2024-11-07T03:26:46.193523Z",
    "lead_time": 5.872
  },
  {
    "text": "The rate is calculated by dividing the total number of new employee hires during FY2023 by the average of the total number of employees at the beginning and end of FY2023.",
    "id": 1276,
    "annotator": 1,
    "annotation_id": 1277,
    "created_at": "2024-11-07T03:26:55.671924Z",
    "updated_at": "2024-11-07T03:26:55.671924Z",
    "lead_time": 9.259
  },
  {
    "text": "2 The methodology for calculating the employee turnover rate has been revised to ensure accuracy.",
    "id": 1277,
    "annotator": 1,
    "annotation_id": 1278,
    "created_at": "2024-11-07T03:26:59.320293Z",
    "updated_at": "2024-11-07T03:26:59.320293Z",
    "lead_time": 3.422
  },
  {
    "text": "The rate is calculated by dividing the total number of employees leaving employment during FY2023 by the average of the total number of employees at the beginning and end of FY2023.",
    "id": 1278,
    "annotator": 1,
    "annotation_id": 1279,
    "created_at": "2024-11-07T03:27:02.535676Z",
    "updated_at": "2024-11-07T03:27:02.535676Z",
    "lead_time": 3.032
  },
  {
    "text": "ANNUAL REPORT 2023 23 SUSTAINABILITY REPORT Training and Education The Group believes in investing in and strengthening its employees' technical, functional and behavioural competencies in line with their job requirements and career aspirations.",
    "id": 1279,
    "annotator": 1,
    "annotation_id": 1280,
    "created_at": "2024-11-07T03:27:09.095998Z",
    "updated_at": "2024-11-07T03:27:09.095998Z",
    "lead_time": 6.386
  },
  {
    "text": "This is done by providing learning and development opportunities to the employees.",
    "id": 1280,
    "annotator": 1,
    "annotation_id": 1281,
    "created_at": "2024-11-07T03:27:12.959786Z",
    "updated_at": "2024-11-07T03:27:12.959786Z",
    "lead_time": 3.681
  },
  {
    "text": "These opportunities can be in the form of on-the-job training, internal training and continuing education programmes.",
    "id": 1281,
    "annotator": 1,
    "annotation_id": 1282,
    "created_at": "2024-11-07T03:27:18.287380Z",
    "updated_at": "2024-11-07T03:27:18.287380Z",
    "lead_time": 5.139
  },
  {
    "text": "The Company is certified with ISO 13485:20163 and has developed a standard operating procedure within the ISO 13485:2016 framework to identify training needs, execute training programs and maintain records of training to ensure proper assignment of job functions to its employees.",
    "id": 1282,
    "label": [
      {
        "start": 30,
        "end": 45,
        "text": "ISO 13485:20163",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 30,
        "end": 45,
        "text": "ISO 13485:20163",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1283,
    "created_at": "2024-11-07T03:27:35.087212Z",
    "updated_at": "2024-11-07T03:27:35.087212Z",
    "lead_time": 16.617
  },
  {
    "text": "Any additional training needs are identified and reviewed annually, and the Group encourages its employees to acquire new skills and keep abreast of developments in their respective fields.",
    "id": 1283,
    "annotator": 1,
    "annotation_id": 1284,
    "created_at": "2024-11-07T03:27:42.936794Z",
    "updated_at": "2024-11-07T03:27:42.936794Z",
    "lead_time": 7.642
  },
  {
    "text": "Employees are given opportunities to attend external courses or trainings that are relevant or will assist in their scope of work.",
    "id": 1284,
    "annotator": 1,
    "annotation_id": 1285,
    "created_at": "2024-11-07T03:27:47.593739Z",
    "updated_at": "2024-11-07T03:27:47.593739Z",
    "lead_time": 4.475
  },
  {
    "text": "Employees are also encouraged to further their studies and funding support may be provided to them on a case-by-case basis.",
    "id": 1285,
    "annotator": 1,
    "annotation_id": 1286,
    "created_at": "2024-11-07T03:28:00.949319Z",
    "updated_at": "2024-11-07T03:28:00.949319Z",
    "lead_time": 13.186
  },
  {
    "text": "The Group monitors training progress by maintaining training records for all its employees.",
    "id": 1286,
    "annotator": 1,
    "annotation_id": 1287,
    "created_at": "2024-11-07T03:28:05.576343Z",
    "updated_at": "2024-11-07T03:28:05.576343Z",
    "lead_time": 4.447
  },
  {
    "text": "In FY2023, all employees received a regular performance and career development review, and employees of the Group achieved an average of approximately 234 training hours.",
    "id": 1287,
    "label": [
      {
        "start": 151,
        "end": 155,
        "text": "234 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 155,
        "end": 169,
        "text": "training hours",
        "labels": [
          "unit"
        ]
      },
      {
        "start": 91,
        "end": 113,
        "text": "employees of the Group",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1288,
    "created_at": "2024-11-07T03:28:51.020168Z",
    "updated_at": "2024-11-07T03:28:51.020168Z",
    "lead_time": 45.269
  },
  {
    "text": "The details of the average training hours per employee in FY2023 are as follows: Average training hours per employee Average training hours per employee   by gender   by employee category 30 30 25 25 24 25 23 22 21 20 20 20 15 15 10 10 5 5 0 0 Male Female Senior Middle Execution General management management level employees level level 3 ISO 13485:2016   Medical devices   Quality management systems   Requirements for regulatory purposes.",
    "id": 1288,
    "annotator": 1,
    "annotation_id": 1289,
    "created_at": "2024-11-07T03:29:01.074743Z",
    "updated_at": "2024-11-07T03:29:01.074743Z",
    "lead_time": 9.82
  },
  {
    "text": "4 Number has been rounded up.",
    "id": 1289,
    "annotator": 1,
    "annotation_id": 1290,
    "created_at": "2024-11-07T03:29:03.371066Z",
    "updated_at": "2024-11-07T03:29:03.371066Z",
    "lead_time": 2.079
  },
  {
    "text": "24 BIOLIDICS LIMITED SUSTAINABILITY REPORT Diversity, Equal Opportunity and Non-discrimination FY2023 Performance In FY2023, no incidents of discrimination were reported.",
    "id": 1290,
    "annotator": 1,
    "annotation_id": 1291,
    "created_at": "2024-11-07T03:29:07.416919Z",
    "updated_at": "2024-11-07T03:29:07.416919Z",
    "lead_time": 3.837
  },
  {
    "text": "The target of achieving zero reported incidents of discrimination was successfully achieved.",
    "id": 1291,
    "label": [
      {
        "start": 51,
        "end": 66,
        "text": "discrimination ",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 24,
        "end": 28,
        "text": "zero",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1292,
    "created_at": "2024-11-07T03:29:20.981509Z",
    "updated_at": "2024-11-07T03:29:20.981509Z",
    "lead_time": 13.369
  },
  {
    "text": "Approximately 67% of employees are female.",
    "id": 1292,
    "label": [
      {
        "start": 21,
        "end": 42,
        "text": "employees are female.",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 14,
        "end": 17,
        "text": "67%",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1293,
    "created_at": "2024-11-07T03:29:31.539229Z",
    "updated_at": "2024-11-07T03:29:31.539229Z",
    "lead_time": 10.33
  },
  {
    "text": "The target of maintaining at least 50% of employees to be female was successfully achieved.",
    "id": 1293,
    "annotator": 1,
    "annotation_id": 1294,
    "created_at": "2024-11-07T03:29:35.840933Z",
    "updated_at": "2024-11-07T03:29:35.840933Z",
    "lead_time": 4.084
  },
  {
    "text": "FY2024 Target Short-term target: Achieve zero reported incidents of discrimination.",
    "id": 1294,
    "annotator": 1,
    "annotation_id": 1295,
    "created_at": "2024-11-07T03:29:39.692406Z",
    "updated_at": "2024-11-07T03:29:39.692406Z",
    "lead_time": 3.634
  },
  {
    "text": "Medium-term target: Maintain at least 50% of employees to be female.",
    "id": 1295,
    "annotator": 1,
    "annotation_id": 1296,
    "created_at": "2024-11-07T03:29:40.640018Z",
    "updated_at": "2024-11-07T03:29:40.640018Z",
    "lead_time": 0.76
  },
  {
    "text": "Long-term target: Continue to implement fair employment practices in adherence to relevant laws and regulations.",
    "id": 1296,
    "annotator": 1,
    "annotation_id": 1297,
    "created_at": "2024-11-07T03:29:41.531310Z",
    "updated_at": "2024-11-07T03:29:41.531310Z",
    "lead_time": 0.677
  },
  {
    "text": "The Group recognises the value of a diverse and skilled workforce and endeavours to create an inclusive and collaborative workplace culture in which all can thrive.",
    "id": 1297,
    "annotator": 1,
    "annotation_id": 1298,
    "created_at": "2024-11-07T03:29:53.486877Z",
    "updated_at": "2024-11-07T03:29:53.486877Z",
    "lead_time": 11.75
  },
  {
    "text": "The Group is committed to promoting a discrimination-free work environment and to providing equal opportunity in all aspects of employment.",
    "id": 1298,
    "annotator": 1,
    "annotation_id": 1299,
    "created_at": "2024-11-07T03:30:00.275050Z",
    "updated_at": "2024-11-07T03:30:00.275050Z",
    "lead_time": 6.567
  },
  {
    "text": "The Group adheres to the principles of equal opportunities and anti-discrimination in every aspect of its employees' careers, including employment, selection, job assignment, compensation, discipline, termination, and access to benefits and training.",
    "id": 1299,
    "annotator": 1,
    "annotation_id": 1300,
    "created_at": "2024-11-07T03:30:04.283551Z",
    "updated_at": "2024-11-07T03:30:04.283551Z",
    "lead_time": 3.817
  },
  {
    "text": "The Group requires all employees to respect each other and does not tolerate any discrimination, such as sexual harassment, verbal attack and assault, regardless of age, gender, race, colour, social status, nationality, religious belief, disability, marital status, pregnancy, sexual orientation, union membership, political association, and other factors.",
    "id": 1300,
    "annotator": 1,
    "annotation_id": 1301,
    "created_at": "2024-11-07T03:30:10.102175Z",
    "updated_at": "2024-11-07T03:30:10.103172Z",
    "lead_time": 5.617
  },
  {
    "text": "Any employees violating the above principles will be subjected to disciplinary sanctions.",
    "id": 1301,
    "annotator": 1,
    "annotation_id": 1302,
    "created_at": "2024-11-07T03:30:17.546774Z",
    "updated_at": "2024-11-07T03:30:17.546774Z",
    "lead_time": 7.259
  },
  {
    "text": "As at 31 December 2023, the Group's workforce totalled 15 employees, all of whom were permanent and full-time employees employed in Singapore.",
    "id": 1302,
    "label": [
      {
        "start": 55,
        "end": 58,
        "text": "15 ",
        "labels": [
          "value"
        ]
      },
      {
        "start": 58,
        "end": 67,
        "text": "employees",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1303,
    "created_at": "2024-11-07T03:30:26.947667Z",
    "updated_at": "2024-11-07T03:31:06.078481Z",
    "lead_time": 18.89
  },
  {
    "text": "Male and female employees represented approximately 33% and 67% of the employee base respectively.",
    "id": 1303,
    "annotator": 1,
    "annotation_id": 1304,
    "created_at": "2024-11-07T03:30:32.222425Z",
    "updated_at": "2024-11-07T03:30:32.222425Z",
    "lead_time": 5.063
  },
  {
    "text": "The Board consists of 5 male directors and 1 female director, with 1 between the ages of 30 and 50 and 5 above the age of 50.",
    "id": 1304,
    "label": [
      {
        "start": 45,
        "end": 60,
        "text": "female director",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 43,
        "end": 44,
        "text": "1",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1305,
    "created_at": "2024-11-07T03:30:48.262582Z",
    "updated_at": "2024-11-07T03:30:48.262582Z",
    "lead_time": 15.849
  },
  {
    "text": "The breakdown of employees by age group and by gender in FY2023 is as follows: Total number of employees   by age group Total number of employees   by gender 4 5 4 FY2023 FY2023 10 7 <30 years old 30-50 years old >50 years old Male Female ANNUAL REPORT 2023 25 SUSTAINABILITY REPORT The breakdown of employees per employee category by gender and age group is as follows: Senior Middle General Execution level management level management level employees Male 2   2 1 Female   2 8   <30 years old     4   30   50 years old 1 2 4   >50 years old 1   2 1 Research and Development\/Innovation The Group's ability to identify and develop innovative technology and products has contributed to the development and growth of the Group.",
    "id": 1305,
    "annotator": 1,
    "annotation_id": 1306,
    "created_at": "2024-11-07T03:31:14.825140Z",
    "updated_at": "2024-11-07T03:31:14.825140Z",
    "lead_time": 6.958
  },
  {
    "text": "The Group strives to utilise its novel, patented technology to create a platform technology in cancer diagnostics which may enable applications throughout various stages of a patient's cancer journey   from cancer screening and staging to personalised treatment, and post-cancer monitoring.",
    "id": 1306,
    "annotator": 1,
    "annotation_id": 1307,
    "created_at": "2024-11-07T03:31:20.808126Z",
    "updated_at": "2024-11-07T03:31:20.808126Z",
    "lead_time": 5.8
  },
  {
    "text": "At the same time, the Group seeks to identify and develop third party technologies and know-how with a focus in developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes.",
    "id": 1307,
    "annotator": 1,
    "annotation_id": 1308,
    "created_at": "2024-11-07T03:31:24.860081Z",
    "updated_at": "2024-11-07T03:31:24.860081Z",
    "lead_time": 3.887
  },
  {
    "text": "The Group's policy on its innovation\/invention and patent protection provides a foundation to exhibit the organic technological innovation capabilities of the Group and highlight the technical capabilities of the Group for joint technical development projects with its technology partners.",
    "id": 1308,
    "annotator": 1,
    "annotation_id": 1309,
    "created_at": "2024-11-07T03:31:29.041437Z",
    "updated_at": "2024-11-07T03:31:29.041437Z",
    "lead_time": 3.998
  },
  {
    "text": "The Group encourages members of its technical team to provide innovation\/invention disclosures when an innovation\/invention can be potentially patented.",
    "id": 1309,
    "annotator": 1,
    "annotation_id": 1310,
    "created_at": "2024-11-07T03:31:32.407609Z",
    "updated_at": "2024-11-07T03:31:32.407609Z",
    "lead_time": 3.183
  },
  {
    "text": "In FY2023, the target of enhancing collaboration was successfully achieved, as staffs' secondment were made to an existing partner on laboratory services.",
    "id": 1310,
    "annotator": 1,
    "annotation_id": 1311,
    "created_at": "2024-11-07T03:31:36.222291Z",
    "updated_at": "2024-11-07T03:31:36.222291Z",
    "lead_time": 3.639
  },
  {
    "text": "As part of its strategic direction, the Group is actively pursuing diversification into New Businesses and scaling down efforts in the research and innovation of the cancer diagnosis segment.",
    "id": 1311,
    "annotator": 1,
    "annotation_id": 1312,
    "created_at": "2024-11-07T03:31:41.465691Z",
    "updated_at": "2024-11-07T03:31:41.465691Z",
    "lead_time": 5.067
  },
  {
    "text": "For the upcoming years, our focus will be on adapting to emerging opportunities and aligning our efforts with the evolving business landscape.",
    "id": 1312,
    "annotator": 1,
    "annotation_id": 1313,
    "created_at": "2024-11-07T03:31:46.727134Z",
    "updated_at": "2024-11-07T03:31:46.727134Z",
    "lead_time": 5.071
  },
  {
    "text": "Customer Privacy FY2023 Performance In FY2023, there were no known cases concerning breaches of customer privacy, identified leaks, thefts or losses of customer data.",
    "id": 1313,
    "annotator": 1,
    "annotation_id": 1314,
    "created_at": "2024-11-07T03:31:50.849244Z",
    "updated_at": "2024-11-07T03:31:50.849244Z",
    "lead_time": 3.931
  },
  {
    "text": "The target of maintaining zero known cases concerning breaches of customer privacy, identified leaks, thefts or losses of customer data was successfully achieved.",
    "id": 1314,
    "label": [
      {
        "start": 26,
        "end": 30,
        "text": "zero",
        "labels": [
          "value"
        ]
      },
      {
        "start": 54,
        "end": 135,
        "text": "breaches of customer privacy, identified leaks, thefts or losses of customer data",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1315,
    "created_at": "2024-11-07T03:32:40.908032Z",
    "updated_at": "2024-11-07T03:32:40.908032Z",
    "lead_time": 34.209
  },
  {
    "text": "FY2024 Target Short-term target: Maintain zero known cases concerning breaches of customer privacy, identified leaks, thefts or losses of customer data.",
    "id": 1315,
    "annotator": 1,
    "annotation_id": 1316,
    "created_at": "2024-11-07T03:32:44.252178Z",
    "updated_at": "2024-11-07T03:32:44.252178Z",
    "lead_time": 3.094
  },
  {
    "text": "Long-term target: Ensure strict compliance with relevant laws and regulations relating to customer privacy.",
    "id": 1316,
    "annotator": 1,
    "annotation_id": 1317,
    "created_at": "2024-11-07T03:32:44.943600Z",
    "updated_at": "2024-11-07T03:32:44.943600Z",
    "lead_time": 0.514
  },
  {
    "text": "The Group is committed to safeguarding the privacy and confidentiality of all its customers' data.",
    "id": 1317,
    "annotator": 1,
    "annotation_id": 1318,
    "created_at": "2024-11-07T03:32:51.896895Z",
    "updated_at": "2024-11-07T03:32:51.896895Z",
    "lead_time": 6.773
  },
  {
    "text": "Keeping its customers' classified data safe is recognised as an essential factor for the Group's sustainable growth.",
    "id": 1318,
    "annotator": 1,
    "annotation_id": 1319,
    "created_at": "2024-11-07T03:32:58.557772Z",
    "updated_at": "2024-11-07T03:32:58.557772Z",
    "lead_time": 6.47
  },
  {
    "text": "The Group adheres to and upholds the provisions of the Personal Data Protection Act 2012 as it seeks to use its patients' data to serve them responsibly.",
    "id": 1319,
    "annotator": 1,
    "annotation_id": 1320,
    "created_at": "2024-11-07T03:33:13.701979Z",
    "updated_at": "2024-11-07T03:33:13.701979Z",
    "lead_time": 14.96
  },
  {
    "text": "Within the laboratory, patients' consent is obtained via forms for collection of personal data prior to the collection.",
    "id": 1320,
    "annotator": 1,
    "annotation_id": 1321,
    "created_at": "2024-11-07T03:33:21.169128Z",
    "updated_at": "2024-11-07T03:33:21.169128Z",
    "lead_time": 7.249
  },
  {
    "text": "The use, disclosure and processing of personal data is limited to healthcare and related use only.",
    "id": 1321,
    "annotator": 1,
    "annotation_id": 1322,
    "created_at": "2024-11-07T03:33:23.869184Z",
    "updated_at": "2024-11-07T03:33:23.869184Z",
    "lead_time": 2.5
  },
  {
    "text": "Should a request for a transfer of patient data arise, the data is transferred to other referral laboratories or other service providers via email in a password-protected zip file or via any encrypted programme or link requested by the client.",
    "id": 1322,
    "annotator": 1,
    "annotation_id": 1323,
    "created_at": "2024-11-07T03:33:28.513888Z",
    "updated_at": "2024-11-07T03:33:28.513888Z",
    "lead_time": 4.464
  },
  {
    "text": "The Group collects the minimum amount of information absolutely needed in providing its services.",
    "id": 1323,
    "annotator": 1,
    "annotation_id": 1324,
    "created_at": "2024-11-07T03:33:31.440742Z",
    "updated_at": "2024-11-07T03:33:31.440742Z",
    "lead_time": 2.746
  },
  {
    "text": "Entry to the Group's laboratories is restricted to access pass holders and the storage area for patient reports and data is restricted to authorised personnel.",
    "id": 1324,
    "annotator": 1,
    "annotation_id": 1325,
    "created_at": "2024-11-07T03:33:34.893443Z",
    "updated_at": "2024-11-07T03:33:34.893443Z",
    "lead_time": 3.279
  },
  {
    "text": "As a means of preventing the leakage of private and confidential information, a Non-Disclosure Agreement is in place and information and patient data are securely stored and encrypted.",
    "id": 1325,
    "annotator": 1,
    "annotation_id": 1326,
    "created_at": "2024-11-07T03:33:39.442190Z",
    "updated_at": "2024-11-07T03:33:39.442190Z",
    "lead_time": 4.377
  },
  {
    "text": "26 BIOLIDICS LIMITED SUSTAINABILITY REPORT Product Quality and Safety FY2023 Performance In FY2023, the target of achieving an average customer satisfaction rating of 80% with the ClearCell  FX1 System, based on at least 5 responses to the customer survey, was successfully achieved.",
    "id": 1326,
    "label": [
      {
        "start": 167,
        "end": 170,
        "text": "80%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 127,
        "end": 163,
        "text": "average customer satisfaction rating",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1327,
    "created_at": "2024-11-07T03:33:58.637675Z",
    "updated_at": "2024-11-07T03:33:58.637675Z",
    "lead_time": 19.01
  },
  {
    "text": "In FY2023, the targets of achieving a 100% pass rate for the ClearCell  FX1 System prior to release and maintaining the CTChip  FRI biochip failure rate due to leaky chips below 5% were successfully achieved, hence resulting in cost savings that improve financial performance.",
    "id": 1327,
    "label": [
      {
        "start": 38,
        "end": 42,
        "text": "100%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 43,
        "end": 82,
        "text": "pass rate for the ClearCell FX1 System",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1328,
    "created_at": "2024-11-07T03:34:21.169346Z",
    "updated_at": "2024-11-07T03:34:21.169346Z",
    "lead_time": 22.301
  },
  {
    "text": "In FY2023, the target of acknowledging 100% of customer feedback\/complaints was successfully achieved.",
    "id": 1328,
    "label": [
      {
        "start": 39,
        "end": 43,
        "text": "100%",
        "labels": [
          "value"
        ]
      },
      {
        "start": 47,
        "end": 64,
        "text": "customer feedback",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1329,
    "created_at": "2024-11-07T03:36:31.175507Z",
    "updated_at": "2024-11-07T03:36:31.175507Z",
    "lead_time": 129.763
  },
  {
    "text": "In FY2023, the targets of completing all Corrective and Preventive Action ( CAPA ) investigations and implementing proposed CAPA within 1 month and 3 months, respectively, were successfully achieved.",
    "id": 1329,
    "annotator": 1,
    "annotation_id": 1330,
    "created_at": "2024-11-07T03:36:41.892963Z",
    "updated_at": "2024-11-07T03:36:41.892963Z",
    "lead_time": 10.482
  },
  {
    "text": "In FY2023, there were no product recalls.",
    "id": 1330,
    "annotator": 1,
    "annotation_id": 1331,
    "created_at": "2024-11-07T03:36:46.200990Z",
    "updated_at": "2024-11-07T03:36:46.200990Z",
    "lead_time": 4.09
  },
  {
    "text": "The target of maintaining zero product recall was successfully achieved, hence resulting in cost savings that improve financial performance.",
    "id": 1331,
    "label": [
      {
        "start": 26,
        "end": 30,
        "text": "zero",
        "labels": [
          "value"
        ]
      },
      {
        "start": 31,
        "end": 45,
        "text": "product recall",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1332,
    "created_at": "2024-11-07T03:36:57.532851Z",
    "updated_at": "2024-11-07T03:36:57.532851Z",
    "lead_time": 11.139
  },
  {
    "text": "FY2024 Target Short-term target: Achieve an average customer satisfaction rating of 80% with the ClearCell  FX1 System, based on at least 5 responses to the customer survey.",
    "id": 1332,
    "annotator": 1,
    "annotation_id": 1333,
    "created_at": "2024-11-07T03:37:03.610946Z",
    "updated_at": "2024-11-07T03:37:03.610946Z",
    "lead_time": 5.848
  },
  {
    "text": "Short-term target: Achieve a 100% pass rate for the ClearCell  FX1 System prior to release and maintain the CTChip  FRI biochip failure rate due to leaky chips below 5%.",
    "id": 1333,
    "annotator": 1,
    "annotation_id": 1334,
    "created_at": "2024-11-07T03:37:04.760598Z",
    "updated_at": "2024-11-07T03:37:04.760598Z",
    "lead_time": 0.965
  },
  {
    "text": "Short-term target: Maintain zero product recall.",
    "id": 1334,
    "annotator": 1,
    "annotation_id": 1335,
    "created_at": "2024-11-07T03:37:05.677894Z",
    "updated_at": "2024-11-07T03:37:05.677894Z",
    "lead_time": 0.729
  },
  {
    "text": "Medium-term target: Acknowledge 100% customer feedback\/complaints within 7 days.",
    "id": 1335,
    "annotator": 1,
    "annotation_id": 1336,
    "created_at": "2024-11-07T03:37:06.414285Z",
    "updated_at": "2024-11-07T03:37:06.414285Z",
    "lead_time": 0.554
  },
  {
    "text": "Medium-term target: Complete all CAPA investigations and implement proposed CAPA actions within 1 month and 3 months, respectively.",
    "id": 1336,
    "annotator": 1,
    "annotation_id": 1337,
    "created_at": "2024-11-07T03:37:07.106478Z",
    "updated_at": "2024-11-07T03:37:07.106478Z",
    "lead_time": 0.507
  },
  {
    "text": "The Group takes product quality and safety seriously.",
    "id": 1337,
    "annotator": 1,
    "annotation_id": 1338,
    "created_at": "2024-11-07T03:37:09.531716Z",
    "updated_at": "2024-11-07T03:37:09.531716Z",
    "lead_time": 2.228
  },
  {
    "text": "Providing products that meet the required quality and safety standards is part of the Group's top priority.",
    "id": 1338,
    "annotator": 1,
    "annotation_id": 1339,
    "created_at": "2024-11-07T03:37:13.187144Z",
    "updated_at": "2024-11-07T03:37:13.187144Z",
    "lead_time": 3.452
  },
  {
    "text": "By maintaining a high product quality and safety standard, the Group also minimises the risk of injury to users, and thus reduces the risk of a product liability claim.",
    "id": 1339,
    "annotator": 1,
    "annotation_id": 1340,
    "created_at": "2024-11-07T03:37:17.643116Z",
    "updated_at": "2024-11-07T03:37:17.644113Z",
    "lead_time": 4.263
  },
  {
    "text": "A product liability lawsuit (which may result in the recall of products or termination of existing agreements by business partners) could damage the Group's reputation, operations and financial performance.",
    "id": 1340,
    "annotator": 1,
    "annotation_id": 1341,
    "created_at": "2024-11-07T03:37:25.143922Z",
    "updated_at": "2024-11-07T03:37:25.143922Z",
    "lead_time": 7.315
  },
  {
    "text": "The Group's quality assurance capabilities have been recognised through its ISO 13485:2016 certification.",
    "id": 1341,
    "annotator": 1,
    "annotation_id": 1342,
    "created_at": "2024-11-07T03:37:29.918883Z",
    "updated_at": "2024-11-07T03:37:29.918883Z",
    "lead_time": 4.578
  },
  {
    "text": "The Group is governed by the guidelines on procedures for the control of records and documents, resource management, product realisation and the monitoring of processes.",
    "id": 1342,
    "annotator": 1,
    "annotation_id": 1343,
    "created_at": "2024-11-07T03:37:32.616287Z",
    "updated_at": "2024-11-07T03:37:32.616287Z",
    "lead_time": 2.515
  },
  {
    "text": "The following processes are monitored by the Group: Annual internal audit; Engaging external auditors to conduct annual audit of quality management system to ensure compliance to ISO 13485:2016; Annual audits of contract manufacturers; Supplier evaluations with annual re-assessment done; Investigation of non-conforming products, and establishing relevant corrective and preventive actions; Quality report log used to track feedback\/complaints for products; Standardised design and development process to evaluate product's safety and performance; and Design and process risk management plans done for all official products under the ISO 13485:2016 framework.",
    "id": 1343,
    "annotator": 1,
    "annotation_id": 1344,
    "created_at": "2024-11-07T03:37:36.474285Z",
    "updated_at": "2024-11-07T03:37:36.474285Z",
    "lead_time": 3.682
  },
  {
    "text": "Constant quality reporting and CAPA are used to monitor and address any non-conformances of the Group's products.",
    "id": 1344,
    "annotator": 1,
    "annotation_id": 1345,
    "created_at": "2024-11-07T03:37:44.012875Z",
    "updated_at": "2024-11-07T03:37:44.012875Z",
    "lead_time": 7.359
  },
  {
    "text": "Regular management meetings are also conducted to review quality objectives and outstanding non-conformance issues.",
    "id": 1345,
    "annotator": 1,
    "annotation_id": 1346,
    "created_at": "2024-11-07T03:37:46.482503Z",
    "updated_at": "2024-11-07T03:37:46.482503Z",
    "lead_time": 2.29
  },
  {
    "text": "ANNUAL REPORT 2023 27 SUSTAINABILITY REPORT SOCIAL AND GOVERNANCE Anti-corruption FY2023 Performance In FY2023, there were no confirmed incidents of corruption\/public legal cases regarding corruption brought against the Group.",
    "id": 1346,
    "annotator": 1,
    "annotation_id": 1347,
    "created_at": "2024-11-07T03:37:52.832252Z",
    "updated_at": "2024-11-07T03:37:52.832252Z",
    "lead_time": 6.14
  },
  {
    "text": "The target of maintaining zero confirmed incidents of corruption\/public legal cases regarding corruption brought against the Group was successfully achieved.",
    "id": 1347,
    "label": [
      {
        "start": 31,
        "end": 83,
        "text": "confirmed incidents of corruption\/public legal cases",
        "labels": [
          "metric"
        ]
      },
      {
        "start": 26,
        "end": 30,
        "text": "zero",
        "labels": [
          "value"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1348,
    "created_at": "2024-11-07T03:38:15.357120Z",
    "updated_at": "2024-11-07T03:38:15.357120Z",
    "lead_time": 22.343
  },
  {
    "text": "FY2024 Target Short-term target: Maintain zero confirmed incidents of corruption\/public legal cases regarding corruption brought against the Group.",
    "id": 1348,
    "annotator": 1,
    "annotation_id": 1349,
    "created_at": "2024-11-07T03:38:17.338941Z",
    "updated_at": "2024-11-07T03:38:17.338941Z",
    "lead_time": 1.729
  },
  {
    "text": "Medium-term target: Provide regular anti-corruption training to employees.",
    "id": 1349,
    "annotator": 1,
    "annotation_id": 1350,
    "created_at": "2024-11-07T03:38:18.023215Z",
    "updated_at": "2024-11-07T03:38:18.023215Z",
    "lead_time": 0.484
  },
  {
    "text": "As a corporation that upholds its business integrity, the Group has zero-tolerance towards any form of corruption, bribery, extortion, money laundering, and fraud, which not only violate laws and regulations but also jeopardise the Group's image and reputation.",
    "id": 1350,
    "annotator": 1,
    "annotation_id": 1351,
    "created_at": "2024-11-07T03:38:22.792269Z",
    "updated_at": "2024-11-07T03:38:22.792269Z",
    "lead_time": 4.581
  },
  {
    "text": "The Group has formulated and implemented the Whistle-blowing Policy and signed the Employment Agreement and the Employee Confidentiality Agreement with its employees regarding code of conduct and ethical issues.",
    "id": 1351,
    "annotator": 1,
    "annotation_id": 1352,
    "created_at": "2024-11-07T03:38:27.668740Z",
    "updated_at": "2024-11-07T03:38:27.668740Z",
    "lead_time": 4.696
  },
  {
    "text": "Such policies are communicated to all employees and Directors.",
    "id": 1352,
    "annotator": 1,
    "annotation_id": 1353,
    "created_at": "2024-11-07T03:38:29.467896Z",
    "updated_at": "2024-11-07T03:38:29.467896Z",
    "lead_time": 1.612
  },
  {
    "text": "All employees are expected to refrain from engaging in corrupt practices, graft, and acceptance of bribes, speculative practices, intentional omissions, and abuse of power to seek personal gain.",
    "id": 1353,
    "annotator": 1,
    "annotation_id": 1354,
    "created_at": "2024-11-07T03:38:35.490191Z",
    "updated_at": "2024-11-07T03:38:35.490191Z",
    "lead_time": 5.847
  },
  {
    "text": "The Group conducted risk assessment related to corruption in all its operations, and no significant risks related to corruption was identified through the risk assessment in FY2023.",
    "id": 1354,
    "annotator": 1,
    "annotation_id": 1355,
    "created_at": "2024-11-07T03:38:39.369750Z",
    "updated_at": "2024-11-07T03:38:39.369750Z",
    "lead_time": 3.693
  },
  {
    "text": "The Group also regularly conducts anti-corruption and ethics training for its Directors and relevant employees.",
    "id": 1355,
    "annotator": 1,
    "annotation_id": 1356,
    "created_at": "2024-11-07T03:38:42.904383Z",
    "updated_at": "2024-11-07T03:38:42.904383Z",
    "lead_time": 3.353
  },
  {
    "text": "All Directors had received anti-corruption training, while new Directors will attend mandatory courses that would be relevant to anti-corruption training provided by the Singapore Institute of Directors.",
    "id": 1356,
    "annotator": 1,
    "annotation_id": 1357,
    "created_at": "2024-11-07T03:38:46.021433Z",
    "updated_at": "2024-11-07T03:38:46.021433Z",
    "lead_time": 2.914
  },
  {
    "text": "Anti-corruption training aims at familiarising the Directors with their roles and responsibilities in ethics management, managerial staff with their roles of managing staff integrity, assessing the risks and preventing corruption in the workplace, and the general staff with the skills to handle ethical dilemmas at work.",
    "id": 1357,
    "annotator": 1,
    "annotation_id": 1358,
    "created_at": "2024-11-07T03:38:51.574005Z",
    "updated_at": "2024-11-07T03:38:51.574005Z",
    "lead_time": 5.374
  },
  {
    "text": "In addition, the Whistle-blowing Policy has been put in place for employees and external parties, such as suppliers, customers, contractors and other stakeholders, to report their concerns or complaint regarding internal control, conflict of interest, collusion with competitors, serious breaches of the Group's policy, unsafe work practices or any other matters involving fraud, corruption and employee misconduct.",
    "id": 1358,
    "annotator": 1,
    "annotation_id": 1359,
    "created_at": "2024-11-07T03:38:55.118101Z",
    "updated_at": "2024-11-07T03:38:55.118101Z",
    "lead_time": 3.345
  },
  {
    "text": "Employees and external parties are allowed to report any suspicious practices or inappropriate activities and bring them immediately to the attention of the AC and\/or the Board.",
    "id": 1359,
    "annotator": 1,
    "annotation_id": 1360,
    "created_at": "2024-11-07T03:38:59.718163Z",
    "updated_at": "2024-11-07T03:38:59.718163Z",
    "lead_time": 4.396
  },
  {
    "text": "The Group will address such reports by taking appropriate action, including, but not limited to, disciplining or terminating the employment and\/or services of those responsible.",
    "id": 1360,
    "annotator": 1,
    "annotation_id": 1361,
    "created_at": "2024-11-07T03:39:04.335480Z",
    "updated_at": "2024-11-07T03:39:04.335480Z",
    "lead_time": 4.445
  },
  {
    "text": "It is also the Group's policy to protect genuine whistle-blowers from any unfair treatment as a result of their report.",
    "id": 1361,
    "annotator": 1,
    "annotation_id": 1362,
    "created_at": "2024-11-07T03:39:06.044001Z",
    "updated_at": "2024-11-07T03:39:06.044001Z",
    "lead_time": 1.519
  },
  {
    "text": "28 BIOLIDICS LIMITED SUSTAINABILITY REPORT GOVERNANCE Maintaining public trust is of utmost priority to any company.",
    "id": 1362,
    "annotator": 1,
    "annotation_id": 1363,
    "created_at": "2024-11-07T03:39:11.739538Z",
    "updated_at": "2024-11-07T03:39:11.739538Z",
    "lead_time": 5.497
  },
  {
    "text": "The Group is committed to upholding high ethical standards and integrity in its operations, and complying with all laws and regulations in its location of operations.",
    "id": 1363,
    "annotator": 1,
    "annotation_id": 1364,
    "created_at": "2024-11-07T03:39:17.501787Z",
    "updated_at": "2024-11-07T03:39:17.501787Z",
    "lead_time": 5.582
  },
  {
    "text": "Environmental and Socioeconomic Compliance FY2023 Performance In FY2023, there were no instances of non-compliance with laws and regulations in the environmental, social and economic areas.",
    "id": 1364,
    "annotator": 1,
    "annotation_id": 1365,
    "created_at": "2024-11-07T03:39:22.089555Z",
    "updated_at": "2024-11-07T03:39:22.089555Z",
    "lead_time": 4.402
  },
  {
    "text": "The target of maintaining zero non-compliance with laws and regulations in the environmental, social and economic areas was successfully achieved.",
    "id": 1365,
    "label": [
      {
        "start": 26,
        "end": 30,
        "text": "zero",
        "labels": [
          "value"
        ]
      },
      {
        "start": 31,
        "end": 119,
        "text": "non-compliance with laws and regulations in the environmental, social and economic areas",
        "labels": [
          "metric"
        ]
      }
    ],
    "annotator": 1,
    "annotation_id": 1366,
    "created_at": "2024-11-07T03:39:36.801088Z",
    "updated_at": "2024-11-07T03:39:36.801088Z",
    "lead_time": 14.522
  },
  {
    "text": "FY2024 Target Short-term target: Maintain zero non-compliance with laws and regulations in the environmental, social and economic areas.",
    "id": 1366,
    "annotator": 1,
    "annotation_id": 1367,
    "created_at": "2024-11-07T03:39:38.369270Z",
    "updated_at": "2024-11-07T03:39:38.369270Z",
    "lead_time": 1.311
  },
  {
    "text": "Medium-term target: Continue to conduct environmental, social and economic compliance training for all new hires.",
    "id": 1367,
    "annotator": 1,
    "annotation_id": 1368,
    "created_at": "2024-11-07T03:39:38.941053Z",
    "updated_at": "2024-11-07T03:39:38.941053Z",
    "lead_time": 0.383
  },
  {
    "text": "The Group's products and business activities are regulated by various laws and regulations governing medical devices in the countries it markets and sells its products in.",
    "id": 1368,
    "annotator": 1,
    "annotation_id": 1369,
    "created_at": "2024-11-07T03:39:45.418787Z",
    "updated_at": "2024-11-07T03:39:45.418787Z",
    "lead_time": 6.297
  },
  {
    "text": "The Group is subjected to extensive supervision by governments and other agencies in various aspects of its operations, including licensing and certification requirements, product registration requirements, quality and safety standards, periodic renewal and reassessment procedures.",
    "id": 1369,
    "annotator": 1,
    "annotation_id": 1370,
    "created_at": "2024-11-07T03:39:49.353368Z",
    "updated_at": "2024-11-07T03:39:49.353368Z",
    "lead_time": 3.75
  },
  {
    "text": "Any breach of applicable laws and regulations may cause disruptions to operations and fines in any particular jurisdiction; hence it is important for the Group to comply with various laws and regulations in the environmental, social and economic areas.",
    "id": 1370,
    "annotator": 1,
    "annotation_id": 1371,
    "created_at": "2024-11-07T03:39:53.083975Z",
    "updated_at": "2024-11-07T03:39:53.083975Z",
    "lead_time": 3.542
  },
  {
    "text": "The Group is committed to providing innovative high-quality biomedical products and services that meet or exceed the expectations of its customers.",
    "id": 1371,
    "annotator": 1,
    "annotation_id": 1372,
    "created_at": "2024-11-07T03:39:56.618043Z",
    "updated_at": "2024-11-07T03:39:56.618043Z",
    "lead_time": 3.349
  },
  {
    "text": "The Group aims to do so by: Meeting and complying with all regulatory requirements of the countries where the product is being sold as per the ISO 13485:2016 requirements; Maintaining the effectiveness of the Quality System and Risk Management in line with ISO 13485:2016 requirements; Maintaining a shared quality vision and a focus on continuous improvement to the products, processes and services (including delivery); Understanding the requirements and meeting the needs of the partners and customers; Training employees in the delivery of quality products and services; and Providing a competent, ethical and fiscally sound management team to ensure growth and long-term stability.",
    "id": 1372,
    "annotator": 1,
    "annotation_id": 1373,
    "created_at": "2024-11-07T03:40:01.253363Z",
    "updated_at": "2024-11-07T03:40:01.253363Z",
    "lead_time": 4.43
  },
  {
    "text": "To ensure that employees of the Group are aware of the relevant regulatory requirements, the Group has included the above activities in the employee training programme.",
    "id": 1373,
    "annotator": 1,
    "annotation_id": 1374,
    "created_at": "2024-11-07T03:40:03.023884Z",
    "updated_at": "2024-11-07T03:40:03.023884Z",
    "lead_time": 1.594
  },
  {
    "text": "ANNUAL REPORT 2023 29 SUSTAINABILITY REPORT SGX CONTENT INDEX Primary Component Section Reference Material environmental, social and governance factors Sustainability Report   Materiality Assessment Climate-related disclosures Sustainability Report   Environmental: Climate Change Mitigation and Adaptation Policies, practices and performance Sustainability Report   Economic, Environmental, Social and Environmental, Social, Social and Governance, Governance Targets Sustainability Report   Economic, Environmental, Social and Environmental, Social, Social and Governance, Governance Sustainability reporting framework Sustainability Report   About this Report Board statement and associated governance structure Sustainability Report   Board Statement for sustainability practices GRI CONTENT INDEX Statement of Use Biolidics Limited has reported the information cited in this GRI content index for the period from 1 January 2023 to 31 December 2023 with reference to the GRI Standards.",
    "id": 1374,
    "annotator": 1,
    "annotation_id": 1375,
    "created_at": "2024-11-07T03:40:08.481047Z",
    "updated_at": "2024-11-07T03:40:08.481047Z",
    "lead_time": 5.278
  },
  {
    "text": "GRI 1 Used GRI 1: Foundation 2021 GRI Indicator Description Session\/Explanation GRI 2: General Disclosures 2021 2-1 Organisational details   Legal name: Biolidics Limited   Nature of ownership and legal form: listed company on Catalist of SGX-ST   Location of headquarters and country of operation: Singapore 2-2 Entities included in the organisation's Sustainability Report   About this Report sustainability reporting 2-3 Reporting period, frequency and   Reporting period: 1 January 2023 to 31 December contact point 2023   Reporting frequency: annually   Publication date: 12 April 2024   Contact point: support@biolidics.com 2-5 External assurance Sustainability Report   About this Report 2-6 Activities, value chain and other Corporate Profile; Corporate Information business relationships 2-7 Employees Sustainability Report   Social: Diversity, Equal Opportunity and Non-discrimination 30 BIOLIDICS LIMITED SUSTAINABILITY REPORT GRI Indicator Description Session\/Explanation 2-9 Governance structure and Boards of Directors, Executive Officer, Sustainability composition Report   Board Statement; Corporate Governance 2-10 Nomination and selection of the Corporate Governance highest governance body 2-12 Role of the highest governance body Sustainability Report   Board Statement, Materiality in overseeing the management of Assessment; Corporate Governance impacts 2-13 Delegation of responsibility for Sustainability Report   Board Statement managing impacts 2-14 Role of the highest governance body Sustainability Report   Board Statement, Materiality in sustainability reporting Assessment 2-15 Conflicts of interest Corporate Governance 2-27 Compliance with laws and regulations Sustainability Report   Governance: Environmental and Socioeconomic Compliance 2-29 Approach to stakeholder engagement Sustainability Report   Stakeholder Engagement GRI 3: Material Topics 2021 3-1 Process to determine material topics Sustainability Report   Materiality Assessment 3-2 List of material topics Sustainability Report   Materiality Assessment GRI 201: Economic Performance 2016 3-3 Management of material issues Operations & Financial Review; Sustainability Report   Environmental: Climate Change Mitigation and Adaptation 201-1 Direct economic value generated and Financial Statements distributed 201-2 Financial implications and other risks Sustainability Report   Environmental: Climate Change and opportunities due to climate Mitigation and Adaptation change ANNUAL REPORT 2023 31 SUSTAINABILITY REPORT GRI Indicator Description Session\/Explanation GRI 205: Anti-corruption 2016 3-3 Management of material issues Sustainability Report   Social and Governance: Anti-corruption 205-1 Operations assessed for risks related Sustainability Report   Social and Governance: to corruption Anti-corruption 205-2 Communication and training Sustainability Report   Social and Governance: about anti-corruption policies and Anti-corruption procedures 205-3 Confirmed incidents of corruption Sustainability Report   Social and Governance: and actions taken Anti-corruption GRI 305: Emissions 2016 3-3 Management of material issues Sustainability Report   Environmental: Climate Change Mitigation and Adaptation 305-2 Energy indirect (Scope 2) GHG Sustainability Report   Environmental: Climate Change emissions Mitigation and Adaptation 305-4 GHG emissions intensity Sustainability Report   Environmental: Climate Change Mitigation and Adaptation GRI 306: Waste 2020 3-3 Management of material issues Sustainability Report   Social and Environmental: Occupational Health and Safety (including Effluents and Waste) 306-2 Management of significant waste- Sustainability Report   Social and Environmental: related impacts Occupational Health and Safety (including Effluents and Waste) GRI 401: Employment 2016 3-3 Management of material issues Sustainability Report   Social: Talent Retention (including Training and Education), Diversity, Equal Opportunity and Non-discrimination 401-1 New employee hires and employee Sustainability Report   Social: Talent Retention turnover (including Training and Education) 401-2 Benefits provided to full-time Sustainability Report   Social: Talent Retention employees that are not provided to (including Training and Education) temporary or part-time employees 401-3 Parental leave Sustainability Report   Social: Talent Retention (including Training and Education) 32 BIOLIDICS LIMITED SUSTAINABILITY REPORT GRI Indicator Description Session\/Explanation GRI 403: Occupational Health and Safety 2018 3-3 Management of material issues Sustainability Report   Social and Environmental: Occupational Health and Safety (including Effluents and Waste) 403-1 Occupational health and safety Sustainability Report   Social and Environmental: management system Occupational Health and Safety (including Effluents and Waste) 403-2 Hazard identification, risk Sustainability Report   Social and Environmental: assessment, and incident Occupational Health and Safety (including Effluents investigation and Waste) 403-4 Worker participation, consultation, Sustainability Report   Social and Environmental: and communication on occupational Occupational Health and Safety (including Effluents health and safety and Waste) 403-5 Worker training on occupational Sustainability Report   Social and Environmental: health and safety Occupational Health and Safety (including Effluents and Waste) 403-9 Work-related injuries Sustainability Report   Social and Environmental: Occupational Health and Safety GRI 404: Training and Education 2016 3-3 Management of material issues Sustainability Report   Social: Talent Retention (including Training and Education) 404-1 Average hours of training per year Sustainability Report   Social: Talent Retention per employee (including Training and Education) 404-3 Percentage of employees receiving Sustainability Report   Social: Talent Retention regular performance and career (including Training and Education) development reviews GRI 405: Diversity and Equal Opportunity 2016 3-3 Management of material issues Sustainability Report   Social: Diversity, Equal Opportunity and Non-discrimination 405-1 Diversity of governance bodies and Sustainability Report   Social: Diversity, employees Equal Opportunity and Non-discrimination GRI 406: Non-discrimination 2016 3-3 Management of material issues Sustainability Report   Social: Diversity, Equal Opportunity and Non-discrimination 406-1 Incidents of discrimination and Sustainability Report   Social: Diversity, corrective actions taken Equal Opportunity and Non-discrimination ANNUAL REPORT 2023 33 SUSTAINABILITY REPORT GRI Indicator Description Session\/Explanation GRI 418: Customer Privacy 2016 3-3 Management of material issues Sustainability Report   Social: Customer Privacy 418-1 Substantiated complaints concerning Sustainability Report   Social: Customer Privacy breaches of customer privacy and losses of customer data",
    "id": 1375,
    "annotator": 1,
    "annotation_id": 1376,
    "created_at": "2024-11-07T03:40:18.531141Z",
    "updated_at": "2024-11-07T03:40:18.531141Z",
    "lead_time": 9.861
  }
]